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Thesis Abstract 
Background 
To find an effective strategy for regulating pharmaceuticals, it is essential to learn 
lessons from foreign experience; to consider salient contextual specific factors; and to 
establish good scientific evidence that can be used in decision-making. During the last 
ten years, South Korea has experienced an unprecedented transformation in the 
pharmaceutical market. So far, few researchers have questioned whether the Korean 
strategy is an appropriate and efficient measure for regulating pharmaceuticals. 
Objectives 
" To explore the impact of policy Interventions in the global pharmaceutical market 
  To investigate the impact of pharmaceutical policies in the Korean market 
  To study contextual factors contributing to gaps between evidence and practice, 
and contextual challenges In evidence-based policy-making in the Korean market 
Methods 
1. Systematic reviews were conducted of existing rigorous studies that evaluated the 
impact of pharmaceutical policies internationally. , 
2. Korean pharmaceutical claims were examined using an interrupted time series 
design to explore two recent Korean pharmaceutical policies. 
3. Semi-structured in-depth interviews were conducted with eight core personnel, who 
are either policy-makers or those who influence policy-making to discuss contextual 
challenges in the Korean pharmaceutical arena. 
Results 
Despite the usefulness of international experience, reviews highlight the lack of validity, 
generalisability and transferability of specific research findings In the pharmaceutical 
arena. Strikingly, 78% of Included studies came from five countries - Canada, Spain, 
Sweden, the UK and the US, which are more affluent. Little evidence was found that 
provides direct pragmatic lessons for South Korea, but there were still some worthwhile 
implications. Some of these were clarified by the following empirical studies. The 
empirical investigation suggested that the present Korean policy Interventions might 
achieve only marginal success In containing pharmaceutical costs, but could potentially 
increase social inequity and reduce market competition. Even participants, who are 
closely involved in the process of the Korean pharmaceutical policy cycle, recognise the 
major weaknesses of the current system, but face considerable resistance to moving 
towards strategies that may be more effective. In South Korea, regulating 
pharmaceuticals is challenged by lack of available information, widespread distrust, 
resource constraints, and strong professionals. 
Conclusion 
It is important to remember that drug policies are often derived from a complex mix of 
constrained evidence, sometimes irrational judgments and wishful thinking, perhaps 
focusing on benefits and ignoring the potential negative consequences. At the same 
time, it is necessary to develop policy-making capacity in the face of an Immature 
evidence base. Efforts that build research capacity and seek local evidence are 
essential to strengthen such capacity as well as to be an ultimate solution to the 
absence of a knowledge base. 
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INTRODUCTION: SCOPE AND OUTLINE 
Over recent decades, funding and use of pharmaceuticals have become global 
concerns, giving rise to Intense debates across many countries, both rich and poor. 
There is little doubt that the challenges of this market differ across countries, which Is 
natural given that problems are driven by a combination of factors that can differ from 
one nation to another. The pharmaceutical agenda for very poor and very rich 
countries is illustrated by a high volume of literature (see Figure 1-1). Rising costs are 
considered an urgent challenge in many high-income, developed countries (Docteur 
and Oxley, 2003; Jacobzone, 2000; Mossialos, 1998; Mossialos eta/., 2004), whereas 
concerns around the paucity of essential medicines are debated In low-income, 
developing countries (Farmer, 2005; Melrose, 1982c; Smith et al., 2001; Whyte etal., 
2007). 
Enhancing the rational use of medicines is an important Issue across markets with 
different characteristics. Affluent countries are more likely to be concerned with how to 
utilise medicines cost-effectively to lower spending without compromising quality of 
care (Almarsdottir and Traulsen, 2005b; Jacobzone, 2000; King and Kanavos, 2002). 
Poorer countries are still searching for a way to use medicines properly In order to curb 
basic epidemic diseases, partly caused by the lack of proper education and trained 
health workers (Melrose, 1982a, 1982d), but also Inevitably associated with the 
shortage of essential drugs under the current market system (Lichtenberg, 2005b; 
Pecoul eta/., 1999). Pharmaceutical access in low Income developing countries Is 
potentially viewed as a 'human right' and is Increasingly found on the agenda of 
International organisations, Including the World Health Organization and several Non- 
governmental Organizations (Ford eta/., 2009; Medecins Sans Frontieres, 2006a; 
Sachs eta/., 2001; Smith eta/., 2001). This is an Important Issue for pharmaceutical 
regulations and fuels immense debates, but falls outside the scope of this thesis. 
Relative to rich and poor countries, there is a lack of attention to pharmaceutical 
market challenges in the middle range of countries. Most studies evaluating 
pharmaceutical policies have emerged from a handful of limited environments in the 
world's most developed societies in North America and Western Europe. Not 
surprisingly, nations located geographically closer to developed countries such as the 
Czech Republic, South Korea and Taiwan, may share common challenges with the 
developed nations. This, however, does not imply that what is observed in their 
neighbourhood settings must also be the case in these nations. 
Figure i-1: Challenges in pharmaceutical markets by national wealth 
" Rising costs 
  Rational use of medicine for containing costs, 
effectiveness, equity, etc. 
2 "w 
i`,..... 
Countries in the middle 
  Broad spectrum 
" Under-studied 
9'or etanrpfe, 
South Korea 
" similar current challenges to those in 
high income developed countries 
However, 
" generic-oriented industry 
  positioning at low band of high income 
" weak research environment 
" young reformer in drug market 
" Asian background 
-low Income 
developing a Access to essential drugs 
countries 
Rational use of medicine for curbing epidemic diseases 
* Countries within the figure were lined up by GNI per capita 2008 (PPP int. $) statistics released by World 
Bank (World Bank, 2009). A comparable figure for Taiwan came from Taiwanese governement website 
(available at: hhttp: //eng. stat. gov. tw/ oint. asp? index=l). 
Traulsen and Almarsdottir (2005) stated that policy analysis is comprised of two 
elements; "predicting the impacts of possible policies" and "evaluating past policies": 
Nowadays in the public policy arena, it occurs ubiquitously that policy-makers watch 
and learn from foreign policies (Guillen and Cabiedes, 2003; Klein, 1997; Rose, 2005; 
Stone, 1999). In the policy process, there are many nation-specific factors influencing 
policy formation and outputs (Dolowitz et a/., 2000). Thus, 'predicting the impacts of 
possible policies' is often conducted by combining foreign experience with some degree 
of contextual consideration. Contextual factors, however, cannot be fully captured in 
simulation, and there is no way of knowing whether the outcome of a certain policy will 
be in line with its anticipated effects in advance. In this regard, it is becoming clear 
that 'evaluating past policies' is essential in a sound policy system. 
high income 
2 
.'s 
ýý Kýýý;, ý1 
There are at least three reasons why making the study of policy impact in individual 
nations is essential. This is particularly the case in countries where many 
pharmaceutical regulations have been emulated, but rarely evaluated after their 
introduction, as in South Korea. 
First, experience in analysing policies allows governments to seek an effective strategy 
for their own arrangements. Bloor and Maynard (2004; p61) argue that in regulating 
pharmaceutical markets "there is no 'best' regulatory system", but all [policy 
objectives] involve trade-offs": Their claim implies that an individual government should 
find an effective strategy in trading off competing objectives In their own society. A 
good strategy can hardly be specified until an In-depth Insight Into its success or failure 
Is reached by widening the pool of analytic knowledge. For example, the effect of 
policies encouraging generic use on drug expenditure may be smaller in a nation 
maintaining a premium price for generics than in another nation keeping prices low. 
Faced with smaller policy Impacts, how is a nation able to confirm Its own problem (e. g. 
high price of generics), If it lacks infrastructures such as databases that capture reality, 
but just follows the global trend of encouraging cost-effective utilisation? Even though 
It is capable of recognising Its own problems, It may be hard nowadays to match the 
complex requirements of stakeholders without rigorous evidence. Such Infrastructures, 
for example a database taking prescribing claims or national measures distinguishing 
generics from brand-named drugs, are unable to be established quickly. Even when 
there Is a database, it Is quite a different matter to just hold data rather than making it 
available and useful (Garrison et al., 2007; Majeed etal., 1997; Wong and Hellinger, 
2001). There are frequent calls for changes In the variables In existing databases In 
many developed countries, where there has been a relatively rich experience In policy 
analysis (Majeed et al., 1997; St Leger eta/., 1992). 
Second, and more importantly, as Maynard (2005) Indicates, policy can damage 
population health, as would the use of new and untested pharmaceuticals. Prescription 
capping In US Medicaid is an example of this. As shown In Chapter 4, It reduced the 
state of health In the elderly poor as well as pharmaceutical costs Incurred by Medicaid 
on their behalf (Soumeral et al., 1991). Additionally, making the wrong choice could 
carry unwanted consequences not only in population health, but also in resource 
utilisation. Making a choice among several policy options always creates opportunity 
costs, depending on what must be given up (e. g. the next best alternative) as a result 
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of the decision (Morris eta/., 2007b). For instance, taxes spent on supplying hospital 
beds could alternatively be spent on building schools or houses. In this case, wasting 
resources by a wrong decision in the healthcare arena loses an opportunity for better 
educational or living environments In a society. 
Third, existing evidence is not sufficient either in quantity or quality, regardless of 
setting. The accelerated increase in pharmaceutical expenditure has prompted many 
industrialised nations to establish various cost-containment policies since the 1970s. 
Consequently, efforts have been made to evaluate the impact of newly introduced 
regulations. However, such efforts are far from satisfying all demands (Kanavos eta/., 
2004). Soumeral et al. (1993; p219) remark that "policy makers have often 
implemented cost-containment policies with little empirical evidence about their true 
impact": This comment was made nearly two decades ago and still holds true (see Part 
2). 
Unfortunately, 'evaluating past policies' has been overlooked in South Korea, one of the 
countries positioned in the upper band of the middle arena. This argument is 
supported by the fact that there are few available empirical studies in Korea. In part, 
this is due to the country's short history of pharmaceutical policy and evaluation. It has 
been just a decade since Korean policy-makers paid attention to evaluating the 
performance of policies In the pharmaceutical field (see Chapter 2). 
South Korea Is a country that has already established a basic system for controlling 
epidemic diseases, and has begun to encounter problems similar to those in the 
developed countries. For example, Korea is currently experiencing a sharp increase in 
chronic conditions among Its ageing population (NHIC and HIRA, 2007). The aged 
population has Increased sharply by 50 per cent from 1994 to 2004 (see Table 2-6 in 
Chapter 2). Alongside this, health expenditure (public plus private) has inflated from 
5,000 billion to 22,500 billion Korean Won (2.5 billion to 11.25 billion In pound sterling 
at 2008 exchange rates) In the corresponding 10 year period (NHIC and HIRA, 2007). 
In its healthcare system, especially relating to pharmaceuticals, South Korea has 
experienced an unprecedented transformation in the span of just ten years. It started 
with the unification of insurance funds, and reached a pinnacle with the separation of 
prescribing and dispensing of drugs (SPD) initiated in 2000 (Hwang, 2006b; Kwon and 
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Reich, 2005). In parallel, vital government bodies such as the Korea Food & Drug 
Administration (KFDA), Health Insurance Review & Assessment Service (HIRA) and 
National Health Insurance Corporation (NHIC) were established or restructured around 
the same time. Largely, a series of reforms initiated from 2000 onwards modernised 
the Korean regulatory framework for pharmaceuticals In line with structures observed 
In the most developed countries (see Chapter 2). 
The reforms and subsequent measures since the late 1990s have entirely reorganised 
the pharmaceutical market. Regulatory authorities changed the reimbursement pricing 
mechanism, so that the reimbursed price is the same as the real acquisition cost, 
eliminating potential profit from dispensing pharmaceuticals In medical Institutions. 
This was Implemented to remove the extra Income derived from dispensing drugs, so 
as to Introduce the separation policy smoothly a year later. A reduction of around thirty 
per cent cut of the drug reimbursement price was carried out In November 1999. In 
return, the government rearranged a remuneration system for professionals, 
Introducing an annual payment contract between the government and each 
professional group. This, along with a substantial Increase In patient visits after the 
separation policy, put a great financial burden on national Insurance funds, almost to 
the point of bankruptcy (DailyPharm, 2001b, 2001c). In the pharmaceutical arena, 
after the separation policy, pharmaceutical expenditure surged, partly because of cost 
shifting from the private to the public sector. The substantial Increase in patient visits 
resulted In a similar increase In publicly reimbursed prescriptions (Cho etal., 2003; Cho 
etal., 2002; Kim, 2002b; NHIC and HIRA, 2007). Evidence also suggests that rising 
expenditure has been associated with changing prescribing patterns In favour of more 
expensive drugs (Cho etal., 2003; Cho etal., 2001; Jang etal., 2001; Kim, 2005; Lee 
and Malone, 2003). 
It may be surmised, from the brief history above, that the issue of pharmaceutical 
costs has come to the forefront of policy debate. The government has made various 
efforts to contain costs, and many subsequent policies following the SPD were devised 
to handle the financial crisis. Figure 1-2 demonstrates major pharmaceutical policies 
implemented in South Korea during the current decade in chronological order. This will 
be discussed in more detail in Chapter 2. 
5 
Figure i-2: Major pharmaceutical policies in Korea from 1999 and onward 
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In the process of policy development, Korean policy-makers often benchmark 
interventions in the world's most developed countries. Learning from abroad is 
certainly valuable in determining potential policy options and finding out how to 
institutionalise them in order for their effects to result. Equally importantly, it provides 
opportunities to observe the considerable contextual variations within and between 
policy programmes. A similar policy may generate divergent effects across countries, or 
each national government might respond differently to a common problem, taking 
internal conditions into account. The transferability of a certain policy and the 
genera lisability of its results are limited to a great degree between countries (Kanavos 
et al., 2004). 
Pawson and Tilley (1997; p57) describe this situation, arguing that "programs work 
(have successful 'outcomes') only in so far as they introduce the appropriate ideas and 
opportunities ('mechanisms') to groups in the appropriate social and cultural conditions 
('contexts'). " This implies the importance of understanding foreign policies 
(mechanisms) and specific surroundings (original contexts) in observing the effects of 
policies. At the same time, it is necessary to consider 'environments in a target setting 
(own contexts)' for successful policy outcomes. They expressed the idea as the 
following conceptual formula: "outcome = mechanism + context'. 
South Korea has quite a different background from the most developed countries, 
especially in political, industrial and cultural environments, and even in an economic 
capacity, although it is now often considered an industrialised country in many aspects. 
Many factors, such as shortages of political will, social consensus, money, personnel, 
and administrative capability, could be obstacles not only In introducing policy, but also 
In enacting it successfully (Chapter 2). All such factors must Interplay with 
interventions and bring about somewhat different outcomes (Pawson and Tilley, 1997). 
Thus far, few researchers have questioned whether the Korean strategy is appropriate 
for regulating pharmaceuticals within local conditions. There is a pressing need to 
examine the actual impact of interventions within Korean-specific environments in 
parallel with learning from foreign experience to speed progress in this area. However, 
evaluating pharmaceutical policies has lagged far behind in South Korea, compared 
with some developed countries. 
Therefore, the purposes of this thesis are: 
  To explore the impact of policy interventions in the global pharmaceutical 
market 
  To investigate the impact of pharmaceutical policies in the Korean market 
  To study contextual factors contributing to gaps between evidence and practice, 
and contextual challenges in evidence-based policy-making in the Korean market 
Given the lack of high quality studies from a global perspective, South Korea provides 
an excellent setting to study the Impact of several pharmaceutical policies, in the 
context of a regulated pharmaceutical market during this decade. This is even more 
interesting, given that South Korea has a dissimilar economic status and industrial 
structure to nations in North America and Western Europe, and a considerably different 
political, historical, and societal background from those settings. 
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Outline of thesis 
The thesis comprises four parts; background, systematic review, empirical research 
and prospects for the future. The background study consists of two chapters, which 
are dedicated to shaping the theoretical framework of the thesis from two angles - 
mechanism and context according to the ideas of Pawson and Tilley (1997). Chapter 1 
will address, firstly, evidence and causes of market failure for pharmaceuticals from a 
welfare economics perspective and, secondly, various policy devices currently in place 
and how they would function in the pharmaceutical market against factors causing the 
market to fail. This will give a brief general background of the policy mechanisms. 
The initial chapters are followed, in Chapter 2, by depicting several salient 
environments seen in South Korea, largely from four perspectives - health status, 
economic stance, political environment and cultural background. In this chapter 
pharmaceutical policies implemented in South Korea during recent decades are also 
outlined. This helps to explain the two policies explored in the empirical research (Part 
3) in the broader context. Thirdly, there is a discussion of the significance of good 
grounds for policy-making, tools of policy evaluation and the weaknesses of existing 
Korean studies, and the shaping of a methodological framework for the whole thesis. 
The second part of the thesis reviews the most rigorous evidence currently available in 
a global context concerning the impact of pharmaceutical policies. Measures regulating 
pharmaceuticals and their impact or consequences are explored through systematic 
review (Chapter 3 through 7). Chapter 3 Illustrates the methods of systematic review in 
the thesis and the following three chapters present findings from systematic reviews 
categorised by policies Influencing patients, providers and industry. The final chapter 
on the systematic review discusses issues emerging from the methods and lessons for 
the empirical investigation In Part 3. It also summarises key findings from the 
systematic review. 
The third part of the thesis investigates empirical data in the Korean pharmaceutical 
arena, beginning with a description of time series methods in general (Chapter 8). 
Chapter 9 provides detailed backgrounds of policies of interest and investigates their 
impact on overall pharmaceutical expenditure, utilisation and prices, Chapter 10 
examines their impact on essential drug utilisation and the generic market with two 
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therapeutic drug classes, to gain a better understanding of how policies work in the 
market. Chapter 11 discusses the meanings of the findings from the empirical 
Investigation. 
Finally, there is a qualitative examination of the views of local experts, either policy- 
makers or those who Influence policy-making. The primary aim of the qualitative study 
is to explore contextual difficulties in evidence-based policy-making from the local 
policy-makers' perspective, using in-depth Interviews (Chapter 12). This enables 
specification of the current stances, challenges and uncertainties in local 
pharmaceutical policy-making, which illuminates the subjects of future drug policy in 
South Korea. 
Lastly, in Chapter 13 all the major themes found within this thesis are drawn together. 
Key findings are summarised, shaping local challenges in pharmaceutical regulations. 
Study limitations are discussed along with contributions to the existing literature. Based 
on lessons from systematic reviews and empirical research, recommendations for 
future pharmaceutical policies in South Korea are addressed. The thesis closes by 
highlighting other research opportunities. 
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PART 1 BACKGROUND 
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CHAPTER 1: PHARMACEUTICALS AND MARKETS 
1.1 Introduction 
Regulating pharmaceuticals in relation to safety and clinical efficacy has been accepted 
as a vital role of the state after an iatrogenic tragedy caused by thalidomide in the 
1960s (Annas and Elias, 1999; Britten, 2008). Since the 1970s, interest in 
pharmaceutical policies has been augmented beyond safety and efficacy internationally, 
as concerns grow over rising pharmaceutical expenditure. Efforts to regulate 
pharmaceuticals have diversified in the span of less than three decades. Most 
industrialised countries in North America or Western Europe are ahead In this 
movement (Ess et al., 2003; Guillen and Cabiedes, 2003; Jacobzone, 2000; Kozma et 
a/., 1993; Mossialos and Le Grand, 1999; Mossialos etal., 2004; Reeder et al., 1993). 
The subject of public regulation itself is, however, still controversial. At one extreme, 
Stigler (1971) is concerned that public regulation does not serve the purpose of "the 
protection and benefit of the public" because it is `captured' in a strongly capitalist 
society by industry, so over time regulation tends to be designed and operated 
primarily for industry's benefit. The same is asserted by Navarro (1986b). 
At the other end of the scale, some writers worry that public regulation could do more 
harm than good in curtailing economic freedom and market competition. Danzon and 
colleagues demonstrated empirical evidence In their Investigation of International 
commercial sales data that price control may be adversely associated with Innovation 
and price competition among generics (Danzon and Chao, 2000; Danzon and Furukawa, 
2003). Industry and Its advocates continue to insist that excessive efforts to reduce 
profit may result in shrinking Industry's R&D activity (Grabowski et al., 1978; Vernon, 
2005; Vogel, 2007d), which would have a negative influence on public welfare such as 
health and choice In the long term (Reekie, 1996). Some writers warn of over- 
regulation by listing all known consequences of reimbursement policies with little 
proper assessment (Levy and Cocks, 1999). 
From a broader perspective, the pharmaceutical industry is an important employer, 
investor, and a source of wealth. In the UK, for example, 73,000 people were directly 
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engaged in the pharmaceutical industry in 2004. Those were more than 0.2 million in 
Japan and the US In 2000 (Department of Health, 2006a). In this sense, although 
regulating industry could contain healthcare expenditure, there is some loss of benefits 
from reducing employment and potentially decreasing the development of profitable 
patent drugs in return (Schweitzer, 2007e). 
The issues surrounding pharmaceuticals may be approached from several different 
perspectives, including economic, social, political and philosophical views. This thesis 
approaches the subject mainly from a welfare economics perspective. Welfare 
economics aims to achieving more efficient use of available resources by "making 
judgments about the relative desirability of alternative ways of delivering health and 
health care" and seeking potential Pareto improvements in terms of their effects on the 
well-being of society (Morris eta/., 2007e). 
The first purpose of this chapter is to consider why government interventions are 
widely accepted in pharmaceutical markets despite considerable debate. This develops 
a better understanding of the theoretical mechanisms underpinning policy interventions 
in this arena. The present chapter, then, explores pharmaceutical policy, including the 
objectives of regulation and measures that are In place. 
1.2 Markets and health care 
1.2.1 Scarcity of resources 
Mooney (2003b; p1) writes that In the beginning, middle and end was, is and will be 
scarcity of resources", expressing the supreme economic challenge that every society 
confronts. Resources available for health care, Including pharmaceuticals, are certainly 
limited all over the world. Despite finite resources, demand in health care continues to 
grow and "the more health care we choose, the more of something else must be 
sacrificed" (Morris et al., 2007b; p3). In 2005, OECD countries spent around 6-15% of 
their national wealth on health (OECD, 2008). Pharmaceuticals, the central subject of 
this study, occupy a significant proportion of health expenditure, representing around 
8-30% of the total health budget in OECD countries (OECD, 2008). In particular, the 
recent growth rate of public pharmaceutical expenditure is evident and outpaces other 
public expenditure as shown in Figure 1-1. 
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Figure 1-1: Public expenditure on overall social protection, health, and 
pharmaceuticals in OECD countries (OECD average) 
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(Data source: OECD, 2008; see Annex 1 for the raw data) 
1.2.2 Markets in theory 
Deficit necessitates choice. Society faces choices between competing demands - 
whose needs come first, who makes prioritisation decisions, and how such decisions 
are made in the pharmaceutical market. A real difficulty in this regard is that answers 
to these questions are likely to be as many as there are individuals. Since interests are 
too diverse to make a single choice, society needs a set of criteria justifying decisions 
in order to attain legitimacy. These days, criteria appearing most commonly are 
efficiency and equity (Gray, 1993; Le Grand et al., 2008b; Stevens, 1993a). 
Efficiency can be defined as maximising benefits (for instance health) to society, from 
a given resource constraint (Stevens, 1993a). The pursuit of technical efficiency does 
not determine who gets what and how much of it. It only relates to the total amount of 
benefits produced from a given amount of inputs (Palmer and Torgerson, 1999). Hence, 
a system can be technically efficient without implying fairness, and without 
guaranteeing society maximum welfare from a broader perspective. Allocative 
efficiency takes account of the distribution of these outcomes, with discussion of 
opportunity costs and patients' utility (Mooney, 2003a). 
The distribution of resources is often skewed towards a small proportion of the 
population in the real world. Another criterion for choice, equity, puts distributional 
justice at the centre of discussion. Equity is a more debatable concept, as definitions 
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vary according to the definer (Mooney, 1994c). The term 'equity' tends to be used 
interchangeably with fairness or justice. Equity in health can be defined horizontally, 
equal treatment for equal need, or vertically, preferential treatment for disadvantaged 
groups (Culyer and Wagstaff, 1993; James et al., 2005; Mooney, 1994c). 
Pursuing equity often costs society some degree of efficiency and vice versa, which has 
been one of the greatest dilemmas that society has to address. There is no clear-cut 
solution to harmonising two criteria to achieve the best result. Thus, society should 
always make a choice in a trade-off between equity and efficiency (B(nsmead and 
Williams, 2004; James eta/,, 2005; Rice, 2002; Sassi eta/., 2001). To make choices, 
societies have devised various sets of mechanisms including religion, tradition, military 
power, markets, experts, consensus, voting, representative systems and so forth 
(Stevens, 1993b). Of these, a combination of market provision with government 
intervention is currently employed for pharmaceuticals in most leading societies. 
1.2.2.1 Markets and efficiency 
Markets consist of the interaction of demand and supply. In a free market place, the 
price mechanism ensures that the market reaches an equilibrium point between 
demand and supply. If there is a change in the quantity of demand or supply, price 
changes until a new equilibrium is reached. Equilibrium equates the marginal benefit to 
consumers with the marginal cost to producers. From the economic perspective, the 
most efficient level of output is that which maximises the sum of consumers' surplus 
and producers' surplus, i. e. maximises the net economic value (Johansson, 1991b; Le 
Grand et al., 2008b; Stevens, 1993a). 
This theoretical mechanism is achieved in a real market if the following conditions are 
satisfied (Barr, 2004c; Johansson, 1991a; Stevens, 1993c): 
" consumers are sovereign with perfect information; 
  markets are competitive; 
" all elements are certain; 
  goods or services are private goods. 
Economists call this a perfect market. In a perfect market, all actors, goods and factors 
are able to self-adjust to allocate resources in the most efficient way as follows. Prices 
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of goods or services are determined at the level that consumers are willing to pay for 
them. Informed consumers are able to make a choice to maximise utility. Rational 
consumers must not pay for any goods that use more resources and give less benefits; 
hence, inefficient goods will be eliminated from the market soon after being introduced. 
At the point of equilibrium, the marginal benefit of any activity is just equal to the 
marginal cost of resources necessary to produce the activity. No unpaid costs are 
imposed on others. Competition keeps producers efficient and drives high cost 
producers out of business. Under perfectly competitive conditions, no one producer can 
influence the market over another. Extra profits would induce other participants into 
the market and drive profits back to an acceptable level. As a result, perfect markets 
achieve an optimum distribution of goods, services and resources in the process of 
production as well as in use, which maximises benefits for society. 
1.2.2.2 Markets and equity 
In modern welfare states, an equally important debate is about equity. This concept is 
broadly integrated across the whole of the healthcare establishment, including the 
pharmaceutical arena. Inequalities in health among social groups exist everywhere, but 
some variations are avoidable. Avoidable inequalities are created by unfair 
opportunities to use health care resources, and this Is considered Inequitable. 
Mooney (1994c) defined the concept of equity with three concepts: equal health; equal 
use; and equal access. Equal health refers to the equal distribution of health, implying 
vertical equity that supports greater benefits given to the vulnerable. Equal use for 
equal need denotes treatment given according to Illness, Irrespective of personal 
characteristics such as ability to pay. This Indicates horizontal equity and justifies the 
subsidy of fees for the poor. Equal access denotes equal opportunity for the utilisation 
of health services, which can guarantee neither equal health, nor equal use in 
consequence. The definition of equity In health and health care Is however unsettled 
and includes several conflict concepts and arguments (Culyer and Wagstaff, 1993). In 
general, most healthcare systems currently aim for equal access, rather than equal 
health (Gulliford, 2003; Mooney, 1994c; Wagstaff, 1991). 
Since a market, a widely accepted trade-off tool, works primarily for efficiency, debates 
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over equity have been raised among different ideological schools. Libertarianism 
advocates Individual freedom, the ideology of laissez-faire, competition, so implying 
preference for the absence of coercion in the market (Barr, 2004b; Friedman, 1962). 
The concern of libertarians is that the pursuit of equity would reduce or destroy liberty. 
Hence, they assert that markets with less restraint are the most effective in resource 
allocation. Not surprisingly, efficiency weighs more heavily than equity in a libertarian 
society such as the US or the UK under the Thatcher government (Ham, 2004a; Walker, 
1986). 
In contrast, collectivism advocates social solidarity and mutual aid (Barr, 2004b; 
Mooney, 2009b). Collectivists are sceptical that equity could be achieved within a 'free' 
market (Nafstad eta!., 2009; Navarro, 1986a). They argue that pervasive giobalisation, 
consumerism and Individualism have Increased social Inequality during the regime of 
neo-liberalism In past decades, which Is associated with reducing overall standards of 
health (Coburn, 2000; Mooney, 2009c). Collectivism supports government action to 
correct unfair allocation In the market to achieve social equity or justice even though it 
costs some efficiency (Barr, 2004b; Mooney, 2009a). This Ideology Is dominant In 
European welfare states such as the Scandinavian countries (Blank and Burau, 2010b). 
Their contrasting views over government interventions are described by Barr : 
Libertarians argue that there is too much planning in the welfare state, Marxists 
that there is not enough ... (Barr, 2004b; p55). 
Barr (2004b) explains that these conflicts originate from the different concept of 
freedom; libertarians define it as "the absence of coercion"; but collectivists define It 
as "some guarantee of economic security" implying government redistribution of 
wealth to secure purchasing power. In this way, two views draw different conclusions 
with respect to the concept of equity. This is linked tightly to the degree to which 
government action is advocated to attain social equity at the cost of efficiency. The 
former asserts the attainment of minimum standards; the latter proclaims the 
fundamental concept of horizontal equity: equal treatment for equal need (Hauck et al., 
2004). 
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1.3 Market failure 
1.3.1 Markets in reality 
In the real world, there is no perfect market. The role of the market is increasingly met 
by considerable scepticism, particularly as a way of allocating health care resources. 
Writers argue that the market severely discriminates against the poor. 
The relative absence of coercion, the ability to make free and Independent decision, 
Is central to any distinction between markets and government. ... (however], 
markets also coerce people in very real ways. The rich and the poor aren't equally 
free to make economic decisions. (Stevens, 1993c; p55-56) 
This indicates that resources may be highly biased towards the rich rather than being 
allocated efficiently across society. 
In some sense, the market may already be flawed because, as Swedberg (2003; p57) 
remarked, "[markets] alone can lead to capitalism; [because] production in a capitalist 
economy is driven not only by the need for consumption but also by the desire for 
profit": This argument was also asserted by Navarro who sought the causes of 
explosive growth In healthcare demands in two aspects; the nature of capitalism and 
Infinite demand for'health". 
Growth and Ineffectiveness thus seem to be the two main characteristics of our 
Western system of medicine....... [These] result from the needs created by the 
process of capital accumulation on the one hand and the demands expressed by 
the working population on the other. (Navarro, 1986a; p25) 
It has been recognised for many years that any of the four assumptions of a perfect 
market (i. e. perfect information, perfect competition, certainty and private goods) 
seem to occur rarely in the health care market. In the market for pharmaceutical 
products, for example, consumers are usually subject to medical and industry suppliers' 
professional knowledge, and information asymmetry can affect patients' demands to 
favour medical professionals. Competition is limited due to barriers to entry and 
differentiated products, facilitated by the International legal system. Uncertainty is 
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particularly high in this market; demand for medicines is likely to occur unexpectedly; 
benefits to consumers are often implicit; prices in the pharmaceutical market are often 
affected by various factors not always measurable. In some conditions, 
pharmaceuticals qualify as public goods whose benefits the members of society share. 
These issues will be revisited in more detail. 
1.3.2 Evidence of failure in pharmaceutical market 
1.3.2.1 Has a market been efficient with pharmaceuticals? 
Increasing expenditure on pharmaceuticals may not be good news for the payer - the 
government in most welfare states. From a broader perspective, however, it should not 
necessarily be regarded as evidence of inefficiency. For example, with inflated 
expenditure ascribed to increasing coverage for essential consumption, with a resulting 
increase in the overall level of societal health, one may not consider such costs 
inefficient. 
Two situations, however, give clear indication that the pharmaceutical market is 
currently Inefficient. First, preventable demands appear to represent a substantial 
share of cost inflation. Second, an increase in resource input is not necessarily 
associated with a corresponding increase in health output. 
To address the first argument, it may be necessary to look at what constitutes drug 
expenditure growth. Common causes often shown in the literature include: 
" aging populations, in other words, transferring social morbidity towards chronic 
and degenerative illnesses; 
" new demands Induced by technological and social changes (e. g. breakthrough 
treatments for many cancers previously untreatable, and lifestyle drugs); 
" expensive new drugs; 
" increases in people's expectations. 
(Almarsdottir and Traulsen, 2005a; Blank and Burau, 2010a; Mays, 1993; Mosslalos 
and Oliver, 2005; Salter, 2004d) 
Of these, the greatest controversy generally concerns new demands and expensive 
new drugs. Life-style drugs are likely to bring about an intensive debate over "quasi- 
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drug products" and sustainability (Walley, 2004). Some writers Introduce new 
vocabulary, "medicalisation" or "pharmaceuticaiisation", to express concerns about 
over-medication by encouraging consumers to use pharmaceuticals even In 
unnecessary conditions (Abraham, 2009; Blech, 2006a; Illich, 1975; Illich, 2003; 
Moynihan and Cassels, 2005). 
Breakthrough medicines have been few (Angell, 2004; Grabowski and Wang, 2006; 
Guell and Fischbaum, 1995). Newly developed drugs are often blamed for being not 
truly Innovative, merely expensive with a minor Incremental clinical value; hence, they 
are pushing pharmaceutical bills up sharply, but Improving health only marginally 
(Morgan eta/., 2005; Young and Surrusco, 2001). In the analysis of drug expenditure, 
studies conventionally separate the two components: price and volume (Enos and 
Sultan, 1977c; Huber, 2006; Strunk and Ginsburg, 2004). Some researchers have 
argued that these two existing components may not be enough to capture the change 
in overall price per unit dose (e. g. defined daily dose), that it is not due to drug price 
inflation. They have named this "product shift" (Mullins et al., 2001) or "a residual" 
(Gerdtham et al, 1998a, 1998b). This third element comprises treatment shift from 
less-expensive therapies toward new and more-expensive ones. Critics believe that the 
industry primarily leads the trend by spending sizable sums of money on marketing 
activities, which society would prefer to see spent on R&D activity (Braithwaite, 1984a; 
Pecoul et al., 1999; Trouiller et al., 2002). 
Moving on to the second argument, it is well-known that the US currently has the 
greatest expenditure on pharmaceuticals and is the only one among industrialised 
countries where there is no systematic national health system (Navarro, 1992). Does 
higher spending result in an improved overall level of health? This would seem unlikely, 
given the example of the US. International health indicators, such as life expectancy, 
show that high spending does not achieve greater health gains (Schmitt and Zipperer, 
2007). Relevant data are presented in Chapter 2 (see Table 2-5 to 2-7 In Chapter 2). 
1.3.2,2 Has a market created fairness in access to or use of 
pharmaceuticals? 
It is well known that the pharmaceutical industry is one of the top businesses 
worldwide (see Table 2.5 at p38 In Vogel, 2007c). While the industry enjoys 
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unprecedented success, pursuing profitability is likely to bring an imbalance of resource 
allocation Invested in R&D relative to marketing, and it generates a `neglected diseases' 
market (Angell, 2000; Pauly, 2005; Smith etal., 2001). Trouiller etal. (2002) who 
examined new chemical entities (NCEs) between 1975 and 1999 reported that there 
were at least three times the number of NCEs for the main diseases In high-income 
countries than those of the poor. These are ascribed to the characteristic of profit- 
seeking firms that are likely to respond to market demand rather than health needs 
when they determine research priorities (Mays, 1993; Pecoul etal., 1999). Without 
doubt, developing products that will be sold In a lucrative market Is a rational business 
strategy to the drug industry. However, It Is not necessarily justified from a societal 
point of view. 
1.3.3 Causes of failure in the pharmaceutical market 
Evidence briefly described here illustrates that so far the market has not created 
efficiency or equity In use of pharmaceuticals. This section explores the theoretical 
aspects of underlying causes of unsatisfactory outcomes in the pharmaceutical market, 
mainly from a welfare economics perspective. 
1.3.3.1 Monopolistic industry 
At a glance, the pharmaceutical market does not appear to be highly monopolised. 
There are many manufacturers and medical providers in the marketplace and they 
appear to be aggressive competitors, none of them seeming to overwhelm another by 
occupying an excess share of the market. Nonetheless, many writers have raised 
concerns regarding competition in the pharmaceutical market (Bodenheimer, 1985; 
Braithwaite, 1984a; Melrose, 1982c). Why is this so? 
The monopoly or oligopoly status of this industry is hardly avoidable owing to three 
aspects. First, new entry is suppressed in the pharmaceutical market due to rigorous 
demands for safety in handling and high costs of R&D processes to meet legislative 
requirements to demonstrate safety, efficacy and manufacturing quality standards, 
which raise circulation and production costs (Grabowski eta/., 1978) and reduce the 
number of firms competing on the basis of price (Morris etal., 2007d). 
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Second, among hundreds of thousands of pharmaceuticals, comparability is limited to 
relatively small therapeutic categories (Reekle, 1996; Schweitzer, 2007d). Substituting 
one drug with another is clearly restricted according to the purpose of use; hence, 
competition among medicines exists quite differently from that of sale of fruit in a 
marketplace. As all kinds of fruits are substitutable, one can buy oranges, berries, or 
whatever affordable according to one's preference. However, one cannot consume 
digestives or antibiotics instead of anti hypertensives for controlling high blood pressure. 
In other words, a drug manufacturer who produces antihypertensive products would 
not compete with those who produced digestives or antibiotics. Therefore, the 
concentration of manufacturers in the pharmaceutical Industry needs to be regarded 
not as an overall market, but by each sub-market comprising products within a 
therapeutic category. In light of this, the structure of the pharmaceutical industry 
appears to be a near-monopoly market (Braithwaite, 1984a). 
Third, and most fundamentally, there is a legal system, supporting about 20 years of 
exclusive rights for new medicine patentees (Schweitzer, 2007c). Of course the 
rationale for patents is to provide an incentive for investment in innovation because 
pharmaceutical R&D, as is well-known, is one of the most time-consuming and 
resource-demanding fields (Reekie and Weber, 1979; Weissman, 1996). This has, 
however, been greatly contentious since its establishment (Barton and Emanuel, 2005). 
There are severe ethical arguments that patent monopoly reduces patients' access, 
particularly to essential medicines in poor countries (Medecins Sans Frontleres, 2006b). 
There has also been wide disagreement as to how much incentive Is justifiable 
(Braithwaite, 1984a; DiMasi and Grabowski, 2007b; Smith at al., 2001; Young and 
Surrusco, 2001). Many writers argue that existing Incentives may be too high for 
several reasons, First, R&D spending may be exaggerated (Smith eta/., 2001). Second, 
profits from a patent right may not lead to Increased R&D spending (Canadian Generic 
Pharmaceutical Association, 2008). Third, the industry benefits considerably from 
publicly funded basic research, which is often ignored In the calculation (Angell, 2000; 
Young and Surrusco, 2001). Fourth, the Industry enjoys a patent right beyond the 
designated period (Hudson, 2000; Kesselheim, 2007), or extra Incentives from the 
popularity of a 'brand name' built during such a long period of exclusivity (Schweitzer, 
2007c), 
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Opponents claim there should be more incentives for the industry (such as 
strengthening a patent right) In order to foster further innovation (DiMasi and 
Grabowski, 2007a; Grabowski and Moe, 2008), but this seems less persuasive given 
the continuous success and greater, occasionally unethical, spending on the marketing 
activities of `big pharma' over several decades (Healy, 2006; Lovell, 2006). 
The oligopolistic structure of the Industry In the real world has brought major success 
to pharmaceutical manufacturers in the recent past, and several unwanted 
consequences to society. As already mentioned, profit-seeking firms are more likely to 
respond to demand from lucrative markets rather than from health needs when 
deciding research priorities. This generates an orphan drug market in which the least 
privileged are the most victimised (Smith eta/., 2001). Even within a lucrative market, 
resources have been spent on 'me-too' products rather than on truly breakthrough 
medicines (Angell, 2004). Subsequently, producers of me-too products tend to 
compete with each other not by Innovation, but by commercial promotion (Chetley, 
1990b; Melrose, 1982b, 1982c). While pharmaceutical companies spent 5-7 per cent 
of sales on research and development In the first half of the 1980s, they paid out 
about three times more on promotion In the same period (Chetley, 1990a). This gap 
was not narrowed in the late 1990s (National Economic Research Associates, 1998) or 
this decade (Schweitzer, 2007b; Vogel, 2007a). Unfortunately, there Is substantial 
evidence of scandals between manufacturers and medical professionals (Blech, 2006b; 
Blumenthal, 2004; Braithwaite, 1984b; Moynihan, 2003; Schweitzer, 2007b; Weiss, 
1997). 
1.3.3.2 Overwhelming agency 
Sovereign (Oxford English Dictionary, 2009) 
1. a king or queen who is the supreme ruler of a country 
2. possessing supreme or ultimate power 
3. (of a nation or Its affairs) acting or done Independently and without 
outside Interference 
In the market, what brings sovereign power to consumers may be knowledge and 
money (Le Grand etal., 2008a). Consumers can enjoy sovereign status in the market 
as they are capable of making decisions by themselves over what they need based on 
'reasonable' knowledge and how they can afford their decisions (Morris etal., 2007c). 
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Pharmaceuticals, however, are different. The body of knowledge concerning medication 
is abstruse as well as enormous; hence, consumers may find it difficult to exploit it in 
an effective and proper manner. This being so, decisions over drug use are normally 
made by qualified personnel on behalf of a patient in practice (the agency relationship). 
Information asymmetry between providers and consumers is the norm in the 
pharmaceutical market (Morris et al., 2007a). The role of consumers has been very 
limited In the decision-making process. Specialised knowledge creates a prestige 
position for medical providers, which is amplified by licensing and specialising (Enos 
and Sultan, 1977d; Turner and Samson, 1995). 
Society wishes every doctor to make a decision based upon his or her patients' best 
interest, also upon society's, not upon one's own. Mooney (1994a; p94) viewed a 
perfect agency to be constituted by two aspects: 
... first, agency which is perfect from the standpoint of the 
doctor's patients; and 
second, agency which is perfect from the standpoint of society as a whole. 
Leaving aside 'perfect' agency, making a choice as an 'impartial' agent is rarely realised. 
One's own interests are likely to be reflected. Ample evidence suggests that fee-for- 
service (FFS) payment, In which providers are reimbursed for each item of care 
supplied, often motivates providers to offer more services, prescriptions and tests than 
would rationally be used, some of which appear unnecessary (Basky, 1999; Etter and 
Perneger, 1998; Gosden et al, 2000; Greenfield eta/., 1992; Maynard and Bloor, 
2003b; Steiner and Robinson, 1998; Yip and Eggleston, 2004). Namely, these Incentive 
structures may create a false demand, a so-called "supplier-induced demand" (Mooney, 
1994b; William, 1999). 
1.3.3.3 Externalities and uncertainty 
From outward appearances, pharmaceuticals seem close to being purely private goods 
like shoes, clothes and fruit. They can be consumed only by one specific person at one 
time, sold one unit at a time, and withheld from the market by producers at any time 
(Johansson, 1991a; Stevens, 1993c). Pharmaceuticals, however, also present features 
similar to public goods such as roads, clean air and fine views. This becomes 
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particularly obvious in cases of medication for communicable diseases. Suppose, for 
example, that one patient takes medicine to treat tuberculosis. Medicines carry, firstly, 
private benefits to the patient by counteracting symptoms and treating one's disease. 
Simultaneously, they convey secondary 'extra benefits' (positive externalities) to others 
who are potentially exposed to the risk of contagion. These external benefits from 
preventing communicable diseases from spreading are shared by many people who are 
at risk of infection and are unable to be withheld from a potential beneficiary, which 
are features of public goods. 
In the presence of externalities coming from the features of public goods, the total 
social benefits or costs can be viewed as follows: 
private benefits + external benefits = social benefits 
private costs + external costs = social costs (Le Grand eta/., 2008a; p36) 
The greater the size of the externality, the greater the divergence between social and 
private costs or benefits. Suppose that there is one case in which private costs 
outweigh private benefits, but benefits to the whole society outweigh costs. In this 
case, being treated would be efficient for the society as a whole. Nevertheless, a 
'rational' consumer is likely to abandon a chance to be treated under the market 
system because an individual is usually concerned solely about private costs and 
benefits. Thus, public subsidy has been justified for some pharmaceuticals to maximise 
benefits to the society. In this sense, externalities create a situation where some 
benefits or costs to society are not reflected in market prices (Johansson, 1991a), 
indicating that externalities may Increase the uncertainty in drug pricing. 
Besides externalities, there are many factors increasing the ambiguity of pricing for 
pharmaceuticals. New pharmaceuticals require an Inordinate amount of research and 
development, in other words, money and time (Vogel, 2007b). In addition, 
pharmaceuticals are subject to high standards of safety requirements throughout the 
whole process, Including research, development, manufacturing and distribution. They 
require expertise in handling, prescribing and dispensing. All these properties not only 
incur additional costs, but also, and more importantly, augment uncertainty in pricing. 
Uncertain features are also derived from unpredictable demand, a gap between 
expected and observed behaviour of the physician, uncertain product quality, and 
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uncertain effects of treatment (Arrow, 1963). 
1.3.3.4 Moral Hazard 
Moral hazard exists when an individual or institution does not take full responsibility for 
the consequences of its actions, creating a tendency to act less carefully than it would 
otherwise. In the pharmaceutical market, various pharmaceutical benefit schemes ease 
the financial burden of individuals at the time of drug use and could cause actors to 
commit moral hazard. 
People search for pharmaceuticals when they have an uncomfortable condition. 
Illnesses are likely to occur unexpectedly and result in unpredictable expenses for 
people. Unexpected expenses for pharmaceuticals are sometimes negligible, but 
sometimes large insofar as they inhibit people from seeking treatment. This creates a 
mechanism for pooling risk - Insurance - to relieve money worries in times of illness 
(Barr, 2004a). Public funds are raised differentially across nations (Blank and Burau, 
2010c). For example, in the UK National Health System (NHS), funding comprises 
mostly general taxation, whereas in countries like Germany and South Korea patients 
contributions are prepaid in a national health insurance system. In the US, a variety of 
bodies exist ranging from federal and state subsidised programmes (Medicare and 
Medicaid) to commercial health Insurance organisations. Regardless of country, services 
provided by professionals are generally remunerated by funds from a third-party 
payment financing structure. 
Insurance or third-party payment is tightly linked to moral hazard, a clear source of 
market failure (Arrow, 1963; Barr, 2004a; Enos and Sultan, 1977c). A third-party 
payment financing structure can mislead patients. A body of evidence supports the 
hypothesis that patients' demand for medicines may become relatively price-inelastic 
because they are free of charge at the time of use (Gianfrancesco et al., 1994; 
Newhouse, 1993; Rudholm, 2005). Insensitivity to prices may encourage patients and 
providers to make unnecessary use of drugs. This Is well described In the following 
remarks by Guillen and Cabiedes (2003; p23): 
In particular, In the prescription-drug market financed through public funds, "who 
consumes neither chooses nor pays, who pays neither consumes nor chooses, and 
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who chooses, neither pays nor consumes. " In such a context, it is obvious that 
doctors' decisions are not sensitive to prices, unless their public employers use 
specific measures to counteract such Insensitivity. 
1.4 Public regulations in the pharmaceutical market 
So far, it has been argued that without regulation the pharmaceutical market may 
allocate resources neither efficiently nor equitably. Existing evidence clarifies the 
speculation that the pharmaceutical market is rarely governed by solely economic 
principles. In parallel, potential causes were discussed to explore why the 
pharmaceutical market does not satisfy the conditions for a perfect market. Regulatory 
policies have been developed to correct flaws seen in markets and, by doing so, to 
increase efficiency and equity in the pharmaceutical arena. There are considerable 
cross-national variations in pharmaceutical policies. In the US, pharmaceutical policies 
are more concerned with safety and clinical efficacy (Wiktorowicz, 2003) with broader 
regulation of the industry left largely to the market and regulation of professionals or 
patients performed in a fragmented fashion at state level or private Institution level 
(Kozma eta/., 1993; Reeder eta/., 1993). In contrast, the regulation of all stakeholders 
has been exercised in European countries where they are governed by the Ideology of 
the welfare state (Guillen and Cabledes, 2003; Mossialos etal., 2004). 
1.4.1 Policy objectives 
Maynard (2005; p280) remarks that regulations in the healthcare arena attempt "to 
influence the price, volume and quality of the goods and services that are produced 
and traded and ensure that the performance of markets is more consistent with social 
goals': Currently, the core objectives of pharmaceutical policies are cost containment, 
e>ficlency, equity and safety or quality. 
1.4.1.1 Cost containment 
Cost-containment itself is not an ultimate goal of society, so thus far I have focused on 
efficiency and equity. However, the issue of costs has been an important force in real 
world pharmaceutical policy-making. "It is evident that without successful initiatives to 
constrain costs, healthcare systems face severe funding crises, and perhaps breakdown, 
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in the not toö distant future" (Blank and Burau, 2010d; p118). Statistics tell us that 
most developed countries and many developing countries have experienced a 
considerable increase in pharmaceutical expenditure during recent decades. According 
to OECD Health Data, between 1990 and 2005, total spending on pharmaceuticals as a 
percentage of GDP increased by more than 70 per cent in Canada, Czech Republic, 
Finland and the US and around 50 per cent in Portugal, Spain, Sweden and Switzerland. 
In the UK, the growth rate was about 40 per cent in the 7-year period between 1990 
and 1997 (OECD, 2007b). In response to budget deficits, governments have not only 
sought methods of curbing demand, but also have sought a way to utilise resources 
more efficiently. 
1.4.1.2 Efficiency 
To Increase efficiency in the utilisation of health resources, policy interventions aim to 
produce maximum health at minimum cost. Over recent decades two concepts have 
created Intense debates: rationing (or priority setting) and the use of cost-effectiveness 
information In pharmaceutical reimbursement decisions (Bowling, 1996; Holm, 1998; 
Klein, 1993; Kleinert, 1998; Maynard, 1993; Maynard and Bloor, 2003a). Rationing 
denotes "withholding potentially beneficial treatment" because of limited resources, 
making it necessary for policy-makers to determine whose needs get priority (New, 
1996). 
Cost-effectiveness Information is increasingly used in making rationing decision 
(Donaldson and Mooney, 1991; Klein, 1993; Mason and Drummond, 1993). Over a 
relatively short span, the term `cost-effectiveness' became Initially a contentious 
subject in this arena, but has since become more widely accepted. Since the Australian 
government formally applied this criterion to its reimbursement decisions in 1993, It 
has quickly spread across governments who sought to improve both technical and 
allocative efficiency (Dickson etal., 2003; Yang, 2009). The use of economic evaluation 
to determine the relative cost-effectiveness of treatment options also strengthens a 
trend toward evidence-based medicine and evidence-based policy-making (Banta, 
2003; Mooney, 2003c). Some writers described the new policy objective of using cost- 
effectiveness Information in reimbursement decisions as a `fourth hurdle' alongside 
existing objectives, i. e. safety, efficiency and equity (Maynard and Bloor, 2003a; Taylor 
et al., 2004). It Is argued to be unethical if decisions relating to healthcare expenditure 
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are made without consideration of cost-effectiveness. 
... to be ethical we must examine our healthcare expenditures in light of how they 
affect other societal needs. To fail to do so is unethical in any society with finite 
resources. (Harrison, 1992; p148) 
1.4.1.3 Equity of Access 
Policy interventions must also pay attention to the concept of social equity. Many 
modern healthcare systems were principally brought about by the increased awareness 
of human rights (Webster, 1988). This was well described in the core principles of the 
UK NHS (NHS, 2009), which elucidate that the NHS is "free at the point of delivery" 
and delivered "based on clinical need, not ability to pay"". 
As briefly stated in an earlier section, most healthcare systems aim for equal access to 
health care for equal need (see 1.2,2.2). Often, pursuit of cost containment and 
efficiency goals leads policy-makers away from equity, which could undermine the 
health and welfare of some parts of the population. Linked to this, Mooney (1994c) 
argued for the Importance of regular monitoring of the effect of any public 
Interventions on access to health services. Access to pharmaceuticals may be affected 
by the content of lists of reimbursed drugs, or the level of cost-sharing of drugs. 
1.4.1.4 Safety and Quality 
In the early years of regulation, the key objective of regulating pharmaceuticals was 
clinical safety and effectiveness, and these are still clearly of great importance. The 
current safety and effectiveness regulation systems (e. g. US FDA) cover pre-market 
testing to post-market advertising and manufacturing. 
Pharmaceuticals accompany professional services such as prescribing and dispensing. 
The recent UK NHS report expanded a conventional safety concept to a whole concept 
denoting 'quality care' (NHS, 2008). The basis of quality is certainly patient safety: 
The first dimension of quality must be that we do no harm to patients. This means 
ensuring the environment Is safe and clean, reducing avoidable harm such as 
excessive drug errors or rates of healthcare associated infections. 
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Added to safety, it proposed that quality should include "quality of caring" the patients 
experienced and "effectiveness of care" concerning people's well-being as well as 
clinical effectiveness. The proposed elements are linked closely with ensuring access to 
the most effective therapy and measuring outcomes reflecting patient satisfaction in 
relation to pharmaceuticals. 
1.4.2 Policy interventions 
As markets are networks of buyers (demand) and sellers (supply), previous studies 
tended to discuss regulations from demand-side and supply-side (Busse eta/., 2005; 
Mossialos and Le Grand, 1999; Mossialos and Oliver, 2005; Mrazek, 2002). The 
pharmaceutical market, however, seems more complex and cannot be described purely 
In terms of demand and supply. Professionals are linked with consumers as their 
agents, and under this relationship most decisions over drugs are made by 
professionals on behalf of a consumer. In this sense, healthcare providers have 
features not only as a service supplier, but also a consumer In the market (Monday, 
2002). Hence, some differences in approach are to be expected, for example, 
mechanisms and effects of policy Interventions differ between those Influencing patient 
demand and those affecting provider demand. In addition, the quality of services that 
providers supply for their patients should be considered separately. Therefore, it is 
appropriate for the pharmaceutical market to be explored with one more vital player, 
I. e. `a service provider' comprising a variety of professionals, and bridging the 
consumer and a product supplier. With a similar rationale, some preceding research 
explored pharmaceutical policy Interventions by targeted stakeholders (Bloor and 
Freemantle, 1996; Bloor et al., 1996; Freemantle and Bloor, 1996), which will also be 
followed In this thesis. 
Irrespective of whether policies target demand or supply, each intervention can be 
viewed as a response to the problems of the current market. In this regard, 
pharmaceutical policies largely affect market players in three ways. Firstly, regulations 
try to reduce extravagant utilisation, which mostly falls on patients. Secondly, 
regulations try to amend prescribing (or dispensing) behaviours toward efficient use, 
which falls on providers. Thirdly, regulations try to correct the monopoly status and 
excessive entrepreneurial activity of manufacturers with the least cost of R&D activity, 
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which falls on industry. Whichever categorisation is employed, however, there is 
inevitably a blurred aspect because a single policy, in reality, may act upon the 
demand-side and supply-side simultaneously, as seen in the example of a reference- 
pricing programme below. 
1.4,2.1 Policies influencing patients 
As already discussed in the preceding section, the subjects of externalities and equity 
have justified public subsidy for pharmaceuticals. Accordingly, patient demand for 
medicines may become relatively price-inelastic (Gianfrancesco et al., 1994; Newhouse, 
1993; Rudholm, 2005). Hence, the most common measure to curb patients' excessive 
demands is to increase cost-sharing. The rationale of cost-sharing is that prices help to 
convey information and enable individuals to economise in their resource consumption 
(Hayek, 1945). If patients are subject to some charges at the time of consumption, 
they are more likely to value the money spent in purchasing some medicines against 
other alternatives. Cost-sharing has been developed into many different features 
(]acobzone, 2000). 
Other ways of limiting demand include medication caps, where demands can be limited 
directly and allowed only to a pre-determined degree, for instance, five items per 
prescription. Another method of limiting patients' access to medicines is an amending 
their categorisation. Most nations group pharmaceuticals into two or three sub-sets 
such as prescription-only medications (POM), over-the-counter (OTC) drugs and/or 
general sales list (GSL). The original underpinning reason for this was safety. POMs are 
restricted from use without professional authorisation and are more likely to be 
subsidised publicly, while medications designated OTCs are considered safe, and are 
usually used in temporary, symptomatic illnesses under patients' own responsibility and 
at their own cost. Drugs on GSL are between the two categories and are usually sold 
under the supervision of pharmacists. Recently, categorising drugs as OTCs, a so-called 
OTC switch, is often exploited as a way of saving money for reimbursement agencies, 
through excluding some pharmaceuticals from public coverage, but it is also a way of 
companies retaining brand loyalty of consumers following the end of a patent 
protection period. 
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1.4.2.2 Policies influencing providers 
Because of information asymmetry, medical providers may occupy a dominant position 
over their patients in terms of pharmaceutical decision making (1.3.3.2). Thus, the 
authorities in this area are likely to pay more attention to defending the patient's 
vulnerable stance to avoid moral hazard potentially nurtured by professionals. 
A relatively soft approach to influencing providers may be to provide guidance on 
practice and to encourage providers to be involved in a programme on a voluntary 
basis. Examples include many kinds of educational interventions, such as guidelines, 
protocols, or prescribing feedback, and some voluntary based incentive programmes 
such as UK fund-holding. 
A harder option could be to place some legal limitations on prescribing (or dispensing). 
This includes a lot of reimbursement restricting regulations. Some countries impose 
responsibility on providers, for example, if they fail to satisfy their duties, providers 
incur some penalties. Examples may include the German prescribing budget with 
mandatory financial disadvantages, although negative penalties have seldom been 
exercised (Chapman etal., 2004; Walley and Mosslalos, 2004). 
Capitation and Diagnosis-Related Groups, although not solely related to drugs but 
more to overall healthcare services, were developed as one of various ways of 
remuneration, moving away from a conventional FFS system in order to avoid supplier- 
Induced demand (Schweitzer, 2007a). Global budgets have been argued to be a more 
effective policy option "because (price or volume controls alone] cannot be avoided by 
raising volume when prices are fixed or raising prices when volume is fixed" (Blank and 
Burau, 2010d; p109). 
During recent years, electronic decision support systems allow one to convey a variety 
of real-time information - ranging from drug-specific to patient-specific - to physicians' 
desks. Examples include drug utilisation review programmes at various levels from a 
single Institute to the whole nation, and computerised decision supporting devices with 
a variety of purposes. 
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1.4.2.3 Policies regulating industry 
Pharmaceutical policies regulating industry are often related to controlling oligopolistic 
market conditions to restore market competition. Over a long time period, 
governments have set price limits, profit limits, and mark-up limits to restrain 
producers from exploiting their monopolistic position in pricing. Some governments 
negotiate pharmaceutical prices with Industry through mutual agreements such as a 
price-volume agreement (Mrazek and Mossialos, 2004). 
Price control alone has been considered not as successful as expected in containing 
costs (Jacobzone, 2000). Guillen and Cabiedes (2003; p9) argued: 
That the Introduction of stricter price-control mechanisms Is usually accompanied 
by greater levels of pharmaceutical spending leads some authors to conclude that 
the Industry Is able to create 'escape valves' by increasing the volume of sales of 
already commercialised products and/or obtaining more favourable prices via 
product differentiation through new trademarks. 
In line with this perception, a reference-pricing system has been developed for 
avoiding the artificial substitution of more expensive products. Reference-pricing 
schemes originated from Germany in 1989 (Ioannides-Demos etal., 2002). These have 
been increasingly exercised with multifaceted aims, firstly functioning to influence 
patients, throughcopayments, but largely expected to be less likely to obstruct patient 
access because patients would opt for fully-reimbursed drugs rather than just giving up 
access. It also influences providers, through creating a reimbursement restricting 
formulary and lastly, it motivates manufacturers to lower prices to the reference line or 
below. 
In the UK, the regulatory authority sets a limit on marketing resources to suppress 
excessive inefficient competition in marketing (Department of Health, 1996,2006b). In 
recent years, reimbursement decisions increasingly require cost-effective evidence, 
through which the government wishes to curb expensive but marginally innovative new 
drugs by refusing public subsidy (Dickson et al., 2003). 
Global efforts to encourage R&D investment have been made through the enforcement 
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of Intellectual Property Rights by the World Trade Organisation since 1986 (Schweitzer, 
2007c). Coupled with Intellectual property, a growing trans-national Industry blurs the 
distinction of national borders, which sets clear limits on a range of actions taken by a 
national government. On this issue, International collaboration of counter-industry 
actors has recently been called for in this area (Buse et al., 2002). Linked to this, new 
measures such as compulsory licensing have been issued to ameliorate drug 
accessibility In developing countries after the establishment of powerful Intellectual 
property rights on patent drugs (Ackiron, 1991; Braithwaite, 1984a; Oriola, 2008). 
1.5 Summary 
This chapter outlined the working of the pharmaceutical market in terms of theory and 
practice, largely from a welfare economics perspective. It has been argued that 
symptoms indicating inefficient and unfair allocation of resources have been observed 
in the pharmaceutical market, and these have become a spur to government action. 
The salient characteristics of the pharmaceutical market that make a market system 
hardly able to achieve efficient resource allocation have been discussed. Next, four key 
objectives of pharmaceutical policy - cost containment, efficiency, equity and safety or 
quality - were addressed. This chapter ends with tackling current policies and their 
expected mechanisms. These are grouped by three market actors - patients, providers 
and industry - and this structure will be repeated throughout this study. The next 
chapter explores realistic issues in pharmaceutical policy studies, which are contextual 
factors and methodological considerations. 
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CHAPTER 2: PHARMACEUTICAL POLICY AND LOCAL CONTEXT 
2.1 Introduction 
In order to achieve a proper understanding of the lessons from policy evaluation, it is 
necessary to recognise a set of general policy mechanisms and the context in which a 
programme Is activated (Pawson and Tilley, 1997). With this In mind, the preceding 
chapter discussed a basic mechanism of drug policy. This chapter will discuss the 
second issue, which is `context: 
The objectives of this chapter are, firstly, to discuss the importance of contextual 
considerations in policy studies, and secondly, to describe Korean pharmaceutical 
policies and explore contexts surrounding the pharmaceutical policy-making process. 
Arguments over context develop a further subject of policy evaluation. Thus, the third 
aim of the chapter is to address evidence-based policy-making from theoretical aspects 
to practical issues. Lastly, methods employed overall in the thesis are outlined. 
2.2 Policy and context 
As is well-known, the overall shape of policy, especially in the healthcare arena 
including pharmaceuticals, is formed by the interplay of political, social, economic and 
historical determinants (Blank and Burau, 2010b; Enos and Sultan, 1977a, 1977b; 
Navarro, 1992). For instance, it Is certainly difficult to think of the British NHS without 
thinking of the political context of Britain during the 20th century (Ham, 2004a, 2004b). 
Thus, Salter (2004c; pxiil) remarked that "the British NHS is part of the basic fabric of 
British political life" 
Even a single intervention often shows great diversity across settings. For example, co- 
payment of prescription drugs is a policy used to curb patient demand across many 
countries (Chapter 1). Within the simple idea of curbing consumption by charging, 
each nation has developed various co-payment structures with different types of 
exemptions, copayment limits, amount of payment and so forth (]acobzone, 2000). 
This may be due to the "adaptation" of co-payment programmes to local circumstances 
(Klein, 1997). 
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Context-bound factors affect not only policy Interventions but also, more importantly, 
influence policy outcomes. Recently, Dolowitz et at.. (2000) analysed four British 
policies: the Child Support Agency; an internal market In the NHS; post-compulsory 
education; and the electronic monitoring of offenders. These policies were imported 
from the US, by a framework of policy transfer. They suggested several factors that 
made these programmes unsuccessful In Britain. Factors they specified, of course, 
included some procedural difficulties, such as insufficient information or problems with 
importing. However, it seems that contextual issues occupy a more central part among 
such factors. Contextual factors include: 
" insufficient attention paid to the differences between the social, political and 
Ideological contexts 
  differences In organisational/institutional circumstances 
  lack of demand for the Introduced policy in the applied setting 
" absence of active support from the local elite pressure groups 
" hostility of the progressive local press 
" opposition from the public and the medical profession 
" differences in social attitudes and medical practice (ideology and culture) 
Pawson and Tilley (1997; p70) argued: 
Programs are always introduced into pre-existing social contexts and, as we shall 
see, these prevailing social conditions are of crucial importance when it comes to 
explaining the successes and failures of social programs. ... It is futile for 
researchers to ignore and anonymize the contexts of their programs as in 
experimental evaluation.... 
Taken together, two things are becoming clear. First, it is necessary to understand 
contextual conditions before discussing policy outcomes. Contexts might be regarded 
as one of two forms - those in which a programme has already worked or failed and 
those to which a programme has been newly applied. The former can be achieved by 
studying overseas experience, deriving lessons that can help policy-makers seek 
effective measures for their existing social arrangements, construct appropriate 
conditions for a new intervention, or avoid repeating mistakes made in other countries. 
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As to the latter, the upcoming subsection will discuss core Issues about Korean contexts. 
Second, policy evaluation studies need to be constructed in each national context in 
order to determine the real impact of programmes after being influenced and amended 
by such factors. As seen from the British examples above, even though a programme 
works in one place, there is no guarantee that it will in another. Situations can be 
improved by a close inspection of the contextual conditions both abroad and at home. 
Nevertheless, it may be Impossible to remove all uncertainty constituting the policy 
environment and outcomes. Faced with such uncertainty, assessing the policy may be 
the best strategy to know its the true impact. This stresses the significance of policy 
evaluation. Moreover, expertise from rigorous evaluation can contribute to a better 
understanding of policy options leading to future improvements. In line with this, more 
issues concerning evidence-based policy-making and methods studying policy are 
discussed in section 2.6. 
2.3 Overview of the Korean health care system 
In 2007, the Korean National Health Insurance (NHI) celebrated its 30th anniversary. 
After its inception in 1977 as a patchy social health insurance benefiting employees 
only in sizable workplaces', the Korean NHI has expanded rapidly in a government- 
oriented manner (Hwang, 2006b). From 1989, only 12 years later, it provided universal 
coverage for Korean residents, and its benefits reached 98 per cent of the population 
by 2006 (NHIC and HIRA, 2007). The Medical Aid Programme (MAP) has 
complemented the NHI In order to provide a more comprehensive coverage to low 
income households. 
The Korean NHI has been financed by beneficiaries' contributions with a substantial 
out-of-pocket payment at the point of use. It Is In part funded from public money, but 
only to a very limited extent - around 17 per cent of all revenue in 2006, while 
beneficiaries' contributions were 80 per cent in the corresponding year (NHIC and 
HIRA, 2007). Beneficiaries' contributions are determined based on their income 
(employee) or income & property (self-employed). Employers and employees share 
The first wave of compulsory medical Insurance programme was initiated to involve limited 
companies whose employees were more than five hundred. 
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equally the employees' contribution, while beneficiaries in the self-employed group pay 
individually. Figure 2-1 illustrates the flows of services and finance in the Korean health 
care system. 
Figure 2-1: Flows of services and money in the Korean health care system 
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(Source: National Health Insurance Corporation, 2008) 
Conventionally, the Korean health care delivery system consists of three level of care; 
primary (clinics), secondary (hospitals) and tertiary (teaching hospitals) care. However, 
with the exception of co-payment differences restrictions did not exist until January 
2002. Patients generally enjoyed substantial freedom of choice among health care 
providers as long as they were willing to pay a premium fee. In January 2002, a 
compulsory two-tier system was instituted by law. The new Medical Act required 
patients to see physicians in primary care first, and then if necessary be referred to 
hospitals ( The Medical Act, provision 3). Primary care physicians have rarely 
undertaken the expected role as a gatekeeper to specialist services until recently (Lee, 
2005a; Lee, 2005b; Yang, 1997). 
Currently most Korean healthcare providers are engaged in private practice and paid 
on a fee-for-service basis. There are no public community pharmacies and few public 
hospitals. According to a recent report released by the Ministry of Health & Welfare 
(MOHW), only 8.5 per cent of hospitals and 20.6 per cent of acute beds were managed 
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on a public basis in 2005 (Ministry of Health & Welfare, 2006b). 
2.4 Outline of Korean pharmaceutical policies 
Until the 1990s, copayments and direct price control were two major pharmaceutical 
policies existing In addition to safety regulations In South Korea. Since the late 1990s, 
South Korea has experienced an unprecedented transformation In the pharmaceutical 
arena, ranging from the organisational structure to the policy agenda. Table 2-1 shows 
key government bodies involved in regulating pharmaceuticals in Korea. It shows the 
Korean stance assimilated with global trends around 2000, with a great development In 
Institutions engaging In audit and evaluation. At the same time, several significant 
changes took place in pharmaceutical policies. Amongst others, the separation of 
prescribing and dispensing of drugs (SPD), the Better Prescribing Project (BPP) and the 
Pharmaceutical Expenditure Rationalisation Plan (PERP) brought about the biggest 
changes. 
Table 2-1: Government bodies over pharmaceuticals in South Korea 
Role Name Note 
Establishing national 
pharmaceutical policies 
Ministry of Health & Welfare (MOHW) since 1948 
Core decision advisory committee Central Phramceutical Affairs Council since 1963 over pharmaceuticals (CPAC) 
Safety control 
Korea Food & Drug Administration Independent from the ministry 
(KFDA) since 1998 
established in 1998 to merge 
Administrating the national health Nalotnal Health Insurance Corporation patchy source of funds;. full 
Insurance system (NHIC) Integration was completed In July 
2003 
Reviewing and assessing Health Insurance Review & restructed from the National 
insurance claims Assessment Service (HIRA) 
2ederatton of Medical Insurance in 
2000 
ýry YV4 Searching/disseminating cost- National Evidence-based Healthcare since 2009 
` 
effectiveness evidence Collaborating Agency (NECA) 
2.4.1 Separation of prescribing and dispensing of drugs (SPD) 
Before the SPD, there existed a combined system of drug prescribing and dispensing. 
Patients' pharmaceutical products were generally prescribed and dispensed by medical 
doctors at clinics. For slight ailments, they often dropped Into community pharmacies 
and could access medications without authorised prescriptions, The roles of prescribers 
and dispensers were separated only at medical Institutions greater than a certain size. 
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The unseparated system was subject to criticism if it could foster large and 
Inappropriate drug consumption. For instance, the pervasive appearance of antibiotic 
resistance in microorganisms - more than 70% of the incidence of penicillin-resistant 
pneumococcus strains in the late 1990s - may have been caused by the inappropriate 
use of antibiotics in the community (Kim et al., 2004; Korea Health Industry 
Development Institute, 2006). 
The primary aims of the SPD were 1) to prevent misuse and overuse of medicines, and 
2) to facilitate the judicious use of pharmaceuticals by double-checking all prescriptions 
and by banning pharmacists from prescribing. The SPD was expected to result in 
encouraging professional collaborations and reducing inappropriate drug use. In 
addition, the authorities hoped that it would have some favourable effects on 
containing pharmaceutical spending (Ministry of Health & Welfare, 1999b). 
With similar alms, the SPD Is a measure increasingly adopted in Asian settings such as 
South Korea, Taiwan and Japan. In Taiwan, doctors are still able to dispense drugs at 
their premises by hiring pharmacists, even after the Implementation of the SPD. In 
Japan separation has been recommended and professionals can freely choose to 
practice it. The establishment of the SPD In South Korea was, however, different from 
that In Taiwan or Japan. The Korean government rolled it out nationwide In July 2000. 
No on-site pharmacies were allowed at clinics. In hospitals, In-house pharmacies were 
to be devoted to Inpatient services. Outpatient dispensing services were allowed for 
only a small number of exempted cases such as emergency episodes, patients with 
severe disability or with specific groups of disease (including Alzheimer's disease, AIDS, 
haemophilia, rare types of leukaemia or cancer and so forth) (Korean Pharmaceutical 
Affairs Law, provision 23). Additionally, there are regional exceptions resulting from the 
scarcity of Institutions In some remote districts. 
The SPD certainly affords substantial changes In the environment of pharmaceutical 
provision. It has Initiated a 'cultural revolution' In every aspect of the Korean 
pharmaceutical market. Technically, it verified the function of health professionals such 
as prescribers or dispensers, but it has revealed that the reality might be much more 
than just separation. On the one hand, many of the preliminary changes such as the 
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MAC-AAPZ and the BVP3 were introduced to build an environment supporting the SPD 
(Chung and Kim, 2005). On the other hand, many subsequent changes such as the 
BPP and the PERP were established to cope with the consequences of the SPD, since it 
was followed by an unexpected increase in pharmaceutical expenditure. Most of all, 
severe debates lasting over several years concerning the introduction of the SPD 
roused public awareness of problems in current pharmaceutical spending and 
physicians' routine practices over pharmaceuticals. 
2.4.2 Better Prescribing Project (BPP) 
Public awareness has been increased by information produced by a continuous audit of 
prescribing activity. The BPP, a national prescribing monitoring and feedback 
programme, has generated a variety of information concerning prescribing practices 
nationwide since 2001 and communicated to the public since 2002. Outcome variables 
include the rate of antibiotics prescribed, the rate of injections prescribed, the number 
of items per prescription and costs per prescription, followed by the rate of pre-defined 
drugs prescribed by diagnosis. For instance, the rate of antibiotics prescribed for J00 N 
306 (the national diagnostic codes for acute upper respiratory infection and acute nasal 
Infection, namely the common cold) has been investigated. Gradually, evaluations have 
been expanded to cover expensive drugs4 (rate since 2003, value since 2008), steroids 
(2004), NSAIDs5 (2005), polypharmacy6 (2006) and gastrointestinal drugs (2007) 
although details still remain the simple comparison of aggregate prescribing rates 
rather than the quality of prescribing. 
It is noteworthy that the BPP has provided an opportunity for insight into prescribers' 
behaviour. It suggests that a rapid increase in pharmaceutical spending might account 
for poor prescribing practices. It also uncovers large and often puzzling variations in 
drug spending and utilisation. For example, the highest prescriber spent thirty times 
2 Maximum Allowable Cost - Actual Acquisition Price system 
3 Blo-equivalence Validation Programme 
4 defined the most expensive drug among each unique chemical ingredient group which has at 
least three products available in the reimbursement list. Categories in which the most expensive 
drug Is priced less than 50 KRW are excluded. 
5 non-steroidal anti-inflammatory drugs 
6 defined as daily Intake of six or more drug items per prescription 
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more than the lowest in average costs per prescription for the common cold in the 
fourth quarter of 2003 (DailyPharm, 2003b). Figures for use of antibiotics for the 
common cold, usually not recommended by scientific evidence, seems to be much 
worse; the prescribing rate per patient visit varied from 0 to 99% across clinics in 2006 
(DailyPharm, 2006). 
After the BPP, aggregated claims data show a steady decrease in the problematic 
utilisation of antibiotics and injections over time. However, it became clear that the 
prescribing audit had merely a temporary effect often ignored by doctors (DailyPharm, 
2004b). To improve the adherence to recommendations, information on the 
performance of hospitals and clinics has been made public since 2006. The disclosure 
brought about immediate changes in prescribing behaviour, particularly for the rate of 
antibiotics as shown in Figure 2-2. The biggest changes occurred in medical institutions 
where doctors prescribed antibiotics for more than seven in every ten visits with the 
common cold (Figure 2-3). With the exception of antibiotics and injections it remains 
unclear if the audit activity influences the physicians' prescribing behaviour. 
Figure 2-2: Changes in antibiotics prescribing in patients with the common cold by 
type of institution from 2002 to 2009 
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Figure 2-3: Number of institutions against the rate of prescriptions for antibiotics in 
patients with the common cold after the public disclosure of the BPP results 
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Although the overall impact does not seem substantial, the new system clearly set a 
milestone in the history of pharmaceuticals. Information described above never existed 
before the SPD and the BPP. It was previously impossible to capture an outline of 
pharmaceutical consumption in the whole territory. Insurance claims provided only a 
partial figure because most medicines sold in community pharmacies were omitted. 
Transaction data might be an alternative way of measuring pharmaceutical use, yet, it 
was not recommended for two reasons: firstly, the Korean pharmaceutical market was 
too complex to be defined only with transaction data; secondly, transaction data itself 
is often produced spuriously. 
2.4.3 Pharmaceutical Expenditure Rationalisation Plan (PERP) 
Before the PERP, regulations often tended to be inconsistent and so offset potential 
influences one against another, seemingly due to implementation with the absence of 
systematic planning. In this respect, there was a great need for comprehensive 
measures making policies work in harmony. With this objective, the PERP was enacted 
on 29 December 2006, about 8 months after it was initiated in May 2006. It was 
launched with the dual goals of minimising unnecessary drug expenses by modifying 
prescribing behaviour and promoting transparency in the market. 
The PERP is a comprehensive package of pharmaceutical regulations and consists of 
four sub-domains, which are price control, volume control, quality control and the 
restructure of the pharmaceutical market (Table 2-2). Many of the measures in the 
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PERP are little more than existing regulations drawn together which previously were 
fragmented. However, some, such as the positive list and price-volume agreement, 
were new measures replacing the traditional regulation structure. 
Table 2-2: Pharmaceutical Expenditure Rationalisation Plan 
Contents Date of implementation 
Price control 
Price-volume`ý ayrctiments (new bodies, the CERM & the CRRM, 29, December 2006 
established) 
Price cut by 20% for off-patent products 29, December 2006 
Volume control 
Positive list 29, December 2006 
Formal requirements for cost-effective evidence in the 29, December 2006 
reimbursement decision 
Strengthen prescribing review continuous activity 
Quality control 
Stiengthen the koequivalence validation programme continuous activity 
Upgrade of standards for re-evaluation system continuous activity 
Strengthen recall and adverse event reporting system continuous activity 
Establishment of a central drug information centre (pharmacy- July 2007 
information network) 
Strengthen drug identification system21 continuous activity 
1) CERM; Committee on Evaluation of the Reimbursement of medicines, CRRM; Committee on reconciliation 
of the reimbursement of medicines 
2) carved out in the mid of 2006, update of a barcode system, a pilot test of the Introduction of radio 
frequency identification (RFID), introducing a smart card system in a pharmaceutical purchasing procedure 
2.4.3.1 New pricing system 
Before 2006, a cross-national price comparison (hereafter, A7 average price system) 
was employed when prices for new chemical entities (NCEs) were determined. The 
average wholesale prices in seven industrialised countries' were considered as the 
international comparator. This was criticised as potentially inflationary as it compared 
drug prices with countries with much stronger economies than South Korea (Bae and 
Kim, 2001; Lee, 2006). Moreover, the prices of generics after patent expiry might also 
be higher because of the linkage price system8 in Korea. Some recent evidence 
' France, Germany, Italy, Japan, Switzerland, the UK and the US 
8 The first to fifth generic drug is set at less than 80% of cost for its off-patent alternative. The 
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indicates that direct price control might damage generic competition, maintaining 
relatively high generic prices in Korea (Huh et al., 2006; Shin and Choi, 2008). 
The PERP Included changes in the determination of reimbursement prices of 
pharmaceuticals. Average price systems were replaced by a price agreement between 
the authorities and manufacturers. The initial price is reassessed in the second year 
according to sales volume during the first year. PERP also Included a price cut for out- 
of-patent products, and consequently, their generic counterparts. Details for the new 
system follow. 
Before 1997, patent drugs were priced according to the total amount of the ex- 
factory price, value-added tax and distribution mark-up. When prices were determined, 
market prices of existing drugs with a similar therapeutic range were the most 
Important reference. From 1997, the A7 average price system was employed to set an 
Initial price for Innovative patent drugs. The term 'innovative' has never been precisely 
defined and innovative patent drugs were likely to remain at premium prices In South 
Korea, sometimes even more expensive than In more affluent countries (DailyPharm, 
2001a). Mounting opinion was in favour of reducing pharmaceutical prices to an 
affordable level for Korean patients (DailyPharm, 2004c; Kim, 2002a; Korean 
Pharmacists for Democratic Society, 2006; Lee, 2006; People's Solidarity for 
Participatory Democracy, 1998). 
The PERP employed price-volume agreements for the pricing of all patent drugs, with 
the authorities publicising statements that evidence of cost-effectiveness would be the 
first and most important parameter of pricing. However, owing to the scarcity of 
economic studies (Choi, 2008), a cross-national price comparison seems likely to play a 
role in pricing for some time to come. Taiwan and Singapore, with similar economic 
environments to Korea, have recently been added to the group of reference countries, 
when economic evidence is lacking (Pharmaceutical Price Agreement Guideline, 
National Health Insurance Corporation 4fflclal Instruction 2006122; provision 11). 
One year after the first decision, the volume of each product consumed in the 
sixth and later product Is set at the 90% price of the least expensive alternative (MOHW Official 
Instructions 2005-14; pro vision 6). 
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healthcare sector is studied based on data from pharmaceutical claims. If a product's 
consumption is 30% higher than predicted, then the price of the product should be 
lowered in proportion to the increasing volume9. From the second year, products with 
consumption of 60% or greater than the preceding year will be the target of re- 
pricing10 (MOHW Official Instruction 2006-165, Pharmaceutical Price Agreement 
Guideline; provision 12). 
Off-patent drugs are reduced in price by 20% when the first generic counterpart is 
submitted for listing. This was applied to all existing off-patent drugs when the new 
system was Implemented, reflected in the Maximum Allowable Costs (MAC) edition of 
January 2007. 
The pricing system for generics maintained the same rules as before PERP. Prices for 
generics are linked to those of pre-existing drugs with the same active molecules. 
Since November 2001 from the first to the fifth generic there must be at least a 20% 
price cut relative to the original equivalent (MOHW OfcialInstruction 2001-595. The 
sixth generic should offer an additional 10% price cut relative to the least expensive 
corresponding drug at the time of listing. In actuality, the new system cuts the price of 
the off-patent original drugs by 20% making the price of generic products equal to 
64% of the price of the original counterpart in the previous system. Other related 
regulations such as the MAC and the Actual acquisition price (AAP) are maintained as 
before. 
2.4.3.2 New listing system 
The reimbursement listing system replaced a negative list with a positive one. Listing 
and reimbursement decisions are determined based on cost-effectiveness. Under the 
positive list system, the authorities are able to refuse a listing when they consider the 
candidate drug less cost-effective than existing alternatives (HIRA Guldeiines for 
economic evaluations ofpharmaceutica/s). To avoid exclusion from benefit coverage, 
manufacturers must prove that their drugs are cost-effective compared with the most 
9 New price = 0.9x (current price) + (1-0.9) x (current price x (predicted volume/actual 
volume)). 
10 New price = 0.85x (current price) + (1-0.85) x (current price x (volume In a year before 
previous year /volume In the previous year)). 
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frequently used drug(s) or technique(s). 
After implementing the new list system, more than 16,000 items remained on the 
reimbursement list. The authorities stated that they kept every drug previously on the 
benefit list, excluding ghost products that were listed but not actually produced, to 
avoid chaos at the beginning of the new list, but would continue to downsiae according 
to the progress of economic evaluation. From the second half of 2007, a 
comprehensive review of the cost-effectiveness of each product has been undertaken 
and will continue until 2011 (Ministry of Health & Welfare, 2007b). The authorities 
predict that the number of items on the benefit list will be reduced to around 5,000 
after completing the evaluation. In reality, however, few changes have been seen in the 
total number of pharmaceuticals in the list. The first step of economic evaluation 
(including antihyperlipidemics, antimigraine preparations) was delayed by almost six 
months, completed in May 2008 (Health Insurance Review & Assessment Service, 
2008d). 
The initial effects of the PERP are investigated in Chapter 9 on overall drug expenditure, 
utilisation and market prices and Chapter 10 on essential drug utilisation and generic 
utilisation. 
2.4.4 Detailed anatomy of pharmaceutical policy 
Table 2-3 exhibits Korean pharmaceutical policies since the inception of NHI, 
categorised into interventions influencing patients, providers, and industry. 
2.4.4.1 Policies Influencing patients 
Since its establishment, the Korean NHI system has included a cost-sharing scheme to 
curb patient demand. Recently, the structure of cost-sharing was changed as detailed 
in the following section. The impact of this will be explored In Chapter 9 and 10 along 
with the PERP. On the demand side, other measures such as consumer education have 
seldom been used. The OTC or self medication market has not been well-defined. Most 
potential OTC drugs must be sold under the supervision of pharmacists. Up to date, 
direct-to-consumer (DTC) advertising has been allowed only for drugs on the general 
sales list (GSL) (KPAL Regulation, provision 84). 
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Structure of cost-sharing before the change: The Korean NHI system has had a 
cost-sharing scheme since its inception in 1977. Medical institutions could dispense 
medicines until the implementation of the separation policy in 2000; copayments for 
prescription drugs were combined with those for general medical services. 
For the first decade after the establishment, there was only a coinsurance scheme; 
beneficiaries paid 30-40 per cent (20 per cent since July 1979) of total costs for 
inpatient service and 30-50 per cent for outpatient services at the point of consumption. 
In 1986, a fixed co-payment was imposed upon patients who dropped into clinics. 
Since then a dual-system of copayment and coinsurance has existed. Patients pay 
slightly more out-of-pocket to use services provided by dentists or herbal doctors than 
at the usual clinics. Drug consumption through community pharmacies began to be 
subsidised from 1989, the share of total healthcare spending being negligible until the 
introduction of the separation policy. Table 2-4 demonstrates the structure of cost- 
sharing of pharmaceuticals at outpatient services from 1997 to 2007. 
Table 2-4: Cost-sharing on pharmaceuticals at outpatient services 
Sept 1997- Jul 2000- ]an 2001- Jul 2001- From Cost-sharing Institution 
Jun 2000 Dec 2000 Jun 2001 Jul 2007 Aug 2007 
copayment(in KRW ) 
upper limit clinics up to 12,000'1 """" Prescribing and Di spensing for drugs (SPD) 
pharmacy up to 3,00031 up to 8,000 up to 10,000 up to 10,000 up to 10,000 
seniors4) clinics 2,200 
pharmacy 900 1, (. )00 1,000 1,200 I 
general clinics 3,200 1 IN` ' 
30't 
pharmacy 900 1,000 1,000 1,500 (d,, inyt"d to 
coinsurance) 
coinsurance 30% of total spending (when total expenses is over the upper limit) 
1) 2000 KRW - LI in June 2008 
2) total expenses including physician consulting fee and costs for prescription drugs 
3) total expenses including dispensing fee and costs for prescription drugs 
4) seniors; 70 or more from December 1995 to June 2000,65 or more from July 2000 
Source; Park 2002, National Health Insurance Act Regulation, provision 22-1, Appendix 2 
From 2001 to July 2007, for every prescription dispensed at a community pharmacy 
patients paid a fixed copayment of 1,500 KRW (£0.75), unless the total drugs cost per 
single prescription (including a dispensing fee) exceeded 10,000 KRW (£5). In this 
regard, there had been considerable concern that a fixed copayment would 
disproportionately benefit patients with temporary, symptomatic illnesses, because a 
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prescription for chronic medications was more likely to go over the upper limit. In 2006, 
nearly 60% of prescriptions were priced lower than the upper limit (10,000 KRW), the 
average costs of which was about 7,500 KRW. Hence, patients prescribed medications 
costing less than 10,000 KRW per slip paid only around 20% of total expenses 
(Ministry of Health & Welfare, 2007a). 
There are some exemptions to in the cost-sharing scheme. In December 1995, seniors 
started to pay lower costs for the same services. Beneficiaries aged 70 (65 since 2000) 
or older paid slightly less. When total expenses exceed the limit, the amount of co- 
payment was determined proportionally regardless of age. There were no generous 
benefit schemes for children until August 2007 (NHL4 Regulation; provision 22-1, 
Appendix2). If patients see doctors in public health centres, then they pay less. Some 
patients with severe diseases such as cancers, rare and incurable diseases, or those 
covered by the Medical Aid Programme also incurred lower charges (National Health 
Insurance Act Regulation; provision 10-. 2). Since July 1979, institutionalised patients 
have paid 20% of costs for services including pharmaceuticals. 
A stop-loss (copayment ceiling) was Implemented In July 2004, with the NHI 
subsidizing all extra costs exceeding a certain limit. If a patient pays more than 3 
million KRW (E1500) out-of-pocket within the period of six consecutive months (later 
lowered to 2 million KRW in July 2007) he/she is exempt from any further copayments 
(National Health Insurance Act Regulation; provision 22-1). In this case, out-of-pocket 
includes the whole spending on medical services Including pharmaceuticals by 
statutory cost-sharing, but excludes voluntary uninsured out-of-pocket. 
Copaymentincrease for prescriptIon drugs: In April 2007, the authorities 
announced the removal of a fixed copayment for patients aged between 6 and 64 and, 
instead, applied a 30% coinsurance scheme (Table 2-4). In other words, non-elderly 
patients have to pay 30% of total drug costs per prescription even when the total 
amount of expenses is under the previous `upper limit. For instance, for a prescription 
costing 7,500 KRW In total expenses, payment is 2,250 KRW, where previously the 
payment was only two thirds (1,500 KRW) because total expenses were less than 
10,000 KRW. Because of the new cost-sharing schedule, the actual increase in the out- 
of-pocket rate was around 50% from 20% to 30% in prescriptions previously under the 
fixed-copayment scheme. The elderly population continue to pay a fixed copayment as 
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before. A slightly lower cost-sharing rate began to apply to children under six, which 
since August 2007 has been 70% of the adults charge. 
2.4.4.2 Policies influencing providers 
Reimbursement criteria were first developed by the National Federation of Medical 
Insurance (NFMI) and later by the Health Insurance Review & Assessment Service 
(HIRA). They have been used to screen beneficiaries' prescriptions to identify 
deviations from pre-specified refundable services in terms of quantity (including 
overdose, under-dose, or days of supply) and quality (including drug-drug interactions, 
drug-disease contraindications, or therapeutic duplications). In cases of inappropriate 
services (prescriptions), refunds would be refused or curtailed. To date, however, it has 
hardly influenced medical providers because such disadvantages have been negligible 
in practices, around 1-3 per cent between 2000 and 2001 (Jo and Lee, 2002). The 
HIRA, a successor of the NFMI, currently strives not only to expand evaluation criteria, 
but also to convey the Information concerning prescribing practices through the BPP, as 
discussed earlier. Most recently, a national drug utilisation review programme (DUR) 
was piloted in limited local regions with the purpose of guiding the rational use of 
drugs (Ministry of Health & Welfare, 2009). 
Before the Initiation of the positive list, pharmaceutical manufacturers (Importers) have 
to apply for listing within 30 days after market approval In order to have their new 
products reimbursed. Applications were generally accepted until the first negative list 
was Implemented in 2001 (NationalInsuranceBenefitRegulation, provision£. Over 
five years, the government excluded more than two thousand Items from public 
subsidy for reasons either that they treated only minor symptoms or had Inferior 
clinical effectiveness. In 2002, nonetheless, almost two thirds of pharmaceuticals on 
the market (about 18,000 products) were reimbursed (Ministry of Health & Welfare, 
2003). There was mounting concern that a long list of Insured drugs may not only 
Increase administrational expenses, but also restrain take up of cost-effective 
pharmaceuticals, which appeared to Increase pharmaceutical expenditure more than 
necessary (Bae and Kim, 2001; Korean Pharmacists for Democratic Society, 2006). This 
stimulated the launch of a positive list at the end of 2006 in the PERP. Thereafter, the 
authorities could refuse listing when they considered the candidate drug Inferior, for 
Instance less cost-effective, to existing alternatives (HIRA Guidelines for economic 
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evaluations of pharmaceuticals). 
From the beginning of the SPD, pharmacists were allowed to substitute a prescribed 
medication for an equivalent product unless doctors explicitly stated 'no substitution 
allowed' on the prescription pad. Originally, the primary purpose of a substitution policy 
was not to encourage the use of less costly drugs, but to ease consumers' 
inconvenience and the burden of stockpiling in community pharmacies. The policy aim, 
however, soon reverted to the former as a couple of studies continuously suggested 
that an increasing use of expensive drugs might be the cause of increasing 
pharmaceutical expenditure after the SPD (Cho et al., 2002; Cho et all 2001; Jang et 
at., 2001; Lee and Malone, 2003). The authorities introduced incentives for generic 
substitution for pharmacists in July 2001. Thereafter, pharmacists have been allowed to 
keep one-third of the savings made via the use of less costly generic alternatives 
(MOHW Off/cla/Instruction 200134. It soon revealed that incentives for substitution 
are unlikely to contain pharmaceutical spending. According to the MOHW the rate of 
substitution has been negligible, less than 0.03 per cent in 2005 and 2006 (Ministry of 
Health & Welfare, 2006b). 
2.4.4.3 Policies influencing industry 
In the Korean market, pharmaceutical manufacturers are free to set drug prices. 
Retailers, i. e. pharmacists, have also set their own prices for each drug since 1999 
when open prices were Introduced aimed at price competition (Lee, 1999) (Korean 
Pharwaceuttca/Affairs law; provision 7-. Inevitably, there have been some 
differences between the market price and the reimbursement price for the same 
product. After the SPD, POMs are no longer allowed to be sold without authorised 
prescriptions, Implying that POMs are unlikely to be consumed at suppliers' market 
prices. Instead, the Maximum Allowable Cost (MAC) seems to govern the market price 
for POMs in most cases. 
The MAC Is, as its name implies, a form of price cap that sets an upper limit of 
remunerative payment for each pharmaceutical product, and has been in force since 
the beginning of NHI. It is decided at ministerial level via a process involving several 
government bodies. Different rules apply to in-patent drugs, off-patent drugs (newly 
introduced by the PERP) and generics (see 2.4.3 for details). The MAC list is revised 
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regularly via ä price survey to catch up with the market dynamics and three major 
changes have taken place in the survey guideline: Investigating price system; 
Reporting price system; and Actual Acquisition Price (AAP) system. 
During the era employing the investigating or reporting price system, the differences 
between the reimbursement price and the actual acquisition cost were a source of 
income for providers (People's Solidarity for Participatory Democracy, 1998,1999); this 
was sizeable, over 40 per cent of the total revenue of physicians' clinics (Ministry of 
Health & Welfare, 2000 cited by Kwon, 2003). To remove such an unmerited profit, the 
authorities adopted the AAP In 1999 just prior to the SPD. At the onset of the AAP, the 
authorities undertook a major Inspection of pharmaceutical prices on the market, and 
consequently Imposed a mandatory cut in drug prices by 30 per cent on average 
(DailyPharm, 1999c). 
2.4.5 Summary: Korean pharmaceutical policies 
During the last decade, South Korea has experienced a sharp increase in 
pharmaceutical expenditure. To cope with the cost inflation, the Korean government 
has introduced several new strategies. Nevertheless, Korean policies still seem to be 
focused on measures influencing patients or pricing, showing little ability to control 
Prescribers. 
Notably, there had been no diverse measures in the pharmaceutical market until the 
SPD, as shown in Table 2-3. Before 2000, cost-sharing, reimbursement criteria and 
price control were the only measures regulating the pharmaceutical arena, except for 
safety controls. Most of all, this shows that interventions focused on providers had 
been totally neglected until 2000s. After the SPD, a body of empirical evidence from 
the BPP has invariably caused alarm that curbing inappropriate prescribing behaviour is 
essential to lower the growth of pharmaceutical spending. Hence, some measures such 
as generic prescribing, incentives on the prescribing budget savings have recently been 
piloted to influence prescribing practice. There Is also animated discussion over 
Potential policies such as a reference-pricing scheme (Lee and lee, 2007). 
Overall, it is clear that the policy agenda Is- moving from regulating prices and patient 
demand toward regulating prescribing behaviour. While, outwardly, it has followed 
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global trends, Korean pharmaceutical policies in reality still seem to rely more on 
measures limiting patient demand or pricing. Interventions influencing prescribing 
behaviour are rarely developed further after initial piloting attempts. The underpinning 
difficulties of this reality are explored in Chapter 12 by conducting in-depth interviews 
with Korean policy-makers. 
2.5 Overview of the Korean context 
The next sections explore the Korean context In five respects: pharmaceutical 
expenditure; health status; economic and resource capacity; political; and cultural and 
societal context. To highlight the similarities and differences of these issues between 
nations, some brief comparisons are made between South Korea and eight other 
nations on certain limited topics. These countries are Australia, France, Germany, 
Japan, Sweden, the UK, and the US. These countries were chosen because they are 
included frequently in systematic reviews (see Part 2) or in comparisons by Korean 
policy-makers (Annex 26d). 
2.5.1 Pharmaceutical expenditure 
Korea spends a relatively large sum of money on pharmaceuticals. Until 1995, its share 
of total health expenditure was in excess of 30 per cent. Although this figure has 
declined steadily to around 25 per cent in recent years, this decline is mainly ascribed 
to a rapid expansion of spending on overall healthcare rather than a specific decrease 
in pharmaceutical spending. As seen in Figure 2-4, spending on pharmaceuticals has 
increased sharply since 1998, and the growth rate outpaces that of the general 
economy from 2004. 
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Figure 2-4: Trends of pharmaceutical expenditure in parity comparison with total 
healthcare expenditure and general economics, at the basis of the value of 
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(Data source: OECD, 2007b) 
Table 2-5: Pharmaceutical spending and growth rate between 1995 and 2005 in the 
selected countries 
PharmaceutK il ex pet 1119 1 ire Pharmaceutical expenditure, 
per capta, US$ PPP" % of TEND 
1995 2005 Growth 1995 2005 Growth 
Australb 195 426 118.5 12.1 14.3 18.2 
Canada 284 595 109.5 13.8 17.2 24.6 
France 314 553 76.1 15.0 16.7 11.3 
Germany 292 506 73.3 12.9 15.1 17.1 
Japan 346 489 41.3 22.3 19.8 -11.2 
South Korea 137 332 142.3 26.1 25.7 -1.5 
Sweden 215 406 88.8 12.3 13.7 11.4 
UK 3) 206 n/a n/a 15.3 n/a n/a 
us 324 790 143.8 8.7 12.0 37.9 
1) purchasing power parity 
2) total expenditure on heath 
3) n/a refer to not available 
(Data source: OECD, 200 9) 
Spending on drugs was US$ 332 PPP" per capita in 2005, still less than other selected 
countries; however, the growth rate between 1995 and 2005 was more rapid than 
other nations in the comparison, and similar to the US, the biggest drug consumer in 
the world (Table 2-5). 
" Values adjusted by purchasing power parity (PPP) was used to eliminate price level 
differences in inter-country comparisons, conversions using purchasing power parities equalise 
currencies to allow the purchase of the same basket of goods and services in different countries. 
57 
2.5.2 Health status 
In recent decades, Korean society has faced common problems found in the most 
industrialised countries, especially in those with aging populations and an increased 
burden of chronic conditions. According to the recent OECD profile, the life expectancy 
of the Korean population was 78.5 in 2005. It caught up with that of the US and 
reached that of the UK (see Table 2-6). Although the aging population (over 60 years) 
is still smaller than other developed societies, it has increased substantially - at least 
twofold - compared with Japan or Germany, where they have experienced the highest 
expansion of an aging population among these selected nations. In addition, mortality 
caused by major chronic conditions was similar to that in the comparison countries. 
Mortality from diabetes was rather higher in Korea; and mortality from acute 
myocardial infarction increased between 1995 and 2005 while it decreased in other 
places in the same period. Not surprisingly, this changing health status brought about 
similar challenges to those seen in industrialised societies, such as expenditure inflation 
in the pharmaceutical arena, as illustrated in the preceding sector. 
Table 2-6: Aged population and chronic conditions in the selected countries 
(Data sources: OECD, 2009; WHO, 2006) 
Population Life 
aged 601 yvar>", 'G, expectant y') AMI "'' Cancer's Diabetes4) 
Growth 1994 2004 2005 1995 2005 1995 2005 1995 2005 
Australa 15.4 1/. 0 10.4 80.9 88. / 443") 173.8 154.3'') 13.4 13.45) 
Canada 16.0 17.5 9.4 80.4 66.5 41.55) 180.7 169.051 16.4 18.451 
France 20.3 20.9 3.0 80.2 32.2 21.4 181.1 165.6 6.9 10.9 
Germany 20.6 24.8 20.4 79.4 73.8 46.3 185.9 159.3 18.6 16.2 
Japan 19,9 25.6 28.6 82.0 30.6 18.7 158.9 142.3 8.4 5.7 
South Korea 8,9 13.3 49.4 78.5 17.3 26.6 166.7 158.3 28.8 30.2 
Sweden 22.1 23.0 4.1 80.6 96.1 54.5 154.1 148.5 10.6 11.3 
UK 20.9 21.0 0.5 79.1 100.2 45.3 197.3 1.73.3 7.8 6.7 
U5 16.3 16.5 1.2 77.8 68.5 37.9 183.1 157.9 19.5 20.3 
1) The World Healh Report 2006 
2) at birth, Total population (n years) 
3) Acute myocardial vitarctnn 
4) deaths per 100,000 population 
5) in 2004 
2.5.3 Economic stance 
South Korea is in an economically weak position compared to the other selected 
countries. Its GDP is about half of that of the US; and two thirds of the other European 
countries or Japan (Table 2-7). A weak economic position is associated with lower 
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spending on health. In 2005, South Korea spent 6 per cent of its GDP on health and 
was still below international levels. As can be surmised, when costly programmes are 
involved, such as expensive drugs or medical treatment for all citizens, financial 
constraints are, to date, one of the most important obstacles in South Korea. 
Sometimes, the authorities intentionally excluded medical technologies such as 
positron emission tomography (PET), or new expensive medicines, from the list of 
benefits owing to the economic burden on public funds (MOHW Regulation 266). 
Table 2-7: Spending on health and growth rate between 1995 and 2005 in the 
selected countries (Data sources: OECD, 2008; OECD, 2009) 
GDP/capta, Tot al expendit ure on Public expendit ure on 
uss t'pp° heath, %c oin health, % of it 10 
2005 1995 2005 Growth 1995 2005 Growth 
Australe 34259 7.4 8.7 17.6 65.8 67.4 2.4 
Canada 35079 9.0 9.9 10.0 71.4 70.3 -1.5 
France 29644 10.4 11.1 6.7 79.7 79.3 -0.5 
Germany 30495 10.1 10.7 5.9 81.6 77.0 -5.6 
Japan 30312 6.9 8.2 18.8 83.0 82.7 -0.4 
South Korea 21342 4.1 6.1 48.8 36.3 52.1 43.5 
Sweden 32770 8.0 9.2 15.0 86.6 81.6 -5.8 
UK 31585 6.8 8.2 20.6 83.9 81.9 -2.4 
us 41740 13.6 15.7 15.4 44.9 44.4 -1.1 
1) purchasing power panty (OECD 2008) 
2) total expendture on heath 
Linked to the lack of resources, high private expenditure has been subject to strong 
criticism in South Korea (Choi et al., 2005b; Lee, 2005b; OECD, 2005,2006,2007a). 
The Korean health system has kept a relatively high legal copayment level, almost a 
quarter of total expenditure on health until recently. In practice, figures are even higher. 
Patients are required to pay nearly half of total expenses out-of-pocket at the point of 
care, which consists of legal copayments plus out-of-pocket derived from uninsured 
services (Kim and lung, 2005; Kim and Lee, 2006). Over time, people became used to 
copayments and to inequity among the social groups by ability to pay. A philosophy of 
victimisation has been present throughout Korean society. 
There has been extensive anecdotal evidence concerning the increase in social 
inequality. The growth rate of household expenditure on health was 25 per cent in the 
first quarter of 2003, which was the highest growth rate in the top 10 household 
expenses (DailyPharm, 2003a). One in four leukaemia patients and their families 
reported declining from middle class to a low-income class after illness occurred in the 
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household (Kim, 2003). A third of the beneficiaries in the lowest contribution group 
have had experience in giving up access to healthcare services owing to the financial 
burden entailed (DailyPharm, 2005a). 
On the other hand, the industrial context may confirm South Korea in a different 
position from the selected countries. Globally, the pharmaceutical industry is regarded 
as promising and profitable (Fortune, 2008; Reekie and Weber, 1979), whereas the 
Korean pharmaceutical industry still has little influence on the national economy. The 
share of the national GDP made up by the pharmaceutical industry has reduced slightly 
since 1998, and was lower than 1.5 per cent in 2005 (Korea Health Industry 
Development Institute, 2007). In the same year, 546 manufacturers produced 
pharmaceuticals. Among them, 20 producers recorded more than 100 billion KRW (£50 
million) of annual sales, and these sales represented 70 per cent of the whole (Korea 
Health Industry Development Institute, 2007), indicating that most producers are still 
small businesses in South Korea. 
Table 2-8: Pharmaceutical industry 
top 100 drug top 20 drug 
company'' company' ), 2) volume 
Australia 1 
Canada 5 
France 4 
0 15.5 
Generic share, % 
value ratio3) 
10.2 0.7 
year references 
1998/9 Lofgren 2002 
0 43.5 17.4 0.4 2006 
1 12.0 6.4 0.5 2004 
Germany 6 2 41.1 22.7 0.6 2004 
Canadian Generic 
Pharmaceutical Association, 
2007 
European Generic Medicines 
Association, 2004 
European Generic Medicines 
Association, 2004 
Japan 18 2 18.7 6.4 0.3 2007 Phcunrä Marketletter 2008 
South Korea 00 42.8 39 0.9 2004 Huh 2006 
Sweden 11 39.4 12.3 0.3 2004 f uropean Generic Medicines Association, 2004 
UK 62 49.3 20.6 0.4 2004 European Generic Medicines Association, 2004 
USA 37 10 69.0 16.0 0.2 2008 Generic Pharmaceutical Association, 2009 
1) Where the headquarter being situated is considered a host nation of each company. The global top 100 of 
pharmaceutical cornpaies are listed by Scrip 2007. 
2) AstraZeneca is included both in Sweden and the UK because it establishes the headquarter in both nations. 
3) ratio - value/volume 
The numerical figures in Table 2-8 confirm Korean the industrial environment. In 2006, 
Korea had no pharmaceutical companies in the world's top 100 companies (even 
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Including important generics manufacturers). 
Linked to this issue, most Korean manufacturers have largely neglected any research 
and development activity. No new chemical entity was developed by a local 
manufacturer until 1999 (Korea Health Industry Development Institute, 2006). Average 
R&D investment remained less than 5 per cent of annual sales in 2006 (Korea Health 
Industry Development Institute, 2007), which was far behind the 15 per cent in 
international patent holders in the late 1990s (National Economic Research Associates, 
1998). Korean companies conventionally make more efforts in selling generics and, as 
a result, the volume share of generics in the pharmaceutical market was quite high, 
over 40 per cent in early 2000s (Table 2-8). This figure is comparable with Sweden or 
the UK, who greatly encourage the use of generics (Andersson etal., 2007; Simoens 
and De Coster, 2006). However, it should be noted that the share of value may be as 
high as of volume, unlike Sweden and the UK, indicating the low possibility of saving 
by using generics. It implies that generic policies, which are advocated as useful 
measures easing cost crises in other settings, might not be as effective in South Korea 
if this situation persists. Issues relating to this are explored further with the empirical 
data in Chapter 10. 
2.5.4 Political environment 
Since Independence, modern Korean society has been Influenced considerably by 
American traditions In every respect. Additionally, South Korea has developed through 
state-led industrialisation programmes (Hasan, 1976). Until recently, the Korean 
government has been more likely to prioritise economic development than welfare 
(Hwang, 2006a). A weak Inherent ideology of welfare coupled with limited national 
wealth made past governments construct a minimum benefit package at the expense 
of quality of care, and the structure was retained for more than two decades until the 
end of 1990s. Hwang (2006b) provides a good description of how political Imperatives 
were exercised above economic principles or welfare concerns In the decision-making 
process of healthcare provision in that same period. Equity Issues were paid less 
attention until the late 1990s, as the function of social insurance was health security 
for limited beneficiaries (the relatively better-off), not wealth redistribution (Hwang, 
2006b). 
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Recently, Korean society has experienced a change in this inherent tradition. During the 
last decade, the growth rate of public expenditure on health rose from 39 per cent in 
1996 to 53 per cent in 2005 (OECD, 2007b) The preceding two governments (1997- 
2002; 2003-2007) emphasised social solidarity (Hwang, 2006c; Kwon and Reich, 2005), 
moving "informal, familial, community-based mutual support" towards more state- 
provision of welfare systems (Hwang, 2006a). As a result, debates over equity appear 
more often in the public arena these days, even though social consensus in the whole 
society has not yet been reached (Lee, 2009). 
At the micro-level, details are more likely to reflect the power of relationships between 
stakeholders, Pharmaceutical policy-making involves a multiplicity of stakeholders 
whose interests often compete. In practice, politicians, healthcare providers, 
manufacturers, payers and experts are ultimately concerned with their own influence, 
reputation, and research funds. It is, thus, far from surprising that a power game 
among Korean stakeholders is serious and highly complex (Kwon, 2003). Herbal 
medicines also form a considerable portion of the healthcare system and this multiplies 
the complexity of this market (Cho, 2000). 
Since the beginning of the 1990s, South Korea has seen conflict among professionals 
over pharmaceuticals, for example between pharmacists and practitioners of traditional 
medicine. This created a new professional, the `herbal pharmacist' In 2000 (The 
Association of Korea Oriental Pharmacy, 2004). Severe tensions were also evident at 
the Inception of the Korean SPD. There were five nation-wide physicians' strikes 12 
during the year that the SPD was Introduced, which Influenced greatly the details of Its 
regulation and payment rate (Choi, 2000; Kwon, 2003). For Instance, the classification 
of prescription-only-medicines (POMs) kept changing for up to a year after the 
Implementation. More recently, troubles between domestic wholesalers and Zuellig 
Pharma, an international wholesaler in the Asia Pacific region, saw the entire country 
struggling with a situation where certain trans-national corporations' (TNCs) products 
were `out of stock' for almost a month in 2007 (Medical Today, 2007a, 2007b). 
Among stakeholders, evidence suggests that medical professionals may play a 
substantial role In policy outcomes. One survey undertaken by an online press In the 
i2 February, April, June, August and October 2000 
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year preceding the SPD showed that seven physicians out of ten practicing In Seoul, 
the capital city of South Korea, responded that they would prescribe original drugs 
when the SPD was implemented (DailyPharm, 1999a). Doctors expressed concern for 
their reputations if their prescriptions were disclosed to the public, as the SPD lets 
patients take prescriptions away to be dispensed in their catchment pharmacies. 
Although the survey did not provide the number of original drugs prescribed at the 
time of the survey (before the SPD) by the doctors surveyed, it showed clearly that 
physicians had an unfavourable opinion towards generics and foretold a future trend of 
market dynamics. About two years after the survey, the Health Insurance Review & 
Assessment Service (HIRA) reported to the National Assembly that spending on 
expensive drugs (mostly original drugs and some expensive branded generics) doubled 
from 1,466 KRW (E 0.75) per day In the two months before the SPD to 3,130 KRW 
(f1.5) per day in the three months after the SPD (DailyPharm, 2001d). This was not 
surprising because the demand for prescription drugs Is determined largely by 
prescribers' preferences (Chapter 1). 
Contrary to this, civil society has been in a weak position until very recently. Its voice 
has steadily increased, generating a social consensus over the SPD against the power 
dynamics between the government and professionals at the end of the 1990s (Choi, 
2000; Kwon and Reich, 2005). Albeit augmenting the role of civil movements, there is 
still scepticism about whether the official process of pharmaceutical decisions pays due 
regard to consumers' welfare, given that formal committees have been largely 
dominated by professionals to date (Choi, 2005; Hwang, 2004). 
2.5.5 Cultural background 
It should not be overlooked that drug consumption is determined to a substantial 
extent by cultural factors (Bradley et al., 2004; Crawford, 1984). As depicted in the 
preceding section, Korea spends relatively large amounts of money on pharmaceuticals. 
Low spending on healthcare with a high proportion of pharmaceutical spending is 
certainly typical In Korea. Presumably, this is partly caused by a drug-oriented custom 
that had been established during poor economic periods in Korea. People were used to 
community pharmacies for relieving their health problems and considered medical 
institutions more expensive, time-consuming and authoritative. It might also be 
explained by the tradition of Chinese medicines, within which there has been no 
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separation between prescribers and dispensers. This culture was expanded to 
encompass the system of western medicines. No legal barriers existed to dispensing 
pharmaceuticals until 2000, when the separation policy required authorised 
prescriptions for POMs. 
As already mentioned, the separation policy has recently been adopted in several Asian 
nations with the expectation of reducing drug expenditure and achieving clinically 
desirable drug consumption. This is in sharp contrast with the situation in many 
Western countries where independent roles of prescribers and dispensers have been 
steadily developed over time with little mandatory power (Savage, 1994). This is also a 
different trend from the US where dispensing doctors have recently emerged 
(Schweitzer, 2007a), or the UK attempting an alternative role with nurse practitioners 
and pharmacists allowed to prescribe from a limited formulary, with the purpose of 
saving salaries and time of medical professionals (Department of Health, 2009). 
2.5.6 Summary: Korean context 
This section has probed the Korean contextual factors that may influence 
pharmaceutical policy interventions. Health parameters indicate that the health status 
of the Korean population Is aging rapidly, resulting in a sharp Increase In health 
spending, similar to most Industrial countries. At the same time, there are several 
points making South Korea different from such settings, Including economic, political, 
and cultural Internal contexts. 
Firstly, the Korean economy is in a relatively weak position, resulting in less available 
healthcare resources than other countries, including in the pharmaceutical field. The 
private share of health costs is currently higher than other welfare states. Under such 
conditions, social inequity caused by income differences seems considerable. Secondly, 
the Korean drug industry is uncompetitive in the global market. At home, there is 
concern over too much reliance on generic business by the pharmaceutical 
manufacturers. Thirdly, political imperatives seem to be more influential In policy 
decisions. Economic development has been of great importance to Korean politicians in 
the period since independence. Considerations over social equity and social security 
have only a decade of history and are limited. Fourthly, tensions are high and complex 
among actors in the health arena. Whilst professionals' influences are considerable in 
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the establishment of pharmaceutical policies, the strength of civil society is still weak 
compared with that of other actors. Fifthly, Korean consumers have a high level of 
dependence on pharmaceuticals. 
2.6 Evaluating pharmaceutical policy outcomes 
In this section, increasing demands for a sound basis in policy making is addressed 
briefly, followed by the framework of research methods frequently used in policy 
evaluation, to allow discussion of practical difficulties of policy analysis in certain areas. 
Finally, discussion returns to the local context from a perspective of the quality of 
evidence currently available in South Korea, to help to understand the research 
questions and methods for this study. 
2.6.1 Evidence base for policy-making 
While government Intervention Is needed to correct the failures In the drug market, 
there seems to be no particular reason to assume government Intervention will 
necessarily be either efficient or equitable on Its own. Some writers are concerned that 
public policies could potentially be Ineffective (Dolowitz eta/,, 2000), could Increase 
inequity (Mastilica and Bozikov, 1999), or could cause more harm than good In some 
conditions (Soumerai etal., 1991). 
Over the past 15 years, voices proclaiming the link between science and policy have 
become apparent, as the belief that scientific evidence can improve the rigour of 
decision-making has spread. Over a relatively short time period the concept of 
`evidence-based' policy-making (EBP) has succeeded in permeating governments as a 
principle (Department of Health, 2008; van Kammen et al., 2006; Wilson et al., 2007). 
This trend has been partly facilitated by the social environment increasingly calling for 
transparent, accountable as well as efficient policy-making (Daniels and Sabin, 1998). 
As the population's expectations and costs of health care continue to grow, problems 
with finite resources worsen. Electorates ever more ask politicians to justify their 
decisions, forcing them to seek evidence. 
The idea of an 'evidence-base' or'knowledge-base' was firstly used in medicine as 
'evidence-based medicine (EBM)' which requires "the conscientious, explicit and 
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judicious use of current best evidence In making decisions about the care of individual 
patients" in clinical care (Sackett et al., 1996; p71), in which effectiveness or efficiency 
is the first and best cause for a decision (Gray, 2001b). EBP is the concept expanded 
from EBM In shaping decisions for Individual patients to policy decisions for groups of 
people. The key element of EBM and EBP Is the importance of evidence In decision- 
making. Cookson (2005; p118) defined the term EBP "as a set of rules and Institutional 
arrangements designed to encourage the transparent and balanced use of evidence In 
public policy-making': In healthcare, it was firstly Interested In "doing things cheaper" 
then moved onto "doing the right things right" by Incorporating quality concerns (Gray, 
2001a). 
Although this new agenda has been widely accepted In recent years as a concept, 
translating this concept Into practice has proved challenging. Several causes may 
underlie this. First, as discussed earlier, policy-making can be Influenced by many other 
factors, such as political Interests. For example, Kay (2002) demonstrated how efforts 
seeking evidence for policy decisions were neglected in the UK fundholding scheme 
from its introduction to abolition, as political thinking dominated. Second, scientifically 
good research may not necessarily be ready for use in policy-making. For example, 
research conducted in developed countries may not provide a proper solution to 
context-specific problems In developing nations (Behague et al., 2009). Moreover, 
conclusions from each study are usually single-faceted and frequently remain 
ambiguous or uncertain. Wilson et al. (2007; p248) argued that "'good research on 
(policy] Issues is necessary but not sufficient to underpin [policy decisions]" Linked to 
this, writers indicated that the concept of evidence might differ between the producers 
and users (Choi et al., 2005a; Innvaer eta/., 2002; Sharpe, 2004). Third, evaluating 
policies Is still a weak area and generally proves more difficult to conduct compared 
with clinical research. Often, a robust design such as a randomised trial is impractical 
or unethical, so policy Impact Is confounded by uncontrolled external and Internal 
factors. As a result, good quality, available evidence Is often lacking. 
Impact assessment of concomitant policies is a growing field of research in the 
provision of pharmaceuticals, in line with illustrating the significance of EBP. Despite 
efforts over the past two decades, robust studies are still scarce in this field (Kanavos 
et al., 2004; Soumerai et al., 1993). Existing evidence is fragmented and concentrated, 
limited to a small number of regions, as shown in both the body of existing literature 
66 
and the three systematic reviews in this thesis (see Chapter 3 to Chapter 7). 
A number of suggestions have been made to cope with such obstacles. They can be 
broadly categorised into two types: firstly, researchers and policy-makers working 
together; and, secondly, encouraging the establishment of a good knowledge base 
sensitive to policy demand (Behague eta/., 2009; Elliott and Popay, 2000; Sharpe, 
2004; Soumerai eta/., 1997; van Kammen eta/., 2006; Wilson eta/., 2007). The 
purpose of this thesis is related closely to the latter. 
2.6.2 Tools for studying pharmaceutical policy 
Studying policy is a complicated task, which has its base In social science and Is by 
nature multidisciplinary, ranging from political science and economics to sociology. 
Moreover, policy analysis within the pharmaceutical arena requires sound knowledge 
concerning epidemiology and natural sciences in order to utilise secondary Information 
because pharmaceutical provision is rooted in natural science. 
In clinical science, randomised designs are generally employed, typical examples of 
which are drug trials measuring the safety and efficacy of a new chemical entity (NCE). 
In randomised experiments, subjects are allocated randomly either to an intervention 
group or to a control group (Shadish eta/., 2002d). For high quality studies, it is 
necessary to maintain `randomised' allocation throughout the study period by adhering 
to allocation concealment and intention-to-treat analysis (Tilling eta/., 2005). Any 
break in randomisation introduces bias that may produce false conclusions. Among 
several designs, randomised controlled trials (RCT) are considered a `gold standard' 
study design with the least bias and increasingly required in all research fields. In 
research addressing pharmaceutical policy issues, the famous RAND health insurance 
experiments were performed using a randomised experimental design (Newhouse, 
1993). 
However, true experiments are challenging in policy studies. Firstly, it may be simply 
not feasible in the context of social policies, let us assume there is a researcher who 
plans to evaluate public policy introduced at the national level, but is unable to find a 
proper control group because the policy affects the whole population. One may select a 
comparable population from outside of the country but it is clear that subjects have not 
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been allocated randomly. Secondly, randomisation often entails ethical considerations 
(Edwards eta/., 1999; Mahler eta/., 1982; Resnik, 2008). For example, it is unethical 
to assign persons at random into an intervention that may cause significant harm, such 
as heavy copayments on essential drugs. 
When these events occur, researchers resort to quasi-experiments. Among others, two 
relatively well-designed tools are interrupted time series (ITS) and controlled before 
and after (CBA) designs. Time series designs are valued for their power in ruling out 
many threats to internal validity and are highly feasible (Shadish eta/., 2002c). A time 
series is a sequence of observations made on a single variable at successive time 
intervals. ITS refers to a particular form of time series that is interrupted by an external 
intervention, for instance, a copayment change. This design will be explored in greater 
detail in Chapter B. 
CBA designs are quasi-experiments in which the allocation of intervention and control 
groups is determined not by a random process, but in some other manner (Shadish et 
at., 2002a). Data is collected before the intervention and then further data collected 
after the intervention is introduced, and outcomes are usually discussed in terms of 
group differences in pretest-posttest changes (Cook and Campbell, 1979b). In this case, 
an evaluator seeks a comparable population outside of the intervention state as a 
control, which is an example of CBA. The most likely threat to internal validity in this 
design is selection bias, because there may be unidentified differences between the 
intervention and control groups that could confound the results. 
There are also several designs scientifically less advocated but frequently employed, 
such as one-group posttest-only design, one-group pretest-posttest design, or posttest- 
only design with non-equivalent groups (Shadish et a/., 2002b). These designs have 
value in suggesting new ideas, yet they are normally thought insufficient to 
demonstrating a clear relationship between cause and effect. They often exaggerate 
policy outcomes (Soumeral et al., 1989). However, they are still used frequently in 
policy studies. According to the recent article by Kanavos et al, (2004), these kinds of 
studies occupied more than 80 per cent of 18 studies examining the cost-containment 
policy they reviewed. 
Quantitative approaches described so far tend to be limited to areas where the 
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collected data can provide explanation. Faced with such limitations, qualitative 
approaches can be useful. Not only can qualitative research illuminate the research 
question in ways that a quantitative approach cannot, but also it has advantages in 
disclosing hidden issues or underlying meanings, or to help with better understanding 
of quantitative findings (Pope and Mays, 2006). Recently, studies employing 'mixed' 
methods combining qualitative and quantitative designs have emerged. These types of 
study are expected to answer a wider range of questions and increase the reliability of 
study (Denscombe, 2007b; O'Cathain and Thomas, 2006). 
A single study may produce a false conclusion and is often in contrast with another. 
Generalisation of results from one study beyond a certain condition is often limited. In 
this respect, reviews are a useful toot to draw together sometimes inharmonious 
evidence. Nowadays, researchers, practitioners and policy-makers are overwhelmed 
with unmanageable amounts of evidence. Thus, easily accessible, up-to-date evidence 
is as essential for further evidence-based studies. Moreover, reviews can highlight 
fields that are neglected in research. However, conventional narrative reviews often 
suffer from poor quality and are often regarded as another unreliable source of 
information (Egger et al., 2001). By contrast, a systematic review has a predefined, 
explicit, reproducible protocol involving several steps. A protocol contributes to the 
minimisation of bias and reduces uncertainty in comparison with a narrative review, 
allowing a more transparent appraisal (Egger et al, 2001). 
2.6.3 Evaluating pharmaceutical policy in South Korea 
Before moving onto the framework of methods for the thesis, it is useful to tackle the 
common weaknesses of the preceding research of Korean pharmaceutical policies to 
highlight the contributions of this thesis to the existing literature. 
First, pharmaceutical policy evaluation has been made on limited subjects in South 
Korea. Little Is known about the impact of the most of policies on pharmaceutical 
spending and utilisation, although many policies have been Introduced. Any existing 
studies have been dedicated primarily to investigating the separation policy (SPD). 
Second, the Impact of the policies on medication for chronic diseases is largely under. 
studied. Although the HIRA has assessed prescribing practices since 2001, it Is likely to 
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be limited to certain particular parameters, mostly assessing medication for acute 
conditions - including antibiotics, NSAIDs and gastro-intestinal preparations. 
Third, robust methods have rarely been employed. Lack of proper statistical analysis is 
a widespread problem across studies. Most evaluations for pharmaceutical policies in 
Korea have used the intuitive pre-post comparison approach so far (Cho etal., 2003; 
Cho et al., 2002; Cho et al., 2001; Jang et al., 2001; Lee et al., 2001). Some used a 
time series design, but without a proper statistical analysis or only over a short time 
period (Kim, 2002b; Kim, 2005; Lee and Malone, 2003). 
A pre-post design with small data points can be subject to numerous possible threats 
to validity such as maturation, history, testing, and attrition (Shadish et al., 2002b). 
Given that many confounders probably exist In a rapidly changing environment like 
South Korea, researchers should have considered employing a more robust design to 
avoid biased conclusions. For example, in 1999 a year before the SPD, there were two 
important changes which might have promoted the use of brand-named drugs- the 
deregulation of the market approval process for new entities (DailyPharm, 1999b) and 
the expansion of benefit coverage for expensive brand-named drugs (Ministry of 
Health & Welfare, 1999a). Nevertheless, few researchers took this Into consideration 
when they examined changes in the utilisation of expensive drugs before and after the 
SPD. 
A short period of data collection seriously damages the credibility of studies. In the 
existing evidence on Korean pharmaceutical policy, authors often used a single month 
or an even shorter period of claims data before and after the intervention (Cho eta/., 
2003; Cho et al., 2002; Cho et al., 2001; Jang eta/., 2002; Jang eta/., 2001), or a 
single month every year over one or two years (Kim, 2005). 
Fourth, there was no reliable dataset before the SPD. One of the greatest challenges 
for Korean researchers in policy pharmaceutical studies is the lack of a comparable 
national database relating to the consumption of pharmaceuticals before the year 2000. 
Hence, many researchers depended on data collected using a cross-sectional survey 
with small study population in order to fill the gap between the national claims 
database and real consumption (Cho et al, 2003; Cho et al., 2002; Cho et al., 2001; 
Jang etal., 2001). Results were varied across sample groups even within a single study 
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although participants were randomly selected. 
To summarise, although many studies were conducted to examine the impact of 
Korean pharmaceutical policies on drug spending and prescribing behaviour, evidence 
from empirical research still seems fragmented, spurious and in short supply. Certainly, 
there is a great need to evaluate the impact of the SPD and other subsequent changes 
on the pharmaceutical market over a longer-term period with well-designed methods in 
Korea. 
This study, therefore, was carried out in order to extend empirical evidence of the 
impact of Korean pharmaceutical policies and to explore what have been the barriers to 
evidence-based policy-making. Table 2-9 illustrates designs and research methods 
employed in this thesis to study and evaluate pharmaceutical policy. In the table, four 
studies are displayed including either the research or evaluation questions posed as 
well as a specific chapter in which the results of each study are presented. 
Table 2-9: Methodological framework for the thesis 
Study Research/evaluation questions Design Methods used 
1) What was the Impact of 
pharmaceutical policies on drug 
Evaluation of current costs, utilisation, other 
resource use Systematic Systematic reviews: 
drug policy evidence and 
health? review 1) policies influencing patients (Ch 4) 
(Ch 3) 2) policies Influencing providers (Ch s) across nations 2) What was the methodological 3) policies influencing Industry (Ch 6) 
strength and weakness of studies 
evaluating pharmaceutical policies? 
Evaluation of the 
pa What was the impact of the policy 
Quasi- Interrupted time series analysis of drug 
Im ct in Korean changes on drug costs, utilisation experimantal 
costs, utilisation and prices data 
market and prices? study 
(Ch 8) (Ch 9) 
Evaluation of the changes 
What was the impa 
coft to 
policy 
Quasi- 
Interrupted time series analysis of cost 
and drug utilisation data of two Impact of drug 
policies In essential 
essential drugs? experimantal therapeutic categories grouped Into 
drugs market 2) What was the impacts of the 
study (Ch 8) brand-named and generic drugs 
(Ch 10) 
changes on generic utilisation? 
Investigation of What makes It difficult to formulate Qualitative 
Semi-structured questionnaire and 
telephone Interviews with key policy- Korean policy- evidence-based policy-making in study (Ch 12) makers, and framework analysis making stance South Korea? (Ch 12) 
To draw appropriate lessons, it is essential to explore how programmes work elsewhere. 
Thus, firstly, systematic reviews are conducted to Investigate existing evidence 
internationally. These provide the opportunity to learn general policy lessons from 
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foreign experience and to gain understanding of the contextual surroundings that may 
make a policy succeed or fail. Careful evaluation of international experience could also 
suggest ideas for future Korean policies in seeking the best strategy, with consequent 
benefits to society. Another equally important purpose of reviewing preceding studies 
is to widen the knowledge of methodological designs. With such goals, only the three 
most rigorous designs, RCT, ITS and CBA are included in the systematic reviews of this 
thesis. 
Following the systematic reviews, empirical research is performed both quantitatively 
and qualitatively. For quantitative investigation, ITS designs are employed to examine 
the impact of two Korean pharmaceutical policies using prescription claims data. Two 
quantitative studies are conducted; one deals with general outcomes, the other 
investigates the consequences of the policy interventions by analysing subgroup data. 
Quantitative studies illustrate that there are considerable limitations in research. 
Primarily, quantitative approaches have proven particularly challenging for exploring 
certain subjects because of the low availability of valid data. Faced with such 
limitations, a qualitative study is performed to address the stance and the challenges of 
evidence-based policy-making in Korea from the standpoint of Korean policy-makers 
and those who influence policy. Interviewing local policy-makers and influencers also 
offers a valuable opportunity for understanding policy environments in a local context. 
Details of the three different study techniques will be presented at the beginning of 
each part in Chapters 3,8 and 12, 
2.6.4 Summary: Evaluating pharmaceutical policy outcomes 
Globally, the significance of evidence-based policy-making increased in importance in 
the area of public policy. Accordingly, the demand for good evidence is growing, but 
the supply of available evidence is still limited in relation to pharmaceutical policies. 
Studying pharmaceutical policies is challenging because the presence of unknown 
factors potentially influences the policy impact. Good study design may reduce external 
confounding and increase the reliability of research. 
In a Korean context, previous studies often demonstrated common shortcomings such 
as poor study designs, short-time frames, or the lack of reliable data. Although new 
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strategies continue to be introduced, evaluation activity still seems weak. Little Is 
known either about the impact of current strategy, or about how contextual factors 
affect policy decisions and policy effects. This thesis will undertake a quantitative 
investigation of how current strategies are working in the Korean context. Issues 
relating to contextual factors are also addressed in a qualitative investigation. 
2.7 Summary 
This chapter explores realistic issues in studying pharmaceutical policies focusing on 
two aspects: contextual-specific influential factors; and methodological factors. At the 
beginning, the Korean health care system and pharmaceutical policies were outlined to 
describe this particular local arrangement, showing that pharmaceutical policy-making 
in South Korea is at a crossroads in this decade. The traditional structure has been 
removed, but a new one has not yet been firmly established. In the following sections, 
the salient characteristics seen in the Korean pharmaceutical arena were explored from 
five perspectives: pharmaceutical expenditure; health status; economic and resource 
capacity; political; and cultural context, which support the argument that the 
pharmaceutical strategy requires a different set of tools and knowledge to cope with 
fundamental differences within each context. The second part of this chapter 
addressed the global trend of evidence-based policy-making and several methods 
frequently employed in policy evaluation. Finally, the chapter returned to the Korean 
context to highlight the weaknesses of pharmaceutical policy studies previously 
conducted in Korea. This emphasises the contribution of the thesis to the existing 
literature and the strength of study designs that were presented at the end of the 
chapter. 
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PART 2 SYSTEMATIC REVIEW: 
EVIDENCE ACROSS NATIONS 
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CHAPTER 3: DESIGN OF SYSTEMATIC REVIEWS 
3.1 Introduction 
The first two chapters examined some underpinning rationales and Intended 
mechanisms of pharmaceutical policy. Chapters three to seven explore existing 
experimental and quasi-experimental evidence about policy impact in the 
pharmaceutical arena from three angles: pharmaceutical policies Influencing patients, 
providers, and industry. Three systematic reviews identify rigorous evaluative studies 
and examine them to assess the impact of pharmaceutical policies. 
International experience plays a principal role in constructing a store of knowledge in 
this field. Lessons from foreign experience are evaluated for several pragmatic reasons. 
Some countries share common problems such as demographic changes, technological 
advances, expenditure inflation, finite resources and the growth of global 
pharmaceutical companies, as the society is developed and economically globalised 
(Blank and Burau, 2010a). The distinction between national and international problems 
is blurred In certain quarters. Hence, if policy-makers can learn a proper lesson from 
foreign experience, it may be a shrewd way of saving effort. In addition, there is 
Inevitably a considerable time-lag between implementation and evaluation of policy. 
Thus, lessons from overseas experience may help policy-makers to avoid repeating 
foreign mistakes In their own arrangements before proper evaluation. 
In relation to this project, studying the experience of the international community 
provides a chance to learn the general mechanisms of interventions and to understand 
the original environment which makes them work or fail. This may offer an opportunity 
to learn the strengths and weaknesses of policy programmes, providing insights for the 
Korean pharmaceutical policy, and this effort is also essential to draw lessons from 
empirical studies In Part 3. 
Already, there are several reviews of particular pharmaceutical policies, such as'cost- 
sharing and prescription limits' (Soumerai eta/., 1993), 'educational approaches to 
providers' (Soumerai etal., 1989), 'prior authorisation' (MacKinnon and Kumar, 2001), 
'reference-pricing' (Danzon and Ketcham, 2003; Ioannides-Demos et at., 2002; Lopez- 
Casasnovas and Puig Junoy, 2000) and 'restricted formulary' (Levy and Cocks, 1999; 
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Upsy, 1992; Pearce and Begg, 1992). More broadly, some studies reviewed various 
pharmaceutical regulations in European arrangements (Ess eta/., 2003; Guillen and 
Cabiedes, 2003), In the US context (Kozma et al, 1993; Reeder etal., 1993), or In the 
global context (Bloor and Freemantle, 1996; Bloor eta/., 1996; Freemantle and Bloor, 
1996). None of these studies were conducted systematically and many of them focused 
primarily on policy review, not on actual impact. 
Some reviews were conducted systematically, but the Information becomes out of date. 
One study reviewed pricing mechanisms, focusing on regulation rather than Impact 
(Mrazek, 2002). Gosden and Torgerson (1997) reviewed evidence relating to the 
effects of UK fundholding on prescribing and referral costs. One study reviewed drug 
policies in developing countries between 1966 and 1999, and found no studies 
conducted by robust research designs such as a randomised controlled trial (RCT), a 
controlled before and after (CBA) or an interrupted time series (ITS) design 
(Ratanawijitrasin eta/., 2001). 
There are some existing recent systematic reviews. Goldman et al. (2007) carried out a 
systematic review of primary studies of cost-sharing programmes, defined 
comprehensively, Including copayments, tiering, coinsurance, benefit caps, reference- 
pricing, prior-authorisation and formulary restrictions without any limitations In study 
designs. Puig Junoy and Moreno Torres (2007) conducted a systematic review on prior- 
authorisation. Three reviews were carried out by the Cochrane collaboration; two 
focused respectively on 'pricing policies' (Aaserud etal., 2006a) and 'financial 
Incentives' (Sturm et al., 2007) prior to the current review and one addressed `cap and 
copayments' (Austvoll-Dahlgren et al., 2008) concurrently with this review. Most 
reviews focus on a limited set of interventions and do not provide a comprehensive 
overview about the effect of the wide range of policy Interventions used Internationally. 
The present review has three alms: 
1) To compile the evidence of the impact of pharmaceutical policies applied 
Internationally, which will be useful for researchers and policy-makers in general; 
2) To analyse the evidence available for South Korea; and 
3) To identify and analyse the methodological weaknesses in studies that 
employed a robust study designs, which will help improve the quality of evidence 
in future studies, 
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This chapter details the search strategy, Inclusion criteria, quality assessment, data 
extraction, and data analysis. The chapter closes with an overview of Identified studies. 
The next three chapters (Chapters 4,5 and 6) will present the results of each review on 
outcome variables of Interest; that is separately for patients, providers and industry. 
Methodological Issues and overall findings from the three reviews will be addressed in 
Chapter 7. 
3.2 Methods 
3.2.1 Search strategy for identification of studies 
Published studies were identified with an electronic search using two major databases 
(MEDLINE and EMBASE from 1980 to 2007). This search was conducted In the middle 
of April 2008. Search strategies were developed from strategies used in the Cochrane 
reviews exploring pharmaceutical policies (Aaserud et al., 2006a; Aaserud et al., 
2006b; Sturm etal., 2007). 
For identifying pharmaceutical policies Influencing patients, the strategy Included such 
terms as 'cost-sha ring, 'out-of-pocket, 'copay (or copayment), 'coinsurance, 
'deductible, 'charge', 'fee', 'direct-to-consumer', 'over-the-counter, 'benefit limit; 'caps, 
'tiered benefit, 'drug information service, and 'patient education' alongside several 
terms Indicating pharmaceuticals (Annex 2). 
In order to identify pharmaceutical policies Influencing providers, the strategy included 
the terms `reimbursement restriction (or policy)', 'formulary`, 'positive (or negative) list', 
'benefit plan', 'step-therapy', 'prior-authorisation 'drug (or global/local) budget, 
'fundholding; `capitation; `salary, `incentive; `quality framework or paymentI' 'drug 
information, 'drug feedback (or monitoring), 'academic detailing, 'outreach visit, 
`guideline, `protocol', 'generic policy (or substitution/prescribing); and 'quality payment' 
combined with terms indicating pharmaceuticals (Annex 3). 
To Identify pharmaceutical policies regulating Industry, the strategy Included terms 
'market authorisation; 'licensing, 'price (or pricing), 'patent regulation, 'profit control 
(or return), 'advertising, 'generic market, 'labelling, and 'competition' with 
pharmaceutical policy terms (Annex 4). 
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No language restriction was applied. Additionally, the reference lists of all potentially 
relevant reviews were scrutinised to ensure that all potentially relevant studies were 
identified (Gray, 2001c; McDonald eta/., 1996). In particular, this review expanded the 
information from the previous Cochrane studies by including studies in the lists for 
awaiting assessment in the Cochrane studies if they were satisfying the inclusion 
criteria in relevant policy interventions. 
3.2.2 Study selection criteria 
3.2.2.1 Types of intervention 
A study was Included in the reviews If the article explored the effect of at least one 
pharmaceutical policy. Pharmaceutical policies defined and Implemented by 
government, non-government organisations or private Insurers that were intended to 
directly affect the use or cost of drugs were Included. 
3.2.2.2 Types of studies 
The reviews Included studies with true experiments and strong quasi-experiments. 
A study design was clarified according to the Cochrane Effectiveness Practice and 
Organisation of Care collaborative review group (EPOC) definitions as follows 
(Cochrane Effective Practice and Organisation of Care Review Group, 2002): 
  Randomised controlled trial (RCT): a study in which the participants (or other 
units) were assigned prospectively to one or two (or more) alternative forms of 
health care using a process of random allocation 
" Interrupted time-series design (ITS): a study in which there is a clearly 
defined period of intervention and at least three data points before and three data 
points after the Intervention 
" Controlled Before and After study (CBA): Involvement of intervention and 
control groups other than by random process, and inclusion of baseline period of 
assessment of main outcomes 
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3.2.2.3 Types of participants 
Participants were healthcare consumers and providers within a large jurisdiction or 
system of care. Jurisdictions could be organisational, regional, national or International. 
3.2.2.4 Types of outcome measures 
A study was included in the reviews if the article investigated at least one of the 
following outcome categories: 
Pharmaceutical expenditure 
  Pharmaceutical prices 
  Pharmaceutical utilisation 
  Other resource utilisation/ relevant costs relating to pharmaceuticals 
" Health outcomes relating to pharmaceuticals 
N Patients' or providers' behaviour changes concerning pharmaceuticals 
3.2.2.5 Exclusion criteria 
Studies were excluded from the reviews if they met any of the following criteria: 
  Interventions conducted within a single hospital or clinical practice were 
excluded to reduce potential confounding by the characteristics of a study 
Institution. It was thought that the way in which the intervention affected 
participants within a single institution would differ considerably from that in multi- 
centre study. 
  Pharmaceutical care services or disease-managed care were excluded. 
Pharmaceutical care services were excluded because they comprised of another 
wide-ranging field of research, focusing on the new roles of clinical pharmacists 
and collaboration among stakeholders rather than just pharmaceutical regulations 
(Guillen and Cabiedes, 2003). Disease-managed care studies were excluded 
because they were more likely to focus on the Improvement of patient compliance 
to a course of medical prescription Including diet, exercise, life style as well as 
medications to `manage'their Illness (e. g. Eccles etal., 2002). Hence, these would 
be out of the scope of this review. 
  Studies with less than a 6-month follow-up were excluded In order to avoid 
biases from any transition phase and to focus on longer term effects of 
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interventions. 
ITS studies with less than 12 months study period (overall) were excluded to 
avoid bias from secular trends. 
  CBA studies were excluded if data were not collected contemporaneously or 
the author(s) failed to demonstrate rationales for the choice of control site or 
activity. 
Studies were excluded if they did not provide relevant and interpretable data 
because it would be hard to appraise the quality of the study. 
3.2.3 Study quality assessment 
The quality assessment criteria for each study design were developed based on the 
standard criteria recommended by the EPOC and Centre for Reviews and Dissemination 
to assess the methodological limitations of studies (Centre for Reviews and 
Dissemination, 2001; Higgins and Green, 2008). On each criterion, the reviewer scored 
CLEAR when a paper satisfied the criterion, UNCLEAR when a paper did not provide 
enough information to judge, NONE when a paper provided no information on the 
criterion, or when it was clear that the study did not meet the criterion. All figures and 
tables were closely investigated to confirm whether their practices were in line with 
their statements. Details of quality criteria are presented in Annex S. 
The quality criteria for an RCT study were: 
1) concealment of allocation; 
2) blinded assessment of primary outcome(s); 
3) baseline measurement; 
4) reliable primary outcome measure(s); 
5) employment of an intention-to-treat analysis; 
6) attrition rate; and 
7) reasons for drop-out of participants explained. 
The quality criteria for an ITS study were; 
1) protection against secular changes; 
2) data were analysed properly; 
3) reasons for the number, of points pre and post intervention given; 
4) shape of the intervention effect was specified; 
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5) use the same methods of data collection before and after the intervention; 
6) blinded assessment of primary outcome(s); 
7) completeness of data set; and 
8) reliable primary outcome measure(s). 
A conservative standard was set on the criterion 'protection against secular changes. 
Authors suggest considerably different ideas on the number of data points able to 
control secular trends from more than 100 (Shadish et al., 2002c) to 12 before and 
after the intervention (Wagner et al., 2002) (see Chapter 8 for more details). In the 
present review, it was scored 'HIGH' If the number of data collection points were 1) 
more than 50 before and after the intervention in studies using ARIMA models, or 2) 
more than 12 before and after the intervention (i. e. Included four seasons in each 
period) in studies using segmented regression; scored `MEDIUM' if the number of 
data collection points were 1) between 49 and 20 before and after the intervention in 
studies using ARIMA models, or 2) between 11 and 4 before and after in studies using 
segmented regression and the study period included four seasons in each period (for 
example, 4 quarterly data points before and after); and scored `LOW' if studies did not 
meet the above criteria. 
The quality criteria for a CBA study were: 
1) baseline measurement; 
2) characteristics for control group(s); 
3) reliable primary outcome measure(s); 
4) attrition rate; 
5) reasons for drop-out of participants explained; 
6) blinded assessment; and 
7) protection against contamination. 
3.2.4 Data extraction, analysis and presentation 
The following additional information was extracted from included studies using a data 
extraction form designed for the present reviews: 
" characteristics of the participants; 
  characteristics of the intervention(s); 
a study setting; 
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  main outcome(s); 
" study duration; 
  the results for the main outcome measures; 
  the sponsors of the study. 
Crucial findings such as study design, intervention, population in the study and the 
control groups, study drugs, primary outcomes, conclusions, relative effect sizes, and 
settings were tabulated in summary tables by intervention. If there was more than one 
time point measuring outcomes, results from the longest point were taken in this 
review. But meaningful mid point outcomes were also discussed in the context. In 
cases where a study employed two or more study designs, the primary design was 
generally included. For example, Knowlton and Knapp (1994) compared intervention 
pharmacists with a control assigned by randomisation (RCT) as well as with another 
control group from a different geographic region (CBA). In this case, outcomes from 
the RCT were firstly taken into account; those from the CBA were also considered in 
context if necessary, 
Regarding educational interventions targeting providers, many interventions were 
observed with just a slightly different form one to another. It was difficult to 
differentiate clearly between them because many of them employed a multifaceted 
strategy rather than a single intervention. They were often overlapping each other. In 
this review, educational interventions were categorised according to: firstly, the 
materials distributed such as guidelines, protocols, prescribing feedbacks or drug 
utilisation reviews; and, secondly, the methods of dissemination, such as passive 
contacts, group detailing, individual contacts, or computerised devises. 
It is usual In policy evaluation studies, that baseline characteristics of the intervention 
group and those of the comparison group might differ (Cochrane Effective Practice and 
Organisation of Care Review Group, 2001). To adjust for the baseline imbalance, the 
effect size was presented as a relative percent change. In cases where both empirical 
numbers in the pre- and the post-intervention period were available, the proportion of 
relative change was computed as presented in Table 3-1. 
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Table 3-1: Calculation of relative changes warn.. nrarr+wi r rr r m"+ 
baseline post differences % changes 
study group ab b-a e= {(b-a)/a}x100 
control group cd d-c f= {(d-c)/c}x100 
relative changes e-f 
(Cochrane Effective Practice and Organisation of Care Review Group, 2001) 
In other cases, if primary authors provided a relative effect size and they did not 
present a complete set of pre and post scores, change scores provided by authors 
were extracted; if such scores were not reported, only primary authors' conclusions 
were presented. For studies with no comparison group, primary authors' conclusions 
were also quoted. Level and slope changes in studies using an ITS design were 
illustrated in cases of statistical significance. Absolute changes in real terms (e. g., $10 
per capita expenditure differences between groups) were not considered highly 
significant because there seemed little value in comparing such effect sizes across 
countries with different currencies and economic conditions, or across time periods 
with almost a three-decade gap. 
3.3 Overview of studies and interventions included 
Overall, 176 studies were included across the three reviews, Six studies were reviewed 
multiple times because they explored different interventions within a single study. Thus, 
the number of studies included is 184 by intervention. Table 3-2 summarises the 
Intervention studied for each review. 
85 
Table 3-2: Intervention and studies included 
Intervention Number of studies 
polkies influencing patients 46 
Cost-sharing 30 
Tiered formularies 9 
Prescription caps 5 
Educational approach 1 
Over-the-counter switch 1 
policies influencing providers 119 
E ducatiomrl approaches 63 
Reimbursement restrictions 33 
Incentives 17 
Distribution of samples 3 
Mandatory generic substitution 1 
Repeat prescribing i 
Separation policy 1 
policies regulating industry 19 
Price control- reference-pricing 13 
Price control- others 3 
Market authorisation 1 
Patent regulation 1 
Profit control 1 
Total 184 
3.4 Summary 
This chapter summarises the methods employed for the systematic review of 
pharmaceutical policies. In principle, the methods, criteria, definitions used by the 
Cochrane EPOC were adopted. Studies published from 1980 to 2007 were identified 
with an electronic search using two major databases in April 2008, each study was 
assessed against pre-defined inclusion and exclusion criteria, and 176 studies were 
finally included. Results from the reviews are presented in the following three chapters 
grouped into three sectors: pharmaceutical influencing patients, providers, and industry. 
Lessons learned from the reviews and implications will be discussed in Chapter 7. 
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CHAPTER 4: THE EFFECTS OF PHARMACEUTICAL REGULATIONS 
INFLUENCING PATIENTS 
4.1 Introduction 
The objective of this chapter is to present findings from the systematic review 
examining pharmaceutical policies Influencing patients, In brief, studies for the first 
review were identified from two major databases, MEDLINE and EMBASE, and were 
included if the article (1) explored the effects of pharmaceutical regulations aimed at 
influencing patients; (2) examined the effects of such interventions on at least one of 
the relevant outcomes depicted in Chapter 3; (3) analysed primary or secondary data; 
and (4) performed this with one of three most robust designs, RCT, ITS, or CBA. 
Details on method were presented comprehensively in the preceding chapter. 
4.2 Overview of included studies 
From the search (the strategy is illustrated in Annex 2), 287 studies were identified 
(Figure 4-1). Fifty-six studies were retained after the initial screening of titles and 
abstracts. From these 56 studies, 44 met the inclusion criteria (see Table 4-1). Two 
studies were included twice because they explored two different interventions - cost- 
sharing and prescription capping (Starmans etal., 1994), or over-the-counter (OTC) 
switch (Gurwitz et al., 1995). 
The large majority of studies explored the effects of 3 Interventions: cost-sharing 
(n=30), tiered formularies (n=9), prescription capping (n=5). Single studies explored 
the effects of an educational Intervention, and OTC switch programme. No studies 
addressing direct-to-consumer (DTC) advertising satisfied the inclusion criteria. 
Reasons for exclusion are reported in Figure 4-1 and Annex 6. 
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Figure 4-1: Flow diagram of studies (patients) 
Studies identified n= 287 
" Medline (n 158) 
" Embase (n 102) 
" References (n=27) 
Excluded n=88 
  duplicates 
Studies retained for initial 
screening of titles and abstracts 
n=199 
Excluded n=143 
" exploring irrelevant interventions 
Studies retained for screening of 
quality assessment 
n= 56 
Excluded n=12 
" before and after study design (6) 
" less than 6 months (3) 
" posttest only control group design (3) 
Studies eligible for inclusion 
n= 46* 
" Cost-sharing(30) 
" Prescription caps (5) 
" Tiered formularies (9) 
" Educationala proach(1) 
" OTCswitch(1) 
* Two studies were included twice because they explored multi-interventions. (Gurwitz et al., 1995; 
Starmans etal., 1994) 
Table 4-1: Studies included 
Intervention Studies 
Aknarsdottr et a/. 2000, Andersson et a!. 2006, Blas et a/. 2001, Blais et al. 
2003, Foxman et a/. 1987, Gibson eta!. 2006, Gurwitz et al. 1995, Harris et 
a/. 1990, Holloway et a/. 2001, Hughes and McGuire 1995, Johnson et al 
1997, Kephart et al. 2007, Kiepser eta!. 2007, Kozyrskyj eta!. 2001, Lavers 
Cost-sharing 30 1989, Lee et al. 2006, Lebowitz et al. 1985, Liu and Romeis 2004, Martkanen 
eta/. 2007, McManus eta!. 1996, Nelson eta!. 1984, O'Brien 1989, Ong et 
a/. 2003, Reeder and Nelson 1985, Roblin et a/. 2005, Ryan and Brch 1991, 
Starmans et al. 1994, Sun and Lee 2007, Tamblyn at al. 2001, Wnkeknann 
2004 
Tiered Farman et al. 2003, Gbson et a/. 2005, Huskamp et al. 2003a, Huskamp et 
formularies 9 a/. 2005, Landon et al. 2007, Landsman et a/. 2005, Motheral and Fairman 
2001, Motheral and Henderson 1999b, Nar et al. 2003 
Prescription 
5 
Martin and McMdan 1996, Soumerai et al. 1987, Soumerai et al. 1994, 
caps Soumerai et al. 1991, Starmans et al. 1994) 
Educational 
1 Vales et al. 2003 approach 
OTC swtch 1 Gurwtz et a/. 1995 
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4.3 Policies influencing patient demand 
The interventions which appeared most frequently were a cost-sharing schemes across 
settings. These required patients to pay a fixed or a proportional charge of the cost of 
a prescribed drug. Cost-sharing structures have been changed over time from a simple 
flat rate copayment to a more complicated form, such as coinsurance or tiered 
copayments. 
In some countries, the share of private pharmaceutical expenditures have increased 
over time (Jacobzone, 2000). As the proportion shared by patients has risen, concerns 
about inequity have increased. As a result, cost-sharing structures have become 
combined with safety net exemptions. Examples seen in the reviewed studies included 
an annual maximum ceiling that appeared universally across countries from the West 
to the East, pharmaceutical allowances for a disadvantaged group in Australia, or an 
Income-based formulary in Canada to avoid excessive suppression in the demand for 
drugs. These may lessen net policy effects. 
Many commercially managed health plans in the US employed complex interventions 
such as tiered formularies to reduce the use of expensive drugs. Tiered formularies In 
the retrieved studies have two kinds of structure according to the method of 
categorising medications Into each tier; they have a generic/brand-named drugs 
structure, in which a lower copay tier is allocated to generics and an upper one for 
brand-named drugs (2-tier), more recently, for formulary and non-formulary brand- 
named drugs (3-tier). 
Prescription capping places limits on reimbursable amounts per patient within certain 
time periods. Interventions included were 'a three-drug monthly payment limit' or'a 
five-prescription limit' in American Medicaid programmes, or'prescription regulation' 
which restricted prescribing for each prescription item to dosages for a 30-day 
maximum in the Netherlands. OTC switch is also used in attempts to reduce patient 
demand by shifting products from lists of reimbursable drugs to over-the-counter 
purchasing. In one Spanish study, an educational approach was employed to deliver 
information on use of generics. Basic characteristics of the included studies and 
outcomes from the review are discussed In the following sections according to 
intervention. 
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4.4 Cost-sharing schemes 
4.4.1 Characteristics of included studies 
The basic characteristics of included studies are presented in Annex 7. Evidence for 
cost-sharing programmes came from various settings, although 16 out of 30 (53%) 
studies were from North America. All but two RAND studies (Foxman et al., 1987; 
Leibowitz etal., 1985) employed a quasi-experimental design, CBA (n=8) or ITS 
(n=20). Among the eight CBA studies, six selected a comparison population in a 
comparable plan or place, or a comparable activity. The other two studies from 
Germany and Taiwan used the exempted population as a comparison group, and 
baseline differences between groups seemed to be more problematic (Liu and Romeis, 
2004; Winkelmann, 2004). Most studies followed up in a short or Intermediate time 
period; only four British studies tackled a long-term effect of more than 60 months. 
Most studies used aggregated claims data held at an organisational level, but six 
studies employed market sales data, constructed by commercial companies such as 
IMS Health, data constructed for the RAND experiments, carbon copy prescriptions, or 
a national annual survey. 
4.4.2 Impact on drug utilisation 
Twenty-six studies examined the effects of cost-sharing on the use of pharmaceuticals. 
Cost-sharing programmes have been shown to lower drug utilisation significantly in 
most settings (Table 4-2). Across studies, it was observed that copayments might lower 
not only discretionary drugs, but also essential drugs (including anti hypertensives, 
asthma drugs, oral hypoglycemics, statins) to a considerable degree when priced 
moderately. Conversely, small copayments might fail to Influence patient demand. 
However, we must be cautious in our interpretation as the studies were of mixed 
quality. There appeared to be little relationship between the study findings and quality. 
Evidence Is very limited regarding the association of cost-sharing with increases In the 
utilisation of generics. Among three studies addressing this issue, only one study 
suggested that beneficiaries exceeding the reimbursable limit tended to consume 
generics about 20% more than those below this limit (Sun and Lee, 2007). However, 
this was not supported by the other two studies, which used a more balanced control 
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population. (Klepser eta/., 2007; Leibowitz et al., 1985). 
Table 4-2: Impact of cost-sharing on drug utilisation 
on overall on specific drugs Study Population 
utilisation Essential Less-essential 
Setting 
Introduction of cost-sharing programme in Western Europe 
no change- 
Starmans eta/. 1994 General higher (+6- +14%) or Nettierlands 
lower (-4' -9%) 
Increased cost-sharing in Western Europe 
Anderson etaI 2006 
no change (smaller policy changes) 
[nixed') (larger policy changes) Sweden 
Ong et al. 2003 no cnange« ngner 
Hughes and McGuire lower 
1995 C neral 
Lavers 1989 lower UK 
O'Brien 1989 lower 
Ryan and Birch 1991 lower 
[creased cost-sharing in Western Europe 
Martlkainen ct al. 2001 C1ýner al higher (+21"- +109%) Finland 
Introduction of cost sikirrng programme In ft rth America 
Foxrnan of . ii. 1087 
lower (-46%) 
Harris et al. 1990 General 
lower no change- lower (-11-- -16%) USA (-8' -10%) lower (-13%) 
Leibowitz etat. 1985 lower (-22ti -39%) 
81ais etat. 2003 
no change- 
lower (-37%) 
Canada 
Vulnerable no change- no change" Kephart eta!. 2007 lower (smaller) lower (-5- -15%) 
Nelson et a/. 1984 lower (-3ti -11%) USA 
Jncreased cost-sharing In Mirth America 
Gibson eta/. 2006 lower 
Gurwitz etal. 1995 no change 
Kiepser etal. 2007 General no change lower (-4- -6°hß) 
USA 
no change Roblin et at. 2005 N 
61ais et al. 2001 
Kozyrskyj eta/. 2001 
Tamblyn eta/. 2001 VuIr enable 
lower ( 9- 16% 
Johnson et al. 1997 no 
change- 
lower (_6- -8%) 
Sun and Ice 700! luwor ( 18%) 
Introduction of cost-sharing programme in other settlrnc s 
Liu and Romeis 2004 luwcr (ýi! 4 ) 
Vulnerable 
McManus et iL. 1996 (1) 
kirreasr d cast-stkaring In other settings 
Holloway et a/ 2001 no 
change 
General lower (-21- -310%) 
lower (-1 %o) 
no change no change 
lower (-15%) Canada 
lower ( 9-- - 19%) lower (15- -22%) 
USA 
lower ( 26%) lower (-38%) Taiwan 
lower (smaller) lower Australia 
Nepal 
McManus et at 1996 (2) lower (-18%) 
1) no change-, lower (levels), lower or higher (slopes) 
lower (-25%) Ausiralii 
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Based on evidence from included studies, this review found a number of factors 
Influencing the size of the impact of cost-sharing on drug utilisation: 
First, the size of effect varied across drugs as displayed in Annex 8. In spite of this, one 
very general figure from the reviewed studies was that use of discretionary drugs 
tended to decrease at a greater rate than essential drugs. In Sweden, the cost-share 
scheme did not change the market trend, such as the explosive use of psychiatric 
drugs (Ong et al., 2003). 
Second, the level of cost-share or magnitude of change resulted in various effects. The 
greater the cost-share or changes that occurred, the greater the effects. In the US, 
Harris et al (1990) demonstrated that copayments smaller than a certain threshold 
($3) could have a selective influence on non-essential drug utilisation. Roblin et al. 
(2005) found that a large increase in cost-sharing (>$10) reduced the utilisation of oral 
hypoglycaemic agents by 18.5%, which was at least twice the other two levels of cost- 
sharing - an increase of small ($1-6) and moderate ($7-10) amounts showing a non- 
significant decrease. In Sweden, smaller changes did not affect the upward trend of 
drug utilisation in the switch from copayment to coinsurance with a stepwise scale 
(Andersson et al., 2006). 
Third, the patientcspecific situation could generate different results. Evidence from 
included studies supported the fact that patients who were newly diagnosed were 
more likely to give up their medication (Gibson etal., 2006). The presence of annual 
payment limits could diminish the reduction effects of cost-sharing programmes 
because it influenced only those patients who were unlikely to reach the limit (Kephart 
et a/., 2007). But it is hard to discern from this review whether the vulnerable 
population is more likely to be affected by cost-sharing (Table 4-2). 
Fourth, the measurement units used by the researcher could generate different results. 
This was often seen in utilisation outcomes because the level of drug utilisation could 
be presented in various ways, such as the number of prescriptions issued, the number 
of days prescribed per person(s) or prescription(s), and the number of drug doses 
prescribed per person(s) or prescription(s), One Dutch study suggested that 
prescribers reduced the number of prescriptions but Increased the prescription size 
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when copayment per prescription was introduced; as a result, no significant change 
was actually made (a limitation on size brought reverse results in the same study, 
illustrated later in the section on prescription capping) (Starmans eta/., 1994). There is 
an implication that a single facet of drug utilisation may mislead the researcher into 
overestimating policy effects. 
4.4.3 Impact on drug expenditure 
Of the thirty studies, twelve explored the impact of cost-sharing on drug expenditure. 
As shown in Table 4-3, most studies examined drug spending from a payer's 
perspective and produced mixed outcomes. 
Table 4-3: Impact of cost-sharing on drug expenditure 
Drug expenditure Study Population Setting 
Overall Payer Out-of-pocket 
Increased cost-sharing In Western Europe 
Alrnar, clottir no change Iceland 
et al. 2000 
General 
Andersson et no change (copay increase) 
al. 2006 lower (stepwise coinsurance) 
Sweden 
Introduction of cost-sharing programme in Abrth Amerka 
Narr is et X. lower 
1990 (-5--7%) 
General 
Leibowitz et lower 
al. 1985 (-31 -56%) 
USA 
Nelson eta/. lower (-12- -14% until 2nd 
1984 year, -1% in 3rd year) Vulnerable 
Reeder and 
no change lower Nelson 1985 
Increased cost-sharing In I brM America 
Kiepser et al. General lower (-3%) no change no changes 2007 
Johnson eta/. lower 
1997 (-14--16%) USA 
Vulnerable 
Sun and Lee lower (-30%) higher (+94%) 2007 
Introduction ofcosst-sharing programme In other settings 
etal. General no change 2006 2006 
Taiwan 
Liu and Vulnerable 
Romeis 2004 
lower (-25%) 
Increased cost-sharing in other settings 
Holloway et General lower Nepal 
at. 2001 (- 25 - -96%) 
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In Western Europe, evidence is very weak that copayments may lower drug 
expenditure, but it was inconclusive because only two studies from Nordic countries, 
with mixed methodological quality, were included. In the US, generally studies with 
higher quality rating indicated that cost-sharing schemes reduced payers' expenditure. 
In two studies with low quality from Taiwan, a greater reduction in drug expenditure 
was observed in a vulnerable population, compared to the general population. Among 
the reviewed studies, the greatest reduction was seen in a Nepal study with moderate 
quality. Evidence concerning private expenses was extremely limited. Only two of the 
studies investigated out-of-pocket expenses. Kiepser et al. (2007) found no significant 
change in out-of-pocket among the general population. Conversely, elderly patients 
who were spending more than the permissible limit, paid 94% more out-of-pocket than 
those spending less than the limit (Sun and Lee, 2007). 
In a similar way to utilisation, the impact of cost-sharing on budgets could differ 
depending on conditions such as the amount of copayment change and drug 
classifications. Reeder and Nelson (1985) showed, unexpectedly, that the imposition of 
copayment yielded a significant reduction in expenditure on essential medications such 
as cardiovascular, diuretic, cholinergic, and psychotherapeutic drugs, rather than those 
from discretionary medications in a Medicaid population. 
4.4.4 Summary: Evidence about cost-sharing scheme 
Cost-sharing schemes have been shown to lower drug expenditure by reducing 
utilisation across settings. Despite that the included studies were of very mixed quality, 
apparent differences were not found between the high and low quality studies In terms 
of the findings. The dilemma is that small changes may fail to affect the existing trend; 
however, moderate changes could see a substantial decrease in demand for essential 
drugs. It has been thought that savings were ascribed partly to budget shifting, but 
this was inconclusive because of the paucity of evidence in the present review. Generic 
substitution effects were not supported by studies with higher quality and it seems that 
evidence about this issue is still lacking. Factors influencing the effect size may be 
study drugs, patient charges, patient conditions, and measurement units. 
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4.5 Tiered formularies 
4.5.1 Characteristics of included studies 
Nine studies examined the association between tiered formularies and study outcome 
variables. Overall these studies were of moderate quality. The basic characteristics of 
Included studies are presented in Annex 9. All studies were conducted in the US and all 
but one used a CBA design. Motheral and Fairman (2001) undertook an ITS analysis 
with a control group. Seven studies used aggregated claims data held by private health 
plans and two employed market sales data constructed by commercial companies such 
as IMS Health. All studies followed up the impact of intervention in a short or 
intermediate time period. 
All authors compared enrollees who experienced changes in a tiered structure with 
those who stayed with the same benefit structure during the pre-post change period. 
Changes were increased or decreased copayments without alteration In the benefit 
structure, or a modification of the benefit structure from a 1- or 2-tier to a 2- or 3-tier. 
Huskamp eta/. (2005) performed research with a child population. Nair eta/. (2003) 
confined their investigation to participants who suffered from at least one of five pre- 
determined chronic diseases, while others explored the impact of interventions on 
general plan members. 
4.5.2 Impact on drug utilisation 
Table 4-4 illustrates the impact of policy changes on drug use grouped by the benefit 
structure and suggests that the modification of a tiered formulary could curb an 
increase In drug utilisation. A greater decline was achieved In demand for non- 
formulary brand-named drugs as a greater Increase was made In copayments for those 
drugs; few changes were observed in the demand for generics. Only Gibson et al. 
(2005) reports an unexpectedly large decrease in the use of generics. The change 
looks sizable In a relative term, but the absolute change was actually negligible both in 
the study and control groups because the denominator (a previous generic share in 
each group) was so small. 
The magnitude of change varies depending upon the change in structure. Greater 
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changes in benefit design generally yielded a greater decrease in use, (Huskamp et a/., 
2003a; Landon et al., 2007). The effects decrease over time (Fairman et al., 2003; 
Gibson et al., 2005). Across drug classes, the demand for symptom-relief medications 
might be more susceptible to copayment increase. Two studies found that essential 
drugs (including medication for heart conditions and depression) were also more likely 
to stop after a moderate benefit structure change (Huskamp et al., 2003a; Landsman 
et a/., 2005). However, this was not observed in work by Motheral and colleagues that 
showed slightly higher quality, who found no adverse effects on the use of medication 
for chronic illnesses such as anti hypertensives and antihyperlipidemics (Fairman eta/., 
2003; Motheral and Fairman, 2001; Motheral and Henderson, 1999b). 
Table 4-4: Impact of tiered formularies on drug utilisation 
Brand-named drugs Study Overall Generics 
for nit l.. y nonforinulary 
from J-der to 24ler 
Gibson et al. lower (-22%) lower (-21%) >on91e source; 
lower ( 21%) 
2005 multi sources; lower (-6/%) 
from 1-tier to 3-tier 
Huskamp et lower (-24- 
al. 2003a (1) -34%) 
Huskamp et lower (-17%) 
al. 2005 
Landon et at, higher (+1.9'-, i't% in 3/5) 
2007 (1) no change (in 2/5) 
from 2-tier to 2-der copayment Increase 
Motheral and 
Iý'nder , nn tower (-27%) no change 
19111)b 
fiom 2-tier to 3-der 
Fairman rt 
no change no change a/. 2003 
lower ( I% in 1/5) lower (-0.9., " 4.6% in 3/5) 
no change (in 4/5) no change (in 2/5) 
lower (-27%) 
no change lower (-31%) 
Huskamp et 
no change 
al. 2003a (2) 
Landon et al, higher (+1-+3.6% in 2/4) 
lower (-2.5% in 1/4) 
2007 (2) no change (in 2/4) 
higher (+2.8% in 1/4) lower (-1''-3.6%) 
no change (2/4) 
Landsman et lower 
al. 2005 
Motheral and lower (-6%) no change lower (-4%) lower (-24%) Fairman 2001 
Nair et a/. 
unclear unclear unclear unclear 2110 3 
from 3 -her to 3-tier copayntent Increase 
1 `rrr`3on et `r/ no change no change no change 2001 (3) 
from 3-tier to 3-der copayment decrease 
Landon et al. 
2007 (4) no change no change no change 
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4.5.3 Impact on drug expenditure 
Eight out of nine studies investigated the impact of tiered formularies on drug 
expenditure. As shown in Table 4-5, in the majority of cases, benefit changes function 
on payers' (decrease) and patients' expenses (increase). Whereas the size of the 
reduction was moderate in overall expenditure (about 3-22%) and slightly larger in 
payers' expenditure (about 2N58%), the increase was much greater in patients' 
expenses (around 5N205%), compared to the absence of change. Two studies 
suggested that less intensive changes failed to curb the upsurge in expenditure 
(Huskamp et al., 2003a; Landon et al., 2007). The effects diminished over time 
(Fairman et al., 2003; Motheral and Fairman, 2001) 
Table 4-5: Impact of tiered formularies on drug expenditure 
Study Drug expenditure Overall Riyer Out-of-pocket 
from 1-der to 2-her 
Gibson et a/. 2005 lower (-2811/0) 
from 1-der to 3-der 
Huskamp eta/. 2003a no change- lower (-14--58%) higher (+118+148%) 
(1) lower (-3'%) 
Huskamp et al, 2005 no change lower (-43%) higher (+46%) 
Landon eta/. 2007 (1) 
lower (-7«-130/ in 4/5) lower (-15«-43%) higher (+13-+205%) 
no change (in 1/5) 
from 2-b'er to 2-tier copayment increase 
Motheral and lower (-22%) lower (-33%) higher (+31%) 
Henderson 1999b 
from 2-der to 3-6er 
Fairman et a/. 2003 no changes lower (-27%) higher (+47%) 
Huskamp eta/. 2003a no change - higher no change - lower no change - higher 
(2) (4-2-+3%) (-2--6%) (+5-+8%) 
Landon et al. 2001 (2) 
lower (-4«-7% in 2/5) lower (-24«- 27% in 3/5) higher (+21ý+149%) 
no change (in 2/5) no change (in 1/5) 
Motheral and Fairman lower (-7%) lower (-33%) higher (+34%) 2001 
Nair et a/. 2003 unclear unclear unclear 
from 3-der to 3-der cogayment Increase 
Landon et 3/. 2007 (3) lower (-9' 10%) lower (2»-28%) higher (+27. W3%) 
from 3-der to 3-der copayment decrease 
Landon et a/. 2007 (4) higher (+7%) higher (+29%) lower (-29%) 
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4.5.4 Summary: Evidence about tiered formularies 
Tiered formularies have been shown to lower public drug expenditure both by reducing 
the utilisation of non-formulary brand-named drugs and by budget shifting in the US. 
There was little evidence for generic substitution effects. Although a greater drop was 
seen in symptom-relief medications, the benefit structure changes accompanying the 
increase in copayments might see patients' access to essential drug constraint 
moderately. Overall, the quality of studies was generally moderate with little variation 
in findings across studies. 
4.6 Prescription caps 
4.6.1 Characteristics of included studies 
Five studies examined the effects of prescription capping. The basic characteristics of 
included studies are displayed in Annex 10. All but one study examined policy effects 
on a vulnerable population in the US Medicaid arrangements, two of which involved the 
most vulnerable patients. All included studies employed an ITS design to analyse 
claims data maintained at state organisational level (Medicaid or Sickness funds). 
Starmans eta/. (1994) collected data biannually and investigated the effects of an 
intervention more than 2 years (30 months) after the intervention, whilst others used 
monthly data and followed up policy effects for no longer than 12 months. 
4.6.2 Impact on drug utilisation 
Four studies Involving a vulnerable population showed that prescription capping 
lowered drug utilisation significantly by 7-49% (Table 4-6). The magnitude of the 
reduction was greater in Soumeral and colleagues' studies, which were rated as high 
quality, and different across therapeutic classes that was less in essential drugs 
(1.8.28%) than In symptom-relief drugs (11-38%). 
Conversely, a Dutch study found little change in the general population after capping 
prescribed drugs. A 24% Increase in volume was offset by a 17% reduction in size, 
while the opposite was the case when the cap was replaced by a cost-sharing 
programme as mentioned in the previous section (Starmans et al., 1994). 
98 
Table 4-6: Impact of prescription caps on drug utilisation and expenditure 
Study Population Drug utilisation 
Drug expenditure Setting (layer) 
Martin and McMillan Poor lower (-7%) 1996_ 
Sourneral eta/. 1987 Poor lower (-30%) lower (-19%) USA 
Soumeral eta/. 1994 Poor elderly lower (-15. v-49%) lower (-23%) 
Soumeral eta/. 1991 Poor elderly lower (-35%) 
Starmans eta/. 1994 General various Netherlands 
4.6.3 Impact on drug expenditure 
Two studies explored the impact of prescription capping on payers' drug expenditure. 
They found a 19-23% decline in payers' monthly spending after the cap (Table 4-6). 
Soumeral et al. (1994) suggested that savings through cutting expenditure on drugs in 
patients with schizophrenia might be overwhelmed by expenses incurred from the 
increased use of mental health services (see also Table 4-7). No studies made a formal 
investigation of out-of-pocket expenditure, but there was some evidence of a budget 
shift (Martin and McMillan, 1996; Soumerai eta/., 1987). 
4.6.4 Summary: Evidence about prescription caps 
Prescription capping has been shown to lower drug expenditure by reducing drug 
utilisation and possibly by budget shifting in the US good quality studies. Similar to 
other interventions that restrict patient demand, although a greater drop was seen in 
symptom-relief medication, prescription capping also considerably lowered the use of 
essential drugs in vulnerable populations. In the Netherlands, the effects of capping on 
prescription size were lessened by increasing prescription volume. 
4.7 Educational approach 
Valles et al. (2003) examined the association between an educational approach 
targeting patients and 1) generic drugs utilisation, and 2) drug expenditure using a 
clustered RCT design over a 12-month period which had been rated as being of 
moderate quality (Annex 11). 
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Patients were about 2.5 times more likely to be prescribed generics, compared to those 
In the control group. Generic substitution resulted In an 11% reduction of the drug 
expenses (those with available generic counterparts) In the eight study centres in 
comparison with the control centres. However, authors argued that generic substitution 
was very limited in Spain due to the low availability, thus reduction in expenditure was 
also limited. 
4.8 OTC switch 
Gurwitz et al. (1995) examined the association between OTC switch of vaginal 
antifungal products and drug utilisation using an ITS design over two 12-month periods 
which was rated as good quality. Participants were female, aged 11 and older at one 
health maintenance organisation in central Massachusetts, US (Annex 11). 
The study found that prescription rates for drugs that were switched to OTC decreased 
to zero after six months. Drugs. that remained only available by prescription also saw 
an abrupt reduction after the change, but there was little alteration in trend. Patients' 
behaviour after the OTC switch was not investigated, so it Is unknown whether they 
shifted to non-study alternatives (such as oral antifungal products), or endured health 
complaints without treatment. 
4.9 Impact of interventions discouraging patients' drug demand on 
other resource use 
Nine of the included studies explored the association of Interventions and other 
resource utilisation and was rated as being of high quality (see Table 4-7). Evidence 
from North America shows that interventions limiting demand for medication may lead 
to an increase In the use of other healthcare resources In vulnerable populations. In a 
Canadian cost-sharing scheme, Tamblyn et al. (2001) found that the reduction in 
essential drug use (including antihypertensives, antihyperlipidemics, antidepressants, 
etc. ) was followed by a small but significant increase in ER visits. Prescription capping 
in the US saw elderly patients with chronic diseases about twice as likely to be 
institutionalised in a nursing home, compared to those who were not subject to a cap 
(Soumeral et al., 1991). Patients with schizophrenia were 50% more likely to visit 
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mental hospitals, although it is hard to generalise due to small study samples 
(Soumerai et al., 1994). 
Two studies reported that suppressing patient demand was accompanied by a 
moderate decline in physician visits (Gurwitz eta/., 1995; Winkelmann, 2004), 
indicating an increase in self-medication or forgoing treatment altogether. 
Table 4-7: Impact of interventions discouraging patients drug demand on other 
resource use 
Study Population Study drugs Variables Effects Setting 
Folio 
up 
cost-staring 
Gurwitz eta/.. 
1995 General Less essential physician visits no change M 
USA 
Johnson eta/. medical 
1997 Vulnerable 
Overall 
expenditure 
no change M 
Tamblyn et 
Overall/ ER visits no change- 
al. 2001 
Vulnerable Essential/ increase (+2« +50%) Canada M 
Less-essential hospitalisations no change 
Winkelmann 
2001 General Overall physician visits 
decrease (-7" -13%) Germany M 
tiered formularies 
Fairntan et. W. General Overall office visits M 2003 
ER visits no change USA 
Motheral and Gene ral Overall hospitalisations g Fairman 2001 
prescript/on caps 
Soumerai et health centre visits increase (+50%) 
a/ 1994 
Vulnerable Essential S 
. hospitalisations no change 
hospitalisations no change 
USA 
Soumerai et 
a/ 1991 
Vulnerable Essential nursing home S 
. admissions increase (RR 1.8) 
OTC switch 
Gurwitz rata/. General Less-essential physician visits decrease USA M 1995 
1) L refer to longer than 60 months; M the period between longer than 12 f ront hs and 60 months; S equal or less than 12 
months. 
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4.10 Discussion 
From the search of two major electronic databases and relative references, 44 studies 
examining the effects of pharmaceutical regulations influencing patients demand were 
identified. The majority of studies investigated cost-sharing changes or tiered 
formularies. A few studies addressed the impact of prescription capping, educational 
intervention, or OTC switch. More than a half of the included studies were conducted 
under public or private insurance in North America. 
Overall, this review found the following from Included studies: 
" Studies exploring the impact of copayment Increases were of mixed 
methodological quality; those exploring the impact of tiered formularies were of 
generally moderate quality, with little variation in findings. Among studies exploring 
the impact of prescription caps, high quality studies suggested a greater change In 
drug utilisation and payer's expenditure. Studies exploring the association between 
the interventions and other resource utilisation were of mostly good quality and 
suggested the Increase use of other medical services In the vulnerable population 
after the Interventions that restricted patient demand. 
" Copayment Increases could decrease drug utilisation; the size of the decrease 
may vary by drug class, level of copayment, patient-specific situation, or 
measurement unit. The differential Increase of copayments (generally greater 
Increases In nonformulary brand-named drugs) could achieve a more significant 
decline In the use of nonformulary brand-named drugs. There was little evidence 
for substitution of decreases in drugs with lower priced alternatives such as 
generics. 
  Copayment Increases could lower payers' costs for pharmaceuticals; however, 
only limited evidence is available about overall and private costs. Existing evidence 
suggests that the copayment changes may Increase a financial burden in a 
disadvantaged population. The differential increase of copayments could bring 
about a substantial decrease in payers' expenses, a marginal decrease In overall 
drug costs, a dramatic Increase In private expenses, clearly Indicating a budget 
shift. 
" Prescription caps can lower drug utilisation and expenditure, but constrain 
essential as well as unessential drugs and many create unintended consequences. 
Evidence from included studies suggests that capping could Increase the use of 
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some other medical services in the most vulnerable populations, such as poor and 
elderly with chronic conditions. 
  Interventions discouraging patient demand may lead to a greater decrease in 
the use of less-essential drugs, but a moderate rise in the private financial burden 
could decrease essential drug use as well. Thus, there are some concerns about a 
decrease in overall health. 
  In general, interventions showed only short-lived effects, as patients 
accommodated to the changes. 
  -There was a lack of rigorous evidence available to establish the effects of other 
interventions such as educational interventions, OTC switch (self-medication), or 
DTC advertisements. 
Previous reviews were mostly concerned that drug spending might shift from the payer 
to the patient rather than an absolute decline by interventions discouraging patient 
demand. In this review, a budget shift was not studied in detail In cost-sharing 
programmes, but It was clearly seen in tiered formularies. In addition, given that most 
included studies used claims data, which most likely covers the utilisation of 
prescription drugs reimbursed by payers and gives scant attention to OTC consumption, 
the magnitude of out-of-pocket spending could be more than that of primary authors' 
observations. 
Given the policy aims or underlying theory, it was unexpected that patients did not 
consume less costly alternatives. From the included studies, there are few favourable 
findings supporting the fact that imposing restrictions on patient drug use leads them 
to seek less pricy alternatives. Even under a tiered formulary scheme, in which patients 
may have more opportunity to be informed about generic alternatives, the reduction in 
the use of expensive brand-named drugs appeared not to translate into generic 
utilisation. Patients may just give up their medication or pay more out-of-pocket. 
This might be due to decision making processes in clinicians' offices, where the right to 
choose prescription drugs is delegated to prescribers (Chapter 1). Patients still seem to 
rely on their physician's opinion when they select pharmaceuticals, despite the recent 
attention to consumer power and collaboration between professionals and patients 
(Bradley et al., 2004; Salter, 2004b). In these circumstances, patients may have two 
options - to GO or NOT go. If they GO to see their doctors, they are most likely to be 
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subject to the doctors' decisions. But, doctors may have little concern about 
copayments, or be more likely to think of the satisfaction of patients sitting next to 
them rather than considering the complex aspects of healthcare resources. Closely 
linked to this, it was observed that prescribers tended to increase the average 
prescription size under a fixed copayment scheme, meaning that patients would 
receive more units for each item, or a longer duration of therapy in a single 
prescription, reducing the number of prescriptions for which they were charged 
(Holloway et al., 2001; Starmans etal., 1994). This would lessen the policy impact. In 
this regard, an educational approach informing patients about reimbursable (less- 
expensive), interchangeable products would be a useful measure to improve the policy 
impact. However, this has received little attention in the literature. 
If patients do NOT go to visit their doctors, the result could be a drop in consumption 
and expenditure. It may also result In the deterioration In overall health by reducing 
essential utilisation. A number of North American studies suggested that an extra 
financial burden may function discriminately In a vulnerable population, which might 
result In Increasing the use of other medical services, such as ER visits or 
institutionalisations In such populations. This needs further investigation In order to 
generalise over other settings or populations. 
One Cochrane review exploring the effects of cap and copayment on drug use was 
Issued published at a similar time to this study (Austvoll-Dahlgren et aL, 2008). Both 
drew similar conclusions in the Impact of cap and copayment on drug expenditure, 
utilisation and other relevant outcome variables, but the current study includes 
additional studies that are awaiting assessment in the Cochrane review. 
In this review, only two studies came from countries similar to South Korea in terms of 
economic position and Asian background, but they were rated as poor quality (Lee et 
at., 2006; Liu and Romeis, 2004). Hence, it is difficult to generalise the results of this 
review directly to the Korean context. Despite such a limitation, this review suggests 
several implications for South Korean pharmaceutical policy-makers: 
As discussed in Chapter 2, the level of cost-sharing Is already high in Korea. This 
means that there might be little room for raising the copayment. So, first, the 
copayment increase may yield a minimal effect on drug consumption and spending in 
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South Korea, because empirical evidence in this review shows that only considerable 
and continuous changes achieve any success in practice. Linked to this, it may be 
surmised that, on one hand, most consumers in advantaged groups in Korea may be 
extremely inflexible regarding such a small increase because they have been used to 
high out-of-pocket expenditure. 
Second, a copayment increase would appear to discriminate against the poor. This 
population may already bear a heavy financial burden due to high cost-sharing in 
Korea and will generally show a greater response to even a small increase In out-of- 
pocket than those better-off. 
Third, it would seem necessary to follow-up closely after any increase in copayment, as 
to whether this increase is too great for patients to obtain essential medication. 
4.11 Summary 
Pharmaceutical policies influencing patient demand, especially cost-sharing 
programmes, are frequently exploited across various settings. They have been changed 
from a simple dichotomous (yes/no) form to something complex. This review found 
that cost-sharing and prescription capping reduced drug volume in both essential and 
non-essential drugs. Although the interventions yielded sizable decreases in payers' 
drug expenditure, the net effect in spending seemed small overall. Drug costs were not 
ultimately being reduced, but shifted from payer to consumer. Although a few high 
quality studies suggest that increasing the private financial burden may have a 
disproportionate influence on socially disadvantaged groups, the conclusion Is 
debatable because of the relatively small number of studies identified. Given the pre- 
existing high level of cost-sharing, the copayment increase would achieve limited 
success In South Korea, while reducing access to pharmaceuticals. Further discussion 
over methodological aspects of the reviewed studies and implications for the present 
research are continued in Chapter 7. 
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CHAPTER 5: THE EFFECTS OF PHARMACEUTICAL REGULATIONS 
INFLUENCING PROVIDERS 
5.1 Introduction 
The objective of this chapter is to present findings from the systematic review 
concerning pharmaceutical policies influencing providers. In brief, studies for the 
second review were identified from two major databases, MEDUNE and EMBASE, and 
Included if the article (1) explored the effects of pharmaceutical regulations aimed at 
influencing providers; (2) examined the effects of such interventions on at least one of 
the relevant outcomes depicted in Chapter 3; (3) analysed primary or secondary data; 
and (4) performed this with one of three most robust designs, RCT, ITS, or CBA. More 
detailed methods and the criteria of selection were presented comprehensively in 
Chapter 3. 
5.2 Overview of included studies 
In the second search for pharmaceutical policies influencing providers (Annex 3), 731 
studies were retrieved, of which, 191 studies were retained after the Initial screening of 
titles and abstracts. Finally, 117 studies met the Inclusion criteria (Table 5-1). One 
study was included for three Interventions (O'Malley et al., 2006) - educational 
approach, Incentives and distribution of free drug samples. 
The large majority of studies explored the effects of 3 interventions: educational 
approaches (n=63), reimbursement policies (n=33), incentives (n=17). Three studies 
explored the impact of free drug samples. Single studies explored the effects of a 
generic substitution reform, repeat prescribing programme and separation of 
prescribing and dispensing drugs, Table 5-1 displays the reviewed studies by sub- 
intervention. Reasons of exclusion are reported in Figure 5-1 and Annex 6. 
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Figure 5-1: Flow diagram of studies (providers) 
Studies identified n= 731 
" Medline (n=360) 
" Embase (n=314) 
  References (n=57) 
Excluded n=253 
" duplicates 
Studies retained for initial 
screening of tides and abstracts 
n=478 
Excluded n=287 
" exploring irrelevant interventions 
Studies retained for screening of 
quality assessment 
n= 191 
Excluded n=74 
" before and after study design (47) 
" less than 6 months after change (15) 
" post-test onlycontrol group design (3) 
  qualitative study (3) 
" no interpretable data presented (2) 
" single institution (3) 
" improper comparison group chosen (1) 
Studies eligible for inclusion 
n= 119* 
" Educationalapproaches(63) 
" Rei nib ursement restrictions (33) 
" Incentives (17) 
" Distribution ofsamples (3) 
" Mandatory generic substitution (1) 
" Repeat prescribing (1) 
" Separation policy (1) 
" One study was included three times because of addressing multi-interventions (O'Malley et a/., 2006). 
5.3 Policies influencing providers 
In recent years, educational initiatives have been introduced with the hope of 
improving physician prescribing behaviour across settings. Inappropriate prescribing 
decisions could not only waste resources through using inefficient therapies, but also 
cause deterioration of health through adverse drug reactions. Therefore, 'improving 
prescribing behaviour' generally involves both economic and clinical aspects (Soumerai 
et a/., 1989). The interventions include providing educational information, or 
informative data from prescribing analyses in terms of volume and cost. Owing to the 
variety of contents, the present review classified them into three groups: guideline-like 
information; prescribing feedback; and drug utilisation review (DUR). 
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Table 5-1: Studies included 
Intervention Studies 
Educational approaches 
Jones eta!. 1.996, Martens eta!. 2006, O'Malley eta/. 2006, Sheldon eta!. 2004, 
Tu eta!. 2002 
Avorn and Soumerai 1983, Bernal-Delgado eta!. 2002, Bexell eta!. 1996, Chazan 
eta!. 2007, Coen 1998, Diwan etal. 1995, Fessler etal. 2006, Hagen eta!. 2005, 
Guideline-like Knowlton and Knapp 1994, Maclure eta!. 1998, Midlov eta!. 2006, Mohagheghi et 
information 32 a!. 2005, Soumerai and Avorn, 1986; 1987 
Freemantle eta!. 2002, Jackson eta!. 2004, Mason eta!. 2001, Pit eta! 2007, 
Shuval eta! 2007, Simon eta!. 2005, Weatherby eta!. 2001 
Filippi et a1.2003, Martens eta!. 2007a, McMullin eta/. 2004, Murray eta/. 2004, 
Tamblyn eta!. 2003, Vedsted eta!. 1997 
Bradley et a1.2000, Braybrook and Walker 1996; 2000, Calvo-Alcantara and Inesta- 
Garcia 1999, Horn etal. 2007, Lassen and Kristensen 1992, Perez-Rodriguez eta!. 
1996, Sicras-Mainar and Pelaez-de-Lono 2005, Sicras-Mainar et al. 2007, Sicras- 
Prescribing feedback 21 Mainar et al. 2004, von Ferber eta!. 1999, Wilson eta/. 2003, Witt eta! 2004 
Finkelstein eta! 2001, Hux eta/. 1999, Madridejos-Mora etal 2004, Nilsson et 
a1.2001, O'Connell eta!. 1999, Pimlott eta!. 2003, Raebel eta!. 2007, Wensing 
eta!. 2004 
Allard eta!. 2001, Atthobari eta/. 2004, Collins eta!. 1997, Culbertson eta!. 
Drug utilisation review 10 1999, Fretheim eta/. 2006a; 2006b, Goldstein eta!. 2005, Gregoire eta!. 2006, 
Rascati eta!. 1996, Samore eta!. 2005 
Reimbursement restrkc/ons 
t (listing 4 
Breen eta!. 2004, Campbell eta!. 2003, Soumeral eta!. 1990, Zechnich etal. 
1998 
Abdelgawad and Egbuonu-Davis 2006, Christian-Herman eta!. 2004, Huskamp et 
Formulary and al. 2003b, Kephart et al. 2005, Lichtenberg 2005a, Motheral and Henderson 
Preferred Drug List 10 1999a, Murawski and Abdelgawad 2005, Ridley and Axelsen 2006, Virabhak and 
Shinogle 2005, Wang et al. 2003 
Carroll eta/. 2006, Delate et al. 2005, Fischer eta/. 2004, Hartung et al. 2004, 
Prior-authorisation 10 Kotzan et al. 1993a, Kotzan et al. 1993b, Marshall et al. 2007, Roughead et a/. 
2006, Smalley eta!. 1995, Yokoyama et al. 2007 
Step-therapy and 
Dunn et a/. 2006, Fretheim eta!. 2007, MacCara et al. 2001, Mamdani et al. 
Limited use 
9 2007, Marshall eta!. 2006, Motheral eta!. 2004, Schneeweiss eta!. 2004, 
Schneeweiss etal. 2006, Sun cat al. 2007 
Incentives 
Baines eta!. 1997, Bradlow and Coulter 1993, Corney and Kerrison 1997, Harris 
UKfundholding 9 and Scrivener 1996, . 
Rafferty eta!. 1997, Whynes eta!. 1995; 1997, Wilson eta!. 
1995, Wilson eta!. 1999 
Global budget 4 
Etter and Perneger 1998, Granlund eta!. 2006, Lee etal. 2006, Yip and Eggleston 
2004 
Others 
Distribution of 
samples 
Mandatory generic 
substitution 
Repeat prescribing 
Separation of 
prescribing and 
dispensing of drugs 
4 
Elhayany eta/. 2001, Law and Wu 2003, Martens eta/. 2007b, O'Malley eta/. 
2006 
3 Mukamal etal. 2002, O'Malley etal. 2006, Scott etal. 2007 
I Andersson et al. 2007 
I Bond et al. 2000 
1 Chou eta/. 2003 
Guideline-like information includes standardised therapeutic guidelines such as NHS 
NICE guidance, hypertension guidelines, a variety of educational information with the 
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purpose of influencing prescribing practices such as a stepped-care prescribing protocol, 
campaigns encouraging generic use or discouraging antibiotic use, evidence-based 
prescribing algorithms, or cost comparison information. Prescribing feedback covers 
interventions providing prescribers' data generated from the analyses of prescribing 
data of prescribers' practices. DUR contains interventions informing patients' individual 
medication histories or prescribing recommendations to their medical care providers. 
DUR is relatively a recent device, with most trials in a North American context in 
identified studies. 
Although some nation-wide cases were Included, such as British programmes based on 
prescribing analysis and cost (PACT) or NICE guidelines, German prescribing feedback 
programmes known as'Quality circle', or American campaigns encouraging the use of 
generics, most studies Included in the review explored educational interventions at 
multi-institutional or regional level. Mostly, Interventions were not enforced, but were 
conducted on a voluntary base. 
Another voluntary-based intervention that frequently appeared was the Imposition of 
Incentives on healthcare providers to improve routine practices. Interventions Included 
a global pharmacy budget or one-off bonus. Non-financial advantages were not 
specified In the current review. Budgetary control may have provided an incentive to 
constrain the costs of prescribing by allowing prescribers (or dispensers) to keep some 
of the savings. Among the Included studies, a British fundholding programme was 
evaluated most often. Britain had introduced individual general practice budgets 
between 1991 and 1998. Recently, the UK NHS Introduced another voluntary Incentive 
scheme, named 'Quality and Outcomes Framework (QOF)' In 2004 (Lester, 2008). 
Studies evaluating the Impact of the QOF on pharmaceuticals were not identified In this 
review. 
Without enforcement drives, interventions may be easily Ignored, Thus, most 
governments (or private insurers) often Implement regulatory measures through 
reimbursement decisions. Reimbursement policies stipulate that payers prioritize 
publicly funded drugs, which are Intended to make prescribers prescribe drugs fully- 
subsidised away from those limited, Under these regulations, some products are ruled 
out from reimbursement (delisting, negative or positive lists). Although most countries 
have a set of reimbursable list, the impact on prescribing practices has been evaluated 
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rarely except In North America. 
In the US and Canada, to have access to restricted medications, patients must either 
pay an extra premium (formularies, preferred drug lists, etc. ) or undergo pre-requisite 
procedures (prior-authorisation) or treatments (step-therapy). Prior-authorisation and 
step-therapies are often applied to expensive medications for minor illnesses, such as 
new non-steroidal anti-inflammatory drugs (NSAIDs). 
Several interventions were also included, such as free drug samples, mandatory 
generic substitution, repeat prescribing and separation policy. However, these were all 
very limited, hence, this review principally evaluated the impact of the three 
interventions described above. The basic characteristics and outcomes of the included 
studies are discussed in turn by intervention. 
5.4 Educational approaches 
5.4.1 Characteristics of included studies 
Of 63 studies, 32 addressed guideline-like Information which were rated as more mixed 
and/or poor quality; 21 dealt with prescribing feedback with moderate quality in 
general; and 10 Investigated DURs with moderate to high quality (Table 5-1). For the 
purpose of analysis, the first level category was sub-divided by the mode of 
dissemination: passive, such as mail or bulletin; group education; individual contact; 
computerised devices. Basic characteristics of Included studies are displayed in Annex 
12. 
Educational measures have been tested in various settings: North America (n=25), 
Western Europe (n=29), Australia (n=5), Israel (n=2), Iran (n =1) and Zambia (n=1). 
Six studies employed ITS designs with moderate to low quality; 21 used CBA designs 
with moderate quality; 36 were conducted using RCT designs with moderate to high 
quality. 
Nearly two-thirds of the studies followed up participants no longer than a year after 
the introduction of interventions. In only six studies was the period longer than 3 years 
(Bradley et al., 2000; Fessler et al., 2006; Horn eta/., 2007; Sicras-Mainar et a/., 2007; 
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Tu eta/., 2002; Weatherby eta/., 2001) and none was longer than 5 years. 
Two thirds of the studies used aggregated claims data at organisational level. Most of 
the remainder employed data in medical records held at institution level. Other sources 
included commercial or academic databases. Two RCT studies analysed data collected 
from patients (Allard eta/., 2001; Pit et al., 2007). 
5.4.2 Impact on prescribing behaviour and drug utilisation 
Evidence from the included studies suggested that educational approaches might have 
a limited improvement in prescribing behaviour (Table 5-2). In particular, studies with 
higher quality suggested smaller improvement of about 0N7% regardless of contents 
or contact method (Allard eta/., 2001; Bradley eta/., 2000; Freemantle eta/., 2002; 
Goldstein etal., 2005; Hux eta/., 1999; Madridejos-Mora eta/., 2004; Tamblyn eta/., 
2003). However, such Improvements did not necessarily lead to changes In drug 
utilisation (see Table 5-3). In Britain, for Instance, aggregated prescribing feedback 
increased prescribing appropriateness, but failed to make any difference to 
consumption (Bradley eta!., 2000). No association between quality and results was 
apparent for drug utilisation. 
Individual prescribing feedback has not been shown to affect the trend of drug use in a 
well-designed randomised study in Australia (O'Connell et al., 1999). The authors 
concluded that "unsolicited, centralised, government-sponsored feedback based on 
aggregate data had no impact on the prescribing levels of general practitioners" (p510). 
Likewise, as seen In Table 5-3, broadly-focused educational interventions were less 
likely to change the existing utilisation pattern. 
Conversely, educational interventions with a clear purpose may be effective in 
improving prescribing profiles (Table 5-4 through 5-6). Regardless of setting or 
Intervention, change was more likely when Information was delivered supported by 
widely-agreed evidence (for Instance, discouraging Inappropriate prescribing in 
antibiotics or benzodiazepines, encouraging appropriate prescribing in 
anti hypertensives or antihyperlipidemics). In contrast, Interventions focusing on certain 
drug classes (including asthma medications, antiulcer medications, antipsychotics, or 
antidepressants) were less likely to Influence prescribing practices. 
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Table 5-2: Impact of educational approaches on prescribing appropriateness 
Study rý Study drugs 
Prescribing 
Setting 
appropriateness 
guideline-like Information, group detailing 
Bexell etal. 1996 essential drugs no Iilmge "- higher (+12%) Zambia 
Coen 1998 overall higher (+5%) 
9 European 
Countries 
Diwan etal. 1995 lipid-lowering drugs higher (+20%) Sweden 
lipid-lowering drugs, 
Fessler etal., 2006 antidiabetics, (no change) Germany 
cardiovascular drugs 
Maclure et al. 1998 antihypertensives in elderly no change - higher Canada 
Simon eta/. 2005 (group detailing) diuretics, beta blockers higher (OR-1.4 at the Ist year) USA 
guideline-/Ike Information, individual detailing 
Freemantle etal. 2002 
antiplatelets, ACE inhibitors, higher (+5%) UK NSAIDs, antidepressants 
Pit et al. 2007 
NSAIDs, low-dose thiazides, 
no change Australia benzodiazepines in elderly 
Shuval etal. 2007 thiazides, statins no change Israel 
Simon eta/. 2005 (individual detailing) diuretics, beta-bbckers no change 
-- - USA Weatherby eta/. 2001 cisapnde higher 
guideline-/Ike Information, cnmputer/sed devices 
Martens etal. 2007a antibiotics, asthma medications little change Netherlands 
Murray etal. 2004 antihypertensives no change USA 
Tamblyn eta/. 2003 111, upp1op1wite presciibings no change-, higher Canada 
group-le w/ prescribing feedback group detailing 
gastrointestinal, cardiovascular, 
Bradley eta/. 2000 respiratory, central nervous, higher UK 
musculoskeletal medications, 
antibiotics 
group-level pi-escr/b/ng feedback Individual detailing 
Perez-Rodriguez et al. 1996 overall no change (p=0.08) 
Sicras-Mainar etal. 2004 antiulcers, antidepressants, no change 
Sicras-Mainar and Pelaez de Lono antihypertensives, higher (+2%) 
Spain 
2005 antiasthmatics, antibacteriais, 
Sicras Mainar et a/. 2007 
NSAIDs 
no change 
Ind/vdual-level prescribing feedback passive 
Flux et X. 1999 antibiotics higher (+6%) Canada 
lndiwdual-level prescribing feedback group detailing 
Madridejos-Mora etal. 2004 antibiotics, 
NSAIDs, 
antiukerative: agents 
no change Spain 
drug udl/sadon review, passiv 
Allard eta/. 2001 inappropriate prescribings no change (p=0.08) Canada 
Collins et al. 1997 (Physician only) no change 
Collins et al. 1997 (Pharmacist only) dipyridamole no change- higher (OR=2.22) 
USA 
Collins el a/. 1997 (Both) higher (OR=2.103.81) 
Rascati c't a/. 1996 antiulcer medications higher (+17%) 
drug udllsatyon review, individual contacts 
Goldstein e[ W. 2005 antihypertensives higher (t7%) USA 
Gregoire etal. 2006 cisapride no change - higher Canada 
1) ACE; angiotensKrconvertiog enzyme: NSAID; non steroidal anti-infla mmatory drug 
2) In cases no proper statistical evidence given but more than 10% differences reported, the results are in 
perantheses. 
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In spite of intended changes in the utilisation of targeted drugs, smaller changes were 
often seen in overall related utilisation (Table 5-4 through 5-6), possibly owing to the 
fact that the primary hope of educational interventions were in general not to reduce 
drug use, but to improve prescribing practices. As a result, a reduced utilisation was 
often compensated by substitutes; for example, the increasing use of recommended 
NSAIDs offset the reduction of those NSAIDs which were discouraged, hence, few 
differences were observed in overall prescription volume (Bernal-Delgado et a/., 2002). 
Table 5-3: Impact of broadly-focused educational approaches on drug utilisation, 
Drug utilisation 
Study Study drugs overall related increase intended decrease intended 
Setting 
drugs 
guideline-like Information, group detailing 
no change 9 European Coen 1998 overall (16%, p=0.07) countries 
Knowlton and Knapp 
1994 overall no change USA 
guideline-like Informadon computerised devices 
Vedsted el al. 1997 overall no changes Denmark 
group-lei/prescribing feedback group detailing 
gastrointestinal, 
cardiovascular, 
respiratory, central 
Bradley et al. 2000 nervous, no change little change UK 
musculoskeletal 
medications, 
ant ibiot it s 
Lassen and overall no change Denmark Krist: ewsen 1997 
group-leº l prescribing feedback In vidt l contacts 
Sur, e Mainar etal. lower (-15%) antiuk. ers , 2004 
antidepressants, Sicras-Mainar and 
Pelaez de Lono antihypertensives, lower (-9%) Spain 
antrasthmatics, 2005 an t ibacte nals, 
Sicras-Mainar etal. NSAIDs, anakjesics no change 2007 
individual-level prescribing feedback passive 
O'r_rmnell r't al. overall no change no change Australia I`rOrr 
individual-level prescribing feedback group detailing 
Wens. ing ital. 2004 overall no change little change little change Germany 
NSAIDs; non steroidal anti-inflammatory drugs 
In delivering guideline-like information, a few studies demonstrated that active 
dissemination by face-to-face outreach visits either at group- or individual-level was 
more likely to persuade physicians to comply with study intentions, compared to 
passive contacts (Table 5-4). For example, Avorn and Soumerai (1983) examining an 
educational measure discouraging the use of three undesirable drugs, demonstrated 
that face-to-face approaches lowered drug utilisation by about 14% in the drugs 
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targeted, while mailing produced no significant effects. This was supported by another 
American study (Simon et al., 2005). 
Table 5-4: Impact of guideline-like information on drug utilisation 
Drug uti isation 
Study Study drugs* 
guideline-like Information, passive 
Avorn and Soumerai propoxyphene, 
1983 (mailing) vasodilators, 
cephalexin 
)ones et al. 1996 NSAIDs 
overall related increase intended decrease untended drugs 
no change 
no change lower (-31-35%) 
Setting 
USA 
antibiotics no change 
Martens eta/. 2006 asthma drugs no change Netherlands 
statins higher (+23%) 
O'Malley eta/. 2006 generics little change USA 
taxane5 higher 
Sheldon etal. 2004 Alzheimer drugs no change UK 
ürlr. t at higher 
in etal. 2002 anhhypvitensivvs no Change no change Canada 
guideline-like Information, group detailing 
Avorn and Soumerai propuxyphene, 
1983 (group vasodilators, lower (-14%) USA 
detailing) cephalexin 
no change no change 
Bernal-Delgado et 
(vs. conventional (vs. conventional 
a/. 2002 
NSAIDs no change education) education) Spain 
higher (+7-+10%) lower (-24"-37%) 
(vs. no intervention) (vs. no intervention) 
Bexell eta/. 1996 antibiotics lower (-13%) Zambia 
Chazan eta/. 2007 antibiotics lower (-3%) lower (-14%) Israel 
Hagen eta/. 2005 psychotropk drugs no change no change Canada 
Horn eta/. 2007 antihypertensrves 
higher 
higher (+8%) Austaha 
Midlov et al. 2006 antipsychotics -- 
no change 
-- - Sweden benzodiazepnes lower (-26%) 
Mohagheghi et al. antibiotICS, lower (9%) Iran 2005 injections 
guideAlk-//ke lnformadon, /ndividwl contacts ' 
Jackson etal. 2004 antithrombotic no change- drugs higher (+4%) 
NSAIDs, Australia 
Pit et al. 2007 k w-dose thiazides, no change 
benzodiazepines 
guide//ne-/Ike inhumadaL computerlsad aet 
Filippi eta/. 2003 antiplatelet drugs higher (OR-=1.99) Italy 
Martens etal. antibiotics, little change Netherlands 2007a asthma drugs 
* NSAIDs; non steroidal anti-inflammatory drugs 
As opposed to general conclusions drawn in one previous review (Soumerai et a/, 
1989), it is unclear that face-to-face deliveries are more effective in prescribing 
feedback (Table 5-5). Among the papers testing head-to-head comparisons in providing 
prescribing feedback between direct and indirect contacts, studies reported no 
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observed differences in Denmark (Witt et a/., 2004) and only marginal effects in the UK 
(Braybrook and Walker, 1996,2000). Only one Australian study showed favourable 
outcomes for offering prescribing feedback through direct contact in contrast with 
mailing (Wilson eta/., 2003). Evidence for DURs on this issue was relatively limited 
(Table 5-6). 
Table 5-5: Impact of prescribing feedback on drug utilisation 
Drug utilisation 
Study Study drugs* overall related increase intended decrease intended 
Setting 
drugs 
group-le M/ pvsscribWng feedback group detailing 
&aybrook and 
antibiotics no change higher no change lower Walker 1996 
Braybrook and 
Walker er 20 2000 W NSAIDs no change no change" 
higher no change- lower 
Calvo-Alcantara and 
generics higher (+27%) Spain Inesta-Garcia 1999 
Diwan etal. 1995 
Wilson eta/. 2003 
antihyperipklemks 
no change 
(p=0.06) 
antibiotics lower (-15%) 
Sweden 
Austalia 
Witt et, dl. 2004 aslhrna drugs no change Denmark 
Individual-level prescribing feedback pass/re 
Pinilott c, f, ii. 2003 henrudlaiepäie', I (hinge lower (-11%) Canada 
indiuidual-lerel prescrib/ng feedback group detailing 
F-mlook. lom Ptal 
1 antIbKJtK: S lower (-12. -16%) USA 100 
Madridejos-Mord et - 
antibiotics lower (13%) 
a/. 2004 
NSAIDs no change Spain 
atiuker medications no change 
no change- 
antihypertensives no change lower (-31%) Nilsson etal. 2001 - Sweden 
ate ii #"r motile at w, r, : no change no change 
antHtc, lrfi...... mt., no r. hat 
lnctitrkiual-level prescrihhxt tce iback, /nd Mdual cantac 
Raebel et a/. 200/ 
uf. fl, llrulrrwl(O lower 16'/. ) lower (-26%) USA 
pfrýu_rdiii ys 
* NSAIDs; non ster oidal anti InfLimrnatory drugs 
Table 5-6: Impact of DUR on drug utilisation 
Drug utilisation 
Study Study drugs I, vt i tII Iolatecl increaýx intended decrease intended 
Setting 
drugs 
&mg vNiotion review, passive 
Allard eta/. 2001 Inappropriate no change Canada presc_nbNýgs 
Atfhuhm i cat. i. ant dlylxell t nsives, higher Netherlands 
M011 ýildiliylrtrllq, KlemK S (+11- i31°ý) % 
drug utilisation review feedback, group detailing 
i iethr"un iota/ 111111 lyl olte114N(!, higher (-49°/, ) Norway 20001) di It 1(1 Ieliq)KlV mK. S 
drug u t/IIsÜO// review, individual contacts 
Culbertson et al. no change- 
atluklr mcdlcýitwns 19ct9 lower (-6%) USA 
Samore et, )/. 2005 antibntics lower (-12%) 
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In the reviewed studies, individual-specific information on prescribing feedback and 
DURs resulted in better impact over group-level information (Madridejos-Mora et al., 
2004; Samore et al., 2005). Prescribing feedback or DUR is preferable to guideline-like 
information in affecting drug use (Wilson eta/., 2003). Real time advice was more 
likely to affect prescribing routines than that given retrospectively (Gregoire eta!., 
2006). However, extremely sophisticated information was shown to fail to influence 
prescribing practices even when it was provided by ongoing computerised systems in 
several settings, including Canada, Denmark, the Netherlands and the US. This would 
suggest that physicians found excessive and complex information "to be intrusive or 
time consuming" in clinical practice (Murray et al, 2004). This was pointed out by the 
previous review as a problem of "information overload" (Soumeral etal., 1989). 
Greater effects have been shown in studies In which patients (Atthobari et al., 2004; 
Chazan et al., 2007; Finkelstein et al., 2001; Samore et a/., 2005), their carers (Wilson 
eta/., 2003), or pharmacists (Collins eta!., 1997; Raebel etal., 2007) participated in 
the drug use process along with physicians. Physicians were more likely to change 
prescribing practice when they were In agreement with the recommendations (Hux et 
a/., 1999; Jackson et al., 2004; Rascati et al., 1996; Soumeral and Avorn, 1987) or 
when they were actively participating (Midlov et al, 2006; Samore et a/., 2005). High 
prescribers (Virabhak and Shinogle, 2005; von Ferber et al., 1999), small practices 
(Freemantle et at, 2002), or new prescriptions (Tamblyn et al., 2003) were more 
susceptible to educational information. Simple-faceted voluntary educational efforts 
alone may be ineffective (Maclure etal., 1998). The policy effects fade away over time 
(Sicras-Mainar etal., 2007; Simon etal., 2005). In this regard, evidence shows the 
Importance of generating measures which reinforce the message or making the 
dissemination continuous (Chazan et al., 2007; Soumeral and Avorn, 1987). 
5.4.3 Impact on drug expenditure 
Included studies showed smaller variations in the impact of interventions on drug 
expenditure than on utilisation (Table 5-7). The majority of the studies suggested that 
educational approaches could reduce drug expenditure from the payers' perspective. 
Prescribing feedback and DURs appeared to provide more consistent results than 
guideline-like information. It is unclear from those studies reviewed whether the 
method of dissemination was associated with the various effects on drug expenditure.. 
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Table 5-7: Impact of educational approaches on drug expenditure 
Study Study drugs') Generic use rate 
Drug expenditure') Setting 
(payer) 
guide/#e-like /nformalio4 passIi e 
lower 
)ones eta/. 1996 NSAIDs (-29^ 33r%) 
USA 
Soumerai and Avorn propoxyphene, no change 1986 (mailing) vasodilators, cephalexin 
guideline-like information, group detailing 
antidiabetics (-26%) 
Fessler etal, 2006 lipid-lowering drugs Germany , 
cardiovascular drugs 
(no change) 
Knowlton and Knapp 
overall higher (+6%) lower (-8%) 1994 USA 
Soumerai and Avorn propoxyphene, lower ( 13°/o) 
1986 (group detailing) vasodilators, cephalexin 
guldellne-/Ike informadon, computerised devices 
McMullin eta/. 2004 overall lower (-11%) USA 
Vedsted eta/. 199/ overall no change Denmark 
group-leº. el prescribing feedback group detailing 
Braybrook and Walker ° NSAIDs higher (+10- +13 /o) (higher) UK 2000 
von Ferber etal. 1999 various (-12%) Germany 
group-/e / prescrlbing feedback individual detalling 
Perez Rodriguez eta/. 
overall lower (-19%) 1996 
Sicras-Mainar etal. higher (1151%) lower ( 15%) 
2004 antlulcers, antwlepressants, Spain 
Sicras-Mainar and antihypertensives higher (+51%) lower (11%) 
Pelaez de Lono 2005 antiasthmatlcs, 
Sicras-Mainar etal. antibacterials, NSAIDs higher (+41%) lower (-2%) 
2007 
ind/Ndual-level prescribing feedback group detailing 
Madridejos-Mora et antibiotics, NSAIDs, lower (-14%) Spain 
, a/. 2004 antiulcerative agents 
Wevrsrny et a/. 2004 overall higher (+3%) lower (-6%) Germany 
drug ulil/sation review, xssil 
( uh uns et al. 1997 dipyridamole no change (Physician only) 
Collins etal. 1997 dipyridamole lower (-5« -11%) USA (Pharmacist only) 
Collins t>t a/. 1997 dipyndamole lower (22" -29%) (Both) 
drug utlllsatlon review, individual contacts 
Culbertson eta/. 1999 atsilcer medications lower (-13" -14%) USA 
1) NSAIDs; non steroidal anti. inflammatory drugs 
2) In cases no proper statistical evidence given but more than 10% differences reported, the results are in 
perantheses. 
There is some evidence that slight change in utilisation may not necessarily indicate 
little impact on costs. Several studies showed a modest saving, despite no difference in 
overall consumption (Culbertson et a/., 1999; Jones et a/., 1996; Madridejos-Mora et a/., 
2004; Wensing et al., 2004). Two studies from the US and Germany demonstrated the 
increasing use of generic alternatives (Knowlton and Knapp, 1994; Wensing et al., 
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2004). Presumably this would imply improvement in prescribing practices in terms of 
cost-effectiveness. 
In the US, a computerised tool providing Information about the relative efficacy, safety, 
and costs of different therapeutic options was associated with decreasing costs 
(McMullin eta/., 2004), though this was different from a Danish study which provided 
drug cost information via a real-time computer programme, but failed to achieve any 
changes In either utilisation or expenditure (Vedsted eta/., 1997). 
Other factors facilitating the reduction of drug expenditure were similar to those 
yielding a greater Impact on utilisation. Face-to-face detailing rather than mailing 
(Soumerai and Avorn, 1986), Involving more stakeholders (Collins et al., 1997) or 
heavy prescribers (Madridejos-Mora et al., 2004; Perez-Rodriguez et al., 1996; von 
Ferber et al., 1999), or continuous Interventions (von Ferber et al., 1999; Wensing et 
al., 2004) seem to be more effective in reducing drug costs, with other conditions 
being equal, 
Two studies conducted economic evaluations of the intervention programmes taking 
administrative expenses into account (Fretheim etal., 2006a; Mason etal., 2001). 
Mason et al. found a positive net effect in the outreach programme for the prescribing 
guideline of anglotensin-converting enzyme inhibitors in heart failure, but not for 
antidepressants (first-line use of tricyclic antidepressants and second-line use of 
selective serotonin reuptake inhibitors). Fretheim etal. concluded that their DUR 
programme, encouraging thiazides (first-line choice of anti hypertensives) prescriptions, 
might be cost-effective if the Intervention effect is sustained beyond the study period 
(one year) to at least 2 years. 
5.4.4 Other outcomes 
Studies, exploring the effect of educational interventions on other outcomes below, 
were rated as moderate to high quality. No studies reported any meaningful changes In 
quality of life, patient satisfaction, treatment goals, or other service use after 
implementing educational interventions in the short-term (Table 5-8). 
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Table 5-8: Impact of educational approaches on health or other service use 
Study Variables Effects 
Follow- 
up up 
guideline like Information, group (*lalling 
Knowlton and Knapp 1994 hospital admission rate no change S 
guide//ne-like information, indiMdual debiting 
Pit et a/. 2007 quality of life no change S 
outpatient visits no change 
Simon eta/. 2005 hospitalisations no change S 
blood pressure control no change 
guideline-like lnformabon, computerised devices 
emergency visits no change 
hospitalisations no change 
Murray et at. 2004 medical expenditure no change S 
blood pressure control no change 
patient satisfaction no change 
drug utillsatlon review, group detailing 
Fretheim et al. 2006b blood pressure control no change S 
drug utWdon rev4ew, lndMdual contacts 
Culbertson eta/. 1999 other service use no change S 
Goldstein et al. 2005 blood pressure control no change S 
1) L refer to longer than 60 months; M the period between longer than 12 months an d 60 
months; S equal or less than 12 months. 
5.4.5 Summary: Evidence about educational interventions 
Evidence from reviewed studies suggested that educational interventions could lower 
drug expenditure when the focus is on cost-effective information, even when little 
change was shown in utilisation. Drug utilisation profiles can also be improved if the 
information is well-focused on problematic medications, on improper behaviour proven 
by individual-specific data, or with professional support, or provided repeatedly. These 
findings are in line with statements by Sheldon etal. (2004; p1006) that 
"implementation is likely to be improved if the guidance is clear and based on an 
understanding of clinical practice, if the evidence is strong and relatively stable, if 
adequate funding is available, and if the guidance is supported and disseminated by 
professional bodies". In most cases, the impact was modest. Faced with marginal 
impact, a multi-faceted or collaborative approach is suggested across included studies 
to achieve better outcomes. There is no evidence that educational interventions affect 
use of other resources or quality of care. The quality of the included studies was 
generally moderate with few rated as poor or high quality. Thus, readers should bear 
this in mind in the interpretation of the findings. Greater caution might need to be 
given when interpreting the effects of guideline-like information because these studies 
were rated as being of poorer quality. 
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5.5 Reimbursement restrictions 
5.5.1 Characteristics of included studies 
Thirty-three studies explored the impact of reimbursement restrictions Including 
delisting (n=4), formularies or Preferred Drug Lists (PDLs) (n=10), prior-authorisations 
(n=10), step-therapies or limited use edits on reimbursement criteria (n=9). Basic 
characteristics of included studies are shown In Annex 13. The included studies were of 
very mixed quality. Studies exploring the Impact of formularies and PDLs or step- 
therapies or limited uses were rated as moderate to high quality, while those exploring 
the impact of prior authorisations were rated as moderate to low quality. In studies 
exploring the Impact of delisting, half were rated good quality, but the remaining 
studies were rated as poor quality. 
All except two studies - one from Australia, the other from Norway - were conducted 
in North America. Of the 23 studies from the US, 18 examined the impact of 
reimbursement restrictions on vulnerable groups such as the poor in Medicaid 
programmes, wounded veterans, and the elderly; five studies included general 
populations in commercial health plans. All eight studies from Canada involved an 
elderly population on the benefit programmes provided by provinces. 
Twenty-one studies employed ITS analyses and 11 used CBA study designs. Slightly 
more than half of the studies from North America (including both ITS and CBA studies) 
employed control populations from comparable states or health plans. Two CBA studies 
compared a Medicaid population with non-Medicaid population, and raised some 
concerns about baseline differences between groups (Lichtenberg, 2005a; Murawski 
and Abdelgawad, 2005). All but four studies used claims databases maintained by 
national or organisational bodies. Four studies employed commercial databases or 
electronic medical records held at practices. All studies explored the policy effects over 
a short period, no longer than 2 years after the implementation with two exceptions 
that covered around 30 months (Lichtenberg, 2005a; Marshall et al., 2007). 
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5.5.2 Impact on drug utilisation 
Evidence from included studies showed that reimbursement policies could achieve a 
considerable decrease in the use of restricted drugs, which were offset by the 
increasing use of substitutable drugs, for instance, preferred drugs in PDLs, or first-line 
therapies in step-therapy restrictions (Table 5-9 through 5-12). 
Table 5-9: Impact of desisting on dru utilisation 
Patient 
Drug utilisation 
Study 
population 
Study drugs overall related dropped potential drugs substitutes 
Breen etal. 2004 General 
temazepam 
capsule no change 
lower (-73%) higher 
topical 
Campbell eta!, 2003 Elderly corticosteroid mixed') 
products 
Soumeral eta1.1990 Poor 
M 
nonscientific 
drugs higher lower higher (N+282%) 
Zechnich eta!. 1998 Poor OTC drugs mixed') lower highere) 
1) Poky impacts varied by drug classes. 
2) only In hematfnfcs among the nine therapeutic categories 
Such a reduction was unlikely to lead to Improved drug use In delisting. Soumeral et al. 
(1990) studying the effects of reimbursement cessation of 12 categories of drugs with 
questionable efficacy In a New Jersey Medicaid population found that a decline In the 
use of delisted drugs was often substituted by other questionable drugs, more costly 
but with uncertain efficacy. Australian authors assessing the effect of a restriction on 
temazepam (frequently misused benzodlazepine) suggest that complementary 
prescribing guidelines may be required to prevent mis-users from accessing the 
medications through prescription via "fake symptoms" (Breen et al., 2004). 
In other reimbursement restricting policies, the Increase of substitution was smaller 
than the decline of restricted drugs, resulting in a modest drop in total volume (Table 
5-10 through 5-12). The lower volume in target drugs was in part offset by the 
increasing utilisation of alternatives such as generics for brand-named drugs, non- 
narcotic analgesics for NSAIDs, or first-line drugs for upper level therapies. 
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Table 5-10: Impact of formularies and PDLs on drug utilisation 
Drug utilisation 
Study Patient 
population 
Study drugs overall 
restricted Preferred dr 
Abdelgawad and Poor statlns lower Egbuonu-Davis 2006 
Christian-Herman et mineral overall 
lower lower higher 
a/. 2004 (-4%) 
Kephart etal. 2005 Elderly respiratory drugs 
lower O 
(-47 -65%) 
Motheral and mineral overall 
lower 
Henderson 1999a (-41%) 
Virabhak and Poor cardiovascular 
lower ý~ V 
Shinogle 2005 medications (-41--68%) 
Wang etal. 2003 Poor 
proton-pump higher 
.. _a. _...... w . x, ... M., __.,. w .. ..., 
Inhibitors 
...., d., _. -,, H_ (+77N 
+78%)...... 
Table 5-11: Im aý ct of prior-authorisations on drug utilisation 
Study 
Carroll etaL 2006 
Patient 
ýpulatb... n 
Poor 
y 
Study drugs* 
Cox2 Inhibitors 
_ overall related 
Drug utiisatbn 
PA drugs 
ý_ 
lower 
potential 
ýrysubstitutes_ý_.. 
higher 
Delal: e eta/. 2005 Poor proton-pump lower higher 
`ý- 
Inhibitors 
ýýýý . _ý.. _ __.. __ý....... _ 
Fischer eta/. 2004 Poor Cox2 Inhibitors 
lower 
- 'ý 
Hartung eta/. 2004 Poor celecoxib 
lower 
no change 
Kotzan etal. 1993a Poor I1 RIs no change 
IGotzan etal. 1993b Poor NSAIDs no change 
lower 
(-509/0) 
higherl~Y 
Marshall eta/. 2007 Elderly Cox, Inhibitors lower 
Roughead etal. Poor Cox2 Inhibitors no change 
lowö r 
2006 
... ý. ---. _ . V... m. 
(-42%) 
______. -. __-. _. ý _, ____ _. NSAIDs, lower 
, 
Smalley eta!. 1995 Poor analgesics, (-190/0) lower higher 
y. w. _ 
psychotropics 
. _. ý Yokoyama eta/. General AR6s lower 2007 
* ARBs; angiotensin-receptor bbckers, Cox2 inhbitors; cycboxygenase Inhbitors, H2RAs; histamine-2-receptor 
antagonists, NSAIDs; nonsteroäal antHnflammatory drugs 
The amount of reduction In utilisation varied, as seen in the tables. Larger reductions 
were observed when stricter rules were Implemented, for Instance, a closed formulary 
over an open formulary (Motheral and Henderson, 1999a), a prior-authorisation over 
limited use criteria or formulary (Marshall eta/., 2007), more restrictive criteria among 
prior-authorisations (Fischer et al., 2004), a multi-faceted Intervention over a single 
intervention, or a step-therapy over a formulary (Sun et al., 2007). Medicaid 
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formularies might Influence doctors further to prescribe formulary drugs in other 
populations as well as Medicaid populations (Virabhak and Shinogle, 2005; Wang etal., 
2003). According to Wang et at.. (2003), the market share of preferred proton pump 
inhibitors (PPIs) was increased by 1N2% among cash or other third-party payer 
prescriptions in Maine for every 10% member patients' share of the practice after a 
restrictive Medicaid formulary. 
Table 5-12: Impact of step-therapies or limited uses on drug utilisation 
Patient 
Drug utliisatbn 
Study 
population 
Study drugs* overall related TJ restricted 
first-line or 
related drugs 
Dunn eta!., 2006 General antidepressants no change 
Fretheim eta/. 2007 General andhypertenslves 
higher 
(+17%) 
MacCara etal. 2001 Elderly Fluoroquinolones 
lower lower higher 
(-3%) (-80%) (+11N +56%) 
Mamdani eta/. 2007 Elderly fluoroquinolones no change lower higher 
Marshall etal. 2006 Elderly fluoroquinolones lower lower higher 
eewetss eta/. 
ineffective 1ow Elderly 
2004 asthma (-5 14%o 
npdicadon5 
ý 
Schneeweiss eta/. Elderly PPIs no change 
lower higher 2006___ 
ýýý_ 
(-75%) 
_____. ___ 
Sun etal. 2007General NSqs 
lower 
(-28N -36%) 
* NSAIDs; nonsterofdal anthkrflammatory drugs, NSAs; non-sedating antihistamines, PPIs; proton-pump inhibttors, 
SSRIs; selective serotonin reuptake Inhibitors 
However, reimbursement restricting policies may also yield unexpected and unwanted 
outcomes. It was shown that the implementation of generic-only benefits lowered the 
use of medications for chronic conditions, especially in statins prescriptions which 
decreased by nearly 30% In an American Medicare managed organisation (Christian- 
Herman et al., 2004). As shown in Table 5-13, three US studies indicated that patients 
were more likely to discontinue their chronic medications (including sexual hormones, 
antidiabetics, antihypertensives and related heart medications, antipsychotics and 
anticonvulsants) by around 10% In the short-term, Implying that It could reduce overall 
health In the longer-term if the trend persisted. These studies exploring the Impact of 
reimbursement restrictions on drug discontinuation were rated as good quality. 
One study concerned the possible increasing of social inequities by decreasing patient 
access to new medications, because they found Medicaid patients were more likely to 
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take older drugs after the application of Medicaid PDLs (Lichtenberg, 2005a). The 
largest impact was seen in pain management medication, which occurred between six 
months and 2 years, Much less delay (from less than a month to around a year) was 
seen in response to medication for chronic complaints (including antihypertensives, 
antidepressants, diabetic drugs, and cholesterol-lowering drugs). 
Table 5-13: Imp of reimbursement restrictions on drug discontinuation 
Study Patient 
population 
Intervention Study drugs Effects Setting 
Folbw- 
1) 
Motherai and General closed formulary chronic higher (+12%) USA S Henderson 1999a medications 
Ridley and Axelsen 
2006 Poor Preferred Drug Ust statins higher (+13%) USA S 
Schneeweiss et al. Elderly step-therapy proton-pump no change Canada S 2006 inhibitors 
Yokoyama etal. General prior-authorisatio 
n 
anglotensin- higher (+7%) USA S 2007 receptor blockers 
1) L refer to longer than 60 months; M the perbd between longer than 12 months and 60 months; S equal or 
less than 12 months. 
5.5.3 Impact on drug expenditure 
Reimbursement policies may have a substantial effect on lowering payers' drug 
expenditure on related drugs (Table 5-14). The interventions lowered drug expenditure 
between 7% and 53%, which might be achieved by reducing the claims for off- 
reimbursement drugs and increasing the use of less expensive alternatives. Potential 
substitutes were mostly less costly, except for the delisting programmes; thus, the 
changes in use were linked to savings in payers' expenditure for the relevant drug 
classes. 
Among sub-interventions, step-therapies or limited use edits have shown more 
Irregular effects. Four studies reported a 19-33% decrease, while 3 studies found no 
significant changes In public expenditure (Table 5-14). Differences may be partly 
explained by drug categories. Savings from step-therapies were observed In the 
medication classes of PPIs, NSAIDs, non-sedating antihistamines (NSAs), but were 
mixed In fluoroquinolones and did not appear In antidepressants or asthma drugs. 
Mixed results In two studies exploring the Impact of reimbursement criteria on the 
costs of fluoroquinolones may be explained by contextual factors between Nova Scotia 
- showing a significant fall (MacCara eta/., 2001) and Ontario - showing little 
reduction (Marshall eta/., 2006) In Canada. Firstly, restrictions In Nova Scotia seem to 
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be stricter than in Ontario; for example, Nova Scotia requested an extra official form 
alongside the prescription for fluoroquinolones, including for norfloxacin which was on 
the general benefit list in Ontario. Secondly, a couple of fluoroquinolones were not 
available when the Nova Scotia study was conducted. 
Table 5-14: Impact of reimbursement restrictions on drug expenditure 
Patient Drug expenditure 
Study 
population 
St Study drugs* 
overall payer out of- pocket 
Prices 
del/sling 
topical 
Campbell etal. 2003 Elderly eorticosteroid lower 
products 
Soumerai etal. 1990 Poor nonscientific no change drugs 
Zechnich et al. 1998 Poor OTC drugs lower 
formularies or preferred drug lists 
Christian-Herman et al. General overall lower (-12%) no change 2004 
Huskamp eta/. 2003b 
Elderly, 
various 
lower lower 
disabled (-7--41%) (-13--36%) 
Motheral and Henderson General overall lower (-44%) no change 1999a 
prior-autharsations 
Carroll et al. 2006 Poor Cox2 inhibitors lower 
Delate eta/. 2005 Poor proton-pump lower (-50%) inhibitors 
Fischer eta/. 2004 Poor Cox2 inhibitors 
lower 
(-18%) 
Hartung eta/. 2004 Poor celecoxib lower 
Kotzan eta/. 1993a Poor H2RIs lower 
Kotzan et al. 1993b Poor NSAIDs lower 
NSAIDs, 
Smalley eta/. 1995 Poor analgesics, lower (-53%) 
psychotropics 
Yokoyarna irt. i/. 2007 General ARBs lower (-17%) 
step-therapies or Ibn/ted uses 
Dunn et a/., 2006 General antidepressants no change no change 
MacCara et al. 2001 Elderly fluoroquinolones lower (-22%) 
Marshall eta/. 2006 Elderly Fluoroguinolones no change 
PPIs, SSRIs, 
Motheral etal. 2004 General NSAIDs 
lower (-19%) 
ineffective 
Schneeweiss eta/. 2004 Elderly asthma no change 
medications 
Schneeweiss eta/. 2006 Elderly PPIS lower lower lower 
Sun et al. 2007 General NSAs 
lower lower lower 
(-28" -38%) (27" -33%) (31- -43%) 
" ARBs; angiotensin-receptor blockers, Cox, inhit> ors; cyclooxygenase inhibitors, H2RAs; histamine 2-rece ptor 
antagonists, NSAIUs; no nsteroidal anti- inflammatory drugs, NSAs; non-sedating antihistamines, PPIs; proton-pump 
inhibitors, SSRIs; selective serotomn reuptake inhibitors 
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Sun et al. (2007), comparing three cohorts with slightly different interventions, suggest 
that step-therapy could be a more effective strategy to contain drug expenditure than 
formulary changes. The strongest effects were achieved by a multi-faceted 
intervention; spending on non-sedating antihistamines was reduced by 38%. Step- 
therapy alone produced a drop of 28%. Formulary changes alone did not achieve 
statistically significant changes. 
Three included studies examined out-of-pocket payment. Two studies found a decrease 
in private expenses as well as public expenditure after the implementation of step- 
therapies or limited use criteria. However, claims data may not capture out-of-pocket 
expense in real terms. Sun etal.. (2007) disclosed their concerns about cost shifting to 
substitutable OTC products that could not be investigated with claims data. 
5.5.4 Impact on health 
Among the 33 Included studies, only one explored the Impact of the policy on health. 
Fretheim et al. (2007), investigating a thiazide-first step-therapy in Norway, reported 
that there were no differences before and after the intervention in the proportion of 
patients who achieved optimal blood pressure. 
5.5.5 Impact on other resource use 
Table 5-15 presents ten studies Investigating the association between the 
reimbursement restrictions and the utilisation of other services. Seven studies reported 
that the reimbursement policies did not bring any meaningful changes in relevant 
medical service except a temporary Increase in the months Immediately following the 
change (Murawski and Abdelgawad, 2005; Schneeweiss eta/., 2006), The quality of 
these studies was mixed as were either rated as being of high or low quality. 
Evidence from the rest of the studies, rated as being of moderate quality, is mixed. In 
Canada, a rigorous quasi-experimental study found a modest Increase In hospital 
admissions for urinary tract infections, the primary Indication of fluoroquinoiones, and 
a considerable decrease In those for gastrointestinal infections (Mamdanl et al., 2007). 
In the US, Christian-Herman et al. (2004) showed that a generic-only formulary in a 
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California Medicare managed organisation increased overall hospital admissions by 
17% in their controlled study. The authors concluded that higher admissions might be 
owing to the limitation of generic availability in some serious chronic diseases. 
After the introduction of prior-authorisation for celecoxib in a Managed-Care Medicaid 
population, a quasi-experimental study by Hartung eta/. (2004) found that there was a 
significant increase in the slope of emergency department encounters and a temporary 
increased trend in other service use in the overall analysis, which did not support sub- 
analyses with NSAIDs users. Thus, the inference between the intervention and these 
outcomes seems unclear. 
Table 5-15: Impact of reimbursement restrictions on other resource use 
Patient Study Study drugs' 
Variables Follow- 
population physician visits hospitalisations others lý up 
formulary or preferred drug lists 
Christian f#iman et General overall higher (+17%) S a/. 2004 
Kephart eta/. 2005 Elderly respiratory drugs lower lower M 
Muriw : ki and 
Abdelyawad 2005 
piar-authorisation 
Hartung et dl. 2004 
Poor antihypertensives no change no change no change') S 
hinhiýr4) 
Poor celecoxib 
Kotzan etat 1993a Poor H2Rls 
Kotzan etal. 1993b Poor NSAIDs 
N5AIDs, other 
Smalley etal. 1995 floor analgesics, 
psychotropks 
char-Nwranu nr //m/Md ic. 
Marndani et aL 2001 Elderly fluoroquinobnes 
no change no change lowers) 
S 
no change no change') S 
no change no change S 
no change no change m 
no change 
higher')(+8%) 
S 
lowers)(-32%) 
nebuhsed 
Schneeweiss eta/. Elderly bronchoddators, no change no change no change 3) S 2004 steroids, 
cromoglycate 
Schneeweiss eta/. Elderly proton-pump no change no change S 2006 inhibitors 
1) HtRAs; histamine-2-receptor antagonists, NSAIDs; nonstemidal anti-inflam(natory drugs 
2) L. refer to longer than 60 months; M the period between longer than 12 months and 60 months; S equal or 
less than 12 months 
3) other service expenditure 
4) ER visits 
5) gastrointestwial-related encounters 
6) upper gastrointestinal endoscopy 
7) utioary tract infaction related hospi ahsations 
8) gastrointestinal infection related hospitabsations 
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Concerns become greater when focusing on non-significant studies. There did not 
seem enough time to detect meaningful clinical changes in patients, particularly those 
with chronic illnesses. As shown in Table 5-15, all but two studies followed up policy 
consequences for no longer than a year. Episodes of admissions and emergency room 
visits might possibly be too rare to produce statistically meaningful changes over such 
a short period. Thus, it may be inappropriate to make any concluding remarks here, 
because retrieved studies might not be sufficient to generate meaningful information 
for policy consequences in terms of time-span and quantity. 
5.5.6 Summary: Evidence about reimbursement restrictions 
The included studies were of very mixed quality, with little apparent association 
between quality rating and direction or strength of results. Evidence from the retrieved 
studies suggests that reimbursement policies could lower spending on drugs 
considerably by a differential effect on preferred and restricted drugs. Largely, there 
was increasing consumption in fully-funded drugs such as generics or first-line 
medications and decreasing use in restricted drugs, indicating cost-effective prescribing 
in practice. However, worrisome aspects have been seen across studies. Simple 
withdrawal of payment not supported by other interventions such as prescribing 
guidelines could yield other undesirable prescribing. Mandatory reimbursement 
restrictions may increase the use of other resources, often more expensive, and 
discourage patients from adhering to medication schedules. Consequences may be 
exacerbated by inappropriate coverage decisions. It seems essential for policy-makers 
to bear in mind advice from Sun et at.. (2007; p375-6) that "[plans] may need to 
examine the wide-ranging consequences of their medication coverage decisions": A 
systematic review by Cochrane reviewers, published in 2010 (Green eta/., 2010) , 
explored prior-authorisations and step-therapies reimbursement changes, included 
around 50% of the studies included in this review. That review included studies 
published after 2007 that this review could not include and excluded three studies that 
this study included. The two reviews are in accordance that reimbursement restrictions 
reduce payers' expenditure and drug utilisation selectively without explicit adverse 
effects on other resource utilisation. Both, however, also found that these conclusions 
are conditional on appropriate coverage decisions. 
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5.6 Incentives for professionals 
5.6.1 Characteristics of Included studies 
Among 17 studies, 9 examined UK fundholding by comparing fundholding and non- 
fundholding practices, which were rated as moderate to low quality. Four studies 
Investigated the global budget in Sweden, Switzerland, China and Taiwan. Two studies 
from Europe were of moderate quality, while two from Chinese countries were rated as 
poor quality. One examined an itemised budget in Israel (rated as low quality); one 
tested the impact of one-off bonuses on Dutch physicians (rated as good quality); and 
two studies from North America addressed the introduction of financial incentives for 
less expensive therapies on physicians or pharmacists, rated as moderate quality. The 
basic characteristics of included studies are presented in Annex 14. 
All but three studies employed CBA designs, the remaining three were analysed using 
ITS designs. All studies used a claims database maintained by a national or 
organisational body. Nine studies followed up the Impact of Interventions for no longer 
than a year after the Implementation; eight studies addressed the Intermediate-length 
of follow-up period after the policy Interventions. Often, considerable baseline 
discrepancies were seen In CBA studies, especially those for UK fundholding, despite 
matching. Differences were particularly obvious between the first wave fundholders 
and others. 
5.6.2 Impact on drug utilisation 
Existing evidence shows that budgetary constraints may lower drug consumption only 
to a limited degree In the British fundholding programme (Table 5-16). The size of falls 
In utilisation was small - no greater than 5%, and inconsistent. The largest study 
including all fundholding practices from the first to the fifth wave In England showed 
that there were no significant differences between fundholders and non-fundholders In 
drug consumption (Harris and Scrivener, 1996). Some Increases were found to be 
dependent on conditions such as comparators (Bradlow and Coulter, 1993; Wilson et 
a/., 1995). 
As shown in Table 5-17, in the US, reward payments for generic prescribing did not 
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influence prescribing behaviour (O'Malley etal., 2006). One-off bonuses to Dutch 
physicians in return for adhering to prescription guidelines brought only slight intended 
changes in gastric drugs among 10 recommendations (Martens etal., 2007b). 
Table 5-16: Impact of UK fundholding on drug utilisation and expenditure 
Study Wave Drug utilisation 
Drug expenditure Generic prescribing Prices 
(payer) rates (cost/itern) 
Baines eta/. 1997 Ist 
lower higher in Devon (+21%) 
(-12« -13%) no change in Lincolnshire 
Bradlow and Ist higher (+1.4%)') 
lower higher 
lower (-7%) 
Coulter 1993 (-6--9%) (+5"' +13%) 
Cornet' and 1st/2nd no change Kerrison 1997 
Harris and Ist-5th no change (-6%)2) Scrivener 1996 
. 
Rafferty et a/. Ist-3rd no change 
lower higher 
no change 1997 (-7"' -18%) (+9"' +13%) 
Whynrs eta/. ist-3rd lower lower no change 1995 
Whynes et al. 4th 
lower lower higher 
1997 (-3%) (11%) (+14%) 
lower in wave 1&3 
Wilson eta/. 1995 1st-3rd 
(-4" -5%) lower higher no change higher in wave 2 (-3--7%) (+8-+13%) 
(+2%) 
Wilson eta/. 1999 3rd/4th lower lower no change no change 
1) non-dispensing fundholdin g practices, compare d to non-fundholding practices 
2) no statistical analsis given 
Table 5-17: Impact of other incentives programmes on drug utilisation and 
expenditure 
Study Setting Drug utilisation 
Drug expenditure Prices (Payer) 
global budget 
lower er Etter and Perneger 1998 Switzerland (-ql 
Granlund etal. 2006 Sweden no change no change higher 
Lee et ,# 2006 Taiwan 
110 charxIe. ria 
Ili 
Yil. r and Lggloston 2004 China lower ( 4I6%) 
others 
Elhayany rar , /. 2001 Israel ( 60, %) 
Law and Wu 2003 Canada no change 
Martens etal. 2007b Netherlands little change 
O'Malley etal. 2006 USA no change 
1) no proper statistical analysis green 
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5.6.3 Impact on drug expenditure 
Across UK studies, seven studies showed that fundholders spent less on drugs, 
compared to non-fundholding practices (Table 5-16). The magnitude of reduction was 
slightly greater in drug expenditure than utilisation, about 3-13%, indicating that 
fundholders prescribed less expensive medications rather than issuing less 
prescriptions. The utilisation of generics was increased by 5-21% In five out of six 
studies, which was linked to a significant decline in prices in one study which was rated 
as high quality (Table 5-16). 
By and large, savings were largest in the first year of being a fundholder in all waves, 
reducing over time (Harris and Scrivener, 1996; Whynes et al., 1997). Dispensing 
fundholders were more likely to be affected than those that were non-dispensing 
(Bradlow and Coulter, 1993). 
One Swiss university plan was successful in controlling expenditure growth by 
introducing a gatekeeper and a global budget on a capitation basis (Etter and Perneger, 
1998). Drug expenditure was decreased by more than 40%, compared to those of a 
comparison plan with a FFS payment system. A Chinese payment experiment 
presented a similar result. Fourteen hospitals in Hainan where `a prepayment scheme' 
was introduced, a sort of a monthly global budget, appeared to reduce expenditure on 
costly drugs by about 46%, compared to hospitals still operating on a fee-for-service 
basis (Yip and Eggleston, 2004). 
Despite such encouraging results from Included studies, a few methodological points 
are worth mentioning here. Positive results might be confounded by selection bias. For 
example, UK fundholding GPs, In particular those In the first wave, already showed 
better prescribing practices before becoming fundholders. Hence, prescribing behaviour 
of fundholders may be an Inherent characteristic, not a policy achievement. Selection 
could occur in patients as well as providers. In Switzerland, heavy consumers tended to 
move away from a restricted plan into a more generous one when a capitation based 
budget scheme was Implemented. Overall, studies were rated as poor quality. 
Dissimilar to cases thus far, a global budget scheme in Sweden may not have brought 
about the intended changes either In drug utilisation or prices (Granlund etal., 2006). 
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The authors suggested that there might be no room for further savings on drugs 
because the new budget scheme introduced in the region where had been affected by 
several cost containment strategies. In Taiwan, drug expenditure increased 
significantly rather than decreased after the implementation of a global budget scheme 
in hospitals (Lee et al., 2006). Taiwanese authors drew the conclusion that savings 
were not seen because incentives were not directly aimed at prescribers in their drug 
budget scheme. In Canada, incentivised pharmacists could not change prescribers to a 
lower-priced therapy (Law and Yu, 2003). 
An Israeli itemised budget constraint programme slowed the growth of drug costs by 
60% over three years, compared with expenditure in the district as a whole (Elhayany 
et al., 2001). However, such savings were offset by administrative expenses. Saving 
effects weakened and expenditure in ex-fundholding practices returned to the original 
levels with the discontinuation of the intervention. 
5.6.4 Impact on other service use 
The effect of budgetary regulation on referral rates to higher levels of care or more 
expensive services substituted for medications was not investigated In the Included 
studies. On this Issue, a previous review Including less-well controlled studies, 
suggested that fundholding may not be associated with the increase of referral rates 
(Gosden and Torgerson, 1997), which is supported by a large scale quasi-experimental 
study exploring the effect of fundholding after the abolition (Dusheiko et al., 2006). 
However, the association of pharmaceutical use and other service use resulted from 
Incentives on professionals Is unclear In these studies. 
5.6.5 Summary: Evidence about incentives 
The present review shows that budgetary constraints could be an effective strategy In 
containing spending for drugs when direct and constant incentives were given to 
prescribers. According to British studies exploring individual general practice budgets, 
prescribers may accomplish modest savings by prescribing less-costly medications, for 
example generics, rather than reducing the absolute prescribing volume. However, 
readers should bear In mind that these findings were from studies rated as moderate 
to low quality. Although this review Included more studies from varied settings than the 
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previous Cochrane review (Sturm eta/., 2007), there were few differences in 
conclusions concerning the policy impact and little improvement in the quality of 
evidence available. 
5.7 Distribution of samples 
Three studies explored the association between free drug samples and prescribing 
practices in the US (Annex 15). One study used an ITS analysis; two employed CBA 
designs. All studies used a claims database maintained by a national or organisational 
body and tackled short-term effects over less than 3 years. Studies were rated as 
moderate to low quality. 
Evidence from the retrieved studies showed that free drug samples might not be 
sufficient to modify physicians' prescribing behaviour. Doctors did not show a 
significant increase In prescribing generics, even after receiving free generic samples 
over a three-year period (O'Malley et al., 2006; Scott et al., 2007). Likewise, 
restrictions on access to free drugs stocked at physicians' offices did not achieve 
meaningful changes in the utilisation of non-formulary drugs (Mukamal eta/., 2002). 
5.8 Mandatory generic substitution 
One study rated as moderate quality examined the Impact of mandatory generic 
substitution In Sweden, under which pharmacists were to dispense the cheapest 
substitutable products on the benefit list (Annex 15). Andersson et a/. (2007) examined 
the policy Impact on drug expenditure over more than two years, using a segmented 
regression analysis of nation-wide data. The study showed a sharp decrease in both 
public and private expenses on pharmaceuticals, which lasted two years after the 
Implementation. There is no further information as to whether the policy influenced 
utilisation, prices or other service use. 
5.9 Repeat prescribing 
One study, rated as moderate to low quality, explored the impact of British repeat 
prescribing using an Rd study design for a year (Bond etal., 2000) (Annex 15). It 
shows that pharmacists maintaining repeat prescribing brought out some 
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improvements In the quality of medication care by detecting adverse medication 
problems without increasing relevant medical services such as GP visits and 
hospitalisations. However, effects in drug volume and expenses seem negligible. 
5.10 Separation of prescribing and dispensing drugs 
One study, rated as moderate to high quality, tackled the impact of the separation 
policy in Taiwan, using a CBA design (Chou eta/., 2003) (Annex 15). The authors 
compared two regions that adopted the separation policy in 1997 with another two 
regions where there had been no changes. 
This study showed that the Taiwanese separation policy might lower drug utilisation 
and expenditure only in clinics without pharmacists on-site. Patients attending such 
clinics were about 3 times more likely to have no prescriptions in the post-separation 
period, compared to patients in the control settings. Overall drug spending was 
reduced by 12% in clinics with no pharmacist over the study period. However, such 
changes were not found when all study clinics were included in the analysis. The 
authors suggested that physicians still prescribed and dispensed drugs on their 
premises by hiring pharmacists rather than modifying their prescribing behaviour, 
indicating no real separation in such premises. 
5.11 Discussion 
From the search of two major electronic databases and references from included 
studies, 117 studies were identified, which explored the impact of pharmaceutical 
regulations influencing providers. Half of the reviewed studies investigated educational 
Interventions aimed at prescribing practices, followed by studies examining 
reimbursement policies and Incentives for providers. Only a few studies addressed 
other measures such as distribution of free drug samples, mandatory generic 
substitution, repeat prescribing and the separation policy, 
Overall, this review found the following from included studies: 
  Studies exploring the impact of educational interventions were generally rated 
as moderate quality; those exploring the impact of reimbursement restrictions 
were of mixed quality but showed little variation in the findings according to 
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quality; those exploring the impact of incentives were of moderate to low quality. 
Thus, caution should be made when interpreting the findings of this review. 
  Providing prescribing Information achieved a limited success in correcting 
prescribing behaviour. Nevertheless, the improving patterns were likely to be 
associated with the intended outcomes (decrease or increase) in the utilisation of 
targeted drugs and lowering drug expenditure. The magnitude of reduction In drug 
expenditure was generally modest, between 10-20% and diminished over time. 
  Educational Interventions could lower drug expenditure when they focused on 
cost-effective information. In addition, if the information was either well-focused 
on problematic medications with good scientific grounds, on improper behaviour 
with individual-specific data, or supported by professionals, Involved more multi- 
directional participants, disseminated repeatedly, and/or through multiple devices, 
it could also Improve drug utilisation profiles. 
" Educational approaches are unlikely to Influence other resource use, overall 
health, or patient satisfaction. 
  Greater and relatively invariable savings were seen In reimbursement policies 
among the Included Interventions. There were considerable reductions In restricted 
drug use with a slightly smaller Increase in preferred drug use, resulting in 
marginal drops In overall utilisation. The effects of increasing use of less costly 
alternatives were likely linked to reducing drug expenditure. Among reimbursement 
policies, the withdrawal of inappropriate drugs from the benefit lists was less likely 
to change drug utilisation and expenditure than others. 
  Few studies tackled changes in private expenditure after Introducing 
reimbursement policies; there is limited evidence showing that step-therapies or 
limited uses could lower out-of-pocket payment. 
" Some evidence Indicates that reimbursement policies could increase other 
service use within a short term. 
" Budgetary policies might lower drug expenditure only when they provided 
direct and constant financial benefits for prescribers. 
  UK fundholding might have lowered drug expenditure by around 5-15% by 
Increasing less-costly alternative prescriptions, not by decreasing the absolute 
prescribing volume. The greatest changes were achieved in the first year of 
Involvement and weakened over time. However, it seems doubtful whether these 
were true savings or exaggerated by selection bias, because there were apparently 
different characteristics between fundholders and non-fundholders and little 
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change in price variables reflecting the effects of using less costly alternatives. 
  There are few studies exploring other types of intervention. Unlike pre-existing 
beliefs, evidence from the included studies showed that doctors did not seem to be 
affected by free drug samples, these studies were rated as poor quality; 
mandatory generic substitution could lower both public and private expenditure; 
pharmacist-maintaining repeat prescribing brought little change in overall 
utilisation; the separation policy might lower drug utilisation and expenditure only 
in a strictly separated condition between prescribers and dispensers in Asian 
surroundings. 
A shared aspect of policy interventions on providers is that savings were generated 
from the increasing use of less costly alternatives and decreasing a handful of 
expensive products, rather than a decline in overall utilisation. Impact from educational 
programmes and incentive schemes were smaller, compared to those from 
reimbursement policies in drug costs. From the doctors' viewpoint, it may be the same 
with educational interventions, in fact, competing with industry sources of Information. 
In real terms, one of the most important informants is the drug company. In the US, it 
was estimated that drug companies spent $7.3 billion on detailing activity and provided 
$15.9 billion worth of drug free samples to physicians in 2004 (Schweitzer, 2007b). 
Continuing medical education programmes have been supported by drug companies to 
a considerable extent (Angell, 2005). Thus, Witt et al. (2004; p253) argued, "the 
method of academic detailing could easily be dismissed if it was not for the fact that 
the medical Industry spends vast amounts on marketing efforts that include detailing`". 
Although the administrative interventions showed worthwhile decreases in drug costs 
in comparison with other voluntary-based measures, the query about actual savings is 
debatable. Administrative restrictions could raise more concerns about secondary 
consequences, being mostly compulsory measures with little consideration for patient- 
specific clinical characteristics. If they foster using other healthcare resources, the net 
saving would be much less. 
A factor causing confusion in the calculation of savings In educational programmes may 
be administrative expenses, For instance, this review found that educational efforts 
might be positively associated with modifying prescribing behaviour toward evidence- 
based practices. Such changes, as hoped, brought a positive economic effect. However, 
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can savings really be calculated without considering programme expenses? Even if 
individual contacts or computerised technologies achieve greater changes in 
prescribing practices, it would not make economic sense in cases where spending 
exceeds saving - so called "policy cost-effectiveness" (Mason et al., 2001). However, 
evidence of net benefit is almost lacking in this review. In the included studies, only 
two studies addressed this subject and failed to show the positive net effects after 
taking off the administrative costs except one sub-case. 
In addition, little attention was given to questions like whether pharmaceutical 
regulations affect patients' costs and if so, how much those are and whether or not 
such measures influence equity among social groups. Linked to these issues, the 
Swedish mandatory generic substitution policy and two step-therapy studies showed a 
decline in expenses to both insurer and patient. It is worthy of note, given that other 
policies appeared to accrue extra expenses to patients. 
In South Korea, a variety of efforts influencing providers are currently made Including 
positive lists, prescribing budgets, computerised DUR systems and generic prescribing 
(Chapter 2). They seem to encompass every possible option that this review found 
across countries. This review yields little information directly relevant to Korean 
pharmaceutical policy, but demonstrated that many known and unknown factors are 
able to affect policy outcomes. Moreover, the questions about the association between 
the policy interventions and health remain unanswered. Therefore, the vital factor in 
policy-making efforts is to evaluate outcomes and consequences through robustly 
designed experimental or quasi-experimental analyses of empirical data from the 
Korean population. 
Bearing in mind the limited generalisability of the findings, the following information 
should be considered In Korean pharmaceutical policy-making: 
Although prescribing feedback has been Implemented for nearly a decade In Korea, it is 
thought that few actual alterations have been achieved in prescribing practices 
(Chapter 2). The Impact of this policy has been inadequately evaluated. Hence, it may 
be difficult to discover the true causes for Its Ineffectiveness despite that Korean 
prescribing feedback has regularly delivered Individualised data to prescribers. Given 
the findings from this review, one of the important reasons may be that standardised, 
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centralised information has not been supported by prescribers, who may have a 
number of clinical reasons to prefer individual patient databases. This review shows 
that It seems worthwhile in future focusing primarily on problematic prescribers with 
clear clinical reasons rather than giving feedback to every prescriber. 
The current review also shows that inappropriate coverage decisions may yield 
unwanted policy consequences. At present, Korean authorities work on a new positive 
list grounded in cost-effectiveness (Chapter 2). Simultaneously, concerns are growing 
over the quality of pharmacoeconomic evaluation studies available in Korea. Choi 
(2008) asserted several challenges concerning economic evaluation in her recent article. 
First, studies are conducted on integrating local cost data and foreign clinical data, 
owing to the lack of randomised clinical studies in the Korean context. Second, funding 
and experts are scarce for the validation of such mixed research. Third, drug 
companies often resist disclosing the raw data of their economic studies, which is vital 
for validation. In this respect, It should be borne in mind that poor economic studies 
may result in undermining the value of economic evaluation and increasing overall 
costs to the healthcare system if expensive but marginally effective drugs are not ruled 
out. 
Finally, It was observed that various measures explored in the reviewed studies 
contained costs by encouraging utilisation of generics. However, this was not always 
the case. For Instance, the Spanish series of papers demonstrated that an Increase in 
generic prescribing could not affect drug costs as shown in Table 5-7 (Sicras-Mainar 
and Pelaez-de-Lono, 2005; Sicras-Mainar etal., 2007; Sicras-Mainar etas., 2004). 
Presumably, this was due to the low baseline use of generics in Spain (European 
Generic Medicines Association, 2004), subsequently, In the study nursing homes (about 
8%). In such surroundings, generic utllisatlon might hardly affect overall drug 
expenditure, even though generic use Increased by 50%. Thus, for better policy 
outputs relating to generic policies, It seems essential to discover the situation of the 
Korean generic market before taking a step forward. 
Among evaluated interventions, budgetary interventions seem promising as policy 
options encouraging generic use. However, a careful interpretation should be made 
because current evidence is derived from studies rated as moderate to low quality and 
mostly from the UK, with a substantially different healthcare system from Korea. There 
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may be huge administrative challenges in Korea where most providers operate on a 
private basis in contrast with the UK NHS. Alternatively, measures limiting the less cost- 
effective drugs, including prior-authorisations or step-therapies, may be 
recommendable if common sense is exercised about `less cost-effective drugs' In 
society like `antibiotics for the common cold' (Chapter 2). If it merely selects some 
drugs because they are expensive, it may raise policy resistance and social inequity. 
5.12 Summary 
This review found that existing evidence about the Impact of pharmaceutical policies 
influencing healthcare providers Is concentrated on three types of Intervention: 
educational approaches; reimbursement restrictions; and incentives. Although the 
Included studies used rigorous study designs, they were of very mixed quality. Greater 
caution should be made with the studies exploring Incentives that showed poor quality 
In general. Little attention has been paid to other policies such as free drug samples, 
generic prescribing/ substitution, alternative prescribers or the separation policy. 
Evidence from studies suggests that voluntary-based Interventions Including 
educational and budgetary measures are associated with limited and short-term 
success In lowering drug expenditure. Policies restricting drug reimbursement may be 
linked to greater Impact In lowering drug expenditure. In most cases, Impact on drug 
utilisation was selective. Although few studies tested the policy Impact on the use of 
other resources, overall health and private expenses, there are some concerns that 
Inappropriate reimbursement decisions may lead to an Increased use of other 
resources, possibly linked to deteriorating health. Korea has a relatively short history In 
Implementing pharmaceutical policies that influence healthcare providers. It should not 
be overlooked that there are clear limitations to generalising foreign experience to the 
Korean context. Further discussion about methodological aspects of the reviewed 
studies and Implications for the current research are continued in Chapter 7. 
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CHAPTER 6: THE EFFECTS OF PHARMACEUTICAL REGULATIONS 
INFLUENCING INDUSTRY 
6.1 Introduction 
The objective of this chapter is to present findings from the systematic review 
concerning pharmaceutical policies regulating industry. In brief, studies for this review 
were identified from two major databases, MEDLINE and EMBASE, and included if the 
article (1) explored the effects of pharmaceutical regulations aimed at influencing 
industry; (2) examined the effects of such interventions on at least one of the relevant 
outcomes depicted in Chapter 3; (3) analysed primary or secondary data; and (4) 
performed this with one of three most robust designs, RCT, ITS, or CBA. Details of 
methods were presented comprehensively in Chapter 3. 
6.2 Overview of included studies 
In the search for pharmaceutical policies regulating industry (Annex 4), 265 studies 
were identified (Figure 6-1). Thirty were retained after the initial screening of titles and 
abstracts. And of them, 19 studies finally met the inclusion criteria (Table 6-1). The 
majority of these studies are devoted to evaluating pricing controls: reference-pricing 
programmes (n=13), other price controls (n=3). Single studies explored the effects of 
a formal quest for cost-effectiveness information on reimbursement decisions, patent 
expiry and profit control. Reasons for exclusion are reported in Figure 6-1 and Annex 6. 
6.3 Policies regulating industry 
For several decades, governments have been controlling pharmaceutical prices to 
regulate industry (Jacobzone, 2000; Mrazek and Mossialos, 2004). They commonly set, 
cut, or agree prices for drugs. For example, in the studies reviewed, an American 
Medicaid agency set an upper limit of reimbursement for prescribed drugs, which Is 
one of the principles of pricing mechanisms in Korea. 
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Figure 6-1: Flow diagram of studies (industry) 
Studies identified n= 265 
" Medline (n-7115) 
" Embase (n=141) 
  References (n=9) 
Exduded n=72 
" duplicates 
Studies retained for initial 
screening of titles and abstracts 
n=193 
Excluded n= 163 
" exploring irrelevant interventions 
Studies retained for screening of 
quality assessment 
n= 30 
Excluded n =11 
" before and after study design (7) 
" one group posttest-onlydesgn(1) 
  descriptive study (J 
  cross-sectionalstud)y(1) 
  unclear when intervention occurred (1) 
Studies eligible for inclusion 
n= 19 
" Price control-reference pricing (13) 
" Price control-others (3) 
" Market authorisation (1) 
" Patent regulation (1) 
" Profit co ntrol (1) 
Table 6-1: Studies included 
Intervention Studies 
Andersson et al. 2006, Bergman and Rudhotn 2003, 
Grootendorst and Stewart 2006, Grootendorst et al. 2001, 
Reference pricing 13 
Grootendorst et al. 2005, Hazlet and Bbugh 2002, Mabasa and 
Ma 2006, Marshal etal. 2002, Pavenik 2002, Pug-Junoy 2007, 
Schneeweiss et al. 2002b, Schneeweiss et al. 2002c, 
Schneeweiss et al. 2003 
Other price control 3A narsdottr et a/. 2000, Lee eta/. 2006, Sawyer 1983 
Formal quest of cost- I Lundkvst et a1.2006 
effectiveness information 
Patent regulation 1 Roersma et al. 2005 
Profit control 1 Borrel 1999 
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Since Germany, introduced a reference-pricing system in 1989, which indirectly 
controlling prices for drugs, it has been expanded to a number of countries. In 
reference-pricing systems, a reimbursement price Is set for drugs and patients have to 
pay for the difference between the cost of the product prescribed and the reference 
price. Three of the most influential policy factors that determine the Impact size are: 
how to group pharmaceuticals; how to compute reference prices; and whether or not 
to Include patented drugs (Lopez-Casasnovas and Puig-Junoy, 2000). This review 
Identified studies evaluating the Impact of reference-pricing programmes implemented 
in Germany, Sweden, Spain and some Canadian provinces. Early German and Canadian, 
and Spanish systems classified drugs by chemically active Ingredients and the Canadian 
and German systems classified further by therapeutic classes. The German reference- 
pricing programme broadened the drug groups to therapeutic effects. The reference 
price may be the lowest daily cost (Canada), the average price of drugs in a category 
(Germany), the average price of the three lowest price drugs In a category (Spain), or 
the lowest priced drug plus a certain amount of mark up (10% In Sweden). New and 
innovative drugs are excluded by reference-pricing programmes In these countries. 
A small number of countries regulate industry through controlling the profits of drug 
producers. In the British Pharmaceutical Price Regulation Scheme (PPRS), companies 
are allowed freedom of pricing for their products and voluntarily negotiate target 
profits from sales of drugs to the NHS with the authority. In 2005, the target profits 
were 21% on a Return on Capital basis and 6% on a Return on Sales basis 
(Department of Health, 2006b). According to the target, manufacturers earning 
excessive profits may be required to reduce prices of drugs provided to the NHS. 
Licensing or reimbursement decisions are long-lasting ways of regulating industry 
alongside price control. Licensing is a drug approval procedure, processed in most 
countries with the criteria of safety and clinical efficacy. No studies exploring this policy 
were identified. In recent years, governments have increasingly required cost-effective 
evidence in reimbursement decisions, through which the government wishes to curb 
expensive but marginally Innovative new drugs. The global patent system was enforced 
In 1986 to encourage R&D Investment by awarding temporary monopoly power on 
successful Innovation for new drugs. Basic characteristics of Included studies and 
outcomes from the review are discussed by intervention In the following sections. 
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6.4 Reference-pricing schemes 
6.4.1 Characteristics of included studies 
Basic characteristics of included studies are presented in Annex 16. The majority 
explored the impact of reference-pricing introduced in 1990s in Canada. Most Canadian 
studies were rated as moderate to high quality and involved elderly beneficiaries on a 
PharmaCare plan in British Columbia as an intervention population, while Mabasa and 
Ma (2006) analysed the effects of a similar pricing regulation of PPIs on members of 
an employer-sponsored drug plan in Ontario. The remaining four studies were from 
other nations, such as Germany, Sweden and Spain, and were rated as moderate to 
low quality. 
All but two studies employed ITS designs. Most of these used monthly data, whilst two 
utilised quarterly data (Bergman and Rudholm, 2003; Pavenik, 2002) and one utilised 
quarterly (before) - monthly (after) data (Andersson et al., 2006). One study used a 
CBA design (Mabasa and Ma, 2006). Schneeweiss and colleagues explored secondary 
outcomes of the policy using a CBA design alongside ITS analyses for the primary 
outcomes (Schneeweiss et al., 2003; Schneeweiss et al., 2002c). 
Eleven studies used aggregated claims data held by national or provincial-level 
authorities; two non-Canadian studies employed market sales data constructed by IMS 
Health. Two studies explored the impact of longer than 5 year-term policies. Others 
followed up the policy effects at short- or intermediate-term. 
6.4.2 Impact on drug utilisation 
Evidence from retrieved studies demonstrates that reference-pricing programmes may 
be effective in reducing the volume of non-reference drugs and increasing the volume 
of reference drugs. As a result, modest or little impact in overall use has been shown 
(Table 6-2). 
Reference-pricing schemes could carry less-desirable substitution effects. Grootendorst 
et al.. (2005) reported that they observed an increased use of costly opiates after 
applying reference-pricing to NSAIDs, however, their aggregate data could not provide 
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further evidence whether opiates were being prescribed as a substitute for restricted 
NSAIDs, or prescribed due to treatment failure on the part of the lower cost NSAIDs. 
In this respect, two studies exploring the histamine-2-receptor antagonists (1-12111s) the 
reference-pricing, showed that prior-authorisation of PPIs, Introduced simultaneously, 
might be helpful to curb potential Increases in other substitutable noncost-effective 
medications (PPIs in this case) (Hazlet and Blough, 2002; Marshall et al., 2002). 
Table 6-2: Impact of reference-pricing schemes on drug utilisation 
Drug utliisatIon2) 
Study Setting Study drugs') 
Overall Therapeutic Restricted Reference Related 
class drugs drugs drugs 
Andersson et Sweden Overall no change no change a/. 2006 -lower 
ýFW 
oral antkiiabetics no change3) lower no change 
Pavenik 2002 Germany 
antiuicerants no change 4) lower higher 
Puig-Juroy Spain statins 
no change 
2007 -lower 
Grootendorst 
and Stewart Canada ACEIs, CCBs no change 
2006__ 
Grootendorst 
eta/. 2001 
Canada nitrates, CCBs no change (-12N-68 °) (+86N+124%) 
same active no change 
no change 
Grootenclorst Canada 
Ingredient 
NSAIDs - ---- -- 
lower 
--- eta/ 2005 therapeutic no change no change class higher 
Hazlet and 
Slough 2002 Canada H2RAs (PPIs) no change 
no 
change') 
Mabasa and Canada PPIs (-20%) Ma 20064 
Marshall et 
a/. 2002 
Canada H2RAs (PPIs) (+12%)6) (+14%) (-51(VO) 
^y_ý 
(+316%) no 
change') 
Schneeweiss Canada ACEIs no change7I lower lower higher etal. 2002b_ 
a TM ýY Schneeweiss Canada dihydropyridine no change? lower lower higher eta/. 2003 C039 
1) ACEIs; angiotensln converting enzyme Inhibitors, CCBs; calcium channel blockers, HaRAs; histamne-2-receptor antagonists, 
NSAIDs; nonsteroldal antHnflammatory agents, PPIs; proton-purrp inhibitors 
2) In cases no proper statistical evidence given but more than 10% differences reported, the results are in perantheses. 
3) an oral ant dlabetics 
4) all antlulcerants 
5) special authority for PPIs nrplemented concurrently 
6) all gastrointestinal (GI) drugs; an Increase of the use of cisapride was leading to an increase of all other GI preparations use 
7) all antlhypertensNes 
6.4.3 Impact on drug expenditure and prices 
As shown in Table 6-3, encouraging the utilisation of less costly drugs through 
reference-pricing was linked to a considerable decline In payers' spending on drug 
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classes of 11% to 50% in Canada. Greater effects were seen In the scheme with 
therapeutic class clustering rather than chemical Identical grouping. The magnitude of 
effect has decreased over time (Grootendorst and Stewart, 2006; Schneeweiss et al., 
2003). A far smaller Impact has been observed In studies rated as poorer quality, 
undertaken in other settings such as Spain and Sweden. 
Table 6-3: Impact of reference-pricing schemes on drug expenditure and price 
Clustering Drug expenditure 
Study Setting lame active therapeutic " Out-of-pocket) 
Pricer 
ingredient class Payer Out of-p 
Andersson et Sweden Y no change lower 
a/. 2006 
Bergman and Sweden y no change Radhalm 2003 N lower (-16''-21%) 
Pavenik 2002 Germany y Y no change (1989) (1991) N lower 
Puig-Junoy 2007 Spain y lower (-2.2%) lower 
y lower (-11%) higher no change 
Grootendorst et Canada N 
higher 
at.. 2005 Y lower (-44%) higher no change 
N lower 
Grootendorst no change and Stewart Canada y N lower no change 2006 
Grootendorst et Canada y lower (+390%) (-11--39%) 
a/. 2001 (-22 N -50%) 
Mabasa and Ma Canada y (-26%) (no change) 2006 
Marshall eta/. Canada y (-45%) (+16%) (-52%) 2002 
Schneeweiss et Canada y (-19%) 
at. 2002b 
Schneeweiss et Canada y (-12%) 
al. 2003 
1) In cases no proper statistical evidence given but more than 10% differences reported, the results are In 
perantheses. 
In contrast to policy expectation, reference-pricing may result in a minimal price 
reduction (Table 6-3). Included studies came from Canada indicated that reductions in 
payers' expenditure might be achieved substantially by raising patients' out-of-pocket 
payment. Grootendorst and colleagues estimated that elderly patients' out-of-pocket 
payments represented about 8«20% of insurers' savings in their studies (Grootendorst 
etal., 2001; Grootendorst etal,, 2005). As a result, people of low income status may 
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be more likely to give up their medication (Schneeweiss et al., 2003). 
Pavenik (2002) suggested that brand prices might be lowered further where a larger 
generic market had been established, as in Germany and Sweden (Bergman and 
Rudholm, 2003). A Spanish study, rated as moderate quality, however, demonstrated 
that prices tended to converge at a reference price; there was an immediate price 
reduction in products above the reference line, but little impact in those initially below 
the level (Puig-Junoy, 2007). The author argued that the drug price might be dropped 
not by price competition, but by regulatory decisions, i. e. "the method of calculation of 
the reference price" in the heavily regulated Spanish market. 
6.4.4 Impact on other service use and clinical variables 
Four Canadian studies investigated whether restricting the use of costly drugs carried 
any change in other medical services utilisation or clinical variables (Table 6-4). None 
found any meaningful changes in relevant variables within a 12-month study period. 
Table 6-4: Impact of reference-pricing schemes on other clinical variables 
Study Population Study drugs') Variables Effects 
UP 
FO 
P2) 
Hazlet and Elderly H2RAs (PPIs) Office visits lower S 
Slough 2002 ER visits no change 
hospitalisations no change 
length of stay no change 
Schneeweiss et Elderly 
a!. 2002b 
ACEIs 
drug 
discontinuation no change S 
Schneeweiss et 
Elderly ACEIs physician visits no change S 
at. 2002c emergency no change hospitalisations 
_ __ 46 nonemergency 
no change hos itatisations 
long-term care lower 
admissions 
Nmm 
mortality no change 
Elderly Schneeweiss et dihydropyridine physician visits 4 ^` 
no change S 
a!. 2003 CCgs emergency no change 
_hospitaligt! 
gns 
, __ _9P _ nonemergency no change 
other services no change 
exaenditure 
1) ACEIs; ang otensIn converting enzyme inhibitors, CCBs; calcium channel backers, H, RAS; histanlne-2- 
receptor antagonists, PPTs; proton-punp inhibitors 
2) S equal or less than 12 months 
6.4.5 Summary; Evidence for reference-pricing schemes 
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Based on Canadian studies, rated as higher quality in general, this study found that 
reference-pricing schemes could reduce pharmaceutical spending with few changes in 
overall utilisation, suggesting less deterioration in patient accessibility. Savings may be 
achieved through partially increasing the use of less costly medication, namely 
reference drugs, and, in parallel, increasing patient expenses. Hence, it seemed to 
discriminate against patients who faced unavoidable extra out-of-pocket expenses in 
some quarters. Greater effects were observed in reference-pricing schemes that 
grouped drugs by therapeutic class compared to by the same active ingredient. There 
is some evidence for lowering prices in pharmaceutical products above the reference 
price in the market. However, empirical data suggests that the opposite trend could be 
possible if the price was below the reference line. Few studies reported unwanted 
consequences, but the impact of reference-pricing on overall heath and other 
healthcare resources seem still warranted, given that most evidence came from one 
Canadian province and none were truly dedicated to addressing consequences in 
health. 
6.5 Other price controls 
Three retrieved studies were dedicated to Investigating regulations relating to other 
price controls In three different settings (Annex 17). All employed an ITS design to 
Investigate the association between the new policy and drug costs using government- 
level claims data over a relatively long period, 2-7 years. 
Evidence from included studies suggests that price controls may hardly affect drug 
spending (Table 6-5). Although one Taiwanese study rated low quality suggested a 
minimal decline after some of the national pricing scheme changes, the other two 
studies rated as higher quality did not support the changes. 
An early US study examining the impact of the Maryland Maximum Allowable Cost 
(MAC) limit an multisource drugs showed a temporal decrease in total drug 
expenditure after the change. However, the authors concluded that it might be due to 
fewer beneficiaries wanting to get drugs In a newly introduced copayment schedule 
rather than the new pricing policy (Sawyer, 1983). 
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Table 6-5: Impact of various price controls on drug expenditure 
Study Setting Drug expenditure (Payer) 
Almarsdottir eta/. 2000 Iceland deregulation of OTC price set no change 
ist N 3rd mechanisms') no change lee etal. 2006 Taiwan 
4th N 6th mechanisms) lower 
total expenditure lower 
Sawyer 1983 USA 
costs/patient no change 
1) International and Inter-brands price comparison, market price survay 
2) market survey, generic grouping, flat payment rates 
6.6 Formal request for economic evidence 
One study addressed the association between the formal requirements for cost- 
effectiveness information in reimbursement decisions and time lags before 
authorisation using an ITS design with yearly data from regulatory authorities, but the 
quality of the study was poor (see Annex 18 for the basic characteristics). 
Lundkvist and colleagues (2006) Investigated 242 new chemical entities (NCEs) 
approved in Finland and Sweden from 1995 to 2003 and found that the new procedure 
tended to prolong the time until final decision only in the first year of implementation. 
Additionally, NCE drugs launched by the bigger manufacturers or with a bigger volume 
of sales appeared to go more quickly through the authorisation procedure. The authors 
concluded that a crucial determinant of time taken to the new authorisation procedure 
might be linked to the capacity for obtaining requested information. 
6.7 Patent regulation 
In the Netherlands, Boersma et al. (2005) Investigated the trends in the use of 
generics after patent expiry for enalapril, fluoxetine and ranitidine and the price 
changes of these medications over 6 years using a time-series analysis of the 
InterAction Database which holds prescription records covering approximately 300,000 
Dutch patients (Annex 18). Evidence from the study rated as moderate quality showed 
that drug costs per DDD dropped markedly by about 50-70% after patent expiry, 
mainly due to the increasing use of generic alternatives. 
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6.8 Profit control 
One included study explored the rate-of-return (ROR) regulation in the UK PPRS using 
an ITS design with an annual price index between 1980 and 1994, which was rated as 
being of moderate to low quality (Borrell, 1999) (Annex 18). 
Evidence from the study suggests that changes in the ROR cap have had little impact 
on drug price indices; a 1% change in the ROR cap has generated only a 0.15% 
change in the aggregate price index overall. Despite the small impact, the author 
suggested, "the UK regulation of the price of medicines has encouraged innovative UK 
based pharmaceutical firms to diversify into competitive pharmaceutical market" 
(p301). 
6.9 Discussion 
After searching two major electronic databases and relevant references, 19 studies 
examining the effects of pharmaceutical policies influencing Industry were Identified. 
About three-quarters of the retrieved studies explored the effects of price controls on 
drug utilisation and expenditure. Few studies addressed the Impact of profit control, 
market and patent regulations and those studies that did were rated as poor quality. 
Approximately half of the studies came from North America, thanks to Canadian 
exploration of reference-pricing; the other half came from Western Europe, with just 
one study from elsewhere. This study drew conclusions about the Impact of reference- 
pricing primarily based on the Canadian studies, since these were largest In number 
and rated as higher quality. 
Overall, this review found the following from included studies: 
  Reference-pricing schemes may achieve savings partly by increasing the use of 
less costly medication, and, in parallel, increasing patient expenses. There are 
certainly greater effects when clustering drugs by therapeutic class in comparison 
with active ingredient. Evidence supporting the impact of reference-pricing 
schemes on price decreases is currently weak. 
  Few studies report unwanted consequences, though evidence about policy 
consequences still seems to be lacking. 
a While price control is routinely used, it has rarely been evaluated. From three 
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Included studies, little positive evidence was found that direct pricing measures 
were associated with altering the trend of increasing drug expenses. 
" Few rigorous evaluations were found which investigated other regulations such 
as patents, market authorisation, or profit control. Thus, few or no inferential 
conclusions can be made through this review. 
Although this study conducted a comprehensive search without limiting interventions, 
studies exploring interventions other than price controls were rarely identified. Hence, 
figures in this study look very similar to the previous Cochrane review addressing 
pricing policies (Aaserud et al., 2006a). This study included a small number of extra 
studies that are either awaiting review by the Cochrane authors or were derived from 
electronic searches in relation to price controls. 
The previous reviewers argued that policy details could yield considerably different 
outcomes in reference-pricing schemes (Danzon and Ketcham, 2003; Lopez- 
Casasnovas and Puig-Junoy, 2000). This review highlighted the association between 
policy differences and impact in Table 6-3 (see Annex 16 for more details). There were 
certainly greater effects in clustering drugs by therapeutic class in comparison with the 
same active ingredient. The relationship between the other two policy variables and 
impact was inconclusive, because there were insufficient included studies to compare 
with one another. Four non-Canadian studies did not provide comparable information 
about effect size. No studies were identified from countries such as Australia, the 
Netherlands or New Zealand, where on-patent drugs are included in groupings. In 
addition, it was impossible to test previous reviewers' arguments that the new 
regulation might lead to a cutback in R&D activity by the industry in this review, since 
there were no relevant outcomes measured in the included studies. 
Out-of-pocket payments increased by a large amount after reference-pricing, reflecting 
that patients (or prescribers) consumed costly drugs above the reference line by 
paying extra out-of-pocket. No further information was available about what makes 
them endure extra costs. 
Although price control has been Implemented in various countries for several decades, 
rigorous evaluation seems to be lacking. Existing evidence suggests there Is little effect 
in drug costs with a single-faceted price control approach. This may be partly because 
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the price factor affects little the recent pharmaceutical expenditure growth. Nefarma 
data indicates that price factors contributed little (about -1N1%) to the growth of total 
expenditure (about 4-12%) In several major European countries (Mossialos eta/., 
2004). Overall, the findings of this review support the Guillen and Cabiedes (2003; 
p12) remarks; "price-control policies do not guarantee expenditure control when they 
are not accompanied by control of quantity". 
Price control has been one of the most central and longest lasting pharmaceutical 
polices in South Korea (Chapter 2). According to the recent government document, the 
fraction of price factor accounted for -0.67% out of 13.7% total drug expenditure 
growth in 2003/4 in Korea, which is similar to the European figure from Nefarma above 
(Ministry of Health & Welfare, 2006c). This implies that price control may also be less 
effective in the Korean situation. 
The Korean government tried but failed to introduce a reference-pricing system in 2002. 
The causes of failure were universal policy resistance and an initial grouping that was 
too broad to make clinical sense (Lee and Lee, 2007). Owing to the constantly rising 
trend of drug costs, a reference-pricing system has recently been re-highlighted In the 
hope of Influencing all relevant stakeholders. The most recent report suggested 
refinement to the new reference-pricing system; by 1) introducing in a stepwise 
manner; 2) grouping drugs by chemical active Ingredient; and 3) setting the weighted 
average prices of drugs in a category as the reference price (Lee and Lee, 2007). They 
also recommended a gentle transformation for lowering the reference line and 
amending grouping to therapeutic classes. Their Initial suggestions, however, do not 
sound very promising In terms of economics. As the Korean authors mentioned in their 
context, Norway abolished its reference-pricing system due to cost-ineffective 
outcomes when considering administrative expenses (Haga and Sverre, 2002). This 
review clearly demonstrated that reference-pricing systems clustered by the same 
active Ingredient have shown a minimal impact on drug costs, even though they set 
the reference price at much tighter levels than `a weighted average price' that the 
Korean authors suggested. In this regard, it Is worrisome that a reference-pricing 
system may merely increase private expenses and, consequently, augment social 
Inequity. 
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6.10 Summary 
Despite frequent exploitation, robust assessment of policies regulating the drug 
industry are rarely performed and little is known about the policy impact. Most 
evidence found in this review related to a reference-pricing scheme in one Canadian 
province. This review found that reference-pricing reduced drug costs with little change 
In overall utilisation. Therapeutic class clustering may achieve greater savings than that 
of the same chemical Ingredient. Included studies showed that the reference-pricing 
might result in little change In clinical variables or other service use, but at the expense 
of a high increase of private costs. Limited evidence from included studies suggests 
little success In other price control programmes. Given the negligible share of the price 
factor In the recent drug expenditure growth, the effects of price control are expected 
to be small In South Korea. Further discussion of the methodological aspects of 
reviewed studies and Implications for the present research are continued In Chapter 7. 
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CHAPTER 7: LESSONS FROM INTERNATIONAL EXPERIENCE: 
METHODOLOGICAL ISSUES AND KEY FINDINGS FROM 
SYSTEMATIC REVIEWS OF THE LITERATURE 
7.1 Introduction 
Chapter 3 through 6 systematically appraised published research to explore what is 
known about the effects of various pharmaceutical regulations on expenditure and 
utilisation of drugs and other health services. In total, 176 studies were reviewed and 
evaluated critically. This chapter discusses methodological aspects of the included 
studies and highlights the findings from the systematic reviews. At the end, 
implications for the empirical research are discussed. 
7.2 Methodological issues 
7.2.1 Overall study design 
Sixty-seven studies used CBA designs; 71 employed ITS designs; and 41 used RCT 
designs. Details for study designs used in each intervention are displayed in Figure 7-1 
overall and in Table 7-1 by intervention. Some variation in quality rating was seen by 
study design. CBA studies were rated of moderate quality; RCT studies were rated of 
moderate to high quality; but ITS studies were rated of mixed quality. 
Slightly more than a third of ITS studies were equipped with a control series, and most 
of these came from the North American context. It seems natural that researchers in 
Canada and the US are more likely to find a proper comparator than those elsewhere, 
In the North America, since regulations are likely to be implemented at state- or 
private health plan-level, each state (or plan) may act as a good comparator for 
another. Given the difficulty of randomisation to social sciences (Chapter 2), an 
unexpectedly large portion of studies, more than 20%, employed RCT designs. The 
majority of RCT studies investigated educational measures. It may be because studies 
addressing educational measures involve a relatively small population, making it more 
feasible to randomise participants, whether in the intervention or control. 
155 
Figure 7-1: Study design in the included studies 
RCIf 
no control 
ITS 269/u, 
Table 7-1: Study design by type and intervention 
RCT CBA 
ITS Total 
control no control 
number of studies 41 67 24 47 179`) 
by intervention 41 67 24 53 185') 
patients 46 
cost-sharng 2 8 4 16 30 
tiered formulary 7 2 9 
prescription caps 3 2 5 
educational approach 1 1 
OTC switch 1 1 
providers 119 
i duwi anal approaches 36 21 3 3 63 
reimbursement restrictions 1 11 6 15 33 
incentives 14 2 1 17 
distribution of samples 2 1 3 
mandatory generic substitution 1 1 
repeat prescribing 1 1 
SPD') 1 1 
Industry 201) 
reference ptiYig 3 3 8 141) 
price control (others) 3 3 
profit control 1 1 
market authorisation 1 1 
patent regulation I 1 
1) Schneeweiss et a!. 2003 is included two times in CBA and ITS (no control) ie, petrvrly and O'Malley et 
a/. 2006 is included three times in CBA. 
2) Four studies are Included two times (Alinarsdott it e t aL 2000, Anders. son et aL 2006, Gurwitz et at 
1995, Starmans et al 1994) and two studies three times (O'Malley et al. 2006, Lee et al. 2006) 
3) separation of prescribing and dispensing of drugs 
7.2.2 Sources of bias 
7.2.2.1 Randomised controlled trials 
As shown in Figure 7-2, a crucial element to securing the internal validity in an RCT 
design is undoubtedly randomisation. 
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Figure 7-2: Outcomes in quality assessment 
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Concealment of allocation IIIIIIIIIIIIIfllllllllll1111111111111111111111111111111111111111111111111111111111111111t 
Blinded assessment 111111 
Baseline measurement UUI1HIIII " 
Reliable primary outcome measure(s) IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIÜIIIIIIIIIIIIiI 
Intention-to treat analysis 
attrition rate IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIiI'a.; 
Reasons for drop-out parttcpants iIiIIiiIIiiIIiIiiiilllilIIlIIIliiIliIiiIIlUIIIIIIIL i 
a) RCT studies (41 studies) 
0% 20% 40% 60% 80% 100% 
Baseline measurement IIIIIIIIIIIII 
Charactenstres for control ýIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII : ": 
Refable primary outcome measure(s) IIIIIIIIUIIIIII 
Attrition rate 11111111111111111111111111111111111111111111111131 
Reasons for drop-art participants 
Blinded assessment (IIIIIIhI 
Protection against contamnatron IIIIIIillllllll 
b) (UA studies (67 studies) 
0% 20% 40% 60% 00% 100% 
Appropriate data analysis IIIIIIIIIIIIIIIIIIIIIIIIIIIIIII 
Reasons for the number of ports ýýIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIU `s 
Shape of the intervention effect prespecrfitrd 
Same methods of data cokction 
Blinded assessment 
completeness of data 4(, t Illlllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllk 
ReYable prnnary outcome measure(s) IIII 
  high ill Medium +a Low 
Protection aaaaist secular changes IIIIIII IIIIIIIIIIIIWHIM IIIIIIIIII 
(1) 11 studit"s (71 studies) 
157 
More than 70% of included studies failed to provide an appropriate statement 
concerning allocation concealment. There are a number of meta-epidemiological 
studies that have shown that inadequate or unclear allocation concealment are 
associated with larger treatment effect estimates (Hewitt et al., 2005; Kunz and Oxman, 
1998; Kunz eta/., 2007). Among studies included in these reviews, Figure 7-3 indicates 
that effective outcomes (statistically significant decrease or increase) of intervention on 
drug use were more likely reported in studies that failed to assure adequate allocation 
concealment compared to those using adequate methods. 
Figure 7-3: Reported effectiveness of RCT studies in proper versus improper 
allocation concealment of randomisation 
Utilisation 
20 
16 " Reported effect 
No effect 
12 
8 
4a 
none 
Concealment of allocation in RCT studies 
In addition, sound randomisation is maintained throughout the study by proper 
analysis and follow-up (e. g., an intention-to-treat analysis and a small attrition rate). 
However, many reviewed studies did not fulfil these criteria. More than 50% failed to 
offer clear information about an intention-to-treat analysis or withdrawal of participants. 
Along with these issues, the outcomes may be biased to some degree by the 
Hawthorne effect - participants might change their behaviour because of they being 
watched by investigators, not because of the given educational information (Gale, 
2004). 
Another important issue raised in randomised studies is clustering. In most cases, the 
unit of randomisation was groups of people rather than individuals. This might be due 
to the nature of the interventions, which were designed to improve doctors' prescribing 
behaviour (Divine et al., 1992). Hence, the unit of randomisation was often the doctor 
or the practice, and thus the intervention was applied to groups of patients, a cluster 
rather than an individual. 
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Cluster allocation is a useful tool for researchers to avoid potential contamination 
between participants and to convey the intervention eff iciently. However, cluster 
randomisation sees a recurrence of practical problems such as lack of clarity of 
informed consent for cluster members and invalidation of standard statistical 
procedures (Donner and Klar, 2004). Actual policy impact at a clustered level can be 
augmented by analysing at individual level using standard statistical procedures. 
Among the included 41 RCT studies, all but six used cluster randomisation. Among 35 
clustered-RCT studies, 16 carried out analyses at the clustered level, the same as the 
unit of allocation - of which 4 studies showed further statistical considerations 
concerning clustering; 9 studies used statistical techniques to adjust for bias from the 
mismatch of the unit between allocation and analysis; 10 paid little attention to 
clustering. 
7.2.2.2 Controlled before and after studies 
In CBA studies, authors frequently neglected to present the baseline characteristics of 
participants, or provided irrelevant Information. As seen In Figure 7-2, almost 90% of 
Included studies failed to report characteristics for the control group, or to balance 
between the Intervention and the control group. The majority of the 67 CBA studies 
suffered due to baseline Imbalance between the Intervention and the control groups. 
This may be a common challenge In policy evaluation. Studies exploring the UK 
fundholding programme provide a typical example of this (Ess et al., 2003). To adjust 
for discrepancies between groups, included studies often employed various statistical 
techniques. Difference-In-Difference (DID) analysis was a popular way of adjusting for 
differences In baseline characteristics (n=37). Adjustment was also performed by 
Including baseline performance as a covarlate In regression (n=13). However, It was 
unclear in 17 studies whether they performed appropriate statistical analyses; five 
studies made a comparison between pre and post numbers within the group, rather 
than between groups; six studies simply Investigated post-mean differences with little 
consideration for baseline differences. No statistics were found In the other six studies, 
7.2.2.3 Interrupted time-series studies 
In included studies, internal validity in ITS studies was determined primarily by two 
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factors: the quality of the data sources they could access and how well they controlled 
for underlying trends. Both seem closely linked. For proper control of background 
trends, it is necessary to use sufficient data points. In an ITS design, vital factors 
including data points, study length, or measurement units were subject to data sources 
available at the time of the study. As Figure 7-2 shows, a rationale for the number of 
data points was rarely given in reviewed studies. Where information was supplied, it 
was due to data availability and external changes in policy surroundings, such as the 
abolition of study policy or the introduction of other relevant policies. None of which 
were under the control of the investigators. Large variations in the quality ratings of 
ITS studies shown in the current reviews may ascribe to these external limitations. In 
this review, only a third of ITS studies were considered to have enough data points to 
control for secular changes - more than 50 before and after (ARIMA models) or more 
than 12 before and after covering 4 seasons (segmented regression models) (Figure 7- 
2). 
Nearly 80 per cent of studies used monthly data and 3 used weekly data. But, nine 
studies used quarterly data and three studies used annual data. Two studies used a 
different method of data collection before and after the intervention. Starmans et al. 
(1994) used biannual data for the first five years but annual data for the last 4 years 
due to the limit of available data. They performed a weighted least squares technique 
to correct the disparity of data but the reliability of such correction seems questionable. 
Andersson et al. (2006) employed quarterly data before and monthly data after the 
Intervention without providing further Information. 
Faced with such limitations, constructing controlled time-series Is another way to 
Increase reliability, In a study Investigating a Canadian reference-price scheme, 
Grootendorst and Stewart (2006) demonstrated that before and after time-series 
design could overestimate policy effects by about double, compared to the case with a 
comparable control state. Although controlled time-series Is definitely helpful to 
enhance scientific rigour In policy studies, It may not be always feasible. Policies are 
frequently Implemented at the same time nationwide, which makes it difficult to find a 
comparable population which is not Influenced by the policy change, That must be one 
of the most important reasons that two thirds of Included studies have no controls. 
Schneeweiss et al. (2002a) suggested the importance of a transition period just after 
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the policy introduction to avoid overestimation of the policy impact due to temporary 
'shorter prescription duration' after medication changes. Also, unusual responses by 
stakeholders, such as stockpiling, could produce spurious results shortly before or after 
policy changes (Ray, 1997). Among the Included studies, only 14 ITS studies 
Incorporated a transition period of around a few months. Although this review lessened 
bias from transition time by including studies with more than a6 month follow-up, 
cautious interpretations are still recommended for studies with a short follow-up period. 
For sound research, another Important Issue is to employ appropriate statistical 
methods. Table 7-2 illustrates statistical techniques employed In the ITS studies and 
appropriateness of analysis based on quality assessment. Two thirds of included 
studies carried out segmented regression analysis, of which 26 studies adjusted for 
autocorrelation by applying estimated generalised least squares (EGLS) assuming first- 
order autocorrelation among error terms (Ostrom, 1990). Seven studies justified 
ordinary least-squares (OLS) estimates by checking the absence of autocorrelation 
through formal statistical tests such as the Durbin-Watson dstatistic (DW) (Durbin and 
Watson, 1950,1951; Savin and White, 1977). One study partially applied EGLS 
estimation In the presence of autocorrelation. Fifteen studies applied OLS with little 
Information concerning their strategy for controlling for correlated error terms. 
Seventeen studies employed an autoregressive integrated moving average (ARIMA) 
approach. It was unclear In five studies what statistical analyses were undertaken. 
Table 7-2: Statistical techniques and appropriateness of analysis 
Statistic 
techniques 
Number of 
studies clear unclear 
Assessment of uality 
reasons of unclear none reasons of none 
1ý 14 3 <20 data points in pre- Intervention period Intervention 
Segmented regression 
EGISýý 26 20 6 <12 months before and after Intervention 
OLS3) 22 5 11 little hformatbn about 4 <12 months before and 
correcting correlation after intervention 
annual data 
ECAs4OLS ii 
Unclear 55 lack of Information 
Total 71 40 18 13 
1) autoregressIve Intergrated moving average 
2) estimated generalised least-squares 
3) ordinary least-squares 
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Thirteen studies performed either ARIMA technique with less than 20 pre data points, 
(Cochrane Effective Practice and Organisation of Care Review Group, 2002), or 
segmented regression with less than a 12-month period before and after the 
intervention (Wagner eta/,, 2002), raising concerns about potentially inadequate 
control over pre-existing trends. Eleven studies failed to provide proper information 
about how they dealt with the autocorrelation in OLS estimates or gave spurious DW 
values. The association between the approach to the analysis and research outcomes 
was Inconclusive due to the lack of homogeneity. 
7.2.2.4 Inter-design issues 
Soumeral et al. (1989) demonstrated striking contrast in conclusions between well- 
designed and inadequately controlled studies; less adequate designs were much more 
likely to produce significant outcomes. In this review, any potential differences among 
research designs might be overwhelmed by the heterogeneity of included studies such 
as setting, policy details or length of study. Among the retrieved studies, one 
interesting result was exhibited by Schneeweiss et al. (2004) who examined 
reimbursement policy. They found different outcomes from their RCT study and 
observational study; the former returned a non-significant decrease in drug expenses 
for study drugs, whilst the latter showed a significant fall in the same outcome. 
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7.2.3 Other threats to validity 
7.2.3.1 Setting 
Strikingly, a large number of included studies were conducted in North America as seen 
in Table 7-3. Among 176 studies, nearly 56 per cent came from North America and 
about a third came from Western Europe. Only one out of ten studies came from 
elsewhere. 
Table 7-3: Number of studies by setting 
Western Europe Mirth America Others Total 
number of studies 61 98 17 176u 
by intervention 64 101 19 lwl-" 
patients 46 
cost-sharing 10 16 4 30 
tiered formulary 9 9 
prescription caps 1 4 5 
educational approach 1 1 
OTC switch I 1 
providers 110 
educational approaches 29 25 9 63 
reimbursement restrictions 1 31 1 33 
incentives 12 2 3 17 
distribution of samples 3 3 
mandatory generic substitution 1 1 
repeat prescribing 1 1 
SPD8j 1 1 
industry 19 
reference pricing 4 9 13 
price control (others) 1 1 1 3 
profit control 1 1 
market authodsatbn 1 1 
patent regulation 1 1 
1) acutal number of studies without any duplication 
2) number of included studies by intervention but Schneeweiss et a/. 2003 is incl uded once: Four studies are 
included two tries (Atnarsdottir et a/. 2000, Andersson et al. 2006, Gutwitz et al. 1995, Starmans et al. 1994) 
and two studies three tines (O'Malley et al. 2006, Lee et al. 2006) . 
7.2.3.2 Follow-up period 
Table 7-4 displays the period studies have followed policy outcomes after the 
implementation. Approximately 54% of studies investigated the policy impact in a 
single year after the intervention. Almost all studies (97%) addressed less than 5 years. 
The ITS studies were more likely to address a longer time period, whereas evidence 
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from North America was more concerned with short-term effects. Overall, there is a 
notable lack of evidence of long-term policy effects. Follow-up periods are also 
presented in Annex 19 by intervention. 
Table 7-4: Follow-up i_. en th by study design 
Follow-up period 
Study design > 12 months Total S 12 months 5 60 months > 
60 months 
Total (%») 99 (54) 79 (43) 7 (4) 1852) 
RCT 33 8 41 
CBA 39 28 67 
ITS (control) 14 10 24 
ITS (no control) 13 33 7 53 
1) rounded 
2) number of included studies by Intervention; Schneeweiss et al. 2002 is Included twice 
7.2.3.3 Outcome variables 
Table 7-5 displays the outcome variables examined in the reviewed studies (see Annex 
20 for details). It shows that a fairly small number of studies were dedicated to 
exploring the indirect consequences of regulations such as the impact on other service 
use or on health. Most studies paid a great deal of attention to expenditure from the 
payers' perspective and neglected changes in private expenses. 
Table 7-5: Outcome variables appeared in the included studies 
M°. of Outcome variables studies 
Utilisation 137 74 
Expenditure 89 48 
Out-of-pocket 17 9 
Other seNces use 28 15 
Heath outcomes 74 
1) number of Included studies by Intervention but Schneeweiss etal. 2003 Is Included once 
Few studies explored direct variables relating to health outcomes due to the lack of 
patient-level data. In this regard, some authors measured changes in other service use 
and interpreted the outcomes as a reflection of clinical health. Are these proxies 
properly representative? Office visits could be increased when patients change 
medication, regardless of their health conditions, because doctors usually want to 
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monitor them more closely just after altering a course of therapy (Schneeweiss et a/., 
2002a). Moreover, these were mostly short-term studies. The health of many patients 
might deteriorate after discontinuation or change of medication, but not to the extent 
that they visit an emergency room or are hospitalised. Also, the prevalence of disease 
could affect such utilisation. The effects of change in the use of medication for rare 
diseases would not be easily detected by proxies. 
Similar limitations were also found in studies measuring health outcomes. Five studies 
assessed blood pressure and arguments over the use of surrogate end-points also 
apply here (Freemantle eta/., 2004). 
7.2.3.4 Data sources 
As seen in Table 7-6, the majority of studies used administrative claims data hence the 
usual limitations from using such datasets apply here (Fairman and Motheral, 2000; 
Ray, 1997). Ecological issues appeared most frequently across reviewed studies. 
Conducting research with aggregated data definitely has many advantages, but it 
makes it hard to determine whether the effects are translated accurately at an 
individual level. In real terms, the impact of every single policy on each patient might 
differ due to their socio-economic positions or health condition, missing important 
messages from individual patients and possibly misguiding policy-makers in the wrong 
direction. 
Table 7-6: Data sources by study design 
Data Source RCT CBA 
ITS ITS (no Total 
(control) control) (n=1851)(%) 
national- or state-level aggregated 14 32 14 41 101 (54) 
claims data 
health plan aggregated claims data 6 24 6 4 40(22) 
Institutional pharmacy data 10 51 1 17 (9) 
commercial data 2 33 4 12 (7) 
academic pharmacy data 3 1 15 (3) 
Individual pharmacy data 5 1 6 (3) 
others 1124 (2) 
1) number of Included studies by Intervention but Schneeweiss eta!. 2003 Is Included twice 
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Regarding data sources, probably the most challenging aspect in assessing quality was 
that there was a clear limitation to confirming the reliability of datasets employed in 
each study. Authors rarely discussed the reliability of the databases they used. This 
issue seems more serious in data managed by private health plans, because much less 
information is known about such datasets. More effort needs to be made in reporting 
and discussing the quality of data used in these study designs, 
7.2.3.5 Funding sources 
There have been some concerns that a source of funding may be associated with study 
outcomes in drug trials (Jefferson eta/., 2009; Jorgensen et al., 2008; Lexchin et al., 
2003), Despite that this review found little evidence of the relationship between 
funding and results, it was impossible to remove all doubts. Primary authors 
occasionally interpreted similar outcomes differently in context. For instance, an 
industry-funded study found the increase in physicians' visits during the first 6-months 
after introducing formulary and drew the following conclusion: 
The observed range of Increases in hospital and physidan visits is evidence for the possible 
existence of an unintended consequence of PDL Implementation by state Medicaid programs. 
(MurawskiandAbdelgawad, 2005, pSP35) 
In contrast, a remark from a publicly-funded study concerning the upsurge in office 
visits in the three months after reference-pricing was as follows: 
The Insurance coverage restriction for PPIs .... led to substantial uti/izat/on changes and savings 
without negatively affecting major clinical outcomes. (Schneeweiss et al, 2006; p386) 
Any meaningful divergence could be masked by the heterogeneity of studies. 
Additionally, influences from a source of funding appear more complex in health service 
research. Unlike drug trials, it may not be appropriate to group sources of funding only 
into public and commercial bodies. Public funders include not only purely research- 
oriented public bodies, but also government bodies that play a central role as payers in 
the market. Given the reality, it seems difficult to ensure that governments are 
necessarily neutral in the case of `public' money for research activity. Likewise, `private' 
money from commercial health plans may be used differently from that in the drug 
industry. 
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7.3 Key findings from the systematic reviews 
The reviewed studies were of mixed quality and showed clear weaknesses in design 
despite being more robust study design to start. Studies concerning cost-sharing/ 
reimbursement restrictions were in particular of mixed quality; those concerning 
educational interventions/ tiered formularies/ reference-pricing schemes were generally 
rated as moderate quality; those addressing incentives were rated as moderate to low 
quality. Therefore, the findings should be considered based on this quality constraint. 
The following conclusions are drawn about the impact of pharmaceutical regulations. 
0 First, existing robust evidence Is concentrated in a few policies and settings. 
Studies examining cost-sharing, educational approaches, North American 
reimbursement policies, English individual general practice budgets and Canadian 
reference-pricing appeared frequently. The effects of many other policy measures 
remain largely untouched in the Included studies. Thus, empirical evidence is still 
needed for relevant interventions in this arena. 
Cost-sharing or educational measures were evaluated in varied settings. Cost-sharing 
schemes have a long history - more than half a century - and thus more chance of 
being evaluated. A study exploring educational approaches Is relatively easily 
constructed. It can also be conducted with a small number of participants. Random 
allocation is more likely and effects are often realised within a short period. Additionally, 
clinical researchers may be more familiar with this kind of project, as it can be 
constructed to look very similar to a clinical trial. 
Reimbursement policies are popular in various health plans In North America and highly 
evaluated within the US and Canadian contexts. Also, the researchers exploring 
reimbursement policies in these surroundings seem to have strong advantages in 
building research projects In a rigorous manner, because various private health plans 
and state-level drug benefit programmes have been used as good comparators for 
each other. Equally importantly, there is a greater opportunity of funding by various 
payers who wish to confirm or simulate any effects generated by their policies. Similar 
arguments are true in the Canadian reference-pricing scheme. 
Other pharmaceutical policies have been inadequately evaluated. For example, 
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conventional price control programmes seem to be poorly studied even though they 
have as long a history than cost-sharing and wider exploitation. Overall, not only price 
controls, but most regulations primarily targeted at industry activity generally appear to 
be less well studied. Many factors may cause this. It may be harder to access industrial 
data owing to business privacy issues. It could also be tougher to build a rigorous 
quantitative study. Hence, issues concerning the pharmaceutical industry have often 
been explored in qualitative ways (e. g. Braithwaite, 1984c), which is out of the scope of 
this review. 
  Second, outcome variables in the studies concentrate on benefits, but few 
studies measured undesirable consequences. Hence, although this review found little 
explicit evidence on the association between restricted regulations and health or other 
resource use in the short-term period, conclusions are debatable. The long-term 
outcomes concerning these issues are unknown. Moreover, some restrictions were 
certainly tied to curbing patient access to essential drugs for chronic conditions, which 
might be associated with compromising health, or Increasing other subsidised, 
sometimes more expensive resources, over longer periods. Furthermore, small but 
evident adverse trends were seen in vulnerable populations and these occasionally 
reached a statistically significant level during the authors' study period. 
  Third, savings were more evident in policies that directly limited patient 
demand or prescriber practices, such as cost-sharing, prescription capping, tiered 
formularies, reimbursement policies and reference-pricing schemes. Only a modest 
decrease was seen in voluntary-based measures such as educational approaches or 
budgetary constraints. However, questions remain regarding whether or not 
administrative regulations still make economic sense from a societal perspective after 
considering a budget shift to private individuals and its consequences; and If 
educational programmes are still cost-effective after including administrative expenses. 
Although policy effects varied considerably in size across studies, there were some 
apparent differences in the mechanisms of savings across policy interventions. Saving 
was primarily driven by a decrease of absolute volume in regulations limiting patient 
demand, such as flat rate cost-sharing and prescription capping. They hardly improve 
patients' purchasing behaviour toward cost-effective alternatives. A price drop in 
reference-pricing and other price control measures may not be as great as anticipated; 
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there is only limited evidence of price decreases for the former. 
In contrast, volume decrease is seen less often in measures designed to encourage 
appropriate prescribing and purchasing. In differential cost-sharing structures, such as 
tiered formularies or reference-pricing programmes, or tools orienting prescribing 
behaviour such as educational measures or reimbursement policies, saving was 
achieved by the increasing use of less costly drugs combined with the decrease of 
expensive drugs. As a result, although few changes were seen in overall volume, 
sizable saving for payers was observed in drug costs. 
Any form of cost-sharing regulations, including tiered formularies and reference-pricing, 
may partly achieve cost containment by shifting the budget to private individuals. In 
this regard, lower income groups seem to be particularly vulnerable because the 
financial burden of out-of-pocket expenditure tends to fall more heavily on these 
groups. Generally, better-off consumers seem to be inflexible to price increase in 
medication. Decreases were often observed In disadvantaged groups who lowered their 
consumption of essential as well as optional drugs. Thus, any policies possibly 
increasing out-of-pocket expenditure are carefully tracked to explore if they reduce 
social equity for saving costs. 
" Fourth, fostering generics use has been shown to yield positive economic 
returns in a variety of interventions. In consequences, pharmaceutical policies 
encouraging the use of cost-effective drugs, for instance, generics or first-line 
therapies are increasingly highlighted. 
The review showed that pricing policies might hardly have any influence on the rising 
trend of drug costs, given the predominant causes of the trend - volume growth. On 
the other hand, policies restricting patient demand might have adverse effects on 
overall health. In this regard, generics have been of increasing value In pharmaceutical 
policies. 
Strategies aimed at Increasing generics were found in various policies, Including 
educational approaches, reimbursement policies, tiered formularies and reference- 
pricing programmes based upon policy details, and generic substitution or prescribing. 
In budgetary policies, British studies examining fundholding programmes suggested 
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that fundholders saved money by Increasing generic use with little change in absolute 
drug volume. 
In this regard, it Is anticipated that policies directly encourage generics use, for 
instance, mandatory generic prescribing, which would result in greater financial 
savings, but those policies appear less frequently (National Economic Research 
Associates, 1998; Vogler eta/., 2008). One of the key reasons is probably prescribers' 
lack of acceptance of those Interventions (Banahan and Kolassa, 1997; Brust eta/., 
1990; Tilyard eta/., 1990). Budgetary and educational strategies are perhaps 
regulations Imposing least limitations on the authority of prescribers. Others may be 
moderate because generic drugs are just one of the options in measures such as 
reimbursement policies and doctors still take main responsibility of the choice of 
pharmaceuticals. But generic substitution or prescribing may Impose heavy restraints 
on prescribers because the selection of final products Is In the control of dispensers or 
consumers. 
Doubts about the quality=of generic products can be another reason. Even though a 
globally accepted standard has been developed, for example a 'blo-equivalence test', 
some studies argue that this may not be sufficient to prove that the clinical 
effectiveness of generics is equal to their original counterparts (Borgheini, 2003; 
Meredith, 2003). Interchangeable clinical efficacy is undoubtedly a vital condition in 
generic policies, or generic use may result in increasing the use of other resources 
and/or deteriorating health. 
Along with proven clinical efficacy, two factors seem to be required to achieve savings 
In drug costs by generic substitution. First, the generic market should be large enough, 
or an Increase In the generic share would generate little change in overall costs as 
shown In Spanish studies (Sicras-Mainar and Pelaez-de-Lono, 2005; Slcras-Mainar et al., 
2007; Sicras-Mainar et al., 2004). Second, generic products should be priced at a 
significantly lower level (Kanavos, 2007; Lee et a/,, 2008), otherwise, policies 
encouraging use of generics may not necessarily lead to the reduction of drug costs. 
  Lastly, despite rigorous efforts made so far to evaluate the impact of 
pharmaceutical policies across certain countries, several limitations may affect both 
their internal validity (e. g. data availability, inappropriate study procedure, statistical 
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problems, etc. ) and their external validity (heterogeneity in interventions or in settings). 
The range of changes varies considerably across studies even within a single, 
homogeneous measure, indicating that there must be interactions among a number of 
potential endogenous and exogenous factors. The typical examples for the former may 
be methodological devices such as comparators, measurement units, study drugs, 
length of study period or study populations. Those for the latter may include 
intervention details, or a structure of health systems that were built on the political, 
societal and economic milieu in each study setting. 
Although included studies may provide some direction for policy-makers interested in 
adopting foreign regulations in their pharmaceutical segments, it should not be 
assumed that policy performance can be predicted precisely based on this information. 
In future research, an analysis standard (e. g. measurement units, etc. ) needs to be set 
for reliable cumulative outcomes by reducing heterogeneity in methodology. 
Table 7-7 summarises the included studies by the observed impact of the intervention 
for each outcome variable assessed. 
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7.4 Study limitations 
There are several limitations to this study: 
First, this review sets a strict limit on study designs, which Is both a weakness and a 
strength of this work. Including the three most robust study designs lessened the 
potential heterogeneity between well- and poorly-designed studies and Improved the 
reliability of review outcomes. Among the identified studies, 20% In the patient 
category, 36% In the provider category and 33% in the industry category were 
excluded due to poor study designs. Whilst study design was used as an exclusion 
criteria, and limited to more robust designs, there was still great variability In the 
quality ratings. On the other hand, it might exclude many potentially worthwhile pieces 
of research. For example, studies exploring the impact of educational regulations 
Influencing patients or direct-to-consumer advertising might be conducted qualitatively. 
More importantly, excluding studies with weaker designs may neglect studies from 
other developing or middle-income countries that could be useful Information for Korea. 
Second, as with any literature review, this study may be limited by inherent publication 
biases to publish only statistically significant results and by a language barrier although 
there was no restriction made on language in the search criteria. 
Third, two electronic resources may not be enough to explore such a variety of policies 
even though the loss of potential studies was reduced by hand-searching relevant 
references. 
Fourth, the quality of the study was assessed principally based upon the original 
authors' description. It was challenging to confirm the quality of pharmaceutical claims 
used in the reviewed studies, particularly those held by private health plans, which 
might primarily affect the validity of reviewed studies using ITS designs. 
Fifth, per cent changes presented in this review may not be comparable across 
Included studies, Each study employed various measurement units, for example, days 
per prescription versus the number of defined drug doses per patient. Cautious 
interpretation is thought essential and numbers presented should be considered only 
as a reference. 
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Finally, at the time of planning, it was intended that a meta-analysis would be 
undertaken but this proved impossible given the heterogeneity in each study from the 
policy intervention and the method of presenting results, to the study population. Thus, 
many of the conclusions of this review were necessarily qualitative. It was particularly 
difficult to draw general conclusions with educational interventions since they were too 
varied and the authors' Information was often too simple. Varying characteristics and 
behaviours of outreach visitors might have affected physician behaviour, making 
comparisons more challenging. Equally importantly, it was unlikely to be practicable 
that the complexity of the prescribing environment and any changes in the market, 
such as strong promotion of related drugs, was taken into account when interventions 
were compared. 
7.5 Lessons for this study 
This review has Illustrated some implications for the external validity of existing 
evidence in pharmaceutical policy studies. Existing rigorous evidence is limited to a 
handful of settings. Most settings had relatively high economic status, a well- 
established welfare network, and a profitable, competitive drug industry. There is 
practically no evidence from countries comparable with South Korea. 
Other populations with different social conditions may exhibit different behavioural 
responses to pharmaceutical policies. For example, people are more likely to be 
affected by cost-sharing in studies from settings showing weakness in social welfare 
(including Nepal, Taiwan and the US). Moreover, policies may be devised with different 
interests and motivations across national settings. Decisions are often affected by 
political, social and economic Internal and external conditions that vary across settings. 
According to the profitability of the drug Industry, there may be divergences in the 
decisions of Individual governments as to how to balance healthcare and Industrial 
goals. For Instance, governments with profitable companies, such as the US, tend to 
allow more freedom to the Industry in terms of drug pricing, especially for originators. 
Because of these underlying differences, even a single policy, for example, the 
reference-pricing scheme, could be surprisingly diverse in details by country, which 
may produce dissimilar policy effects. Thus, Klein (1997; p1268) remarked "no two 
laboratories are the same" In policy studies. 
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In line with this argument, variations appeared consistently and were considerable in 
terms of policy outcomes and authors' arguments across studies, even within these 
limited settings. Hence, the results from one setting are not easily generalised to 
another in policy studies. 
In this regard, careful assessment should be made of any prospects for success in 
pharmaceutical regulations when they are applied to other settings apart from the 
original. Given the low transferability of policy outcomes and the lack of available 
evidence, there is a pressing need for studies to probe pharmaceutical policy outcomes 
under the inherent surroundings and their interactions in Korea. Nevertheless, to date 
the study of pharmaceutical policy has been given little attention in South Korea. 
Therefore, in the following part, this thesis will explore Korean drug policies with 
empirical data to study how similar policy issues are exhibited and dealt with in a 
Korean context. 
Firstly, the impact of two pharmaceutical regulations will be examined quantitatively. Of 
the three most robust study designs, ITS Is the most appropriate approach because 
there is no comparable population free from policy change in Korea. Secondly, Korean 
policy-makers will be interviewed to address further policy issues. 
Additionally, there are several lessons for improving the quality of quantitative 
investigations. First, the use of less well-controlled time-series analysis may lead to 
spurious outcomes, often overestimated. To cope with this potential problem and to 
verify policy effects, it is advisable to crosscheck time-series data by different analytical 
techniques. Second, outcome variables for drug utilisation tend to be particularly 
sensitive to measurement units (e. g. dose/capita, prescriptions/capita, 
days/prescription, etc. ). Real changes can be misinterpreted In examining changes with 
aggregated volume if the researcher fails to account for population changes. Also, 
measuring the policy Impact with prescription numbers can overlook changes In 
prescription sizes, resulting In incorrect conclusions. Thus, the trend of population 
changes should be taken Into account. Alongside this, measurement units reflecting 
utilisation changes more accurately are advised (e. g. defined dose). Third, policy 
Impact on expenditure should be considered from a societal perspective, 
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CHAPTER 8: DESIGN OF POLICY EVALUATION: INTERRUPTED 
TIME SERIES ANALYSES 
8.1 Introduction 
So far, discussion has been around theoretical backgrounds and international evidence 
concerning the performance of pharmaceutical regulations. The third part of the thesis 
moves debate into the local context. The goals are to explore the impact of 
pharmaceutical policies in South Korea. Empirical investigation in the thesis is 
approached both quantitatively and qualitatively. 
The quantitative studies investigate the effects of two recent Korean pharmaceutical 
policies. The impact of these policies is examined using an interrupted time series (ITS) 
design. The qualitative study tackles the contextual elements surrounding decision 
making and implementation of policy. 
Chapter 8 provides insight into a methodological framework for the ITS analysis, which 
begins with exploring the general background of design and analysis, then outlines the 
data sources used in statistical analysis. It ends by demonstrating the specification of 
ITS models for the data employed in the current project. 
8.2 Interrupted time series experimental design 
A time series is a sequence of observations made on a single variable at successive 
time intervals. Interrupted time series refers to a particular form of time series which is 
Interrupted by a manipulated intervention such as a policy (Wagner et al., 2002). It 
can be charted as: 
...... 
OI-S O/-4 
. 
O! 
-3 
01-2 OI-1 X0 l+l 0 1+2 
0 /+3 01+4 0 /+S ...... 
where, O, f, denotes an observation at time p after (+) or 
before (-) the intervention 
and X denotes an intervention introduced at time I.. As seen in the above sequence, the 
intervention breaks the time series into two segments, a pre-intervention and a post- 
Intervention period. An ITS analysis aims to explore whether or not the time series has 
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changed after the intervention. Effects are commonly investigated in terms of /eve/and 
slope changes. Changes in level indicate that the intervention may be associated with 
an immediate impact at the point of inception, while changes in slope suggest that the 
intervention may affect the rate of increase or decrease in the trend of the series 
(Wagner eta/., 2002). Effects can also be characterised in other ways, such as the 
permanence - continuous or discontinuous, or the shape - immediate or delayed 
(Shadish et at., 2002c). 
In pharmaceutical policy studies, ITS Is frequently employed - as demonstrated in the 
systematic reviews presented in Chapter 4 through 6. Trends of drug utilisation or 
spending can be constructed into time series which provide ideal models for observing 
whether policy changes cause visible and measurable changes in existing trends 
(Shadish eta/., 2002c). Particularly, as already discussed in Chapter 2, the time series 
design is a favourable option when randomisation is infeasible as a policy has already 
been introduced, since it is still effective under such condition in reducing many 
internal threats to validity (Shadish et al., 2002c). Therefore, as mentioned in Chapter 
7, time series design may be the most rigorous option available for this project because 
the policies of interest were introduced at the same time nationwide, so that 
randomisation is impossible. 
With the lack of randomisation to control confounding factors, the validity and 
feasibility of ITS Is primarily determined by the quality of the data source and the 
number of available data points. As discussed in Chapter 7, the scope of Investigation 
using an ITS design is clearly limited by the data available at the time It is carried out. 
Available data Is often inflexible In terms of outcome variables collected, region, 
interval available for analysis and/or the length of the data points because In many 
cases it Is established not for research purposes but for other administrative aims. 
A short time series may fail to rule out problematic confounders such as selection or 
maturation. It may be hard to determine how many data points are sufficient, but 
textbooks suggest a rule of thumb of 50 observations or more (Box and Jenkins, 1976; 
Cook and Campbell, 1979a; McCleary et al., 1980b). According to the most widely 
referenced example, more than 100 data points are recommended to give an accurate 
estimation of autocorrelation among error terms and to facilitate correct model 
identification (Shadish et al., 2002c). However, it is difficult to generalise the exact 
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number of data points required for any ITS analysis and it may depend on specific 
details within the individual studies; for example, the number of data points required 
may depend on the statistical methods used. The Cochrane EPOC group suggests that 
ARIMA techniques require at least 20 observations in the pre-intervention period 
(Cochrane Effective Practice and Organisation of Care Review Group, 2002), while 
Wagner et a/. (2002) suggest that a segmented time series regression analysis requires 
12 monthly data points before and after the intervention. 
8.3 Outline of time series analysis 
In a time series design, changes can be detected by a visual inspection of the series 
after plotting the dependent outcome variable against time (Figure 8-1). 
Figure 8-1: Time series 
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However, a visual inspection cannot remove changes caused by chance or other 
concurrent confounding factors such as seasonal fluctuation. In order to control for 
such factors, several statistical techniques have been developed for policy evaluation 
(McCain and McCleary, 1979; Ostrom, 1990; Wagner eta/., 2002). 
One approach gaining popularity in health services research is a segmented regression 
analysis, which fits a least squares regression line to each segment of the outcome 
variable against time, and assumes a linear relationship between time and the outcome 
within each segment (Wagner eta/., 2002). A segmented regression model provides 
several advantages. It requires a relatively short time series. Wagner eßt a/. (2002) 
suggest 12 monthly data points before and after the intervention. It allows clear and 
easy interpretation of the outputs from hypothesis tests based on ordinary least 
181 
squares (OLS) or estimated generalised least squares (EGLS) estimations. 
There are some concerns about the appropriateness of least squares methods for 
analysing time series data. While one of the main assumptions of the OLS regression is 
that error terms are independent (Gill, 2000), it has been recognised that error terms 
from time-dependent data are often correlated because each observational value in a 
chronologic time sequence variable is likely to be correlated to the next (Ostrom, 1990). 
Correlation of error terms leads to the underestimation of standard errors, which 
means that the t-ratio is inflated producing an artificially low p value and therefore 
increasing the chance of rejecting the null hypothesis (McCain and McCleary, 1979). 
Hence, when using segmented regression It is important that the presence of 
autocorrelation is explained and corrected if possible. To detect autocorrelation, there 
are several diagnostic statistics, such as Durbin-Watson dstatistic (DW) (Hamilton, 
2006). When the presence of autocorrelation through diagnostic tests becomes 
apparent, EGLS estimations (such as the Cochrane-Orcutt estimator or the Prais- 
Winsten estimator) have been employed to overcome bias from autocorrelation. They 
correct standard errors In the model for first-order autocorrelation (Ostrom, 1990). 
Another approach for analysing US data Is the autoregressive Integrated moving 
average (ARIMA) process (McCain and McCleary, 1979; McDowall etal., 1980). In the 
ARIMA strategy, a time series is comprised of two parts - the stochastic component 
and the deterministic component. The stochastic component describes an underlying 
process of unobserved errors, often called a noise component of the model. The 
deterministic component describes the systematic behaviour of the time series (McCain 
and McCleary, 1979). ARIMA modelling is an iterative process of identifying the most 
appropriate model for each time series and then testing this model (McCleary et al., 
1980c). 
There are some concerns about the use of ARIMA methods. While ARIMA modelling 
may be an appropriate method, it may not permit easy interpretation (McCleary etal., 
1980b). Moreover, if the modelling procedure is too sophisticated, there may be room 
for error according to the performer's ability. Veiicer and Harrop (1983) demonstrated 
that highly trained experts were able to identify appropriate ARIMA models in only 
28% of study time series. Even automated methods may not guarantee precise model 
identification (Stadnytska et al., 2008). 
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Furthermore, relatively long observations are required in the ARIMA approach for an 
appropriate model because models are built empirically from the data itself (McCleary 
et al., 1980b). The Cochrane EPOC group suggests that ARIMA techniques require at 
least 20 observations in the pre-intervention period (Cochrane Effective Practice and 
Organisation of Care Review Group, 2002). Without doubt, the more data points the 
better for the identification of accurate models for statistical analysis. One study found 
that model accuracy was 16% higher in cases with 100 observations compared to 
other cases with 40 observations (Velicer and Harrop, 1983). 
In policy studies, researchers are usually limited by the data available at the time of 
undertaking the analysis, which includes the length of the data points, interval 
available for analysis, and outcome variables collected. Policies are often implemented 
immediately and consecutively, and eliminated unexpectedly, which is out of the 
researchers' control. Hence, time series with sufficient data points may not always be 
possible and this may create more problems for ARIMA analysis as it requires longer 
observations for building appropriate models. The reviewed ITS studies in Part 2 of this 
thesis showed that studies using ARIMA analysis were more likely to give insufficient 
data points compared to those using segmented regression (Figure 8-2). Furthermore, 
a poorly conducted ARIMA analysis may be more misleading than a well performed 
segmented regression analysis. 
Figure 8-2: The appropriateness of data points in the reviewed ITS studies 
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In summary, both approaches seem to have different strengths and weaknesses. 
McCleary et al. (1980b; p20) suggested the following guideline in the choice of 
analysing tools: 
When relatively long time series are available, an empirical ARIMA approach will 
ordinarily give the best results. But when relatively long series are not available, 
regression approaches Informed by prior research and/or theory will give the best 
results. 
The time series under study in the present project comprise 66 monthly data points 
with a relatively short follow-up period, 18 months for the first but only 11 months for 
the second intervention. In this respect, a combination of approaches may generate 
the best results, which is also in line with lessons learnt from the existing literature 
(Chapter 7). To maximise benefits and minimise difficulties from each approach, the 
current study employs a segmented regression as its primary analysis, and when 
appropriate, models are crosschecked using an ARIMA method. The practical issues 
and concepts of the two approaches are presented in the following sections. 
8.3.1 Segmented regression analysis 
A segmented regression analysis is a method for statistical modelling time series data 
in which more than two ""segments" are shaped by "a change point" (Wagner et al., 
2002). A change point dividing time series data into two compartments is an 
identifiable exogenous event such as a pharmaceutical policy. Two parameters are 
examined as mentioned in the general background of ITS designs: level and slope. 
The simplest segmented interrupted regression model is as follows: 
Yt= ßo + ß, xtimet + (Zx(ntervention + ß3xtime after (nterventiont + et (Eq. 1) 
(Wagner et al., 2002) 
where, 
Yt ;a dependent outcome variable of Interest at time t 
" timet ;a continuous variable indicating time in basic time intervals (week, month or 
year) at time t from the start of the observation period 
" Intervention ; an Indicator for a particular time point occurring before (intervention=0) 
or during and after (intervention=1) the Intervention 
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time after tnterventiont ;a continuous variable counting the number of time intervals 
after the intervention at a particular time point, coded 0 before the intervention and 1 
at the time of introduction, 2 at the second time point after the intervention and so 
forth 
" ßo a baseline level of the outcome at time zero 
" P, ;a baseline trend of the outcome before the intervention 
" ß2 ;a level change of the outcome immediately after the intervention from the end of 
the preceding segment 
" ß3 ;a change In the trend of the outcome after the intervention, compared with the 
baseline trend before the intervention 
"t; an error term at time t, representing the random variability not explained by the 
model 
Statistical outputs from a segmented regression analysis are easily understandable. 
From the above model, ß2 is a coefficient for the level change, representing an abrupt 
intervention effect; ß3 is that for the change in trend after the intervention, 
representing a gradual change in the value of the outcome during the segment. The 
sum of ßl and ß3 represents the post-intervention slope. 
As stated above, autocorrelation poses bias for the use of simple OLS. To test for Its 
presence in a specified model, the present analysis used the DW statistic. The DW 
statistic tests whether or not the residuals from a linear regression or multiple 
regression are Independent and is designed to detect errors that follow a first-order 
autoregressive process. It tests the null hypothesis Ho that the errors are uncorrelated 
against the alternative hypothesis Hi that the errors are correlated with the next. The 
test statistic Is computed based on the residuals from the least squares estimates as 
follows 
i? 2(et - Ct-1)2 
2: T 3 
t=1 Ct (Verbeek, 2008; p110) 
where er = Yr-- Yt and Yt and Yt are, respectively, the observed and predicted values of 
the outcome variable for individual time t, which is the ratio of the sum of squared 
differences in successive residuals to the residual sum of squares (Gujarati, 2003), The 
critical value is around two, when there is no serial autocorrelation (Savin and White, 
1977). 
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Figure 8-3: Five regions for values of Durbin-Watson d 
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In the presence of a positive autocorrelation the value of the test statistic tends to be 
small, while In the presence of a negative autocorreiation it will be large (Durbin and 
Watson, 1951). The critical values for the test statistic are dependent on both the 
number of data points and the number of independent variables contained in the 
model from which the residuals are derived (Savin and White, 1977). To arrive at the 
decision on the presence of autocorrelation, the significance level of d- the upper (d 
u) and lower (d, ) limits - were established as shown in Figure 8-3. If DW values fall 
between du and 4-du, the OLS estimates can be accepted without fear of a loss of 
efficiency or bias In the estimated variances. If DW values fall between d, and 4- d, 
and outside of the range of du and 4-du, it Is inconclusive and careful consideration 
should be made regarding the OLS estimates (Ostrom, 1990). The acceptable values of 
DW d will be presented for each specified model in each section. 
8.3.2 Autoregressive integrated moving average process 
ARIMA modelling Is an iterative process Involving Identification, estimation, and 
diagnosis (McCain and McCleary, 1979). Annex 22 demonstrates the overall process 
with an example. The procedure begins with the development of a noise model to 
account for the underlying stochastic component: trend or drift, seasonality, and 
autocorrelation In the variable under study by examining the correlogram such as the 
autocorrelation function (ACF) and partial autocorrelation function (PACF) plots. Once a 
tentative noise model is Identified, the parameters (Box 8-1) of the model are 
estimated and diagnosed as to whether all parameters are within each of the criteria 
and the residuals are not different from white noise. If any of these basic criteria is not 
satisfied, the model appears to be unacceptable and the procedure should be repeated. 
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Box 8-1: Definition of ARIMA 
An ARIMA model has three structural parameters, p, d and q, and they are presented as 
ARIMA (p, d, q) In documents. The lower-case p specifies the number of autoregressive 
terms, d specifies the number of times a series must be differenced, and q specifies the 
number of moving average terms. If time-series exhibit systematic periodic shifts as a 
pattern of behaviour repeats itself, It Is desirable to incorporate a seasonal structure Into 
the regular ARIMA (p, d, q) model in order to adjust for seasonality. The seasonal model is 
ARIMA (p, d, q)(P, D, Q), where p, d, and q are the regular structural parameters, P, D, Q, 
and S the seasonal structural parameters. The upper-case P, D, and Q denote seasonal 
autoregressive terms, seasonal differenced, and seasonal moving average terms 
respectively. The S denotes the length of the period, for Instance, which equals 4 for 
quarterly data, 12 for monthly data and so on. (McCain and McCleary, 1979) 
After an appropriate noise model is specified, the intervention model is added to test 
the effect of the interventions. The impact assessment model may be written as 
follows: 
Yt = Nt + f(It) (McCleary etal., 1980a)(Eq. 2) 
where, 
" Yt ;a dependent outcome variable of Interest at time t 
" Nt ;a noise component at time t 
" f(it) ; an Intervention component 
There are generally three patterns of Intervention models (McDowall et al, 1980): 
1) abrupt and permanent; Yt = wf(It) + Nt 
2) abrupt and temporary; Yt = SYFI + wf(It) + Nt 
3) gradual and permanent; Yt = SYc. I + cwf(It) + Nt 
where, 
(Eq. 3) 
(Eq. 4) 
(Eq. 5) 
" Yt. i ;a dependent outcome variable of Interest at time t-i 
" ca a parameter Interpreted as the magnitude of changes at the moment of intervention 
"8; a parameter, determining how gradually the series changed 
The adequacy of the intervention model is also tested by residuals analysis. Despite 
white noise residuals in the tentative noise model, the full impact assessment model is 
not acceptable if residuals are different from white noise. The model-building 
procedure is repeated until a parsimonious and statistically acceptable impact 
assessment model is generated (McCain and McCleary, 1979). 
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8.4 Data 
Aggregated monthly claims data for drug consumption were provided by the Health 
Insurance Review & Assessment Service (HIRA) for the period January 2003 through 
June 2008. Data included claims that provided services between January 2003 and 
June 2008, and were submitted to the HIRA until September 2008. For the present 
study, a dataset was reconstructed on the basis of the date of service because the 
claims dataset has been principally constituted on the date of claim. Data provided for 
this study covers drug expenses, the unique number of patients dispensed and total 
number of units dispensed. Drug expenses are defined as net drug ingredient costs 
plus dispensing fees and include payments from public funds and legal patients' 
copayments. Medications dispensed In episodes covered by auto Insurance, veterans' 
insurance and workers' compensation Insurance are excluded from these statistics. For 
a better understanding of data sources, the procedure for making pharmaceutical 
claims Is detailed In the following section. 
8.4.1 Pharmaceutical claims database 
Since 1995 In South Korea, National Health Insurance (NHI) covers about 98 per cent 
of the population (NHIC and HIRA, 2007). The remaining population, probably the 
most poor in the country, are covered by the national Medical Aid Plan (MAP) (Korean 
Statistical Information Services, 2006). The National Health Insurance Corporation 
(NHIC) is an organisation responsible for administration of the NHI and the MAP In 
terms of eligibility, billing and management of health insurance funds. Retail 
pharmacists and dispensing doctors (only in limited, pre-designated arrangements by 
law since 2000) are reimbursed directly by the NHIC, based on the prescription 
obtained from the patient after going through evaluation by the HIRA (Figure 8-4). 
The HIRA administers a computerised database, which takes prescription information 
regularly reported by both the prescriber and the dispenser within the scope of the NHI 
and the MAP. The database covers information on beneficiaries, prescribers, dispensers, 
fees and dispensing (prescribing) of drugs, payment and reimbursement decisions. 
Refund of claims is the responsibility of the NHIC as mentioned. Before refunding, the 
HIRA determines whether claims are reimbursed, partly reimbursed or declined. 
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Figure 8-4: Claims flow diagram 
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To make the decision, the HIRA assesses all medical and pharmacy claims to see that 
they meet the national guidelines in terms of both quality and quantity. Every provider 
should hand in all prescription claims online or by post and be assessed before being 
reimbursed. Figure 8-5 illustrates a prescription claim sheet used in community 
pharmacies. At the beginning of 2005, nearly 90 per cent of major providers submitted 
claims through the online networking system, an established electronic interface linking 
databases to the HIRA (Kim and Lee, 2006). Currently, the prescription claims data 
recorded in the HIRA's database has provided the only comprehensive information 
about pharmaceutical consumption in South Korea, so has been used for a variety of 
scientific research. 
There are, however, a number of limitations inherent in HIRA claims data. First, data 
before December 2002 Is not fully comparable with that after January 2003, as it was 
defined differently and maintained by a different system. Because of this practical 
difficulty, data before December 2002 was not used for the present project. Second, it 
does not cover the utilisation of over-the-counter (OTC) drugs, consumed outside of 
the scope of the NHI. Third, it has little precise information about the diagnosis for 
which a given prescription was written. Fourth, access to information about the 
characteristics of individuals, including patients, prescribers and dispensers, is 
prohibited owing to confidentiality. 
8.4.2 Time series of interest 
In this study, two sets of time series were constructed to investigate Korean policy 
interventions. The first set includes four time series for individual drug expenditure, 
individual utilisation or aggregated population prescribed and unit prices in terms of 
overall pharmaceuticals, which will be examined in Chapter 9. The second set 
comprises time series established in two therapeutic subclasses to examine the policy 
Impact on the use of essential drugs and generics. For these purposes, six time series 
will be tested for each therapeutic class in Chapter 10. The implications of both 
analyses will be discussed in Chapter 11. 
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8.4.2.1 Choice of therapeutic subclasses 
For the second set of time series, two therapeutic classes (antihypertensives and 
antihyperlipidemics) were chosen. Anti hypertensives were defined as medications in 
WHO Anatomic Therapeutic Chemical (ATC) group C02 (antihypertensives), C03 
(diuretics), C07 (beta-blocking agents), C08 (calcium channel blockers), C09 (agents 
acting on the Renin-Angiotensin system). Antihyperlipidemics were defined as 
medications in WHO ATC group C10AA (HMG CoA reductase Inhibitors), C10AB 
(Fibrates), C10AC (Bile and sequestrants), C10AD (Nicotinic acid and derivatives), 
C10AX (Other lipid modifying derivatives), C10BA (HMG CoA reductase Inhibitors In 
combination with other lipid modifying agents), C10BX (HMG CoA reductase Inhibitors, 
other combinations). 
Classification of each chemical ingredient sold in the Korean market was made 
according to the taxonomy provided by the HIRA in 2007, which linked most chemical 
substances to the WHO classification (Health Insurance Review & Assessment Service, 
2007f). Korean national classification was also used for the unclassified products13. A 
list of Insured products was obtained from the Maximum Allowable Cost list released by 
the HIRA In July 200814. 
For a better understanding of the Korean coding system, Table 8-1 displays an example 
product and the names and codes used In the Korean market. Norvasc, ® a product 
produced by Pfizer, containing amlodipine besylate 5mg per each tablet, Is categorised 
Into C08 (calcium channel blockers) in the WHO ATC system, 219 (other cardiovascular 
agents) In the Korean system and was granted the Insurance Code A03102361 or 
E01890381 during the study period. There may be several insurance codes for one 
product In Korea because the authority grants a new code to the same product If any 
change occurs in its legal market authorisation certificate for documentation reasons, 
Thus, the present study considered all Insurance codes for each product to include all 
products during the study period. 
13 Korean National Code 210 (consisted of 9 sub-codes from 211 to 219) covers most kinds of 
cardiovascular drugs Including blood pressure lowering agents and blood lipid lowering agents, 
14 available at http: //www, hira. orkr common/dam , jsp? pgmid=HIRAFO10104000000 
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Table 8-1: Example codes and names for a pharmaceutical product 
International WHO ATC Korean Korean Brand Name Nonproprietary Classification National Insurance nce Code 
Manufacturer (Unit) Name Code 
amlodipine C08CA01 219 A03102361 Norvasc Pfizer Korea besylate (Smg Tab. ) 
E01890381 Norvasc Pfizer Korea (5mg Tab. ) 
In total, 464 lipid-lowering agents and 1,997 blood pressures lowering agents were 
identified, of which 351 and 1409 products were claimed at least once during the study 
period from January 2003 to June 2008 (see Table 8-2). 
8.4.2.2 Classification of brand-named and generic drugs 
This study defined generic drugs using the European Parliament regulation, which 
characterises generic medicines as follows: 
"Generic medicinal product" shall mean a medicinal product which has the same 
qualitative and quantitative composition in active substances and the same 
pharmaceutical form as the reference medicinal product, and whose bio- 
equivalence with the reference medicinal product has been demonstrated by 
appropriate bloavallability studies. The different salts, esters, ethers, Isomers, 
mixtures of isomers, complexes or derivatives of an active substance shall be 
considered to be the same active substance, unless they differ significantly In 
properties with regard to safety and/or efficacy. (Directive 2001/83/ECArtlcle 10, 
paragraph 2, point (b)) 
A brand-named drug in this study was used as a synonym for an original drug, and 
was defined as a drug having been held or holding a patent for new chemical entities 
unless it was marketed before 1987, when patent regulation had not yet been 
Introduced in South Korea. For products approved before 1987, a product was regarded 
as a brand-named drug if it was marketed for the first time among the same chemical 
substances Internationally. A drug that was granted a patent on the manufacturing 
process, but not on the active Ingredient was considered a generic drug. Similarly, a 
drug with a different salt from the original drug (a type of me-too drug), for example, 
amiodipine camsylate (e. g. Amodipine®) or amlodipine maleate (e. g. Anidipine®), was 
regarded as a generic drug of amlodipine besylate (Norvasc®). Two products would be 
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considered brand-named drugs if both contain the same active Ingredient, but this 
active material was distributed by a different Innovative delivery system from the other. 
An example of this would be a tablet or a capsule versus a delayed release tablet or a 
patch; however, there were no such cases In Identified products. Generic drugs refer to 
all drugs except brand-named drugs defined above. 
Pharmaceuticals were divided into brand-named and generic drugs by the two step 
procedure in order to mirror the real world more accurately. At the first step, products 
were principally grouped according to the following four sources of information about 
Individual product's origin: 
  the Korean blo-equivalent reference drug list; 
  original drug Information from database held by one university affiliated 
hospital in Korea; 
  patent information from Orange book (US FDA, htttp: //www. fda. gov/cdder/gb 
or European Public Assessment Report (EMEA, 
http,: //www. emea. europa. eu/ tms/human/epar/a. h m); 
  Information about licensing agreements between local producers and 
international manufacturers from several medical newspapers 
The Korean blo-equivalent reference drug list has been established for the Bio- 
equivalence Validation Programme (BVP) and regularly updated by the HIRA since 
2000. The BVP was Introduced in 2000, to verify the quality of generic products. In this 
process, generic producers are obliged to prove that their product has a bio- 
equivalence profile equal to their reference drugs in the list. Reference agents are 
selected when they meet three conditions; 1) original drugs; 2) products holding the 
first market approval among products with the same Ingredient; and 3) products the 
most popular In the market (KFDA 4fda/Instruction 2007-23, provision 3-, 2). 
Reference products on the list may not always be original drugs, If they were selected 
because of the second and third conditions. 
Owing to such limitation, other sources of patent information were sought. A database 
held by the pharmacy department in one respected teaching hospital was employed to 
supplement the first sources. The database has been established on the basis of 
information provided by marketing staff from each drug company. However, it does 
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not cover some of the products never prescribed in this particular hospital. 
Consequently, the Orange book published by US FDA and the European Public 
Assessment Report published by European Medicines Agency (EMEA) were also 
considered alongside the other information. In addition, several medical newspapers 
were scanned for information on licensing agreements between local producers and 
international originators, because, until recently, it was usual for an international 
originator to launch products via a local producer, sometimes more than one at a time, 
with different market names. If information from the stated procedure was insufficient, 
then each manufacturer or marketer was contacted for more accurate information for 
grouping. 
At step two, the final list was confirmed by two registered pharmacists currently 
working in a teaching hospital and a community pharmacy in Korea. 
Finally, 284 brand-named drugs and 1,125 generic drugs were identified among 1,409 
drugs for lowering blood pressure. As for lipid lowering drugs, 60 brand-named drugs 
and 291 generic drugs were isolated (Table 8-2). Annex 21 presents an example of the 
classification for amlodipine derivatives. 
Table 8-2: Number of brand-named and generic drugs identified by ATC code 
A7C code 
Brand Generic A'PC code 
Brand Generic 
drugs drugs drugs drugs 
antbypertenrwes antmyper471dem cs 
C02 antihypertensives 29 69 C10AA HMG CoA reductase Inhibitors 33 237 
C03 diuretics 29 73 C10AB Fibrates 10 39 
C07 beta-blocking agents 42 335 C10AC We acid sequestrants 1 2 
C08 calcium channel blockers 70 320 CIOAD Nicotinic acid and derivatives 9 4 
C09 agents acting on the Renin- 114 327 C10AX 
Other lipid modifying 2 9 
Angiotensin system derivatives 
HMG CoA reductase inhibitors 
unclassified 1 C1OBA in combination with other lipid 2 
modifying agents 
CIOBX 
HMG CoA reductase Inhibitors, 3 
other combinations 
subtotal 284 1125 subtotal 60 291 
Total 1409 Total 351 
8.4.3 Definition of outcome var iables 
Outcome variables explored in this thesis include drug expenditure, utilisation, and unit 
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prices: 
  Drug expenditure Is operationally defined as the average monthly costs per 
patient, which Includes both payers' expenditure and patients' legal copayments. 
From the empirical data under study, it was observed that total costs appeared to 
be high in winter, while costs per patient tended to be high in summer. It may be 
a result of an increase In patients with slight Illnesses, such as the common cold, In 
spring and winter, Presumably, patients were prescribed less expensive, symptom- 
relief preparations, which could affect total expenditure In such periods. The 
present study employed a measure of per capita expenditure rather than total 
costs in expenditure to control such variations. In parallel, analysing the net 
expenditure Including payers' and patients' expenses avoids bias from the budget 
shift which Is likely to occur in policies limiting patient demand, such as cost- 
sharing (Chapter 7). 
  Drug utilisation is operationally defined In two ways: aggregated number of 
individuals dispensed and units per patient. Although the 'units per patient' Is a 
measure commonly used when Investigating the utilisation of pharmaceuticals in 
empirical research, the true effects could be masked In a case where both the 
number of patients and the total drug consumption are reduced (or raised) by a 
similar magnitude as seen in Table 8-3. Opposite responses (decrease versus 
increase) In total units or the number of patients dispensed generate the same 
answer In units per patient. It may be particularly confusing If the researcher 
attempts to test the impact of cost-sharing given the way It functions, which Is to 
decrease patient demand for drugs through suppressing patient visits or adherence 
to prescription filling (Chapter 4). Hence, both measures will be used In 
conjunction to Investigate Individual use as well as drug accessibility In this study. 
Table 8-3: Relatlonshi between participation and units er patient 
time point A time point B time point C 
number of units dispensed 100 120 50 
number of patients dispensed 100 120 50 
units per patient 111 
  The unit price of pharmaceuticals is operationally defined as the costs per unit. 
The definitions and calculations for each of the dependent variables are outlined 
below: 
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  Total costs reimbursed for pharmaceuticals is defined as the sum of 
payers' and patients' costs on drugs dispensed on a monthly basis, Including fees. 
  The number of patients dispensed is counted as each unique patient having 
one or more claims during the study period on a monthly basis. 
  Total number of units dispensed Is defined as the sum of (units x 
frequency x days dispensed) for each pharmaceutical during the study period on a 
monthly basis. A unique unit for each pharmaceutical product is designated in the 
pharmaceutical reimbursement list and generally defined depending on the 
formulation of the product, for example, 1 tablet, 1 capsule, 1 pack, 1ml, 1 ampule, 
1g, and so forth. 
" Costs per patient are defined as the total costs reimbursed for 
pharmaceuticals divided by the number of patients dispensed in the corresponding 
month. 
w Units perpatlentare defined as the total number of units dispensed divided 
by the number of patients dispensed in the corresponding month. 
" Costs per unit are defined as the total costs reimbursed for pharmaceuticals 
divided by the total number of units dispensed in the corresponding month. 
8.5 Modelling framework 
Two pharmaceutical policies were evaluated in this thesis: the Pharmaceutical 
Expenditure Rationalisation Plan (PERP) and the extension of coinsurance. Each policy 
was described In detail in Chapter 2. 
8.5.1 Segmented regression model 
8.5.1.1 Basic segmented regression model 
A basic segmented regression model included independent variables to test the size 
and statistical significance of time series changes In level and slope after policy 
Interventions, The data were segregated into three discrete periods for analysis: from 
January 2003 to December 2006 -a pre-intervention period; from January 2007 to 
July 2007 -- the period after PERP enforcement began, a transition period; from August 
2007 to June 2008 - the period after coinsurance extension implemented, a post- 
Intervention period as diagrammed in Figure 8-6. 
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Figure 8-6: Introducing date of policies of interest in data period 
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Thus, the following segmented regression model was established: 
Y, = Pc) + Rixtimer + ß2xPerp + ß3xPerpt + ßgxCo + ISxCot + Et (Eq. 6) 
where, 
" Yt ; dependent outcome variables of interest at time t, which are the monthly mean 
costs per patient, the number of patients prescribed, the monthly mean units 
prescribed per patient and the monthly mean costs per unit 
" timet ;a numerical month variable beginning in January 2003 (month= 1) and 
extending to June 2008 (month=66) 
" Perp ;a dummy variable for the PERP (the first policy change of interest) coded 0 
before January 2007 and 1 from January 2007 
" Perpt ;a continuous variable representing time after the PERP and coded 0 before 
January 2007 and 1 to 18 from January 2007 to June 2008 
" Co ;a dummy variable for the coinsurance (the second policy change of interest) coded 
0 before August 2007 and 1 from August 2007 
" Cot ;a continuous variable representing time after the coinsurance and coded 0 before 
August 2007 and 1 to 11 from August 2007 to June 2008 
" PO ; baseline level of the outcome at time zero 
" ßl ; baseline trend of the outcome before the interventions 
" ß2 ;a level change of the outcome immediately after the implementation of PERP 
" ß3 ;a change in the trend of the outcome after the PERP, compared with the baseline 
trend 
" (34 ;a level change of the outcome immediately after the expansion of coinsurance 
Rs ;a change in the trend of the outcome after the coinsurance, compared with the 
trend after the PERP 
" Et ; error term at time t 
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8.5.1.2 Seasonally adjusted segmented regression model 
Accompanying the policy variables, seasonality was modelled using dummy variables 
where appropriate. Seasonal dummy variables - spring, summer, autumn and winter - 
were incorporated into the general model because sizable variations were seen in 
prescription data by season (for instance, Figure 8-7). 
Figure 8-7: Units per patient (January 2003 N June 2008) 
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Seasonality is a usual feature in monthly prescription data. Less patients may see their 
doctors during certain times of the year (for example, summer) and more during 
others (for instance, winter). South Korea has four clear seasons. March to May as 
classed as spring, June to August as summer, September to November as autumn and 
December to February as winter. Such seasonality needs to be controlled for in any ITS 
analysis because it usually becomes an important source of variability. Moreover, the 
data employed contains different seasonal profiles, for example more winter and spring 
months in the post-intervention period which could potentially confound any apparent 
intervention effect. 
Figure 8-7 displays a time series for units per patient between January 2003 and June 
2008. Monthly measures were plotted by period to inspect the distributions visually. It 
shows a clear peak in winter months. Seasonal dummy variables were used to control 
seasonal fluctuations. After stepwise elimination of non-significant terms, only one 
variable representing summer was included in the final model. This was also the case 
for other outcome variables showing apparent seasonality. Finally the following model 
was specified for those time series: 
Yc= Pc) + PIxtime, + (3zxPerp + P: 3xPerpt + ßgxCo + ß5xCot + 06xS + Et (Eq. 7) 
where, 
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" P6 ; coefficient for a summer variable 
"S; a dummy variable for summer months coded 1 for June, July and August and 0 for 
others 
8.5.1.3 Segmented regression model by therapeutic subclass 
On first inspection, the time series from the two therapeutic subclasses produced quite 
different trend lines with little seasonal variation observed. Substantial increases were 
detected in mid 2004 for the time series for the number of patients dispensed (Figure 
8-8). 
Figure 8-8: Number of patients dispensed 
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In the Korean market, there were big changes with study drugs in 2004. With 
anti hypertensives, the first 'me-too' drug of NorvascR-' was launched in September 2004, 
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A "me-too' drug denotes a product containing a slightly modified active ingredient, but 
generating the same clinical effect as the original product. Norvasc® is a Pfizer's brand 
name for amlodipine besylate, which Is a long-acting calcium channel blocker (CCB) 
and one of world's blockbusters In 2000s (Pfizer Inc., 2006). It had been at the top of 
the Korean prescription drug market over all products until 2005 (Korea Health 
Industry Development Institute, 2007). 
Since 2004, many `me-too' products had sharply encroached upon the market share of 
Norvasc®. The market share of a front-running product among the me-too drugs of 
Norvasc® was placed 8th in 2005 and rose to 4th place with a 30% increase in 2006 
amongst all prescription market products (HIRA document cited by DailyPharm, 2009). 
Because the magnitude of change caused by me-too drugs was considerable in the 
market, it was necessary to take this into account in further analysis. Dummy and 
continuous variables representing this market change were incorporated into the basic 
model. A dummy variable was used for the time at which the first `me-too' product was 
introduced into the market. This captured the start of new competition in this market. 
Although the degree of competition increased from then on as more `me-too' products 
were available, the variable did not reflect changes over time. It is acknowledged that 
the analysis has lost some information by not explicitly including variables that reflect 
the change of the number of alternative drugs available. However, the model kept 
independent variables for non-policy events to as few as possible for reasons of 
parsimony. The following model (named the antihypertensives segmented regression 
, mode, was specified for `the number of patients dispensed' series In 
antihypertensives: 
YY= ßa + ßlxtimee + ß2xPerp + P3xperpt + ß4xCo + tSxCot + ß6xNv + ß, xNvk + Et (Eq. 8) 
where, 
" Nv :a dummy variable for the launch of me-too drugs of Norvasc® coded o before 
September 2004 and 1 from September 2004 
" Nvt :a continuous variable representing time after the launch me-too of Norvasc® and 
coded 0 before September 2004 and 1 to 46 from September 2004 to June 2008 
" ß6 :a level change of the outcome immediately after the launch of me-too drugs of 
Norvasc® 
" p, :a change in the trend of the outcome after the launch of me-too drugs of Norvasc®, 
compared with the baseline trend 
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In the antihyperlipidemics market, Crestor® (rosuvastatin branded by AstraZeneca) was 
launched In July 2004 Into the Korean market (DailyPharm, 2004a). The market share 
of Crestor-® jumped from 76th to 20th place with a 135% increase among all 
prescription market products between 2005 and 2006 (HIRA document cited by 
DailyPharm, 2009). To control such a substantial change In the analysis, dummy and 
continuous variables representing the launch of Crestor® were Incorporated into the 
basic model similarly to the case with anti hypertensives. The final model (named the 
antihyperlipidemics segmented regress/on model) was specified for `the number of 
patients dispensed' series in antihyperlipidemics: 
Yt= Po + ßlxtimet + ß2xPerp + ß3xPerpc + ß4xCo + ß5xCot + ß6xCr + p7xCrt + Et (Eq. 9) 
where, 
" Cr ;a dummy variable for the launch of Crestor® coded 0 before July 2004 and 1 from 
July 2004 
" Crt ;a continuous variable representing time after the launch of Crestor® and coded 0 
before July 2004 and 1 to 48 from July 2004 to June 2008 
" P6 ;a level change of the outcome immediately after the launch of Crestor® 
" 17 ;a change In the trend of the outcome after the launch of Crestor®, compared with 
the baseline trend 
The empirical regression model for each outcome variable was specified through the 
procedure described so far. Details for the model specification will be presented 
together with individual analysis in the following chapters. 
8.5.2 Application of statistical analyses 
Identified segmented regression models were examined statistically in the following 
procedure: 
1. OIS estimation performed; 
2. autocorrelation was explored using the DW statistic; 
3. if the data were found to be autocorrelated, segmented regression analysis was 
repeated by EGLS estimation using the Prals-Winsten estimator; 
4. the sensitivity of segmented regression analysis was crosschecked using an 
ARIMA process whose model specification procedure is addressed In the 
following section. 
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8.5.3 ARIMA model specification 
In the present studies, ARIMA models were constructed for a sensitivity analysis to 
crosscheck results. The following conceptual intervention components were established 
as Equation 10. 
f(It) =o Perp + w2Co (Eq. 10) 
where, 
" f(It) ; an intervention component 
" Perp ; 1) for the abrupt, permanent and the gradual, permanent change: a dummy 
variable for the PERP (the first policy change of interest) coded 0 before January 2007 
and 1 from January 2007,2) for the abrupt, temporal change: a pulse variable coded 0 
before January 2007,1 for January 2007 and 0 again for the rest period 
Co ; 1) for the abrupt permanent and the gradual, permanent change; a dummy 
variable for the coinsurance (the second policy change of interest) coded 0 before 
August 2007 and 1 from August 2007,2) for the abrupt, temporal change: a pulse 
variable coded 0 before August 2007,1 for August 2007 and 0 again for the rest period 
" Ws ; coefficients for the magnitude of changes 
To incorporate the intervention components into the specified noise models, it was 
necessary to choose an intervention transfer function (Equation 3 through 5 In 8.3.2). 
The Intervention models were built firstly according to the analysis results from the 
regression models, because they were considered a reasonable a priori notion as to the 
nature of the policy impact. However, the Identification was not limited to the 
regression results, but broadened If necessary by exploring the graphical appearance of 
actual data and forecasting numbers from the tentative noise model. 
The adequacy of the final models was tested statistically by the Box-Ljung Q test of 
residuals (McCain and McCleary, 1979). The model-building procedure was done 
repeatedly until a parsimonious and statistically acceptable impact assessment model 
was generated. Box 8-2 outlines the series of steps employed in the study. Annex 22 
addresses these in greater detail with the example analysis of the 'costs per patient' 
time series. 
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Box s-z: steps for ARIMA modeili 
1. Visual examination of the time plot of the data series of Interest 
2. Examination of correlogram to Identify a 'noise' model 
3. Estimation of parameters and check with the basic criteria 
4. Examine residuals from the obtained model and assess adequacy 
5. Fit the Intervention component to the Identified 'noise' model 
6. Diagnosis for the residuals of the full Impact assessment model 
(McCain and McCleary, 1979) 
8,6 Summary 
This chapter described a methodological tool for the empirical quantitative studies 
conducted in the thesis. Quantitative studies In this thesis employed a segmented ITS 
analysis to Investigate the Impact of the Korean pharmaceutical policy Interventions, 
which was crosschecked where requested by the ARIMA approach. National insurance 
claims data were provided by the HIRA, a Korean medical services audit body. Specific 
segmented regression models were Identified for each time series of Interest, taking 
seasonal variations and market dynamics into account. Finally, three adjusted models 
were specified alongside a basic segmented regression model, which were seasonally 
adjusted segmented regression models, and anti hypertensives and antihyperlipidemics 
segmented regression models. In parallel, this chapter briefly outlined the specification 
of ARIMA models. More detailed, specific methods, descriptive summaries and results 
are presented in Chapter 9 and 10. 
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CHAPTER 9: ASSESSING THE EFFECTS OF LOCAL 
PHARMACEUTICAL POLICIES ON THE PHARMACEUTICAL 
MARKET 
9.1 Introduction 
The objective of this chapter is to present results from the first empirical study. The 
impact of two recent pharmaceutical policies upon overall pharmaceutical expenditure, 
utilisation and prices are explored. The two policy Interventions are the Pharmaceutical 
Expenditure Rationalisation Plan (PERP) and the extension of coinsurance for 
outpatients' prescription drugs that has been implemented in South Korea. Neither 
policy has been evaluated since Implementation. 
9.2 Policy changes 
9.2.1 Pharmaceutical Expenditure Rationalisation Plan 
The PERP was implemented on 29 December 2006, about 8 months after it was 
suggested in May 2006. The PERP is a comprehensive package of pharmaceutical 
regulations and consists of four sub-domains, which are price control volume control, 
quality control and the restructure of the pharmaceutical market (see Chapter 2 for 
policy details). Many of the measures in the PERP are little more than existing 
regulations which previously were scattered here and there. However, some of them, 
such as a positive list or a price-volume agreement, were measures dismantling the 
traditional regulation structure. The present study aims to explore the impact of the 
new reimbursement pricing and listing system. 
In brief, the PERP employed price-volume agreements for the pricing of all patent 
drugs based on the evidence of cost-effectiveness. One year after the first decision, 
the volume of each product consumed in the healthcare sector is assessed based an 
data from pharmaceutical claims. off-patent drugs are reduced In price by 20% when 
the first generic counterpart is submitted for the listing. This was applied to all existing 
off-patent drugs when the new system was implemented, reflected in the Maximum 
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Allowable Costs (MAC) edition of January 2007. The pricing system for generics 
maintained the same rules as before. Prices for generics are set at a 20-30% reduced 
price to their brand-named counterparts. In actuality, the new system cuts the price of 
the off-patent original drugs by 20% making the price of generic products equal to 
64% of the price of the original counterpart in the previous system. 
The reimbursement listing system replaced a negative list with a positive one. However, 
few changes have been observed in the total number of pharmaceuticals in the list, as 
discussed in Chapter 2. Hence, the present study found few real changes brought 
about by the new listing system. 
9.2.2 Coinsurance 
From 2001 to 2007, patients paid a fixed copayment of 1,500KRW (£0.75) per 
prescription, unless the total drugs cost per single prescription (including a dispensing 
fee) exceeded 10,000 KRW (£5) (see Chapter 2 for more details). In August 2007, a 
fixed copayment for patients aged between 6 and 64 was replaced by the 30% 
coinsurance scheme. In other words, non-elderly patients have to pay 30% of total 
drug costs per prescription even though the total amount of expenses is under the 
previous 'upper limit; Because of the new cost-sharing schedule, the actual increase in 
the out-of-pocket rate was about 50% from 20% to 30% In prescriptions previously 
under the fixed-copayment scheme. The elderly population continue to pay a fixed 
copayment same as before. A slightly lower cost-sharing rate began to apply to 
children under six, which since August 2007 has been 70% of the adults charge. 
9.3 Objectives of study 
The aim of the PERP was to contain pharmaceutical expenditure primarily by achieving 
cost-effective purchasing (Ministry of Health & Welfare, 2006c). In PERP, price cutting 
of off-patent pharmaceuticals was followed by curtailing prices of corresponding 
generic products, consequently lowering the average price of overall medications in the 
market. Decreasing the average price of medications was expected to lower 
expenditure on pharmaceuticals. 
The copayment change aimed to contain pharmaceutical costs by increasing price 
206 
sensitivity in patients, targeting those with temporary symptoms such as the common 
cold (Ministry of Health & Welfare, 2007a). Increasing out-of-pocket expenditure might 
discourage patients from seeking drugs in unnecessary cases, thus decreasing 
pharmaceutical consumption. Decreasing volume might subsequently lead to 
containing pharmaceutical expenditure. 
The effects of the two policy interventions on pharmaceutical expenditure and 
utilisation are still unknown. Therefore, this study seeks to examine whether the 
policies achieved the intended policy objectives. 
9.4 Methods 
9.4.1 Study design and data source 
The design of the study is an observational, retrospective, interrupted time series 
analysis of 66 monthly observations from January 2003 to June 2008. Aggregated 
monthly data concerning drug consumption and expenditure were provided by the 
Health Insurance Review & Assessment Service (HIRA) (see Chapter 8 for details). 
9.4.2 Outcome measures 
The primary outcome variable was drug expenditure per capita to test if two study 
interventions achieved their ends, Le. 'cost containment. Variables reflecting drug 
utilisation and unit drug price were investigated as secondary outcomes to explore if 
they did lower costs how they did so. Drug utilisation was defined in two ways: 'units 
perpatient'and 'total numberofpatlentsdispensed. Unit drug price was defined 
as 'costs per unit: Details of definitions and calculations are presented in Chapter B. 
9.4.3 Statistical Analysis 
9.4.3.1 Primary analysis 
To measure the size and statistical significance of time series changes associated with 
the implementation of these interventions, segmented regression models were 
primarily used (Chapter 8), Time series for each dependent variable was established 
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and visually examined for any extreme variations potentially confounding policy 
outcomes. Considerable seasonal fluctuations were noted in all outcome variables. 
Hence, both general and seasonal models were applied to all outcome variables to 
determine the best framework. Details of definitions and coding were explained in 
Chapter 8 (see 8.5 for modelling framework). As a reminder, the basic segmented 
regression model (Equation 6) and seasonally adjusted segmented regression model 
(Equation 7) were as follows: 
Yt= P() + R, xtimet + 02xPerp + R3xPerpt + 04XCo + 3SxCot + et (Eq. 6) 
Yc= Po + Rixtimet + 02xPerp + 03xPerpt + ßgxCo + 3sxCot + ß6xS + st (Eq. 7) 
Figure 9-1: Drug costs per patient from January 2003 through June 2008 
4U(JI, 
dCwdi, XL f,,, i uWnk, nt 
fitted values 
ERP Co 
C 35000 
Ö 
C 
'Z 30000 
CL 
25000 
0 
U 
20000 
49 61 month 
A visual investigation of the fitted data against the actual value suggested that the 
seasonally adjusted segmented regression model was superior for all time series 
concerned. For example, monthly average drug costs per patient were plotted in Figure 
9-1. It displays the time series of actual costs per patient for pharmaceuticals by month 
(dashed line) along with the corresponding fitted values (solid line) from OLS 
estimation by applying the basic model. From the analysis, a sharp increase in trend 
was suggested after the PERP (p=0.033). However, it seems erroneous given seasonal 
fluctuations - drug expenditure repeatedly increased during the first half of every year 
and tended to fall during the second half (Figure 9-1). In the years before the 
introduction of PERP, a rising trend in the first half was offset by a decreasing trend in 
the second half. Contrary, there was only the first half of the year after the PERP, in the 
segment before the implementation of the second intervention, denying the offset by a 
decline in the second half. In this sense, an increasing trend measured by a simple 
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segmented regression model can hardly be ascribed solely to the PERP implementation. 
To control for such seasonality, a seasonally adjusted segmented regression model was 
applied and this suggests non statistically significant changes in the trend after the 
first policy change. 
The Durbin-Watson dstatistic (DW) was used as a test for serial correlation of error 
terms. Table 9-1 displays critical values for two tentative models at the significance 
level of 5%. If DW values clearly indicated the presence of autocorrelation after 
applying ordinary least squares (OLS), the models for such variables were corrected for 
first-degree autocorrelated errors using the Prais-Winsten estimator. 
Table 9-1: Durbin-Watson critical values for the regression models 
d, d, 2 4-d '} di 
decision uncertain 
critical value 
general model 1 . 4i3S 
1. /6/ 
seasonal model 1.404 1.805 
(Source: Savin and White, 1977) 
2.195 2.596 
A p-value of less than or equal to 0.05 was considered statistically significant. To 
explore the goodness of fit of the segmented regression models, the proportion of 
variability in the data set that was accounted for in the model was also calculated 
(adjusted R2). The segmented regression was carried out using STATA version 10.0 
(StataCorp LP, 2007). 
9.4.3.2 Sensitivity analysis 
For crosschecking the significant results from segmented regression models, 
autoregressive integrated moving average (ARIMA) models were constructed and 
analysed. Using an iterative process as described in Annex 22 until changes in the 
orders of the autoregressive, integrated, and moving average processes resulted in no 
further improvement in fit and the autocorrelation of errors was not statistically 
significant. Finally, the ARIMA(0,1,1)(0,1,0), 2 model was specified from the pre- 
intervention data for the noise compartment in all relevant variables. Using the 
tentative noise model, projections for the post-intervention period were formed to 
provide estimates in the absence of interventions. After the visual examination of 
actual and fitted data, it was found that there was little reason to assume gradual, 
no autocorrelation uncertain 
7.233 2.562 
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permanent or abrupt, temporal intervention effects. Thus, the simplest intervention 
model (abrupt, permanent) was added to represent the effect of the interventions. The 
Box-Ljung Q statistic was used for residual analysis to gauge serial autocorrelation of 
error terms. The ARIMA process and statistical analysis was carried out using R version 
2.11.0 (The R foundation for statistical computing, 2010). The best-fit models were 
compared with closely competing models to determine the impact of alternative models 
on the intervention effect, and the estimates of Intervention effect were robust. 
Although the coefficients varied somewhat, its direction and significance remained 
robust across closely competing models. 
9.5 Results 
9.5.1 Overall trends 
Figure 9-2 and Table 9-2 demonstrate overall trends in aggregated drug costs, the 
volume and the population who were dispensed drugs at least once during the study 
period. During a 5-year period, total costs almost doubled from 465 billion KRW in 
2003 to 913 billion KRW in the first half of 2008. The annual growth rate of 
expenditure was highest, nearly 20%, In 2005 and has shown a downturn since then. 
Volume rose by 42% and the number of patients dispensed increased by 16% in the 
corresponding period. Both also showed the highest growth in 2005, about 12% and 
5% respectively. The pattern of the trend was similar in these two variables. 
Considerable fluctuations were discerned by month with a peak during the spring (April 
and May) and winter seasons (November and December); the lowest was in summer 
(June, July and August) and February. 
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Figure 9-2: Total costs for pharmaceuticals, total number of patients dispensed and 
total number of units dispensed from January 2003 to June 2008 
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Table 9-2: Descriptive summary of overall changes in expenditure, number of 
patients and utilisation on pharmaceuticals during the study period 
Total costs for pharmaceuticals Total patients dispensed Total units dispensed 
(in billion KRW')) (in million) (in billion) 
Annual 
Mean (95% C12) changes Mean (95% CI) 
Year (%) 
2003 465.15 (443.98,486.32) - 22.45 (21.72,23.18) 
2004 548.43 (524.88,571.99) 17.9 23.39(22.61,24.17) 
2005 655.97 (622.58,689.36) 19.61 24.46 (23.33,25.58) 
2006 769.11 (745.76,792.45) 17.25 24.91 (24.20,25.63) 
2007 862.82 (834.81,890.84) 12.18 25.40 (24.63,26.17) 
20083) 913.10 (880.57,945.63) 5.83 26.06 (25.41,26.71) 
1) KRW refers to Korean won. 
2) CI refers to confidence interval. 
3) From January to June 
Annual Annual 
changes Mean (95% CI) changes 
(%) (%) 
- 2.58 (2.44,2.73) - 
4.17 2.77 (2.64,2.91) 7.42 
4.57 3.10 (2.88,3.31) 11.65 
1.86 3.34 (3.20,3.48) 7.83 
1.94 3.47 (3.32,3.63) 3.99 
2.61 3.66 (3.52,3.81) 5.48 
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9.5.2 Impact on drug expenditure 
Monthly `costs per patient' had increased from 20,713 KRW in 2003 to 34,006 KRW in 
2007 with an average annual growth rate of 13%. It was observed that the annual 
growth rate continued to rise until 2005, then fell from 15% in 2005,10% in 2007 to 
3% in the first half of 2008. Sizable variations were observed from month to month, 
peaking during the summer months and bottoming out in April. 
For the segmented regression analysis, after applying OLS estimation, the value of DW 
statistic was 2.37, indicating some concern as to the presence of autocorreiation. 
Hence, the regression analysis was repeated using Prais-Winsten estimator, and 
outputs are displayed in Table 9-3. There was an increasing underlying trend of 281 
KRW per month (p<0.001). The upward trend of pharmaceutical spending was lowered 
after the second intervention by 368 KRW per month, which was statistically significant 
at the 5% level (p=0.030). There was little evidence of change in trend after the first 
policy and in levels after both interventions. Figure 9-3 presents the time series of 
actual 'costs per patient' on pharmaceuticals by month along with the corresponding 
fitted values from estimated generalised least squares (EGLS) estimation. 
Table 9-3: Regression coefficients for costs per patient 
Dw 
urn q Knrean won Coefficient 95% Confidence Interval t-staüstic P-value d-staästic 
Intercept ßu 18155.82 17717.14 18594.49 82.82 <0.001 1.93 
Baseline trend ßl 
Level change after PERP 02 
280.89 265.77 296.00 37.18 <0.001 
-181.16 -1590.33 1228.00 -0.26 0.798 
472.03 1.1 0.276 
841.68 -0.87 0.387 
-36.19 -2.22 0.030 
Trend change after PERP 03 167.30 -137.42 
Level change after coinsurance 34 -650.58 -2142.84 
Trend change after coinsurance ßs -367.88 -699.56 
Summer ßb 1745.52 1276.82 2214.22 7.45 <0.001 
* Estimated generalised least squares estimation 
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Figure 9-3: Observed and estimated costs per patient before and after interventions 
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9.5.3 Impact on unit prices 
The average 'costs per unit' had increased over time with the annual growth rate of 
8% until 2007. Cumulatively it rose by 38% from 181 KRW in 2003 to 249 KRW in the 
first half of 2008. The annual growth rate was highest in 2004 at about 10% and no 
less than 7% until 2007. By contrast, the upward trend appeared to cease during the 
first half of 2008, when it was 0.13%. 
Table 9-4 displays the results from the segmented regression analysis for the 'costs per 
unit'. The value of DW statistic was 1.79 giving little reason for concern about 
autocorrelation. There was an increasing underlying trend of 1.36 KRW per month 
(p<0.001) in the pre-intervention period. Overall, the results demonstrate no 
statistically significant changes either in levels or in slopes after the policy introductions. 
There was some weak evidence to suggest a downturn in the slope after the 
restructuring of cost-sharing schedule (p=0.085) (Figure 9-4). 
Table 9-4: Regression coefficients for costs per unit 
(unit; Korean won) 
Intercept ßo 
Baseline trend 01 
Level change after PERP 02 
Trend change after PERP 03 
Level change after coinsurance pq 
Trend change after coinsurance 05 
Summer (3b 
* Ordinary least squares estimation 
Coefficient 951/u Coididetw lntevvai 
166.4405 161.8334 111.0415 
1.3571 1.1979 1.5164 
-0,1129 -14.1029 13.8770 
0.8236 -2.1808 3.8281 
4.0350 -10.6147 18.6847 
-2.9230 -6.2590 0.4130 
23.8978 19.3253 28.4703 
DW 
t'tatistic P value ci statistic 
12.29 <0.001 1.79 
17.05 <0.001 
0.02 0.987 
0.55 0.585 
0.55 0.584 
-1.75 0.085 
10.46 <0.001 
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Figure 9-4: Observed and estimated costs per unit before and after interventions 
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Because the PERP had not clear effect on the model it is possible that the coinsurance 
assessment may be misspecified. To explore this issue further, the analysis was 
repeated without the PERP terms in the regression analysis (Table 9-5). The results 
from this analysis suggest a statistically significant decrease in the month to month 
cost per unit after the introduction of coinsurance (p=0.004). 
Table 9-5: Regression coefficients for costs per unit without the PERP term 
Dw 
(unit; Korean won) Coefficient 95% Confidence Interval t-statistic P-value d-stabstic 
Intercept ßo 165.6436 161.3939 169.8933 77.94 0.000 1.77 
Baseline trend ßl 1.3969 1.2682 1.5257 21.7 0.000 
Level change after coinsurance P4 8.2326 -2.3655 18.8307 1.55 0.126 
Trend change after coinsurance (i, -2.1391 -3.5886 -0.6897 -2.95 0.004 
Summer 06 24.2404 19.8787 28.6020 11.11 0.000 
x Ordinary least squares estimation 
9.5.4 Impact on drug utilisation 
Monthly 'units per patient' increased from 115 units in 2003 to 141 units in the first 
half of 2008 with the average annual growth rate of 5%. The cumulative growth rate 
was 22% in the corresponding period. Considerable variations were observed from 
month to month, with a peak during December and April and bottoming out in August 
and September. The number of patients dispensed had grown annually by 4-5% until 
2005, but the growth rate stayed at below of 2% since then. It rose by 2.6% in the 
first half of 2008. 
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The DW values of the two outcome variables after OLS estimation were 1.56 for 'units 
per patient' and 1.92 for'number of patients dispensed', respectively. Hence, EGLS 
estimation was performed for the former to correct autocorrelation. As shown in Table 
9-6, there was an increasing underlying trend in both dependent variables, about 0.54 
units per month and 78,207 patients per month respectively (p<0.001 for both). There 
was little evidence of changes in either levels or slopes after both policy interventions 
in these two utilisation variables. Figure 9-5 exhibits time series of both variables by 
month along with the corresponding fitted values. The removal of the PERP terms in 
the regression analysis made marginal differences to the results for the level change 
immediately after the introduction of coinsurance in 'units per patient, but this result 
was not statistically significant (p=0.077) (Table 9-7). 
Table 9-6: Regression coefficients for utilisation variables 
Units per patient 
Intariept (3, ) 
Baseline trend ßl 
Level change after PERP 132 
Trend change after PERP 03 
Level change after coinsurance (34 
DW 
Coefficient 95% Confidence lnteival P-statistic P value d-statistic 
111.5273 109.5237 113.5331 90.59 <0.001 1.94 
0.5414 
-1.1239 
-0.0458 
-4.0883 
0.4756 0.6142 
-7.6123 4.5627 
-1.2858 
-10.6374 
Trend change after coinsurance ßs 0.1491 -1.3622 
Siinuitty (,,, -5.5226 -7.9120 
Nwnimr of patients dispensed 
111h. l (el)t ji . 12300000 
21700000 
12.68 <0.001 
-0.34 0.737 
1.3289 -0.06 0.949 
2.1118 -1.19 0.237 
1.5410 0.18 0.857 
-3.9627 -5.22 -0.001 
23000000 68.92 <0.001 1.92 
Baseline trend ßl 78207 55792 100623 6.98 <0.001 
Level change after PERP 02 -825037 -2794337 1144263 -0.84 0.405 
Trend change after PERP 03 -11625 -434546 411296 -0.06 0.956 
Level change after coinsurance ßq 471425 -1590746 2533596 0.46 0.649 
Trend change after coinsurance ßs -46034 -515629 4? 3560 -0.2 0.845 
Summer 136 -1799130 -2442784 -1155476 -5.59 <0.001 
* Estimated generalised least squares estimation for uns per pa tient'; Ordinary least squares estimation for the 
'number of patients dispensed' 
Table 9-7: Regression coefficients fo r units per patient without the PERP term 
DW 
Coefficient 95% Conti ik lice Interval t statistic Y value d Statistic 
Intercept 13 ,) 111.8139 109.5139 114.1138 97.210 0.000 1.94 
Baseline trend ßl 0.5249 0.4550 0.5948 15.010 0.000 
Level change after coinsurance 04 -4.8141 -10.1657 
0.5375 -1.8 0.077 
Trend change after coinsurance 05 0.1066 -0.6298 0.8430 0.29 0.773 
Summer (36 -5.5073 -7.5568 -3.4579 -5.310 0.000 
* Estimated generalised least squares estimation 
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Figure 9-5: Observed and estimated units per patient (above) and number of patients 
dispensed (below) before and after interventions 
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9.5.5 Sensitivity analysis 
Results from the ARIMA models are shown in Table 9-8, highlighting a significant 
decrease in individual drug costs only after the copayment increase. Figure 9-6 shows 
that the forecasted series (black dashed) with 95% confidence intervals and the actual 
series (gray solid) after the new cost-sharing period. It is seen that there is an 
apparent difference between the two during the second intervention period. 
Table 9-8: Summary of ARIMA analysis of the significance of the policy effects 
Variables PERP') coinsurance ARIMA model 
) value for 
Q statistic' 
costs per patient N3) 4) (0,1,1)(0,1,0) il 0.3136 
costs per unit NN (0,1,1)(0,1,0)12 0.6283 
units per patient NN (0,1,1)(0,1,0)12 0.7603 
number of patients dispensed NN (0,1,1)(0,1,0)12 0.6850 
1) Pharmaceutical Expenditure Rationalisation Plan 
2) The Box-Ljung Q statistic should not be significant, indicating that all residuals are white noise. 
3) N refers to no statistically significant changes 
4)p=0.0066 
Figure 9-6: Observed (solid line) and estimated (dashed line) values of costs per 
patient after the cost-sharing restructure 
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9.6 Summary of findings 
The time series of interest included 66 time points (January 2003 to June 2008) for 
expenditure, unit prices and utilisation of pharmaceuticals. The policy changes came at 
the 49th (PERP) and 56th (coinsurance) time point. Each policy aimed to achieve cost- 
effective purchasing and reduce unnecessary drug utilisation respectively, striving to 
lower drug expenditure. Thus, the present study examined whether the new policies 
achieved the intended effects in drug costs, prices or utilisation of pharmaceuticals, 
employing ITS design. 
The ITS analyses indicate that the increasing trend of drug expenditure fell gradually 
after the cost-sharing restructure. Extrapolating the trend to a year after the 
introduction of the new cost-sharing scheme (at the 67th time point), it was predicted 
that per capita drug expenditure would drop by 12%, compared with the previous 
system. However, the level of savings would be nearly nil if compared with the absence 
of both interventions, implying some increase in drug costs after the PERP, although it 
was not detected by statistical test. No discernable effects were observed in overall 
drug utilisation after the policy introductions, suggesting that the copayment increase 
might not prevent patients from getting their medication. 
Closer Investigations with disaggregated datasets are continued in the following 
chapter to explore the policy impact on the utilisation of essential drugs and generics, 
which provides opportunity for further exploration of the policy impact discovered in 
the present chapter. Implications of the findings from the ITS analyses will be 
discussed in Chapter 11. 
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CHAPTER 10: ASSESSING THE EFFECTS OF LOCAL 
PHARMACEUTICAL POLICIES ON ESSENTIAL DRUGS 
UTILISATION AND THE KOREAN GENERICS MARKET 
10.1 Introduction 
The objective of the present chapter is to present results from the second empirical 
study. The first empirical analyses found little impact in most of the outcome variables 
after the policy introductions, except that the new cost-sharing structure might lower 
pharmaceutical expenditure. However, there are many issues remaining to be 
addressed to make sure of the impact of the study policies. 
It was unclear how the copayment increase lowered pharmaceutical costs without any 
change to the overall drug utilisation in South Korea. With the copayment increase, 
there are three possible scenarios underlying patient behaviour. First, a rise in out-of- 
pocket expense may prevent patients from visiting medical Institutions to obtain 
prescriptions for medication. Second, patients may give up having their prescriptions 
filled. Third, patients may ask their doctors to prescribe other medical services or, 
fourth, to recommend a cheaper version of the drugs to avoid extra charges. Of these, 
the fourth assumption could reduce drug costs with little change In overall drug 
utilisation, and would result In the Increase of generic use as well as the decline In 
brand-named drug use. In this regard, further investigation was essential for a better 
understanding of the findings In the preceding chapter. 
This study explored the policy impact on two therapeutic subclasses for chronic 
conditions. It seems important to examine policy impact on therapeutic subclasses in at 
least three aspects. First, experience from other settings invariably highlights a 
considerable divergence across drug groups (Chapter 4). Moreover, the systematic 
reviews suggest that the consequences of demand-side policies often occur by limiting 
essential drug utilisation (Chapter 4). Hence, it seems crucial to Investigate the policy 
impact on patient access to essential medication. Second, Korean patients may 
respond differently from those in more affluent countries. Korean patients pay greater 
out-of-pocket expenses in relative terms and those with chronic conditions pay even 
more (Chapter 2). Thus, the concern is that Korean patients may show a greater 
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decrease in their use of essential medication even with a small increase in copayment. 
Third, the subset of data, usually less heterogeneous, would provide more opportunity 
to understand the results of the preceding time series analyses. In this study, the two 
groups of medication were divided further into generic and brand-named drugs, 
increasing the possibility of explaining a marginal decline in the price variable by 
testing if the copayment increase encourages use of generics. 
10.2 Access to essential medications 
Reducing less-essential drug consumption Is the primary goal of policy programmes 
limiting patient drug utilisation, such as copayments for prescription drugs (Chapter 1). 
Empirical evidence, however, shows that demand-side policies may unexpectedly affect 
the utilisation of essential drugs as well as discretionary drugs In conditions such as an 
excessive increase in copayments. They may also potentially reduce social equity by 
having a disproportionate effect on disadvantaged groups, for instance the elderly who 
are highly vulnerable to financial constraints are more likely to need medication for 
chronic illnesses (Chapter 4). Restricting essential drugs can have an adverse influence 
on overall social health by allowing the development of more serious conditions. In 
addition, concerns arise that it may result in an Increase in the net cost of illness 
prevalent in society from an economic standpoint. 
This study focused on antihypertensives and antihyperlipidemics as It has been well 
established by several long-term studies that blood pressure and blood lipid disorders 
are clearly related to subsequent cardiovascular morbidity and mortality (Anderson et 
a/., 1987; Franco et al., 2005; Kannel, 1996; McCarron et al., 2000; Shaper et al., 
1985; Stamler eta/., 1993; Verschuren et al,, 1995). Thus, early detection and control 
of hypertension and dyslipidemla can Improve health status and Increase longevity by 
reducing the risk of cardiovascular diseases (Ingeisson eta/., 2008; National 
Cholesterol Education Program Expert Panel on Detection, 2002). Drug therapy plays 
an Important role In controlling these risks and has been developed relatively well 
(Chobanlan eta/., 2003; Cooper eta/., 2008; National Cholesterol Education Program 
Expert Panel on Detection, 2002; Nestel eta/., 2008). In this regard, policy 
Interventions placing obstacles to the utilisation of these drugs may do more harm than 
good for overall health. 
220 
There were two additional reasons for limiting to two therapeutic classes. Firstly, 
medications for hypertension are currently placed in first position in terms of value, 
which was about 9% of the Korean prescription market in 2005 (Ministry of Health & 
Welfare, 2006c). Those for lipid disorder occupied the first position in terms of growth 
rate of value, which was over 380% between 2001 and 2005 (Ministry of Health & 
Welfare, 2006c). Secondly, it was necessary to narrow the range of study 
pharmaceuticals to gain insight into the dynamics of the generic market. It is extremely 
difficult to categorise all products into brand-named and generic drugs because as yet 
there is no national indicator classifying brand-named and generic medications in Korea. 
10.3 Generics utilisation 
For economic reasons, generic drugs nowadays get more attention in the 
pharmaceutical arena. They are regarded as a promising option to expensive brand- 
named drugs since pharmaceutical costs have continued to rise in some decades 
(Chapter 4 through 6). Correspondingly, policies encouraging the use of generic 
medicines have increasingly been highlighted across countries (General Accounting 
Office, 1991; King and Kanavos, 2002; Mrazek and Frank, 2004; Simoens and De 
Coster, 2006; Vogler eta/., 2008). 
A generic drug is identical or bio-equivalent to an original drug, which Is produced and 
distributed after the expiry of the originator's exclusive right. As generic producers do 
not incur the R&D costs, generic products are typically sold at lower prices than their 
brand-named counterparts. As a result, the generics share In value is generally lower 
than the generics share in volume (European Generic medicines Association, 2007). For 
this reason, it has been suggested that money be saved by substituting generics for 
brand-named drugs (Fischer and Avorn, 2003,2004b; Karim et a/., 1996; Simoens and 
De Coster, 2006). 
In South Korea, generic drugs had first been considered for industrial rather than 
budgetary reasons. Recently, a sharp rise in drug expenditure pressed Korean policy. 
makers to pay more attention to policies fostering the use of generics (Chapter 2). On 
this issue, recent evidence from Taiwan suggests that greater use of generics may not 
necessarily be associated with reducing drug costs if the price of generics is not 
significantly low (Lee eta/., 2008). Not surprisingly, the savings can be greater in 
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countries which show the market share of generics to be higher in volume and lower in 
value (Mrazek and Mossialos, 2000; Simoens and De Coster, 2006). 
Thus, there is urgent need to determine the size of the Korean generic market before 
developing generic policies any further. At the moment, however, adequate information 
about the generic market is lacking. One previous local study reported that there was 
little difference in the market share of generics in volume (42.8%) from that in value 
(39%) in South Korea (Huh et al., 2006). The authorities estimated about 40% of 
value ascribed to generics in the Korean market between 2004 and 2006, but they did 
not provide information on volume (HIRA internal report cited by You, 2007). None of 
them dealt comprehensively with the Korean generic market, They used an unclear 
definition of generics as well as analysing only a very short period of data - only one 
or two months per year. 
10.4 Objectives of study 
This study firstly seeks to examine whether the two interventions prevent patients 
from accessing their essential medication. Secondly, it aims to investigate the impact of 
the policy interventions on generic use in the study medication, with the intention of 
tackling not only the relationship between the study interventions and the use of less 
costly drugs, but also to promote a better understanding of the Korean pharmaceutical 
market. 
10.5 Methods 
10.5.1 Study design and data source 
The design of the study is an observational, retrospective, interrupted time series 
analysis of 66 monthly observations from January 2003 to June 2008. Aggregated 
monthly data concerning drug consumption of two therapeutic classes were provided 
by the Health Insurance Review & Assessment Service (HIRA). For reconstructing the 
subsets of data, the list of the Korean Insurance Code for each product under 
therapeutic subclasses and generic and brand categorisation were provided by the 
researcher. (Chapter 8 depicted general aspects of the data, reasons of choice of two 
subclasses and the process of classification of generics. ) 
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10.5.2 Outcome measures 
After classifying brand-named and generic drugs, three sets of data were finally 
established in each therapeutic class: overall, generic and brand-named drugs. To 
examine the impact of two policy Interventions on individual drug use and patient 
accessibility, two outcome variables were employed: units per patient; and number of 
patients dispensed. Therefore, six time series were finally constructed for each 
therapeutic class. Details of definitions and calculations for outcome variables are 
illustrated in Chapter 8. 
10.5.3 Statistical Analysis 
10.5.3.1 Primary analysis 
To measure the size and statistical significance of time series changes associated with 
the Implementation of study Interventions, segmented regression models were used 
(Chapter 8). Time series for each dependent variable was established and examined 
visually for any extreme variations potentially confounding policy outcomes. As little 
seasonal variation was observed, the simple segmented regression model (Equation 6) 
was applied to'units per patient' time series. The anti hypertensive or 
antihyperlipidemics segmented regression model (Equation 8 or 9) taking market 
changes into account was applied to the time series of 'number of patients dispensed' 
In two therapeutic subclasses. Details of the specification of models, definitions and 
coding were explained In Chapter 8 (see 8.5 for modelling framework). As a reminder, 
models were: 
Yt= ßo + pixtimek + ß2xPerp + p3xPerpt + p4xCo + PSxCOt + Et (Eq. 6) 
Yt= ßo + ßixtimet + ß2xPerp + ß3xPerpr + ß4xCa + ß5XCot + ß6xNv + ß7xNvt + Et (Eq. 8) 
Yc= ßo + plxtimec + pZxPerp + ß3xPerpt + ß4xCo + PSxCot + ß6xCr + ß7xCrt + &t (Eq. 9) 
The Durbin-Watson dstatistic (DW) was used as a test for serial correlation of the 
error terms. Table 10-1 displays critical values for these models at the 5% significance 
level. If DW values clearly Indicate the presence of autocorrelation after applying 
ordinary least squares (OLS), the models for such variables were corrected for first- 
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degree autocorrelated errors using the Prais-Winsten estimator. 
Table 10-1: Durbin-Watson critical values for the regression models 
d, d,, 2 4-da 4-d, 
decision uncertain no autocorrelation uncertain 
critical value 
general model 1.438 1.767 2.233 2.562 
therapeutic subclass model 1.37 1.843 2.157 2.63 
(Source: Savin and White, 1977) 
A p-value of less than or equal to 0.05 was considered statistically significant. To 
explore the goodness of fit of the segmented regression models, the proportion of 
variability in the data set that was accounted for in the model was also calculated 
(adjusted R2). The statistical analysis was carried out using STATA version 10 
(StataCorp LP, 2007). 
10.5.3.2 Sensitivity analysis 
For crosschecking the hypothesis test of the segmented regression models, 
autoregressive integrated moving average (ARIMA) models were constructed and 
analysed. After iterative processes (see Annex 22 for the example procedure), a 
tentative model for each data structure was specified from the pre-intervention data 
for the noise compartment in all relevant variables. Using the tentative noise model, 
projections for the post-intervention period were formed to provide estimates in the 
absence of interventions. After the visual examination of actual and fitted values, there 
was little reason to assume gradual, permanent or abrupt, temporal intervention 
effects. Thus, the simplest intervention model (abrupt, permanent) was added to 
represent the effect of the interventions. The Box-Ljung Q statistic was used for 
residual analysis to gauge serial autocorrelation of error terms. The ARIMA process and 
statistical analysis were carried out using R version 2.11.0 (The R foundation for 
statistical computing, 2010). The best-fit models were compared with closely 
competing models to determine the impact of alternative models on the intervention 
effect, and the estimates of the intervention effect were robust. Although the 
coefficients varied somewhat, the direction and significance remained robust across 
closely competing models. 
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10.6 Results 
10.6.1 Overall trends 
Table 10-2 presents overall changes in expenditure, number of patients dispensed and 
utilisation of antihypertensives and antihyperlipidemics during the study period, which 
are displayed in Figure 10-1 and 10-2. 
Drug costs doubled from 62 to 120 billion KRW in blood pressure lowering drugs. 
Those in lipid lowering drugs were even greater, four times higher from 10 to 40 billion 
KRW. Spending on antihyperlipidemics increased two times faster than that of 
anti hypertensives during the corresponding years - 31% and 14% respectively. Annual 
growth rate has declined in anti hypertensives, while it remained greater than 30% in 
antihyperlipidemics until 2007. 
Table 10-2: Overall changes in expenditure, number of patients and utilisation of 
two study therapeutic subclasses during the study period 
Total costs over pharmaceuticals Number of patients dispensed Number of units dispensed 
(in billion KRW') (in million) (in million) 
Annual Annual 
Mean (95% Cl ")) changes Mea n (95% Cl) changes 
Year (%) (%) 
Antihypertens vec 
2003 62.0 (58.9 65.0) - 3.05 (2.95 3.14) - 
2004 75.4 (72.6 78.2) 21.61 3.52 (3.42 3.62) 15.49 
2005 88.6 (85.3 92.0) 17.51 4.09 (3.97 4.20) 16.11 
2006 102.0 (99.4 104.0) 15.12 4.61 (4.53 4.68) 12.81 
2007 113.0 (110.0 117.0) 10.78 4.99 (4.90 5.09) 8.36 
2nnR3) 1)0 n (116_n 124.0) 6.19 5.24 (5.13 5.34) 4.86 
A ntihyperNpkian ics 
2003 10.4 (9.14 11.1) 0.343 (0.326 0.360) 
2004 14.0 (13.1 14.9) 34.62 0.432 (0.412 0.453) 25.98 
2005 19.5 (18.2 20.8) 39,29 0.566 (0.537 0.594) 30.88 
2006 27.2 (25.6 28.8) 39.49 0.740 (0.707 0.773) 30.80 
2007 35.7 (34.0 37.4) 31.25 0.922 (0.891 0.953) 24.64 
20083) 40.1 (38.5 41.7) 12.32 1.008 (0.974 1.041) 9.21 
1) KRW refers to Korean won (2000 KRW=11 in June 2008). 
2) CI refers to confidence interval. 
3) From January to lone 
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Annual 
Mean (95% Cl) changes 
(%) 
154 (148 160) - 
179 (174 185) 16.23 
205 (198 212) 14.53 
231 (226 236) 12.68 
250 (243 257) 8.23 
263 (255 1/2) 520 
12.9 (12.2 13.6) 
16.3 (15.5 17.2) 26.36 
21.4 (20.2 22.7) 31.29 
28.6 (27.1 30.2) 33.64 
36.9 (35.2 38.6) 29.02 
41.6 (40.0 43.2) 12.74 
Figure 10-1: Overall trends in antihypertensives 
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Figure 10-2: Overall trends in antihyperlipidemics 
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The number of patients dispensed antihypertensives on a monthly basis had increased 
over time until 2006 with an average annual growth rate of 13%. Cumulatively, it rose 
by 72% from about 3 million in 2003 to 5.2 million in the first half of 2008. The figure 
for patients dispensed antihyperlipidemics had increased to an annual growth rate of 
28% between 2003 and 2007. Cumulatively, it tripled from about 0.34 to 1 million 
during the study period. Very similar rising trends were observed in volume changes. 
Dispensed drug units had increased by 71% in anti hypertensives and 222% in 
antihyperlipidemics during this period, the annual growth rate being 11 and 27%, 
respectively. 
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10.6.2 Market share of generics 
Table 10-3 and Figure 10-3 display overall changes in expenditure and utilisation of the 
two therapeutic subclasses under study by brand-named and generic drugs during the 
study period. 
Table 10-3: Overall changes in expenditure and utilisation of two study therapeutic 
classes by brand-named and generic groups during the study period 
Anti hype rtensives Antihyper lipidemics 
costs (in billion KRW) units (in million) costs (in billion KRW) units (in million) 
Year brand drugs generics brand drugs generics brand drugs generics brand drugs generics 
2003 52.30 9.64 112.0 41.9 7.14 3.26 7.4 5.5 
2004 62.20 13.20 130.0 49.4 8.34 5.62 8.3 8.1 
2005 67.90 20.70 137.0 67.8 11.50 8.04 10.7 10.7 
2006 75.10 26.90 147.0 83.7 16.60 10.60 15.1 13.5 
2007 81.30 31.80 154.0 95.9 22.70 12.90 209 16.1 
20080 86.00 33.80 160.0 1.03.0 26.20 13.80 24.1 17.5 
Annual growth rate (%) 
2003 - - - - - - 
2004 19 37 16 18 17 72 11 47 
2005 9 57 5 37 38 43 29 33 
2006 11 30 7 23 44 32 41 26 
2007 8 18 5 15 37 22 38 19 
2008' 6 6 4 7 15 7 15 9 
1) From January to June 
Figure 10-3: Number of units dispensed in two study drug classes by overall (solid), 
brand-named drugs (dash) and generics (dot) 
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The generic use of antihypertensives rose greatly in 2005 by 37% compared to the 
preceding year, and then declined to 7% In the first half of 2008. The utilisation of 
brand-named drugs has changed much less over time and the growth rate has been 
between 4 and 7% since 2005. 
Generic use of antihyperlipidemics rose by 47% in 2004, declining sharply to 9% in the 
first half of 2008, while that of brand-named drugs remained high between 30 and 
40% from 2005 to 2007. Brand-named drug utilisation declined to 15% in the first half 
of 2008. The growth rate of spending on generics was greater than the utilisation 
growths in both study medications in each year except 2008, as shown in Table 10-3. 
Table 10-4 describes the changes in market share of generics In two study medications. 
In the antihypertensives market, the volume share of generics rose from 27 to 39% 
during the study period. In the antihyperiipidemics market, the differences between 
brand-named drugs and generics were narrowing until 2005 (half and half) and then 
returned to exactly the same level as In 2003 - 42% generics and 58% brand-named 
drugs In the first half of 2008. In terms of value, expenditure on generics In 
antihypertensives continues to increase from 16 to 28%, while antihyperlipidemics 
increased until the middle of the study period and then fell to a similar level as In 2003, 
which was similar to the volume changes. 
Table 10-4 Market share of e-"rlcs 
Antihypertensives (°k_) Antihyperlpidemics (%) 
Year vawe volume vaAue vowme 
2003 16 _,.. ý.. ý. _ 27__. _. _... ý.. ý31ý__ 42 ý... ý. ýý. 
2004 17 27 40 49 
2005 23 33 41 50 
2006 26 36 39 47 
2007 28 38 36 44 
20081) 28 39 35 42 
1) From January to June 
10.6.3 Impact on essential drugs utilisation 
Anti hypertensives: For the segmented regression, after applying OLS estimation, the 
values of the ßW statistics were 2.42 for 'units per patient' and 2.47 for 'number of 
patients dispensed' respectively, indicating some concern about the presence of 
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autocorrelation. Hence, the regression analyses were repeated using the Prais-Winsten 
estimator, results from these models are displayed in Table 10-5. 
Monthly utilisation has changed little over time, maintained at around 50 units for an 
individual patient during the study period. This was in accord with the findings from 
the segmented regression analysis, indicating little change in the baseline trend of 
individual utilisation after the policy interventions (Table 10-5). 
Table 10-5: Regression coefficients for overall Anti hypertensives 
DW 
Coefficient') 95% Confid ent e Interval t statistic P-value /-statistic 
Units per patient 
Intercept ji;, 50.6998 50.3138 51.0857 262.78 <0.001 2.01 
Baseline trend (3, -0.0100 -0.0238 0.0037 -1.46 0.149 
Level change after PERP 02 -0.5900 -1.8286 0.6485 -0.95 0.344 
Trend change after PERP ß. 3 0.0877 -0.1764 0.3518 0.66 0.509 
Level change after coinsurance ß4 0.1366 -1.1873 1.4606 0.21 0.837 
Treiid rhrincle. ifter coinsur once 1,, 0.0883 -0.3775 0.2010 0.61 0.544 
Number of patients dispensed 
Ililercrpt Po 2/97167 2715560 2878775 68.61 <0.001 1,94 
Baseline trend ßt 38529 31697 45362 11.29 <0.001 
Level change after PERP ßZ -108603 -278732 61527 --1.28 0.206 
Trend change after PERP ßs 7000 -28099 42098 0.40 0.691 
Level change after coinsurance 04 -149442 -325073 26189 -1.70 0.094 
Trend change after coinsurance ßs -17379 -55600 20843 -0.91 0.367 
Level change after Norvasc'0 'me-too' drugs 43740 -58867 146348 
0.85 0.397 
Trend change after Norvasc'>'rne-too' drugs 5719 -2170 13608 1.45 0.152 
1) Estnruted generalrced least squares estirnation 
2) Norvasc; aniodlpine besylate 
Figure 10-4: Observed and estimated units per patient (left) and number of patients 
dispensed (right) anti hypertensives before and after interventions 
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The number of patients who were dispensed anti hypertensives had been steadily 
increasing over time (p<0.001), but was hardly affected by policy interventions or 
market surroundings. A temporary drop was seen after the copayment increase, but 
this was not statistically significant (p=0.094). Figure 10-4 exhibits time series for both 
variables by month along with the corresponding fitted values from generalised least 
squares estimation. 
Antihyperlipidemics: For the segmented regression, after applying OLS estimation, 
the values of the DW statistics were 2.33 for'units per patient' and 2.74 for 'number of 
patients dispensed' respectively, indicating some concern about the presence of 
autocorrelation. Hence, the regression analyses were repeated using the Prais-Winsten 
estimator, results from these models are displayed in Table 10-6. 
Monthly'units per patient' were slowly rising at baseline, differing from 
antihypertensives (see Table10-6; ß1=0.03, p<0.001). The trend has increased 
considerably since 2006. The growth rate of monthly units per patient rose about 2% 
In 2006 compared to a year before and has remained higher than 3% after 2007. The 
statistical analysis Indicated that the trend of 'units per patient' Increased about six 
times from 0.03 to 0.18 by 0.15 (Table 10-6), showing a sizable upsurge in the time 
series line after the first Intervention (Figure 10-5). This, however, was not statistically 
significant (p=0.110) and few changes were seen either in trends or In levels after the 
policy interventions. 
The number of patients who were dispensed antihyperlipidemics steadily Increased by 
7,220 persons per month before the launch of Crestor® (rosuvastatin) and was almost 
doubled to 13,700 persons per month after the launch of the new statin (all p<0.001). 
The growth rate rose significantly to 24,705 persons per month after the PERP and fell 
back to 10,573 persons per month after the cost-sharing restructure (all p<0.001). In 
addition, the cost-sharing restructure might be associated with a drop of about 56,000 
persons in the number of patients dispensed antihyperlipidemics (p<0.001). Figure 10- 
5 exhibits time series for both variables by month along with the corresponding fitted 
values from generalised least squares estimation. 
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Table 10-6: Regression coefficients for overall Antihyperlipidemics 
DW 
COx, tti( wnt" 1)"'Vo nnüdr°n<<ý lulrrv, il I titritI II( P v, ilut> / 
Units per patient 
111torwlit I,,,,, 11.2-161 it, ')/ 11 
Baseline trend ßl 0.0302 0.0205 
Level change after PERP ßz 0.0345 -0.8386 
Trend change after PERP 03 0.1511 -0.0350 
Level change after coinsurance 0.6788 -0.2536 
I wrni (Ir. mot, ýIIt of maI5ur<In( r u 11.16 -0.3187 
Number of patients dispensed 
ii 1t i (_ept ß ))'W006 281229 
Baseline trend ß1 7220 5943 
Level change after PERP 02 -11380 -38533 
Trend change after PERP 03 11005 5374 
Level change after coinsurance ßq -56012 -84326 
Trend change after coinsurance ß5 -14132 -20237 
Level change after Crestor21 -23125 -39647 
Trend change after Crestor) 6480 5090 
1) Estimated generalised least squares estirra tion 
2) Crestor; rosuvastatin 
U. " 1'II 1/:. 91 - 0.001 I I1 
0.0399 6.22 <0.001 
0.9076 0.08 0.937 
0.3372 1.62 0.110 
1.6111 1.46 0.151 
0.0895 -1.12 0.266 
308784 42.86 <0.001 2.02 
8497 11.32 <0.001 
15773 -0.84 0.405 
16637 3.91 <0.001 
-27699 -3.96 <0.001 
-8026 -4.63 <0.001 
-6604 -2.80 0.007 
7870 9.33 <0.001 
Figure 10-5: Observed and estimated units per patient (left) and number of patients 
dispensed (right) antihyperlipidemics before and after interventions 
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10.6.4 Impact on generic drugs utilisation 
Anti hypertensives: For the segmented regression of generic anti hypertensives, after 
applying OLS estimation, the values of the DW statistics were 2.20 for `units per 
patient' and 2.18 for `number of patients dispensed, respectively, giving little reason for 
concern over autocorrelation. Whereas, for the segmented regression of brand-named 
anti hypertensives, after applying OLS estimation, the values of the DW statistics were 
2.33 for 'units per patient' and 2.61 for'number of patients dispensed' respectively, 
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Indicating some concern about the presence of autocorrelation. Hence, the segmented 
regression analyses for brand-named antihyperlipidemics were repeated using the 
Prais-Winsten estimator. Statistical results are displayed in Table 10-7. 
Monthly `units per patient' were slowly rising in both generic and brand-named drugs 
during the study period, while the growth rates were negligible. Statistical analysis 
showed that there was little evidence of change in either levels or slopes ascribed to 
the policy interventions in the pattern of individual utilisation (see Table 10-7 and 
Figure 10-6). 
The number of patients who were dispensed generic anti hypertensives rose greatly by 
35% In 2005 compared to the preceding year, and then the rate of annual growth has 
declined to 13% In 2007 and then 6% In the first half of 2008. The growth rate of 
those dispensed brand-named drugs has fallen since 2005; thereafter, the rate of 
change has been between 4% and 8%. 
Segmented regression analysis provides strong evidence for such trends (see Table 10- 
7). Upsurge In trends In the number of patients dispensed were observed both In 
generic and brand-named drugs at baseline, which were statistically significant (all 
p<0.001). The impact of the launch of 'me-too' drugs of Norvasc® (amlodipine 
besylate) resulted in a sudden jump of patients using generics and a downturn In those 
with brand-named drugs in 2005. The segmented regression analyses showed that the 
number of patients who were dispensed generics increased immediately by 0.15 million 
and the monthly growth rate almost tripled from 10,776 to 28,133 persons per month 
(all p<0.001). The opposite was the case In brand-named drug utilisation. The number 
of patients dispensed brand-named drugs and the monthly growth rate decreased 
sharply (all p<0.001), while the amount of change was mild In comparison with those 
seen in generic drugs. The policy interventions did not alter existing patterns for 
generic, or brand-named antihypertensives (Table 10-7 and Figure 10-6). There was a 
considerable drop In the level after the new cost-sharing scheme In brand-named 
anti hypertensives, however this was not statistically significant at the conventional 5% 
level (p=0.064). 
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Figure 10-6: Observed and estimated units per patient (, tlýýtvt j and number of 
patients dispensed (below) generic and brand-named anti hypertensives 
before and after interventions 
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Anti hyperlipidemics: For the segmented regression of generic antihyperlipidemics, 
after applying OLS estimation, the values of the DW statistics were 2.33 for'units per 
patient' and 2.25 for 'number of patients dispensed, respectively, indicating some 
concern as to the presence of autocorrelation. For the segmented regression of brand- 
named antihyperlipidemics, after applying OLS estimation, the value of the DW statistic 
was 2.50 for `units per patient, indicating the presence of autocorrelation, while that 
for 'number of patients dispensed' was 2.01, suggesting little reason for concern about 
autocorrelation. The segmented regression analyses were repeated using the Prais- 
Winsten estimator for the first three dependent variables. Statistical results are 
displayed in Table 10-8. 
Monthly generic'units per patient' changed little over time, remaining between 32 and 
34 units for an Individual patient during the study period; those of brand-named drugs 
slowly rose over time by 17% from 42 units In 2003 to 49 units in the first half of 2008. 
This was supported by the findings from the segmented regression analysis (see Table 
10-8 and Figure 10-7), indicating no statistically significant changes in generics 
(p=0.232) but an increasing baseline trend of 0.09 units per month In brand-named 
drugs (p<0.001). Neither policy intervention might affect the Individual utilisation in 
generic drugs. In brand-named drugs, there was a weak evidence of increase in the 
slope after the PERP (p=0.081) and in the level after the new cost-sharing 
arrangement (p=0.085). 
The rate of annual growth in the `number of patients dispensed' generic 
antihyperlipidemics was large, 46% In 2004, thereafter declining substantially to 18% 
In 2007 and 8% In the first half of 2008. The growth rate of dispensed brand-named 
drugs suddenly climbed by 27% In 2005 which was three times greater In comparison 
with the previous year of about 8%; then by more than 30% in 2006 and 2007, 
dropping to 10% In the first half of 2008. 
Table 10-8 displays results from the segmented regression analyses. It indicates an 
upsurge in the number of patients dispensed generic antihyperlipidemics by 6,819 
persons per month at baseline (p<0.001). The launch of Crestor® (rosuvastatin) 
resulted In an upward trend in brand-named drugs dispensed by 6,517 persons per 
month (p<0.001), but showed little influence on dispensing of generic 
antihyperlipidemics. 
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Segmented regression analyses suggested that the PERP might raise the growth rate of 
the number of patients dispensed in both generic and brand-named antihyperlipidemics 
(ß3=4,079, p=0.022; ß3=6,202, p=0.016, respectively). The'number of patients 
dispensed' generic antihyperlipidemics indicated that the cost-sharing reschedule might 
be related to an abrupt drop in the level (about 38,000 persons, p<0.001) as well as a 
5,119 persons per month decline in the slope (p=0.009). Those dispensed brand- 
named antihyperlipidemics might not be affected immediately by the new cost-sharing 
scheme, but the influence could be greater over time, showing a larger drop in the 
growth rate by 8,626 persons per month (p=0.003). Figure 10-7 exhibits time series of 
these variables by month alongside the corresponding fitted values. 
10.6.5 Sensitivity analysis 
Results from the application of the ARIMA models are reported in Table 10-9. 
Table 10-9: Summary of ARIMA analysis of the significance of the policy effects 
Variables PERP'") coinsurance's ARDNA model 
p value for 
Q statistic`) 
andhypertensives 
overall units per patient 
number of patients dispensed 
generics units per patient 
number of patients dispensed 
brand 
units per patient 
number of patients dispensed 
antihyperllpldemics 
ovehdii units per patient 
number of patients dispensed 
generics 
units per patient 
number of patients dispensed 
N N (0,1,1)(0,1,0)1 0.0702 
N N (0,1,1)(0,1,0)12 0.1908 
N N (0,1,1)(0,1,0)12 0.0632 
N N (1,1,0)(0,1,0)12 0.6188 
N N (1,1,1)(0,1,0)11 0.4418 
N N (1,1,0)(0,1,0)x? 0.1186 
N N (1,1,1)(0,1,0)0 0.3568 
+(0.033) (0.002) 0.2558 
N + (0.023) (0,0,0)(0,1,0)iz 0.9288 
N --(0.018) (0,1,1)(0,1,0)1 0.1718 
brand 
units per patient N+ (0.057) (1,1,1)(0,1,0)1) 0.6044 
number of patients dispensed N (0.020) (1,1,1)(0,1,0)11 0.2845 
1) Phamiaceutical Expenditure Rationalisation Plan 
2) The Box-t. jung Q statistic should not be significant, indicatxig that all residuals are white noise. 
3) P values are in parantheses; N refers to no statistically signitkant changes. 
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Figure 10-8: Actual and estimated values of outcome variables after the policy 
interventions 
a) overall antihyperlipidernics b) overall antihyperlipidemics 
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Figure 10-8 shows the outcome variables along with the forecasted series with 95% 
confidence intervals. Circles with a solid line represent the observed outcome during a 
given time period. In the post-intervention period, circles with grey lines represent the 
observed outcomes and black solid lines represent the expected association had the 
policy change not occurred. Dashed lines represent 95% confidence intervals of the 
forecasted series. 
ARIMA models suggested little impact on anti hypertensives and a significant growth in 
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the 'number of patients dispensed' overall antihyperlipidemics after the PERP (Figure 
10-8a). Consistent results were also seen in the 'number of patients dispensed' overall, 
generic and brand-named antihyperlipidemics, which might decline after the new cost- 
sharing programme (Figure 10-8b, d, and f respectively). The increasing pattern of the 
individual utilisation of brand-named antihyperlipidemics after the cost-sharing 
restructure was identified through the ARIMA process (Figure 10-8e). 
Some divergences were observed in results relating to the 'number of patients 
dispensed' generic or brand-named antihyperlipidemics after the PERP, and generic 
'units per patient' after the new cost-sharing structure. The increased trends in the 
former two variables after the PERP were not demonstrated by the ARIMA models. 
Although ARIMA analysis suggests some increase in generic `units per patient' after the 
new cost-sharing, it may be difficult to be conclusive with a short-term analysis given a 
large fluctuation by month (see Figure 10-8c). 
10.7 Summary of findings 
The time series of interest included 66 time points between January 2003 and June 
2008 in the use of two medications for chronic conditions - antihypertensives and 
antihyperlipidemics. The policy changes came at the 49th (the PERP) and 56th 
(coinsurance) time point. Each policy aimed to produce cost-effective purchasing and 
reduce unnecessary drug utilisation respectively, without compromising patient 
accessibility to essential drugs. The present study examined whether: firstly, the new 
policies restrict patients from obtaining their essential medications; secondly, whether 
they encourage patients to consume less costly drugs. 
The ITS analyses suggest that the policy Interventions exercised different effects In the 
two essential drug groups. They seemed rarely to affect patient accessibility to 
antihypertensives, but exhibited apparent changes In access to antihyperlipidemics. 
The statistical investigation showed that the PERP might encourage patients to get 
antihyperlipidemics. The number of patients who were dispensed lipid-lowering drugs 
rose about 7% during the 7-month period (between the 49th and 55th time point), 
compared to the absence of the PERP. The trend was reversed after the copayment 
increase. Extrapolating the statistical results to a year after the Introduction of the 
copayment increase (at the 67th time point), It was predicted that patients filling their 
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prescriptions would decline by approximately 18%, compared to before the new cost- 
sharing scheme. 
The intervention influenced patient access to generic and brand-named 
antihyperlipidemics in a different fashion. Patients dispensed generics were likely 
affected immediately, while those dispensed brand-named drugs were Influenced 
gradually. The magnitude of influence was greater in brand-named lipid-towering drugs 
during a given time period, which would result In a greater reduction In brand-named 
drugs use in a one-year period. A year after the new cost-sharing schedule (at the 67th 
time point), a 14% drop In the number of patients prescribed generic 
antihyperlipidemics was expected, compared to the absence of the policy, Including an 
8% drop In the first month of Implementation. In the corresponding period, a 19% 
decline was anticipated In those prescribed brand-named antihyperlipidemics compared 
to the absence of the policy. Implications from the findings from the ITS analyses will 
be discussed in the following chapter. 
240 
CHAPTER 11: LESSONS FROM PHARMACEUTICAL POLICY 
EVALUATION IN SOUTH KOREA 
11.1 Introduction 
Chapter 8 through 10 Investigated the impact of two Korean pharmaceutical policies. 
The present chapter discusses the limitations of the analysis presented in Chapter 8 to 
Chapter 10. The discussion then moves on to focus on the implications of the findings 
from the analysis in terms of the policy impact and consequences. The chapter 
concludes with a discussion of the implications for the Korean generic market and 
future areas of research. 
11.2 Study limitations 
11.2.1 Issues with available data 
Insurance claims data taken by the Health Insurance Review & Assessment Service 
(HIRA), the national medical services audit body, are the most credible and 
comprehensive data currently in South Korea. They are mostly collected through a 
computerised network between the HIRA and healthcare institutions. The lag between 
time that services are provided and claimed is no longer than 2 months according to 
the internal information from the HIRA. Because the data was extracted with a time 
gap of 3 months, the amount of claims potentially omitted were expected to be low. 
As the two pharmaceutical policies tested in this study were introduced recently, data 
were only available for a short post-intervention period. With prescription profiles 
spanning 18 months from the first policy change (Pharmaceutical Expenditure 
Rationalisation Plan, PERP) and 11 months from the second policy change 
(coinsurance), it was Impossible to determine the long-term impact of the policies. 
Furthermore, because of the short follow up period there were few post-intervention 
data points and this reduces the statistical power of the tests of change in level and 
trend. One example of this could be for the cost per unit, despite being able to observe 
a considerable change in the trend in the cost per unit after coinsurance the 
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segmented regression results gave a large standard error and the results failed to 
reach statistical significance at the 5% level (see Figure 9-4). 
Owing to the short follow-up, the models employed in this study assumed an 
immediate impact of the policies. However, in the real world, it may be natural to 
suppose that there would be a time lag between the introduction of the policies and 
the impact of these policies. It would have been desirable, if there were sufficient data 
points for this, to include a time lag in the analysis to allow assessment for a delay in 
the impact of these policies. 
The Interventions were implemented consecutively over a short period hence the data 
were not sufficient to distinguish the impact of one policy from another. To disentangle 
the effects of the PERP and coinsurance, it would require development of outcome 
variables which would respond to the PERP but not to the coinsurance or vice versa. 
One example of this would be the real market prices for pharmaceutical products 
rather than the cost per unit. Another example in relation to the positive list would be 
to explore if there Is any causal relationship between the change In the number of 
products In the benefit list over time and the change In pharmaceutical expenditure or 
utilisation. 
11.2.2 Issues with interrupted time series analyses 
This study used two statistical approaches to overcome the limitations of the short 
post-intervention data period and to improve the reliability of the statistical results. The 
relatively short post-intervention period has consequences for the model specification 
process, especially in the ARIMA approach. Even the best-fitting models provided only 
limited improvement in fit or residual analyses over competing models. Taking this 
limitation into account, the analyses presented in the previous chapters used the 
ARIMA technique only as a secondary analysis tool, which supported the results from 
the segmented regression. 
With the segmented regression, an 11-month post-intervention period would not be 
expected to create such serious problems as for the ARIMA models, Within the 
segmented regression, the presence of autocorrelation was carefully tested and 
corrected. However, in the two situations where the PERP was clearly not having an 
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effect on the model, there was some concern that the equation modelling the effect of 
coinsurance could be misspecifled. If the model was misspecified, then the standard 
error of the coinsurance variables may be affected, leading to an incorrect test of its 
significance. When the models were repeated without the PERP terms one of the 
models suggested a statistically significant change; however, the results were 
inconclusive as the ARIMA analysis did not support this result. In all but five of the 
regression models the adjusted RZ values were greater than 0.9; In the remaining five 
cases the adjusted R2 values were not less than 0.6, thus indicating that all segmented 
regression models fitted well the observed data. 
11.2.3 Issues with outcome variables 
This study used the aggregate number of dispensed units for each active ingredient, 
which might differ in dosages. This variable was used as a proxy for quantity, as it 
allowed me neither to calculate the quantity of the active ingredient, or the number of 
defined daily doses (DDD), nor to calculate meaningful average prices. However, units 
used in this study were a more accurate proxy In comparison with the aggregated 
number of prescriptions, units have been frequently employed as a proxy measure in 
policy evaluation research (Kanavos er al., 2004). The limitation of the aggregated 
number of prescriptions Is that the policy impact could be misinterpreted if prescribers 
increase prescription sizes to reduce prescription numbers and vice versa (Holloway et 
at., 2001; Starmans eta/., 1994). The 'units' employed in this study are clearly defined 
by law and generally equal to a usual one dose, which are able to reflect utilisation 
alteration regardless of size or volume changes. 
In relation to brand/generic classification, it was possible that drugs were misclassified 
as brand-named or generic drugs due to the absence of official indicator for the 
classification in South Korea. However, the guideline used in this study was carefully 
developed by employing multi-faceted information available in the market, which is 
much more accurate than those used in existing Korean studies. For example, Huh et 
at.. (2006) and Yoon (2008) considered that the most expensive drug among 
pharmaceuticals containing the same ingredient was defined as an original drug. 
However, one recent study found that 31 products among 181 selected brand-named 
subjects were priced lower than their generic alternatives in 2005 (You, 2007). Lim 
(2002) and You (2007) defined a first marketed product as an original drug in the 
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Korean market. Their method seems to need further consideration of which is an 
original version across countries, not only in the Korean market, because most new 
entities now tend to be developed by transnational companies. Cho et al.. (2001) 
defined products on the Korean bio-equivalent reference drugs list15 as an original drug. 
However, reference agents on the list could not always be regarded as a brand-named 
drug, as already discussed in the Methods section (Chapter 8). Shin and Choi (2008) 
utilised the same definition as that of Cho et al. (2001), but they supplemented the 
shortcomings in the list by employing the price guide and direct contact with the 
manufacturers if necessary, which is most similar to the current study. 
11.2.4 Issues with the generalisation of the findings 
Lastly, the findings from this study may be generalised to a limited extent. First, it 
must be cautioned in extrapolating the results beyond the study timeframe, which is 
approximately one year following the copayment increase. Reported decreases must be 
interpreted with care. It is not known whether those models with significant linear 
slopes after the policy change represented new equilibriums or would continue in the 
predicted direction. Analyses based on longer-term data would need to be undertaken 
to answer this question. Second, as these analyses used aggregated claims data, it 
cannot be assumed that the findings are evenly shown across individuals. Third, 
caution should be exercised in generalising the findings from two chronic medications 
to other therapeutic classes. Patients may exhibit different behavioural responses to a 
copayment increase when they use medications in other therapeutic classes, 
particularly drugs for temporary symptomatic illnesses or drugs for acute, possibly fatal 
illnesses. Each of the different therapeutic classes may have been sold to considerably 
different market conditions, which may influence the use of drugs substantially. 
11.3 Implications for policy impact 
Theoretically, it has been thought that a rise in out-of-pocket payments could lower 
drug costs by discouraging demand for medication (Chapter 1). This hypothesis was 
15 The Bio-equivalence Validation Programme (BVP) was Introduced to verify the quality of 
generic products focusing on bio-equivalence In 2000. In this process, local manufacturers 
should prove that their product Is equal to bio-equivalence profile of a product with the same 
Ingredient on the blo-equivalent reference drugs list. 
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supported by international evidence available from the systematic review (Chapter 4). 
A body of evidence suggests that the fall in pharmaceutical expenditure generally 
remains within a limited range and is often smaller than the decline in volume after an 
increase in copayment (Chapter 4). Interestingly, the ITS analysis found the opposite 
to be the case. The analyses of Korean claims data indicated that the copayment 
increase might lower drug costs without any visible change in drug utilisation. This can 
be explained if the copayment increase encouraged the use of less costly drugs in the 
Korean prescription market, as opposed to international lessons which suggested few 
substitution effects toward cost-effective medications by the cost-sharing strategy 
(Chapter 7). 
Subsequent investigation, however, suggested that the apparent fall In costs might be 
associated with a decline in utilisation of costly therapies, such as antihyperlipidemics, 
rather than a rise In utilisation of less costly alternatives. Empirical Investigation of the 
two therapeutic classes demonstrated that the Impact of the new cost-sharing 
programme might vary across therapeutic classes. For example, the policy might not 
affect patient access to antihypertensives, but possibly to have prevented access to 
antihyperlipidemics. Although a greater decrease was seen In patients with brand- 
named antihyperlipidemics, there was little evidence to suggest that the new cost- 
sharing schedule led patients to shift from brand=named drugs toward generics. 
It was unexpected that there was no immediate change in the drug price variable after 
the Pi; RP, given that the new price cut lowered drug prices for out-of-patent drugs and 
their generic versions by 20% immediately after the introduction. There could be two 
explanations for this. First, the new scheme might apply to too small a number of 
products to generate detectable impact on the market. However, this seems a little 
unrealistic as the new scheme included almost every product on the market except a 
few products still within their patent In the Korean market. 
A second explanation is the new price cut scheme might increase the availability of 
expensive drugs. That is to say, it might encourage prescribers or patients to consume 
more costly products that were previously restricted mainly because of their prohibitive 
prices, As a result, rising expenditure on relatively expensive drugs offset the savings 
generated by cutting prices, which was highlighted in the subsequent investigation. 
The reduced prices after the PERP might allow patients greater access to 
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antihyperlipidemics, which are relatively expensive in the Korean market. 
This finding is in accordance with existing evidence showing the trend of drug 
utilisation in the recent decade in Korea. After the separation policy, Korean doctors 
became more likely to prescribe original drugs, which has created expenditure inflation 
to a substantial degree (Chapter 2). Summary statistics of the current claims data also 
suggest that pharmaceutical expenditure has expanded faster than growth in utilisation 
over the five year period of the study. According to the recent government paper, the 
growth rate of drug costs was 13.7 per cent between 2003 and 2004 and factors 
contributing to the growth included a rise in volume (76 %) and the introduction of 
new, more expensive drugs (24% and 10% respectively). Pharmaceutical prices and 
savings by use of less expensive alternatives showed a slight decrease and contributed 
adversely to the growth by about 5 per cent during that time (Ministry of Health & 
Welfare, 2006c). 
Thus, findings from the present study concerning the rising baseline trend of `costs per 
unit' may be reflected by the increasing trend towards new, more expensive drugs 
rather than a real increase in market prices. The impact of price cuts may be masked 
by the trend in consumption and even facilitate It by lowering drug prices. 
11.4 Implications for policy consequences 
The finding that the new cost-sharing schedule may be associated with an unintended 
decrease in the use of antihyperlipidemics was unexpected, because the copayment 
Increase was limited to cases In which total expenditure per single prescription was less 
than 10,000 KRW (about £5). It was anticipated that the new cost-sharing structure 
was less likely to influence the use of medication for chronic conditions. From the 
prescription claims data used in this study, the average cost per patient per month was 
20,000 N 23,000 KRW (£10 N 11.5) for antihypertensives and 30,000 N40,000 KRW 
(£15 N 20) for antihyperlipidemics, suggesting that patients taking anti hypertensives or 
antihyperlipidemics were unlikely to be influenced by the new policy change. One 
explanation for the decrease may be that consumers perhaps misunderstood the new 
policy as a simple Increase in copayment, discouraging them from filling their 
prescriptions after the policy Introduction. Alternatively, the concurrent Increase In the 
medical services fee may have discouraged patients from visiting their doctors. 
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Then, why were patients more likely to reduce their use of lipid-lowering drugs? The 
first possible explanation is that the high price of antihyperlipidemics discouraged drug 
consumption. Antihyperlipidemics are generally a costly medicine; average expenditure 
per patient was about 30% higher in 2003 compared with antihypertensives and the 
difference had become even greater - nearly twice as high in 2008 In the Korean 
insurance market. 
Additionally, it may be due to the different clinical characteristics of the two chronic 
conditions. In practice, patients have a better understanding of the pathology of high 
blood pressure and can recognise the benefits of medication more directly. Symptoms 
are easily recognised and patients are usually trained to check their blood pressure at 
home. On the other hand, the pathology of dyslipidemla Is complex and symptoms are 
generally less easily recognised. Serious conditions such as cardiovascular diseases or 
stroke are usually established over a longer time period. Hence, patients are more 
likely to think that anti hypertensives are more crucial medications, compared to 
antlhyperlipidemics. A body of evidence indicates that the demand for medication could 
be more flexible when patients perceive them to be less essential (Chapter 4). 
In line with this, two features found in the current analysis may reflect the fact that 
Korean patients are more vulnerable to financial burden in certain conditions. First, 
patients with an expensive course of therapy such as antihyperlipidemlcs seem more 
sensitive to the Interventions, increasing drug consumption after the price cut, and 
reducing it after the subsequent copayment increase. Second, small but Immediate 
effects in those taking generic antihyperlipidemics similarly suggest the potential loss 
of equity by denying patients access to essential medications to a larger extent in the 
low-income group, who may have been more likely to use generics (Federman et al., 
2006). 
11.5 Implications for the Korean generic market 
Alongside the policy evaluation, this analysis also found a few notable traits of the 
Korean generic market, worthy of discussion here. First, the market share of generics 
of the two study medications had maintained between 30 and 50 per cent over the 
study period. This seems a considerably high figure, given that there have been few 
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intensive generic policies in South Korea (Chapter 2). Spending on generics increased 
rapidly between 2003 and 2005 in anti hypertensives and before 2004 in 
antihyperlipidemics, as seen in Figure 11-1. The trend was often governed by products 
newly launched after patent-expiry of several best selling drugs, for example, Zocor" 
(an original brand of simvastatin) in the antihyperlipidemics market, and some'me-too' 
drugs in the anti hypertensives market, rather than policy regulations. 
Figure 11-1: Generic market shares in anti hypertensives (above) and 
antihyperlipidemics (below) in South Korea from 2003 to 2008 
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Second, the present study indicates that the gap between the value and volume of 
generic share in the two chronic medication markets has been constant at around 10 
per cent in Korea. Previous studies suggested a smaller difference of less than 5 per 
cent. There have been two studies exploring the changes in total pharmaceuticals 
grouped into brand-named and generic drugs in Korea. One used the same claims data 
as the current study but over a different period (2002-2005) and included all claimed 
pharmaceuticals. It reported annual data of the market share of generics, which was 
40«43%o in volume and 35«39% in value (Huh eta/., 2006). The other study also 
performed a comprehensive analysis of pharmaceutical claims, but in a single month in 
2007, and it demonstrated that generics occupied 44% in volume and 41% in value in 
the Korean market (Moon, 2008). It may be hard to make a head-to-head comparison 
between these two studies and the current because both studies used a different 
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classification tool from that used here. Moreover, they included all pharmaceuticals and 
the current study included only two chronic therapeutic classes. Despite such 
differences, the volume estimates only differ slightly. The current study suggests that 
the value of generics of anti hypertensives took about a 10% smaller segment 
compared with all generics in the previous studies, indicating that the 
anti hypertensives market is probably more competitive than others (e. g. 
antihyperlipidemics). This is understandable as the anti hypertensives market has a 
longer history, various sub-therapeutic classes and greater generic availability; and 
hence, there may be more choice of drugs. 
Three further studies have explored the determinants of the market share of generics 
(Lim, 2002; Shin and Choi, 2008) or the first approval drugs (You, 2007). These are 
hard to compare with the current study because they used a different dataset, small 
numbers of selected panel data. Variations in the generics share were very broad, from 
20 to 75% in volume and 40 to 75% in value by item. 
Figure 11-2: Price ratio of generics against brand-named drugs in South Korea 
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* Price ratio = Costs per unit of generics/Costs per unit of brand-narned drugs 
Figure 11-2 demonstrates the price ratio of generics against brand-named drugs 16 
between 2003 and the first half of 2008. It clearly shows that the generic price had 
increased considerably. However, such a marked increase is unlikely to have occurred 
in countries like South Korea, which has implemented price control over several 
decades (Chapter 2). According to the recent government paper, the market price has- 
been negatively associated with drug expenditure (Ministry of Health & Welfare, 2006c). 
In line with this, two previous studies stated that such an increasing trend may be 
"' Price ratio of generics against brand-named drugs = Costs per unit of generics/Costs per unit 
of brand-named drugs 
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associated with the increasing use of expensive generics rather than an augmentation 
of market prices (Lee, 2006; You, 2007). Thus, the price ratio here may indicate an 
Increase in the use of new, more expensive generics, rather than a real price increase 
In the marketplace. 
The figures overall imply that generic prices may be as expensive as those for brand- 
named drugs in some therapeutic classes in the Korean market. Therefore, under 
current market conditions, it is questionable whether the growth of generic volume In 
the Korean market leads efficiently to a fall in drug expenditure. It becomes much 
clearer when making comparisons with figures from other settings where generic 
policies are thought promising. According to two recent reports from Europe, countries 
such as Denmark, Germany, the Netherlands, UK and Sweden, with relatively small 
expenditure on pharmaceuticals, have 2-3 times larger volume share in comparison 
with value In the generic market (European Generic medicines Association, 2007; 
Simoens and De Coster, 2006). Sweden, In particular, has a similar sized generic 
market to Korea in terms of volume at about 44%, but much less in value, around 14% 
in 2004. In Sweden, the share of drug expenditure of total health costs was 12.5% in 
the same year, which is about a half of that of South Korea. In this respect, it is 
Important to address not only how to Increase the volume of generics but also how to 
decrease the price of expensive generics in Korea. 
11.6 Implications for future research 
Clearly, this research would need to be extended with 1«2 years longer observations in 
order to clarify the policy Impact. Two medications for chronic illnesses seem 
Insufficient to explore the market dynamics. Hence, wider analyses Involving various 
therapeutic classes would be Informative. Exploring changes In symptom-relief 
remedies would be particularly interesting. It would also be interesting to investigate 
the Impact and consequences of policies on overall health status, other aspects of 
health service utilisation and private expenses beyond the National Health Insurance 
scope, This Is essential In relation to the copayment programme, because international 
and local evidence Indicates that limiting patient demand may result In reducing social 
equity and deteriorating social health in some conditions (Chapter 4 and 10). Specific 
issues requiring further study Include; the underlying causes of the reduction In 
antihyperlipidemics use; the causes of differential effects by drug class; the effects of 
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the decline In antihyperlipidemics use on long-term health outcomes; and the factors 
encouraging the use of expensive generics in the Korean market. 
11.7 Summary 
Empirical analyses of prescription claims data showed that the two policy Interventions 
may be associated with a decrease in drug expenditure, but only to a marginal degree. 
They seem to contain costs not by the intended mechanisms (i. e. lowering prices or 
encouraging cost-effective consumption), but by reducing patients access to expensive 
medications regardless of clinical necessity. Thus, concerns were raised about potential 
impacts of overall health under such circumstances, for example, chronic Illnesses in 
the lack of understanding by patients or in higher costs for a course of therapy. 
Additionally, some features, such as a sizable response in the antihyperlipidemics 
market or an Immediate response in generic use to policy change, suggest potential 
loss of equity by denying patients access to costly essential medication for financial 
reasons. 
The present investigation Indicates that the gap between value and volume shares in 
the case of two large markets for medication for chronic conditions has been 
maintained steadily at around 10% in Korea, which is far smaller than that in some 
countries enjoying large savings by policies encouraging generics use. There has been 
a clear and considerable Increase In the price of generics against brand-named drugs, 
translated into two possibilities: a faster Increase in generic prices or a higher market 
share of expensive generics. In such market conditions, it Is possible that generic 
policies would be less effective in containing costs. 
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CHAPTER 12: EVIDENCE-BASED PHARMACEUTICAL POLICY- 
MAKING IN THE KOREAN CONTEXT: A QUALITATIVE STUDY 
12.1 Introduction 
The purpose of this chapter is to present a qualitative investigation into the difficulties 
of evidence-based pharmaceutical policy-making in the Korean context from the policy- 
maker's perspective. In the current qualitative study, the policy-maker was defined 
broadly, Including not only personnel who actually make decisions about policy, but 
also people who influence policy decisions in the Korean policy-making process. 
A substantial literature indicates that the cost crisis In pharmaceuticals has been 
caused primarily by. Increased consumption (Mossialos eta/., 2004; Strunk and 
Ginsburg, 2004). Linked to this, systematic reviews Illustrate that the pharmaceutical 
policy agenda has expanded from controlling patients using copayment schemes or 
restricting drug suppliers through price control, to limiting doctors' prescribing practices 
(Chapter 4 through 6). 
A matter of prime Interest In regulating prescribing practices Is currently to encourage 
the use of lower cost alternatives without compromising quality of care (Chapter 5). In 
addition, as it becomes aware of access to medications possibly being reduced by flat- 
rate cost-sharing programmes, interests are Increasing about developing various tools 
that are able to encourage less pricy alternatives such as generics instead of reducing 
utilisation (Chapter 4 to 6). It has been suggested that price control might be 
powerless when confronted with entrepreneur activity In the Industry, for Instance 
marketing for newer, more expensive medications (Healy, 2006; Jacobzone, 2000; 
Lovell, 2006). So, more efforts have been made to reduce prices by promoting 
competition in the market. Examples may include reference-pricing schemes (Chapter 
6). 
During the 2000s, faced with rising drug expenditure, the Korean government has tried 
to contain costs by the simultaneous Introduction of several policy Interventions 
(Chapter2). It Is, however, unknown whether effective policies have been implemented 
to tackle the main cause of expenditure inflation In Korea. For instance, evidence from 
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claims data invariably suggests that first it is necessary to change doctors' prescribing 
behaviour. Nevertheless, the Korean government, as seen in Chapter 2, has focused 
more on measures influencing patient demand or reimbursement prices, rather than on 
those affecting prescribing behaviour overall. 
Obviously, interventions controlling patient demand and prices have achieved only a 
marginal impact in containing costs in Korea (Chapter 9). It may be too early to draw 
any conclusions from the programmes currently under examination. However, given the 
global evidence from the systematic reviews of one-off effects in controlling patient 
demand and direct pricing, it seems unlikely that much greater impact would be 
realised afterwards. Moreover, some unwanted consequences were seen after the 
recent policy changes, such as a considerable restriction in the use of essential drugs, 
and a decline In the use of generics as well as brand-named drugs (Chapter 10). 
In recent years, a variety of attempts to Influence prescribing behaviour has 
increasingly taken place. However, many of them remain In the early stages of 
development (Chapter-2). Even within a single plan, for example, the Pharmaceutical 
Expenditure Rationalisation Plan (PERP), measures influencing prescribing practices are 
less likely to take effect than others, such as pricing (Chapter 9). This raises. some 
questions. What are the factors that can cause a conflict between evidence and policy 
decisions in South Korea? To what extent does the evidence have an effect on the 
policy-makers? What other factors, if any, Influence policy-making, and to what extent? 
While needs exist, few studies have addressed these subjects scientifically so far. 
Results from the systematic reviews illustrated that a few strategies might be effective 
for containing pharmaceutical expenditure in other settings. However, It Is unclear 
whether such strategies would be effective as well as feasible In Korea. Thus, there is a 
pragmatic need to identify the barriers, feasibility and implications of some promising 
policies from other settings In the local context to achieve further improvement in the 
pharmaceutical arena. 
12.2 Research questions 
This study was designed to address the following question from policy-makers' 
perspective: 
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What makes it difficult to formulate evidence based policy-making In South Korea? 
Within this question, the intention was to: 
  Investigate participants' views on current policies and evidence available to 
policy-makers; 
  explore the factors that influence policy decisions; 
  explore participants' opinions of the potential policies available to policy-makers, 
12.3 Methods 
12.3.1 Study design 
For the study, semi-structured interviews were carried out with key influential 
personnel in Korean pharmaceutical policy-making. Semi-structured in-depth interviews 
are performed "on the basis of a loose structure consisting of open-ended questions" 
(Britten, 2006; p13). Whilst the topic area to be explored is determined at the outset 
and some questions can be pre-determined, qualitative semi-structured interviews also 
allow for some questions or topics to be developed within the interviews, allowing the 
respondents to raise issues important to them and that were not considered in advance 
by the researcher. In this sense, they differ from structured interviews which "involve 
tight control over the format of the questions and answers" (Denscombe, 2007a; p17S). 
Fundamentally, this study was not designed to develop theoretical concepts relating to 
the topic area. Rather, it aimed to probe pragmatic issues among experts, making 
semi-structured interviews the best choice for the study. 
12.3.2 Participants 
Potential participants were selected from among the appropriate members of the key 
groups associated with pharmaceutical policy-making in Korea, with the intention of 
Identifying those who are the most relevant to the research alms. Purposive sampling 
was employed -- such non-probability sampling is often used In a small sized, ' 
exploratory qualitative studies (Denscombe, 2007c). In purposive sampling, the 
interviewees are strategically sampled because they are "information-rich cases" 
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(Patton, 1990a). 
To find key names efficiently, a snowballing technique was used (Patton, 1990a). 
Experts involved in the pharmaceutical policy-making process comprise of a group of 
people, who are often difficult to contact directly. Hence, personal connections are 
valued in this field and snowballing is thought an effective way to increase the 
likelihood of obtaining interviews (Marshall and Rossman, 2006). These `information- 
rich' key people were identified by asking a number of different informants to 
recommend colleagues for the study. A few key names were mentioned repeatedly, 
and they were considered as valuable potential interviewees and approached to take 
part. To ensure maximum variation and diversity across relevant organisations in the 
sample (Patton, 1990a), types of potential participant were loosely categorised by the 
organisations to which they currently belonged. At the same time, their previous career 
was also. considered in the categorisation. 
Potential participants were chosen based on appropriateness, relevant experiences, 
and, of course, their willingness to engage in discussion. The selection criteria 
included: 
  experience of the pharmaceutical policy-making process; 
  current or recent involvement in the pharmaceutical policy-making process in 
South Korea either as a policy-maker or as an advisory committee member; 
  experience of academic research into Korean pharmaceutical policies; 
  willingness to discuss personal views; 
  Interests in pharmaceutical policies. 
A total of 49 potential participants were identified through the process, of which 16 
were approached. Nine individuals finally participated in the research, but among them, 
one failed to be followed up after the questionnaire (see the following section for 
details in the procedure of data collection). Recruitment was ended as it appeared that 
saturation had been reached in terms of the views expressed, with similar opinions and 
concepts repeatedly recurring in study topics (Guest et al., 2006). 
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12.3.3 Data collection 
Data was collected between July and September 2009 through a semi-structured, self- 
administered questionnaire and an in-depth telephone interview. A small pilot of the 
questionnaire and interview process was undertaken with selected, interested 
interviewees known to the researcher, who fulfilled the inclusion criteria and had 
expressed a willingness to act as subjects. 
Participants were approached with a request for an interview. An initial letter of 
approach was emailed to the selected individuals, summarising the proposed research 
and inviting participation. This approach was made via a member of the network of 
contacts, or Interviewees. Individuals were followed up by telephone or email to 
confirm receipt of the Initial invitation, and to ask whether they would consider 
participating. Following agreement to participate, a covering letter was sent by post 
with: 1) the information sheet detailing the content of the research; 2) two copies of 
the consent form; 3) the topic guide for participants (Annex 23); and 4) a semi- 
structured questionnaire (Annex 24). Individuals were followed up to confirm receipt of 
these documents. After the return of the signed consent form and completed 
questionnaire, a telephone interview was carried out. 
A semi-structured, preliminary questionnaire was developed and sent to participants to 
complete in advance of the interview. This served two purposes. First, it, was expected 
that a preliminary questionnaire would be useful in reducing the time spent on 
interviewing, and soothing the participants' anxieties relating to the time commitment 
related to the study participation. Second, it was expected that preliminary 
questionnaires would be useful triggers for discussion during the interviews (Adamson 
et al., 2004). They would ensure the interviews were highly focused, making lt possible 
for the researcher to interview participants within limited time (Patton, 1990b). 
The interview guide and questionnaire consisted of four domains: Individual 
characteristics; opinions about existing evidence and evidence-based policy-making; 
pragmatic experience in policy-making; and recommendations for future policy. All 
respondents were asked identical questions in the same sequence, but interviews 
evolved further, concentrating more on key responses from the questionnaires. 
257 
Additionally, as the study recruited participants using a purposive sampling method, it 
allowed for allocation of extra questions relating to each participant's expert field, if 
deemed necessary for the study (Denscombe, 2007c). 
Each interviewee was Interviewed once. Each interview took place over the telephone 
lasting 40 to 60 minutes on a one-to-one basis. All interviews were conducted by the 
same researcher. The discussion was audio-recorded for transcription. Interviews were 
subsequently transcribed verbatim. There was no further follow up of participants for 
collecting primary data, but where necessary, further contact by telephone or email 
was made on a case-by-case basis to verify vague dialogue or to identify further 
participants. A log of all contacts was kept, for audit purposes. 
12.3.4 Ethics 
Consent was freely given, and was not coercive for any reason. Participants were 
informed they could discontinue the interview whenever they wanted to. The consent 
form was sent to participants with the following documents and a semi-structured 
questionnaire to ensure participants were fully informed of their role within the 
research. 
  Participant Information Sheet detailing the process of the interview; 
" Topic Guide highlighting the areas for discussion. 
Interviewees, for their records, retained one copy of the consent form and signed and 
returned a second copy to the researcher for filing as part of the audit trail. The 
researcher's contact details were available throughout the research, to allow 
participants the opportunity to discuss any Issues arising. The researcher was available 
to answer any further questions they might have, both prior to consent and once 
permission had been obtained for the interview to take place. Consent was an ongoing 
process (Lawton, 2001), and was verbally re-obtained and recorded during the 
interview, thus appearing in the transcripts. 
Interviews were transcribed anonymously and the interviewees' identities were 
protected by the allocation of a respondent code. Their names were not reported at 
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any stage and organisations were described only in the broadest terms In order to 
protect Individual's Identity while maintaining the context of Information in the research. 
Additionally, participants had opportunities to see transcripts and excerpts destined to 
be used in the final report. Any Information they gave during the Interview was not 
reported if they expressed any unwillingness to disclose. Personal details had been 
securely retained for contact purposes only and all information collected about 
participants during the course of the research was kept strictly confidential. The only 
people who had access to their identities were the named researchers who ensured 
that steps were taken to maintain security and confidentiality. Tapes and paper copies 
of the transcripts were stored in a locked filing cabinet in the investigator's office, to be 
destroyed when no longer required. Access to data stored on computers was password 
restricted to the researchers. Data will be stored until the project is completed in its 
entirety and securely archived until disposal. 
Prior to being undertaken, the research was reviewed and obtained approval from The 
Department of Health Sciences Research Governance Committee, The University of 
York. 
12.3.5 Data Analysis; framework approach 
The data was analysed employing a framework approach, developed by the National 
Centre for Social Research as a tool for policy and evaluation analysis (National Centre 
for Social Research, 2010). A framework is an analysing tool to find answers to 
qualitative questions deductively, involving a series of well-organised steps and 
increasingly used in qualitative research (Pope eta/., 2000; Ritchie and Spencer, 1994). 
The framework technique, which is relatively formulaic, allows for examination of the 
analysis to take place, indicating high transparency of the procedure (Ritchie and 
Spencer, 1994). Moreover, for the same reason, the framework approach allows rapid, 
targeted progress in qualitative analysis, which reduces the burden of time-consuming 
and labour intensive tasks for analysers. 
Data analysis was done through an iterative process Including familiarisation, 
Identifying a thematic framework, Indexing, charting, mapping, and Interpretation 
(Ritchie and Spencer, 1994). After completing each Interview, tape-recorded data was 
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transcribed by the researcher. Transcription from voice to hard-copies took a 
considerable time, involving listening to tapes and reading transcripts several times. 
While undertaking this, the researcher had time to become familiar with the raw data. 
Additional reading of transcripts was also carried out to list key ideas and to find 
recurrent themes. At this stage, the data were bracketed according to the emerging 
concepts and subjects. Alongside this, brief notes on each concept and subject were 
tagged. 
The data was examined several times until meaningful clusters of text were identified. 
Each identified cluster (theme) was given a unique code. A qualitative data analysis 
software, ATLAS. ti version 5 (GmbH Berlin) was used for coding. When all the data had 
been coded thoroughly, key characteristics of the coded data were considered and 
pulled together. For assuring a picture of the data as a whole, an Excel spreadsheet 
was built for each theme, which displayed quotes or expressions, summarised the vital 
Idea of theme, and contained further details of sub-themes. 
Following initial coding, the data were then examined for potential patterns or 
underlying relationships between themes and sub-themes, In order to develop higher 
order constructs. Where necessary, the transcripts were revisited and themes 
compared and contrasted in order to search for common structure, inter-connections 
and implications. The process was repeated several times. Finally, three higher order 
themes emerged, which were evidence, challenges and prospects. Each main theme 
was comprised of 2 or 5 sub-themes (see Figure 12-1). A prior! themes were combined, 
restructured or displaced by new ones emerging from the data. 
For reporting, the original language was translated into English by an independent 
translator. There Is little evidence that translation would alter the qualitative analysis, 
though some concerns may still arise as to whether translation is accurate and portrays 
the subtle meanings of the original language (Marshall and Rossman, 2006). To reduce 
such concerns and to gain a better understanding of delicate nuances, a separate 
translator, who is a Korean and has a near-native command of English, was engaged. 
Quotations in the original language are presented In Annex 25 in parallel with the 
English version. 
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12.4 Results 
12.4.1 Characteristics of participants 
For this study, eight interviews were undertaken with key persons involved in drug 
policy-making and evaluation in South Korea. The questionnaire was completed by nine 
participants, but one participant (p022) did not agree to be interviewed without giving 
a reason. These answers were included only in the questionnaire analysis. Their 
characteristics are illustrated in Table 12-1. 
Table 12-1: Basic characteristics of participants 
Participant Working for Length Background 
p006 government body 10< Pharmacy 
p014 advisory research body 
p017 advisory research body 
p019 advisory research body, academia 
p022 government body 
p028 government body 
p030 government body 
p047 advisory research body, academia 
p048 government body, academia 
5N10 Pharmacy, Health Sciences 
10< Pharmacy, Health Sciences 
10< Pharmacy, Health Sciences 
<5 Nursing 
10< Pharmacy 
IN Pharmacy 
5-10 Pharmacy, Health Sciences 
5-10 Pharmacy, Health Sciences 
Participant numbers (e, g. p006) are arbitrary, and were simply allocated in the order in 
which names were initially identified during the snowballing process. In table 12-1, 
`Working for' indicates organisations in which participants have been engaged so far, 
'Length' denotes time period that participants have been engaged on relevant tasks 
and `Background' reflects their academic discipline. Half of the participants have 
worked for government bodies at national level and have experienced policy planning 
and Implementation. The rest have worked in an advisory role in either advisory 
research bodies or academia. All but one participant had a pharmacy background and 
among them, five participants had received further training in Health Sciences. 
Participants in government bodies tended to take responsibility closely related to 
current major pharmaceutical policies and were regarded as appropriate key policy- 
makers. Those in advisory organisations had published related subjects across a range 
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of media including government-funded research documents, newspapers and academic 
journals and, hence, were regarded as influential personnel affecting Korean 
pharmaceutical policy-makers. Thus, all participants could be considered appropriate 
key persons in the Korean pharmaceutical arena. 
12.4.2 Emerging themes 
Themes emerging from interviews were categorised into three core subjects as follows: 
" Evidence showed the weaknesses of existing evidence and policy cycles 
undermining scientific evidence in the Korean pharmaceutical arena. 
  Challenges identified practical difficulties that Korean policy-makers have often 
faced in drug policy-making. 
  Prospects brought together suggestions for future drug policy and an effective 
policy-making process. 
Figure 12-1: Illustration of themes 
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Within core themes, a number of sub-themes were identified as shown in Figure 12-1. 
Due to the extent of this illustration, a closer depiction of each theme is presented in 
the corresponding section (see Figure 12-2,12-3 and 12-5). Each theme is dealt with 
in the following sections in turn. In terms of the quotations, the references at the end 
of each indicate the participant reference number, followed by the paragraph numbers 
where the quotation occurs in the transcript. The paragraph numbers were generated 
by a qualitative data analysis software, ATLAS. ti version 5 (GmbH Berlin), which was 
used as a data management tool. For example, the first quotation in the next section is 
referred to as (p030: 8), which indicates that it was said by participant 030, and that 
the comment occurs on the eighth paragraph of the transcript. 
12.4.3 Evidence for pharmaceutical policy-making 
Discussions regarding the first theme, 'evidence, showed the weaknesses of existing 
evidence and uncovered the fact that scientific evidence has been underutilised in 
Korean drug policy-making. Subsequently, dialogues tackled several sub-themes 
concerning the cause of the underuse of evidence, including the scarcity of available 
evidence due to the lack of infrastructure, coordination and independency, policy-based 
research milieu and the presence of other influential factors (Figure 12-2). 
Figure 12-2: Illustration of themes: Evidence 
Low applicability 
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12.4.3.1 Weaknesses of existing evidence 
The weaknesses of current evidence suggested by respondents can be grouped into 
three categories. First, evidence from abroad seems less useful owing to difficulties 
263 
adapting it to the local context. The perception was that there were many factors 
making every policy intervention produce different outcomes depending upon details or 
social environments. 
... even if the evidence were objective, 
its hard to apply it simply because of the difference 
between Korean system and other countries'systems (p030: 8) 
Second, evidence produced in Korea is also considered impractical, since most studies 
conclude with general remarks and, as a result, fail to present any practical 
suggestions. This was particularly stressed by participants engaged in the planning or 
implementing of policies, who might welcome a practical prescription. 
If you look at the outcomes of most evidence produced In Korea, they usually tend to cover just 
the general aspects of It and leave out all the details (p006: 6) 
Third, it Is rare to conduct empirical follow-up after introducing a foreign policy, or to 
Investigate the policy Impact In the local context from various angles. So far, policy has 
most likely been studied focusing on `the system itself, rather than on its lessons for 
Korea. Closely linked to this was the sub-theme, 'policy-based research milieu, which 
was discussed further in the following section. 
Since the policy monograph Is mostly focused on a system itself, /ts too bad that there Isn't 
really any chance to evaluate whether that system would work or not for South Korea. (p014: 8) 
If you take a look at other working papers or essays from other countries, you can see how 
there are various evaluative procedures, we [South Korea] rarely do like that. (p048; 6) 
12.4.3.2 Underuse of evidence 
Throughout, three dominating causes emerged from the data, concerning evidence 
underutilised in the Korean pharmaceutical arena: lack of available evidence, policy- 
based research m1/leu and presence of other Influential factors. 
Lack of available evidence: The difficult situation initially met by participants in the 
policy process was the scarcity of relevant evidence. 
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Its also nöt being used because, so far, there basically hasn't been enough evidence available 
on other previous policy-making processes for us to learn from and use as an example 
whenever we have to make certain future decisions.. (p047: 4) 
The opinions from interviews made it clear that the principal factor placing a hurdle in 
the way of evidence-based policy-making is the lack of available evidence, The 
underlying causes of the shortage, participants identified, were threefold: lack of 
Infrastructure for research; lack of Independence of researchers; and lack of 
coordination in policy evaluation. 
Most participants felt that the dearth of basic Infrastructure might cause available 
evidence to be limited or less valuable. In detail, their statements were omni- 
directional, including the lack of fundamental relevant research, such as "epidemiology 
relating to chemical substances or epidemiologic researches [on local population] 
(p030: 10); "head-to-head data on drugs (p030: 10); "evidence on how to allocate the budget 
[to discuss a prescribing budget] (p029: 21); "costs data in relation to an economic evaluation 
(p019: 8); and "[for prior authorisation] [a standard of fudgment] on whether this person really 
needs this or not (p028: 60)", the lack of workforce - qualified researchers and training 
programmes; the lack of experience In the establishment and evaluation of policy and 
the translation evidence into policy. 
We just don't really have much experience with all of these policy evaluations.. like how to 
evaluate and systematise them.,, (p006: 40) 
Central to the discussion of infrastructure was the demand for properly trained 
researchers. Participants repeatedly mentioned this during interview. The shortage of 
qualified researchers has led to the poor state of evidence. 
There are times when researchers who aren't really specialists In the social science field get 
Involved In the evaluating process, and because of this, they simply make comparison with 
foreign policies or evaluate Korean policies tend to be too generalised,,, (p019.8) 
Participants working as planners or Implementers asserted that they often felt that it 
was necessary to guide public funded-researchers with intensive discussions, since the 
quality of most researchers might not be sufficient otherwise. 
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Most researchers don't necessarily understand very well about the policy direction. So, 
whenever we ask them to write out policy reports to researchers, we normally request them to 
focus and verify the top>cs we mostly discuss and write about. (p028: 14) 
Less-qualified researchers were thought to rely on guidance from the authorities. To 
some degree, even the ability of eligible researchers suffered from a lack of 
independence in policy evaluation. Firstly, it seems to be unavoidably restricted 
because of the shortage of resources like time, background references, colleagues for 
inter-disciplinary research, or fundamental data that are essential to aid the diversity of 
research. Participants such as a researchers or advisors regretted the shortage within 
the researcher pool that often prevented them from undertaking in-depth analysis of 
practice. 
J 'd like to do more about the evidence you mentioned before, such as evidence on a certain 
policy evaluation or a system evaluation that we could use in the future. But lts not easy for us 
to pursue In-depth research because po/icles continue to change, and also there aren't enough 
networks for us to reach out to those who might be able to help. (p014.: 8) 
Secondly, respondents argued that currently researchers in Korea are inevitably 
governed by sources of funding or data. Under these circumstances, the quality of 
studies tend to be of lower standard, respondents arguing that funders (mostly 
administrative government bodies) were likely to require descriptive or general 
outcomes advocating their own arguments, rather than those from a robust scientific 
analysis. 
Either the government or other organlsatlons In South Korea that would recruit researchers for 
policy research prefer more descriptive methods than In-depth analytic ones, they just want 
things to be explained descriptively and In certain ways they want them to be explained. 
(p048: 6) 
In order to improve the quality of evidence, participants felt that it would be essential 
to construct a systematic research framework with long-term planning. One participant 
in particular spent considerable time describing the definition of coordination in policy 
evaluation. She elucidated it in three ways: to plan a policy from simulation to 
evaluation prior to introduction; to set out priority among policies and research to avoid 
wasteful duplication of effort in close collaboration among relevant government bodies; 
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and to construct datasets systematically. She argued that the lack of research 
coordination could cause inferior research outcomes compared with inputs in this field. 
Her concepts reappeared in other participants' interviews albeit in a slightly patchy and 
different manner. Related comments from other participants are "needs alive, close 
network among research institutions (p030: 10) ", "hasn't been enough evidence available_ to 
make certain future decisions (p047: 4) ; "the short-term and fragmented policy evaluation 
(p014: 4) "and "doing another before evaluating a policy Introduced ahead (p048: 4) ". The 
following statement from one participant illustrates, how it has been difficult to 
consider for evaluation at the policy planning stage in practice. 
The evaluat/on for that would be the successors responsibilities... (p028.22) It normally takes 
about three to five years to figure out if policies are really working or not, but policy-makers 
usually end up being replaced after that amount of time. (p028.24) 
Po/i%based research milieu: Besides the three direct causes addressed earlier, it 
was claimed that the deficit of evidence had been exacerbated by the weakness of the 
Korean policy cycle. In South Korea, the policy-based research milieu has been 
constructed on three characteristics of the policy-making process: the limited time 
available to make decisions; the lack of accountability for bad decision-making; and the 
lack of transparency in the process of decision-making. 
Mere are often sudden requests for policy reform, then, [policy-makers] have to come up with 
the request and carry it out in a very limited amount of time. (p006: 4) 
There area number of those [government bodies] who am mainly focused on their group- 
Interest, well, especially with drug pricing policies (p048: 46) 
Evidence does not just appear when needed although, as one participant appropriately 
commented, it is required In a timely manner to influence policy-making. 
So when it comes to policy-making process, we end up using research materials or data that 
are either already done by someone else, or already on the market. I just don T think we really 
have any choice but to rely on experts' opinions. (p006: 4) 
It Is important to conduct research consistently and to build routine information 
systems to improve knowledge, regardless of exogenous environments such as political 
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Imperatives. Participants testified that such sound research environments have hardly 
been put in place in current policy-making conditions. In this decade, as several 
participants mentioned, the government has been under pressure from the cost crisis, 
which required policy-makers to take action in some form. In such conditions, several 
policies have actually been introduced without careful consideration for the local 
situation. 
since we are usually pressured for time, we by to Introduce all these American and European 
policies, just add to, even if they are not necessarily the best ones for our country (p030: 58) 
They basically already liked what they saw in that short period of tlme, so they don't really 
seem to care too much about fully comprehending foreign policies or the systems that they're 
Interested In as long as they like [the foreign systems]. (p014: 4) 
Additionally, evidence could be used selectively, and sometimes misused, according to 
its intended purpose - such as supporting or justifying policies already introduced. 
there were many cases where those evaluations have been made public mainly focused on 
the good aspects'of them. (p014: 4) 
Participants occasionally expressed disappointment about current conditions, arguing 
that they were discouraging and made for poor performance in research activity. 
All these factors are related, and result in hindering the in-depth, diverse evaluation of 
policies and impeding research capacity. Within this vicious cycle, policy-makers are 
often faced with poor evidence at the time of use, which hamper `evidence-based' 
policy-making. 
Presence of other Influential factors: In order to explore how scientific evidence 
is regarded in policy-making, participants were asked to rank factors Influencing policy 
decisions. Additional in-depth discussions over the factors influencing policy-making 
provided a clearer idea about aspects other than evidence. Certainly, various factors 
might be ahead of scientific evidence in consideration of policy. Some of the 
participants felt there was little point in ranking factors, especially those placed in the 
lower positions such as fifth or below, since they thought the power of influential 
factors altered according to the steps in the process. For example: 
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At first, opinion leaders and other people, such as a group of consumers, would announce 
something like 'these are the problems In a policy, and it should be reformed. 'However, when it 
comes to the process of carrying out the policy, cases from other countries or pre-existing 
evaluations are taken into consideration. In the next step, other example cases and evidence 
grounds may play an important role, and then, the pharmaceutical industry or some interest 
groups would play a part In deciding how strongly they enact.. (p047: 6) 
Depending on the organisations and tasks in which each participant had been engaged, 
considerable differences were observed. Different opinions also emerged as a result of 
the participant's interpretation of the query. For instance, some participants replied 
from a personal viewpoint, others made more generalised comments. Some responded 
with answers they felt would be welcomed, others tried to show the reality of their 
workplace. 
Table 12-2: Factors Influencing oil decisions 
ist 2nd 3rd 4th 
Consequences on Opinion leaders' 
p006 pharmaceutical Interest groups Scientific evidence perspective industry 
p014 
Opinion leaders' Overseas experience Political context Scientific evidence 
perspective 
Consequences on Consequences in 
p017 Interest groups pharmaceutical Political context other resources use Indust 
ýý _ý 
Opinion leaders' Consequences on 
p019 Political context Interest groups perspective pharmaceutical Industry 
p022 
Consequences on 
pharmaceutical 
Conventional Opinion leaders' Scientific evidence 
Indust_ precedents perspective 
p028 Political context 
Conventional Overseas experience 
Impacts on 
precedents expenditure 
p030 
Conventional Overseas experience Political context Consumers' groups 
precedents 
p047 
Conventional Political context Scientific evidence Overseas experience precedents 
p048 Political context Overseas experience 
Impacts on Impacts on patients expenditure 
Table 12.2 shows the factors that each participant rated from one to four, Political 
consideration appeared most frequently and had the highest ranking, followed by 
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overseas experience, conventional precedents, and considerations for the 
pharmaceutical industry and opinion leaders' perspectives, in that order. 
Participants felt that political imperatives were be the most powerful factor. They 
recognised that policy is inevitably formulated in the context of political agenda not 
only in healthcare, but also in all other areas. Overseas experience is often used as a 
'backup' for interventions introduced according to political imperatives. 
The conventional precedents largely included four different situations: 1) preceding 
cases for micro-level decisions, such as whether or not a drug was included in the 
insurance benefit list; 2) previous po/icles providing justification for new policies; 3) 
former experience in policy implementation such as the example of the reference- 
pricing scheme, the failure of which discouraged policy-makers to re-attempt 
introduction of this policy despite a growing opinion in favour of the scheme; 4) 
existing policies with which the new policy must interplay. 
Another major factor was `consequences in the pharmaceutical industry. Participants 
expressed the view that the Korean government tended to price generic drugs 
generously, expecting a profitable industry return through innovation. 
Our country has, In some ways, Intended to maintain the domestic Industry by setting generous 
prices for generics (p017: 64) 
Consequences In the pharmaceutical Industry were given more weight in policy 
decisions. The opinions relating to the pharmaceutical industry were strongly linked 
with the challenges caused by the generic industry, which is addressed under the next 
theme. 
Participants also rated opinion leaders' perspectives in relatively highly. They suggested 
that this factor played a leading role in several big changes to date, including the 
separation policy and the formal economic evaluation. 
Interestingly, fewer participants thought that influences from interest groups, such as 
doctors or manufacturers, could be stronger than scientific evidence, which seems 
contrary to the fact that most participants kept mentioning difficulties resulting to 
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policy resistance from such groups. The following remarks may show the reasons for 
such differences. 
Since the Influence of a phanmceut/cal company Is not explicit In outside... (pO47.6) 
I didn't really have to face it directly. However, ifI had been Involved in either the NHIC or in 
the HIRA, then I would've understood the Importance of it. (p014; 12) 
Its like saying this Is one of my top priorities But ifI had to rate this objectively, then it would 
be much more Influenced by Interest groups. (0028: 18) 
A clear implication from discussions is that there is a variety of factors potentially 
influencing policy decisions, often stronger than reliable evidence. It means that other 
factors can override good evidence, presumably more frequently than one would 
imagine. 
12.4.4 Contemporary challenges in pharmaceutical policy making 
The second major theme dealt with 'challenges' that participants have faced within 
the process of policy-making in the Korean context. 
Figure 12-3; Illustration of themes: Challenges 
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Five factors were stressed repeatedly by participants; policy resistance from doctors; 
inherent flaws in policy-making process; excessive profits in generic business; 
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International trade relationship; and worries about Increasing Inequity (Figure 12-3). 
Issues relating to doctors appeared most frequently. Participants identified underlying 
causes of doctors' perceptions against drug policies, citing four sub-themes: financial 
advantages by prescribing; professional conflicts with pharmacists; distrust over 
generics; and the inherent culture commonly observed in auto-regulated professionals. 
12.4.4.1 Doctors' resistance 
All participants spoke of physicians' antagonism in a variety of subjects. They 
acknowledged that medical professionals' opinions strongly affect the Korean drug 
policy process, not only planning or introduction, but also success or failure. Some 
participants felt that a policy, regardless of its scientific grounds, would rarely achieve 
the policy objectives If doctors disliked and undermined it. 
I think gaining the acceptance of doctors is crucial when It comes to carrying out a policy, 
(p017: 20) 
The main Issue is not about the efficiency of medical services in a healthcare system, but about 
getting the approval of doctors: (p006: 24) 
Four causes for doctors' resistance were specified in participants' arguments. First, 
doctors find it hard to agree with the necessity of pharmaceutical policies to contain 
costs because they currently receive financial advantages by prescribing more drugs. 
On the issue of financial benefits, two factors were thought Important- a current 
payment system and an under-the-table deal between doctors and manufacturers. 
Participants pointed out that policies aiming to reduce pharmaceutical expenditure 
could cause a decline in doctors' Income under the current fee-for-service payment 
system. In this situation, many medical professionals find no motivation to behave in 
accord with cost-containment policies. Of equal importance may be the source of 
economic interest resulting from lobbying by drug companies. 
The biggest problem Is that doctors prescribe certain drugs because they have an economic 
Interest In doing so. (p048,52) 
I don't think doctors who had previously been getting Illegitimate financial benefits by giving 
out new drugs or keeping changing prescriptions would change to generic prescriptions 
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suddenly because of a policy. (p014.35) 
Second, they do not want to weaken their power over pharmaceuticals against 
pharmacists. Conflicts between doctors and pharmacists have been another obstacle in 
pharmaceutical policy-making since the Separation of Prescribing and Dispensing of 
drugs (SPD). Domination of pharmaceuticals may include several issues, though most 
participants focused on the fact that such power is likely associated with financial 
advantages, such as bribes or improper material support from the industry. In other 
words, the individual with the power of product choice is directly linked to the one 
receives the benefits provided by the industry. This is actually the same argument as 
the preceding issue. In this respect, participants considered that pharmacists also 
might behave similarly to doctors if they took a dominant position of power in the 
pharmaceutical market. This is the primary reason that participants responded 
negatively to generic prescribing. They argued that it would fuel an extreme dispute in 
society without creating any real benefits. 
Since there s already too much conflict between doctors and pharmacists, I think its best to 
stay neutral rather than firing them by favouring one side over another. (p047.: 14) 
The third cause was doctors' deep-seated distrust of the quality of generics, which 
drives them to undermine any strategy fostering generic utilisation. Participants felt 
this has become an Important barrier which must be eliminated very soon if generic 
policies are to be introduced. 
I don't think people in our country, especially the service prov/ders, still believe that the quality 
of generics is just good as other brand-named drugs. I think this Is what Is holding us back 
from enforcing all these useful policies that are out there. (p097: 16) 
In response to the doctors' doubts over the quality of generics, participants suggested 
slightly different causes. More participants ascribed them partly to the forged bio- 
equivalence test episode which happened in 2006 and partly to insufficient follow-up 
measures of Korea Food & Drug Administration (KFDA) after marketing. In some of the 
participants' responses, it was basically doctors' misunderstanding of the bio- 
equivalence test or their far-fetched and ill-founded arguments. 
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Doctors don't really bei/eve In blo-equivalence test itself. But the thing Is, you can't say that all 
b/a-equivalence tests are completely absurd, and the scientific facts they're learned in medical 
school are absolutely right. (p014: 36) 
Fourth, doctors are likely to adopt an unfriendly attitude because of an intrinsic view 
that prescribing activity is an exclusive right and that new measures undertaken by the 
government threaten these rights. Hence, some participants felt that it might be hard 
to amend prescribing practices with a couple of momentary interventions because their 
prescribing behaviour had usually been established over a long period since their years 
at medical school. 
12.4.4.2 Flaws in policy-making process 
Another key challenge identified during discussion, was that there were some inherent 
flaws in existing policies and the policy-making process, possibly preventing policy 
programmes from being successful. In this regard, three sub-themes were established; 
lack ofa systematic plan, lack of political will and lack of appropriate measures to 
foster the utilisation of less costly drug variations, 
Respondents gave a variety of anecdotal episodes that indicated the absence of an 
overall strategy could lead to drug policies being less successful. Episodes included, for 
example, the cacophony between schooling contents and policy programmes, the 
failure in the Introduction of a reference-pricing programme, the delayed progress of. 
the positive list system, the dissonance among policy programmes, and the loopholes 
In some established programmes. 
Doubts concerning the value of a prescribing budget were closely linked to this issue. 
In theory, participants felt that prescribing budgets might be a useful alternative to the 
current payment system. However, in further discussion, they were unanimous in 
pointing out that it might not be currently feasible because there have been few 
considerations concerning appropriate budget allocation both at research- and 
administrative-level. 
Im not sure if we are going to be able to cant' this [prescribing budget] out in a short period of 
time. We don't really have any Ideas or previous research on how to allocate the budget... 1 just 
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don't think we're ready yet. (p017: 42) 
Participants often concluded that the absence of systematic planning of policies 
resulted from the dearth of available evidence. Another example frequently cited was 
that there has been little guidance backed by robust evidence in pricing agreements. 
As a result of this, discussion between the authority and manufacturers tends to be in 
difficulty by being either operated under monopsony power or governed by the 
Influence of the industry. 
I've heard that there have been some cases where certain negotiations were made under such 
monopsony. (p006: 20) 
Its no surprise that pharmaceutical companies dominating that type of information draw people 
Into their circles with their logic and reason. (p006: 26) 
The lack of political will seems to make the situation worse, Many participants vented 
disappointment when they spoke out on this issue. According to their observations, a 
weakened political will generated the following consequences in practice: 
First, it often distorts the original proposal of policies even after implementation. For 
Instance, according to one participant closely involved in the positive pharmaceuticals 
list, the master plan and affiliated economic evaluation was weakened over time by 
downsizing products on the must-do list as political will was discoloured by a variety of 
interests. Second, it prohibits programmes from being applied in practice as according 
to original intentions. Third, it avoids establishing policies with which powerful 
stakeholders such as doctors are in disagreement. The second and third aspects are 
well described in the following statement. 
So basically, there Is already a structure for this, but Tust not In a more concrete way. Also, they 
can't really do anything when It comes to the cultural aspect of medical professionals, which I 
think Is the most vital part. (p014: 39) 
Participants argued that pricing-centred policies had become one of the greatest 
weaknesses in the current system. They recognised that the current rising trend In 
drug expenditure had been mainly driven by an upsurge in drug utilisation (see Annex 
26h). In addition, participants felt that a product shift towards more costly drugs might 
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be as important a factor as volume in rising pharmaceutical costs. They suggested that 
the trend could be curbed not by pricing policies, but by policies encouraging the 
utilisation of less-costly drugs such as generics. 
The problem with South Koreas current polities is that they're price-centred, controlled ones, so 
they keep on lowering the price anyway. But there 87 a limit to that. We need policies that can 
encourage us to use drugs, or ingredients that are not as expensive. (p006.22) 
12.4.4.3 Excess profits in generic business 
Thirdly, participants suggested that generic prices have remained at a premium in 
Korea with the purpose of fostering innovation; however, the surplus might not be put 
into R&D activity, but would allow manufacturers to lobby professionals to prescribe 
their products. Currently, a generic product can be listed on the reimbursement list 
only if it provides a 20-30% price cut over its brand counterpart. Under the current 
pricing structure, they argued, it would be more attractive for manufacturers to spend 
money on lobbying prescribers to augment their profits than to invest In the research 
and development of new drugs. 
since generics are relatively at a premium price, the manufacturers continue to be In generic 
business for profit rather than to Invest that money towards researching and developing new 
drugs, Its natural from the manufacturers'perspective. (p017: 64) 
I don't think the drug Itself Is very pricy. However, one of our countrys biggest problems Is that 
we tend to use drugs that are relatively high in price. This is because expensive drugs have 
more surpluses, which can cause Illegal financial rebates In the end. (p019: 24) 
On the whole, these factors may not be separated, but are closely linked. Generous 
generic prices may produce surplus, allowing lobbying activity for prescribing excessive 
brand generics and/or for generous pricing. As a result, generic producers can maintain 
the growth of expensive generics markets and/or the pricing system allowing premium 
prices for generics, which produce further profits for lobbying activity. 
12.4.4.4 International trade relationship 
The fourth issue was related to the original industry. Participants invariably expressed 
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concern about the lethargic situation in South Korea. This seems to be caused by the 
fact that the original Industry Is mostly comprised of transnational corporations (TNCs), 
Almost every powerful `big pharma' has its headquarters in the US or Europe where 
Korea has its top trade partners. The situation was broader in perspective and Included 
other businesses, such as the automobile Industry, not just healthcare. 
In line with this, one participant emphasised a concern about accessibility to essential 
medications, giving anecdotal examples of unethical business by original producers 
having refused to offer their products for some years. 
South Korea still doesn't have much control when It comes to certain leading products, and 
there I! a chance that International companies might even refuse to offer their products to us 
(p019.36) 
Another participant testified that this situation has also prohibited the Korean 
government from introducing policies encouraging the use of generics because some 
policies can be appealed against as protective policies. For this reason, he supported a 
reference-pricing scheme, arguing that it might be less likely to be regarded as 
discrimination against TNCs because their products could be fully reimbursed by 
reducing prices below the reference price. 
Since America has plural Insurers, they tend to Implement generic policies easily with thinking In 
the way that someone else will eventually use the brand name anyway. However, [we have a 
single central Insurer so] if we use generic policies, then It would end up being misunderstood 
as protective trade polices. (p028; 40) 
12.4.4.5 Worries over consequences on patients 
Lastly, it appeared that participants paid considerable attention to the potential 
consequences of policies on equity such as reducing accessibility to medication. The 
following remark reflects the basic thought of participants. 
I think It should be the final factor that we carry out this or that which doesn't harm In 
consumers. (p030: 16) 
Participants who currently or previously were engaged with government bodies voiced 
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explicit opinions over this issue during interviews. Other participants expressed this in 
implicitly, either in the questionnaire or in interviews. Figure 12-4 indicates that 
participants regard equality in medication use as more important than cost control. 
Figure 12-4: Should-be-tackled issues in the future policies 
rational use of medicines 9 
equity 5 
cost control 4 
priority setting ýAIý 4 
accountability and transparency 2 
consumers' right 2 
improving efficiency 1 
competitive phamraceutical industry 
Private payment in Korea remains high as a percentage of total health expenditure. 
Respondents were concerned that much financial burden fell on Korean patients at the 
point of use. Greater concerns were shown that this burden might have a 
disproportionate effect on those with chronic diseases. 
Even though we are covered by insurance and can go to a hospital whenever we have to, still 
there are many cases when you can't even go if you 'e in extremely critical condition. (p048: 42) 
12.4.5 Prospects for the future policy 
The last theme brought together ideas about the 'prospects' of pharmaceutical policy- 
making in South Korea from the participant's perspective. Running parallel to the 
subject of challenges were the prospects for future policy. Participants' perceptions for 
future policy were primarily formed based on their opinions of the drawbacks in this 
area. Hence, participants frequently referred to challenges and prospects together. 
They suggested distinctive approaches to each of the five stakeholders in the 
pharmaceutical arena. These included: applying more compulsory measures to 
providers; efforts for a sound system at government level; a differential copayment 
system for patients; bringing greater competition to the generic industry; and 
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developing diverse strategies against the original industry (Figure 12-5). 
Figure 12-5: Illustration of themes: Prospects 
Applying compulsory measures 
to providers 
Efforts for a sound system 
at governmental level 
A differential copayment system 
for patients 
Greater competitions 
in the qeneric industr 
Developing diverse strategies 
against the original industry 
Overall, participants felt that multiple approaches were needed. They often stressed 
that no individual measure would be sufficient and were keen to suggest a range of 
methods that would influence stakeholders in different ways. The important point that 
they invariably made during interviews, was a balance between influences and 
interests, with the prime purpose of improving people's welfare. 
Whether you're a doctor or a pharmacist or a consumer, I just hope they all can at least try to 
understand each other instead of focusing on either their own personal benefit, or their group. 
(p030: 57) 
I think it's important for people to be open-minded and try to find what best for our nation 
people. (p019: 40) 
Providers Participants proposed to introduce compulsory measures applicable to 
healthcare providers from two main angles. First, mandatory standards could foster 
less-costly alternatives, as well as reducing professionals' power in product choice. 
Examples of mandatory standards included letting patients play a more active role in 
choosing, and setting a clear, pre-determined standard, such as mandatory substitution 
with the lowest priced product at the dispensing stage. Second, they insisted on 
imposing strict punitive measures not only to the industry, but also to providers, in 
order to curb improper relationships between them. Otherwise, they thought, it might 
be hard to achieve proposed policy impact, whatever they were. 
Authorities Participants felt that government bodies ought to make a greater effort 
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in constructing a robust system across the whole of the pharmaceutical arena. The 
discussions dealt with a variety of topics that should be top priority for the Korean 
pharmaceutical system, such as the value of evidence, trust, transparency, public 
funding and consideration for the vulnerable. 
Among them, ideas over transparency in policy decisions, channelling more public 
funding into evaluation and welfare security attracted more general remarks as follows: 
though this may sound a very theoretical and like one of those "Confucius sayings. "...... the 
government should continuously make an effort to enhance logical solutions, rationality, or 
clarity when carrying out policies. (p006.32) 
More practical dialogue concerned evidence and trust. Central to the discussion of 
evidence was the role of the government in establishing a system that may take 
comprehensive responsibility for synthesis and dissemination of policy evidence. They 
expected that the system could facilitate the whole process of policy-making from 
planning to evaluation. 
I think /ts Important for the government to focus not only on the quantity aspect of establishing, 
evaluating, and promoting the policy evidence, but also on processing it in a more systematic 
way. (p047: 4) 
Among others concerns in the Issue of trust, participants stressed the urgent need to 
convince society of the quality of generic products. They invariably argued that many 
generic policies could not be promoted with full confidence until a good process of 
quality control is accomplished. They suggested that KFDA should strengthen the 
standard of manufacturing practice and introduce a follow-up monitoring system. With 
this as a basis, KFDA must show greater confidence In the quality of generics to 
acquire social support. 
Patients. A dual approach was suggested for controlling patient demand. On one 
hand, efforts should be made to enlighten patients on the Issue of finite resources In 
healthcare. On the other, a differential copayment system was proposed, which 
required higher copayment for the use of symptom-relief drugs. This was linked to the 
concerns about social Inequity, which were universal among participants. Some 
participants, In this respect, felt that a reference-pricing programme might help to 
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Increase patients' price sensitivity without restricting their access to medication. 
Not surprisingly, participants who were sceptical about regulating professionals - they 
viewed policies influencing professionals unworkable in the short term - were more 
likely to stress measures for influencing patients. 
Technically, the most Important thing to do Is to p/ace both doctors and pharmacists under 
control, but that's easier said than done. So consumers would be the ones who would be 
directly affected by it.... (p030: 35) 
Generic industry, Many participants strongly adhered to a direct price control, 
showing a deep concern about corrupt transactions In the market as follows: 
I can't really think of a good way to ensure this price competition unless we get rid of all the 
///egal trading we discussed so far. (p048.58) 
A few practical suggestions, such as a significant initial price cut and elimination of 
unqualified products from the market, were made to encourage greater price 
competition. Participants agreed that this competition included all products, regardless 
of originality, if patents had expired. 
After patents expire, I think the price competition should be more In force. I also think -- 
consumers pay much more than a marginal cost on the products not resulted from the R&D Just 
In order that such extra expenses can help maintain a certain Industry- Is really unnecessary. 
(p04722) 
Or/g/na/industry. Participants generally felt there was a great necessity to develop 
diverse strategies in order to manage trans-national originators, but with little idea of 
how to go about this. Some ideas appeared to control the original industry, for example, 
imposing limitations on data exclusive rights, or introducing a performance-based risk- 
sharing scheme recently Introduced In some nations such as Australia. However, in 
general, they failed to make pragmatic suggestions. 
281 
12.5 Discussion 
In order to implement an effective strategy, it is essential to probe nation-specific 
factors influencing policy and policy-making, as policy outcomes can vary according to 
"the interactions" among those factors (Guillen and Cabiedes, 2003). This was echoed 
in the systematic reviews, which showed that each policy intervention was introduced 
with a quite different figure and produced diverse results across settings. In South 
Korea, despite substantially different environments in the pharmaceutical arena, there 
is little information on how factors interplay with the drug policies or how policy- 
makers determine and evaluate them. In this study, participants discussed how and 
why policy research has remained a neglected field in Korea, identifying three main 
themes: evidence; challenges; and prospects. 
12.5.1 Issues over evidence 
Participants have recognised the Increasing need for good quality evidence in policy 
decision making. Whilst this need was identified, Korean policy-makers often seemed 
faced with limitations to the research evidence they could use in practice. Quality of 
available evidence is generally acknowledged as being poor and single-faceted. 
One notable aspect observed during discussions was that participants tended to speak 
less positively about policies In which they were more closely Involved. Presumably, 
because they, `insiders, had greater opportunity to know about the facts and the 
`negative' aspects of the case, they were more critical. `Outsiders' may have fewer 
chances to do this. This may be fostered by two situations. First, the government Is 
more likely to release favourable evidence. Second, there Is scant research that deals 
with the negative aspects of policy that generally needs a further step analysis. This Is 
understandable when considering the quantitative analyses In the preceding chapters. 
The unexpected consequences of polices - for Instance, limiting patient access to 
essential drugs - has not been recognised In the first general analysis (Chapter 9 and 
10). 
Given this limitation, although participants generally expressed positive views regarding 
the selected policies (see Annex 26f), these might not reflect the reality of those 
policies, But it might be shaped by the limited available evidence, suggesting a 
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considerable bias in the current perceived policy impact. In line with this, the evidence 
they quoted frequently overlapped, implying that the source of information may not be 
sufficiently diverse. Whilst discussing selected policies, participants seldom cited 
references using a scientifically advanced analysis, but mostly gave simple aggregated 
numbers or anecdotal episodes. They occasionally supplied groundless or intuitional 
comments. 
Discussions were frequently theoretical when evidence was lacking. In general, 
opinions on recent policy, for example the PERP, were more likely to reflect participants' 
expectations, rather than the real impact of the intervention. Irrespective of the 
programme, comments about consequences mostly concerned the shortcomings of the 
policy programmes themselves. Few participants spoke about the side effects of the 
policies on other pragmatic variables (for example, utilisation or costs in relevant 
healthcare services, or drug accessibility). 
Faced with the limitations of available evidence, some suboptimal sources of 
information, such as a policy monograph mainly detailing a foreign system, remain the 
important tools for supporting policy decisions. Careful consideration seems to be 
crucial with this type of information in order to learn from "reflecting on information", 
not from "exotic information" (Klein, 1997; Rose, 2005). Linked to this, Wilson et al.. 
(2007) argued that evidence should be considered from a broader perspective 
than "hard facts and figures", including judgment, opinion and belief, research, data 
generation, and analysis. 
Throughout the Interviews, it was apparent that evidence had not played a central role 
In drug policy-making In South Korea. Political and Industrial perspectives often ruled 
the policy cycle. An interesting facet of this subject was that fewer participants ranked 
interest groups before scientific evidence. However, this does not seem to represent 
reality, but rather what they felt should be done or what they would try to do from a 
personal perspective. It became clear during Interviews that participants, In fact, 
frequently reiterated the influence of Interest groups In the drug policy process. 
Strong unscientific Influences may, in part, be fostered by the fact that available 
evidence was not sufficient to form a store of knowledge for future programme 
developments, more effective Intervention Implementations, and enlightened policy- 
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making. Therefore, the need to produce evidence is an ongoing issue, and is expected 
to continue, if the evidence gap is to be filled. 
12.5.2 Challenges and prospects 
Table 12-3 presents core prospects suggested by participants along with key challenges 
they recognised. In general, policy-makers did not just take account of costs, although 
overall they were in agreement that economic forces often precipitated policy changes. 
Table 12-3: Challenges and rospects emerged during Interviews 
Challenges Prospects 
Resistance from doctors Controlling the dominant power 
Increasing a consumers' role 
Legal discipline on Illegal profits 
Flaws in the process Systematic planning 
Building proper infrastructures 
Overplus In generic business Promoting competition 
International trade relationship Making a policy strategy diverse 
Potential decline of patients' welfare A differential copayment system 
Increasing public awareness on the Issue of a finite resource 
It would appear that participants had experienced some of the greatest difficulties with 
powerful professionals, whose resistance to policy implementation might not be a 
situation unique to Korea. It was certain that the threat of physicians undermining an 
unpopular programme and choosing not to practice under certain conditions was one 
of the great barriers in most healthcare systems (Ameringer, 2002; Harrison and 
Wistow, 1993; Salter, 2004a). Also, underlying factors specified as the sources of 
resistance seem to overlap with findings in other settings (Brust etal., 1990; Sekimoto 
et al., 2006). 
Interestingly, participants often perceived certain factors to be much stronger In Korea, 
including illegitimate profits, conflicts among professionals, and distrust of generics. It 
is unclear the extent to which such perceptions are supported by robust evidence in 
this study, as the discussion was mainly on an Intuitive basis and little research is 
available that provides background information on this. Despite such limitations, it may 
not necessarily be groundless. The point is that such difficulties seem a vital underlying 
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cause why many potential policies have gone no further than the pilot stage, a typical 
example of which was generic prescribing. Arguments by sceptics on generic 
prescribing were exactly In line with the challenges stated so far, and very practical, 
while those from supporters were more likely to be theoretical (see Annex 26g). It is 
thought that opinions from sceptics may be closer reality. The reality is that the 
programme was severely opposed by doctors as soon as It was put Into place in 2007, 
although only as a pilot attempt within a single hospital (DailyPharm, 2007a). The 
majority of doctors expressed strong concern about the safety and effectiveness of 
generic medicines and the role of the pharmacists who would take responsibility for 
product selection under the new programme (DailyPharm, 2007b, 2007c). 
Suggestions from participants on how to hold back the resistance from powerful 
professionals can be separated into two types: limiting professional autonomy; and 
legal discipline. In addition, the need for a new paradigm in medical education was 
called for, although that voice was relatively weak. 
Notably, considerations about efforts to find a point of agreement between the 
authorities and the professionals were surprisingly faint. Participants entered into little 
argument concerning the issue that reliable evidence would generate good persuasive 
power (Cookson, 2005). For instance, most arguments over the perception of the 
safety and effectiveness of generic medicines were not expanded beyond the blo- 
equivalence test. Many participants showed feelings of helplessness towards the 
misconception of the bio-equivalence test among doctors, but they rarely sought other 
ways of verifying the quality of generic products. Examples may include a cohort study 
Investigating clinical outcomes from generics over several years, in comparison with 
those by original products, which would be more likely to be accepted by doctors who 
are familiar with such research frames. 
Rational policy may also be Impeded by complex factors such as Improper policy 
environments, robust Industry, and International trade power. The Issues and 
prescriptions over some of these subjects seem closely linked to those concerning 
evidence, such as the shortage of available evidence, Immature Infrastructures, the 
presence of other influences, or the lack of resources and organising capacity. One 
notable point In this respect was that there was surprisingly little pragmatic discussion 
regarding setting societal priority, although this Is particularly urgent In South Korea, 
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given pervasive anxiety across the whole society. In some sense, developing a sound 
healthcare system starts with setting an agreed priority in the use of limited resources. 
This can soothe tensions among stakeholders and show an easier method of finding a 
point of agreement when Interests clash. Presumably, this is caused by the tradition of 
government-led development in modern Korea. In the past, society has been used to 
following what the decision of the authorities. Nowadays, setting societal priority is 
undertaken largely in a vacuum, as the government's authority has weakened and 
various decentralised powers are becoming stronger. 
Relatively less attention was paid to measures tailored to the industry, Many 
participants expressed the difficulties of In-depth discussion on this subject because of 
a lack of understanding of industrial mechanisms. Participants perception of the 
generic industry was largely in line with the findings in the empirical study of this 
thesis (Chapter 10). Central to discussion was concern about a price bubble in generics, 
even with the existence of a long-lasting price regulation. 
Participants invariably called for building a competitive condition in the generic market. 
On this Issue, some writers argued that abolishing direct price control would be helpful 
In constructing a more competitive market in the US (Danzon and Chao, 2000; Danzon 
and Furukawa, 2003). Others suggested that direct price control could provide 
Incentive to companies to develop `me-too' products with little innovation but higher 
prices, or to encourage moral hazard through heavy marketing (Guillen and Cabiedes, 
2003; Jacobzone, 2000). In contrast to these, Korean policy-makers rarely think that 
the abolition of price control is helpful 'to enhance competition In the Korean market. 
They were deeply concerned about corrupt transactions in the current market, which 
could distort competition under the absence of direct price controls. Their opinion is 
that the current pricing system for generics requesting only a small price cut from that 
of brand counterparts should be changed and prices should undergo a considerable 
reduction. 
Regarding the original Industry, although there was profound awareness among 
participants of the need to develop multi-faceted strategies towards the original 
Industry, actual discussions were rarely noted, It was agreed that few methods would 
be effective to curb such a strongly profit-oriented business within a single nation. The 
Korean situation appears especially difficult, because the Korean economy is mainly 
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dependent upon international trade (Lee and Kim, 2005). Many domestic drug policies 
have not only been opposed by private companies, but have also undergone 
considerable pressure for trade talks with their home governments (Lee, 2004). A 
recent example is the Free Trade Agreement with the US, which offered a clear 
objection to the PERP (DongA Ilbo, 2006). 
Participants acknowledged that social inequity was augmented by insufficient insurance 
benefits and high private payments. However, none of them thought copayment 
useless. They argued for the Importance of controlling patients' extravagant behaviour 
on one hand while channelling the savings for the vulnerable on the other. For this 
purpose, participants were unanimous concerning the need for a differential 
copayment scheme. But, as presented in the systematic reviews, a differential system 
also has a weakness of reducing access to medications if it designs drug categorisation 
Inappropriately. 
12.5.3 Obstacles to evidence-based policy-making 
To recap the themes, four dominating ideas were specified as obstacles to evidence- 
based policy-making In this particular setting: shortage of resources; absence of 
systematic arrangement; lack of trust; and nature of policy-making. 
The first concern was the shortage of resources. Resources ranged from a qualified 
workforce with training, experience or analytic techniques necessary to discern optimal 
strategies, to a network of individuals, organisations and relevant information (for 
instance, epidemiological studies on local population). These may be directly 
associated with the lack in quality and quantity of evidence. 
Second, there was the absence of a systematic arrangement for both planning and 
evaluation frameworks. Since resources for a robust system as stated above cannot be 
established in a short time, It seems essential to organise the different activities and 
individuals or organisations involved in the system to work together in the long term. 
However, in South Korea, the conventional milieu has made policy changes that are - 
sudden and rash. The consistency of a policy has often been ignored. The demand for 
policy change has been formed in a top-down manner, irrespective of evidence and 
then, evidence seems to have been used to justify decisions already made. Within this 
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environment, it may be hard to implement a systematic plan for constructing an 
evidence-based tradition, or set an agreed priority for resource allocation. These 
situations are presumably brought about by a lack of transparency and accountability 
in the policy cycle. Reciprocally, the transparent process can hardly be instituted 
without careful systematic planning. 
Third, it has been brought up in all discussions that the Korean pharmaceutical arena 
has suffered from a significant lack of trust. The belief that illegitimate activities have 
distorted the market order and, consequently, there has been little adequate response 
from pharmaceutical policies so far was universal among participants. Doubts were 
raised between different professional groups, professionals and the authorities, the 
government and manufacturers, or policy-makers and researchers. 
For Instance, on the subject of doctors' resistance, the participants remarked on 
doctors' distrust over pharmacists, quality control of generic products and policy itself 
as underlying causes on one hand. On the other, they voiced their own doubts about 
professionals, expressing the perception that undisclosed interests were a source of 
policy resistance. While it is Inconclusive in the present study how significantly such 
doubts can be supported on scientific grounds, it becomes clear that distrust Is linked 
with the transparent process of policy-making. 
The final Idea participants kept returning to In all themes was to the nature of policy- 
making. To some degree, they acknowledged that it was unavoidable that policy 
decisions could be made differently from what the evidence suggested. As stated 
several times throughout this thesis, policy-making Is an activity Influenced by many 
Internal and external factors that comprise political, social, cultural and economic 
aspects. Hence, It Is thought that the central trait of policy-making is to find a way to 
balance Interests and Influences from a variety of perspectives, which may not always 
be rational. This means that scientific evidence is part of the decision but not the 
whole - and worse, Is often less robust than other factors. Even though this was 
admitted In full, It was Invariably testified In discussions that other considerations 
beyond scientific evidence were stronger than necessary in South Korea. Possibly this 
severely reduces a general perception about the significance of evidence-based policy- 
making, as well as sound research. Consequently, there seems to be a gap where bias 
from outside can enter the policy process, 
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These premises largely overlap with findings in an earlier study that systematically 
reviewed barriers to the use of evidence by policy-makers (Innvaer et al., 2002). The 
authors argued that barriers were "the lack of timeliness or relevance of 
research", "mutual mistrust", "power and budget struggles", "poor quality of research", 
and "political instability or high turnover of policy-making staff"; The idea of systematic 
arrangements in this study indicates the breadth of the concept - ranging from policy. 
making to evaluating, while "political instability or high turnover of policy-making staff" 
focused more on policy-making. Dialogue about personal contact between researchers 
and policy-makers was not apparent in this study, unlike other articles (Choi et al., 
2005a; Innvaer eta/., 2002; Sharpe, 2004; Soumeral eta/., 1997; Wilson eta l., ' 2007). 
This may partly be due to the absence of evidence; any available body of knowledge 
may be still weak and insufficient to notice whether the policy-makers and scientists 
disagreed. 
Unfortunately, in Korea, the milieu for "evidence-based' policy may not be easy to 
realise In the short term, since the underlying causes of the current situation are 
largely the result of a long-lasting and stubbornly held tradition. In order to diminish 
the tradition, and to build a positive atmosphere for evidence-based policy-making, live 
debate should be encouraged more often, in order to raise social interest in this area. 
12.6 Study limitations 
There are some limitations to the study. Firstly, it was designed with a small, selective 
sample of policy-makers from a limited number of organisations and mostly with a 
background In pharmacy. This was, In part, a consequence of the snowballing sampling 
technique used. Participants Identified by this technique were necessarily within 
personal connection networks and more likely to have homogeneous characteristics. 
This certainly limits the generalisability of the study. However, the present sample is 
regarded as typical of policy-makers involved with pharmacy policy, given the culture 
for allotting duties in government bodies in Korea -a person with a background In 
pharmacy is more likely to be involved In pharmaceutical affairs, Moreover, there was 
little evidence in the data that their academic background circumscribed their views to 
any degree. Rather, they expressed a wide range of opinions, giving the researchers a 
much better understanding of the process from the themes that emerged from the 
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data. 
Secondly, the participants tended to have a range of perspectives based on their 
experiences. Some spoke distinctly personally, others appeared to see themselves as 
spokespersons for others in a similar situation or in their organisation. Some addressed 
topics, frequently reflecting back to their own experiences, while others took a more 
abstract view and dealt with questions from a theoretical standpoint. Many participants 
appeared cautious about making comments on record that would end up in the public 
domain, which potentially made their comments more abstract. 
Thirdly, the questionnaire employed for this study created some further issues. It was 
certainly helpful in reducing the time spent on interviewing by quickly getting to the 
point of the discussion. However, it put up certain limits to discussion, even though it 
was used solely for the purpose of initiating dialogue in this study, For example, it 
sometimes impeded participants from discussing issues more deeply and in an 
extensive context beyond the examples displayed in the questionnaires in issues 
concerning potential influences or possible future policies. In addition, some 
differences arose from vague understanding of the intrinsic purpose of inquiries in the 
questionnaire. 
To the best of my knowledge, this is the first study to investigate Korean 
pharmaceutical policy-making in a qualitative manner. This exploratory study has 
identified many of the issues involved in pharmacy policy decision-making for those 
individuals who occupy these roles in Korea. The issues identified here could serve as a 
platform for future research - both qualitative and quantitative, that could explore any 
of these themes in greater depth and across different policy-making contexts. 
Given one of the advantages of mixed methods that a qualitative research Is a useful 
tool to explore the reasons behind the quantitative findings, this thesis would benefit 
from addressing what caused patients to reduce their utilisation of antihyperlipidemics 
after the copayment Increase (Chapter 10). The limitation of time and relevant data 
Identifying proper Interviewees for this aim did not permit this in the current study. 
Further qualitative exploration Is recommended to address these questions, 
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12.7 Summary 
Through in-depth interviews with eight policy-makers involved in the pharmaceutical 
arena, this study found four potential factors hampering evidence-based policy-making 
in the South Korean context: the shortage of resources; the absence of systematic 
arrangements; the lack of trust; and the nature of policy-making. The key challenge 
may be the apparent lack of available evidence. This has been caused by several 
features, such as a scarcity of qualified researchers and background knowledge, or the 
absence of coordinator. Some strong influential factors arising from the study 
confirmed the presence of policy-based research environments in Korea. There were 
also some concerns about the quality of evidence currently available, since most of 
them remained at the stage of theoretical or superficial information. Discussion on the 
impact of current policies confirmed that evidence investigating policy consequences 
has certainly been neglected, creating some bias in the perception of policy-makers. 
The awareness of the need to move towards an Information-based and outcome- 
oriented strategy is Increasing among Korean drug policy-makers, as policy decisions 
have been affected by more decentralised powers. The role of the central government 
was claimed to set the tradition of evidence-based policy-making by arranging policy 
planning and evaluating In a systematic manner. So far, Interests over building up the 
store of reliable information or setting priorities for policy decisions have been weak 
across the whole society. Stimulating social debates in this field seems crucial to 
improve the current situation. Good research can, of course, stimulate this debate. 
Thus, the need to produce high-quality evidence Is ongoing, and is expected to 
continue In South Korea. 
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CHAPTER 13: CONCLUSIONS AND FUTURE RESEARCH 
OPPORTUNITIES 
13.1 Introduction 
This thesis began with three questions: 
  What is known internationally about the impact of policy interventions in the 
pharmaceutical market? 
  What has been the effect of Korean pharmaceutical policy interventions? 
  What are the contextual factors creating gaps between evidence and practice, 
and the challenges of evidence-based policy-making in the Korean pharmaceutical 
market? 
To find answers to these questions, the study has been accompanied by three core 
concepts - mechanism, context and outcome, suggested by Pawson and Miley (1997) 
for `realistic' policy evaluation. 
Chapters 1 and 2 were devoted to shaping the research agenda, which presented a 
general background of 'mechanism' and 'context' of interest in this thesis. The first 
chapter briefly introduced evidence and the causes of market failure In the 
pharmaceutical sector from a welfare economics perspective. This demonstrated that 
the prime reason for pharmaceutical policy is to control the factors that make the 
pharmaceutical market fall. This was followed by a general introduction to public 
regulations which strive for cost control, efficient and equitable allocation of resources 
in this market, 
Chapter 2 first outlined the salient environments that are seen In South Korea, and the 
perception that policy impact is contingent on nation-specific conditions. This led to a 
related argument that there Is a pressing need for evidence-based policy-making in 
each setting to lessen uncertainties originating from divergences In contextual factors. 
In order to build sound scientific grounds for policy-making, it is essential to evaluate 
policy outcomes with empirical data from individual settings, accompanied by study of 
international experience. In this regard, Chapter 2 also explored scientific tools for 
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policy evaluation in general, and specifically those relevant to this thesis. 
From Chapters 3 to 7, the effects of international pharmaceutical policies were explored 
in systematic reviews of published studies. In conducting this review, it was Important 
to acknowledge the set of general mechanisms through which pharmaceutical polices 
work across nations, to understand the original contexts in which policy mechanisms 
were successful or failed, and to learn lessons for Korea and for this thesis. 
Based upon findings from the systematic reviews, empirical investigations were 
conducted in the third part of the thesis, from Chapters 8 to 12. Firstly, Korean 
pharmaceutical claims were investigated in a quantitative way to examine the actual 
impact and consequences of two recent policies. This gave an opportunity to discuss 
similarities and differences between policy outcomes in the Korean context and from 
the results of the systematic reviews. 
Finally, In-depth Interviews were conducted with Korean experts who are closely 
involved In the pharmaceutical policy cycle to explore potential contextual factors that 
result in gaps between evidence and practice. A primary focus was on revealing 
contextual challenges in evidence-based policy-making in the Korean pharmaceutical 
market, in order to improve future decision-making. 
In this concluding chapter, the following issues are discussed: 
  reflection of the methods used in this project; 
  key findings and implications from the main chapters; 
  strengths and weaknesses of this project; 
" recommendations for Korean pharmaceutical policy; 
" knowledge gaps for future research; 
  concluding remarks. 
13.2 Reflection of the methods used in this project 
In this section, the methods used in this thesis are discussed critically with a focus on 
the types of problems that other researchers In the field of pharmaceutical policy 
research may encounter when conducting similar evaluations. 
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The systematic reviews provided a good foundation for the empirical research 
conducted. However, by only selecting three robust study designs this may have lost 
Information that was more relevant to the local study setting of the empirical 
exploration. Within the systematic reviews, the synthesis of Information from such 
diverse studies was challenging due to the heterogeneity between studies, not only in 
policy environments but also in measurement units and concepts of each study. 
Policies are often introduced without thought to how they could be evaluated, and 
interrupted time series analyses are often employed to evaluate such interventions 
retrospectively. The main challenge with this approach is obtaining sufficient numbers 
of observations for analysis. Insufficient observations create a number of problems, 
especially for analytical techniques. As the researcher is often unable to control when a 
policy Is Introduced, or indeed when the next policy is introduced, then it is not always 
possible to obtain a large enough sample to provide robust results. 
Within this thesis an autoregressive integrated moving average (ARIMA) technique 
could not be used as the primary analysis due to a shortage of time points after the 
Interventions, but the number of data points did allow use of segmented regression. 
Although segmented regression is used often in pharmaceutical policy studies, It has 
one Important limitation relating to the assumption of Independent error terms. Hence 
It Is Important to test and correct, If necessary, for autocorrelation. The Durbin-Watson 
adstatistic, is one such test that Is used to detect autocorrelation, however, there Is no 
consensus on the most appropriate technique to address autocorrelation, One 
approach to correct for autocorrelation is to use a generalised least squares estimator, 
such as the Prais-Winsten estimator. The Prais-Winsten estimator, used In this thesis, is 
a method used to correct for first order autocorrelation. Whilst first order 
autocorrelation Is the most frequently occurring type it is possible that higher order 
autocorrelatlon may have been present In the data and this may have led to 
misspecification of the model. Although It Is worth noting that while other possible 
scenarios of autocorrelatlon (e. g. higher order autoregressive structures) could 
potentially arise, they are much less likely to occur when using real world data, 
With these potential limitations of segmented regression, within this thesis, the ARIMA 
approach was chosen as a sensitivity analysis to check the robustness of the results 
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and conclusions drawn. ARIMA was chosen as it was the one of the most commonly 
used techniques in pharmaceutical policy studies, as highlighted in the systematic 
reviews. The experience gained from undertaking the ARIMA analysis identified that 
the best fitting models from the overall diagnostic results still produced spurious 
appearances in some of the residual analysis graphs, which required a close 
examination of competing models to determine the intervention effect. Although the 
coefficients from the models varied somewhat, the direction and significance of the 
results remained robust across closely competing models, which provided more 
confidence in the outcomes from the segmented regression analyses. 
When comparing the two techniques, segmented regression was more useful than 
ARIMA given the complexities involved In specifying the ARIMA models and in 
Interpreting the results. Upon reflection, since both methods of analyses gave similar 
results It may have been sufficient to only undertake segmented regression analysis. 
However, the experience gained from undertaking both segmented regression and 
ARIMA analyses would lead me to conclude that both techniques were required for the 
datasets used in this thesis. No method could be completely advocated but undertaking 
both analyses led to more confidence in the results. This approach is recommended to 
other researchers in the field facing similar data issues. 
Qualitative methods were used as a contrasting, but complementary, approach to 
penetrate the subject of evidence-based policy-making in this thesis. It tackled the 
contextual issues surrounding pharmaceutical policy in South Korea, which is a subject 
that has been addressed rarely by quantitative or qualitative exploration in a 
comprehensive way. 
The questionnaire that was undertaken prior to the qualitative analysis was useful in a 
number of ways. Firstly, lt was helpful in distinguishing between potential Interviewees. 
For example, eligible Information-rich personnel could be distinguished from 
administrative personnel or those who held less relevant roles In the policy cycle. 
Secondly, It assisted the researcher to have pragmatic Information about Individual 
participants and to build interview questions that were more pertinent to each 
participant. Thirdly, It led participants to have a greater understanding of the purpose 
and scope of the study. This may have limited the scope of discussion and if probed 
deeper on other subjects may have led to different insights. Upon reflection, the 
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qualitative research was worthwhile undertaking and provided a greater understanding 
context of pharmaceutical policy-making, which could not have been gained through 
using quantitative methods alone. 
13.3 Summary of findings and Implications 
13.3.1 Evidence of policy impact across nations 
Following a thorough electronic search strategy, 176 studies were identified and 
reviewed systematically. Structured assessment of drug policy studies raises complex 
issues regarding the validity, generalisability and transferability of specific research 
findings. 
Throughout, common challenges have been found across studies. All findings were 
subject to the limitations of available data and largely restricted to short-term and 
aggregate values. Although the reviews included only robust randomised controlled 
trials (RCT) and quasi-experimental designs to Increase the validity of results, studies 
generally had much room for improvement. For Instance, In RCT studies it was often 
unclear whether randomisation had been done properly; controlled before and after 
(CBA) studies occasionally failed to offer appropriate information about their study and 
control groups; and interrupted time series (ITS) studies had been limited by the 
quality of data sources. The quality of studies were slightly better in RCT studies and 
more varied in ITS studies, but the differences were not great and, in general, studies 
were of moderate quality. Studies concerning cost-sharing/ reimbursement restrictions 
were in particular of mixed quality; those concerning educational interventions/ tiered 
formularies/ reference-pricing schemes were generally rated as moderate quality; those 
addressing incentives were rated as moderate to low quality. Overall, the included 
studies were of very mixed quality, with little apparent association between quality 
rating and direction or strength of results. 
The three systematic reviews, focusing on policies targeting patients, prescribers and 
industry, highlighted that existing rigorous evidence is also limited in quantity. The 
paucity of evidence was discerned in three aspects: Intervention; setting; and outcome 
measure. The reviews found that existing robust evidence about the impact of 
pharmaceutical policies is directed to a small range of interventions: cost-sharing 
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programmes; educational approaches; North American reimbursement restrictions; 
British fundholding; and reference-pricing schemes. Most evidence was produced 
within limited settings. Strikingly, 78% of Included studies came from five countries - 
Canada, Spain, Sweden, the UK and the US. Almost no studies came from countries 
comparable with South Korea. Two studies exploring the Korean separation of 
prescribing and dispensing (SPD) were excluded as a result of unreliable methodology. 
Outcome measures of interest concentrated on the effects on drug utilisation and 
public expenditure after policy changes. Evidence about policy consequences on drug 
accessibility, private expenditure and other service utilisation occasionally appeared. 
Very few studies examined health outcomes, and of those that did, most employed 
surrogate outcomes. Thus, the causal relationship between pharmaceutical policies and 
health remains unanswered. 
Another factor limiting the generalisability of findings was that even a single policy has 
a range of different structures across settings. Consequently, a large divergence was 
found In policy outcomes. A number of factors influencing drug policy appeared 
repeatedly, Including therapeutic classes, intensity of the policy changes, patient- 
specific situations, market surroundings, characteristics of providers, concurrent 
policies, and some methodological factors. Additionally, a large number of underlying 
factors influence policy details, for example, determinants of clustering in reference- 
pricing, but extracted data from included studies did not allow these to be 
distinguished. 
Thus, it is difficult to interpret policy Impact without ambiguity for most settings. 
Nevertheless, some regularity about pharmaceutical policies was seen, which offered 
implications for this project and for South Korea. 
Firstly, policies focusing mainly on restricting, patient demand may be harmful to equity 
and health. Although some are carefully structured to reduce unnecessary utilisation or 
to facilitate less costly utilisation, they can still be a threat to socially disadvantaged 
populations who generally show greater price elasticity of demand in response to 
increases in out-of-pocket payments. 
Secondly, policies aimed at Improving prescribing behaviour seem to have an Impact on 
Improving efficiency In prescribing profile without compromising equity or health, If 
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they are supported by providers and well-designed information with good grounds. 
However, improved prescribing profiles may control total expenditure to only a limited 
degree. 
Thirdly, price control alone is rarely linked to success In cost containment. Jacobzone 
(2000) viewed this as the result of direct price control encouraging firms to seek 
"bypass" strategies such as `me-too' innovation or increasing the volume of sales. 
Reference-pricing, as an Indirect way of drug pricing, has been Increasingly 
Implemented to reduce costs by fostering price competition. However, it is unclear 
whether reference-pricing schemes achieve the intended objective In existing studies. 
Rather, they appear to produce similar outcomes and consequences to cost-sharing 
programmes. 
Fourthly, therefore, greater attention has been paid to the promotion of cost-effective 
use of drugs. In this respect, policies encouraging the use of generics have been 
attempted in a variety of areas. However, it has become obvious that generics can be a 
`cost-effective' option only if they have clinically interchangeable quality, sizable market 
share and lower prices. 
Lastly, careful consideration of the possible consequences followed by complementary 
policies may Improve policy results by reducing adverse effects. Here, 'possible 
consequences' vary considerably by local factors. It seems vital for a better future to 
make a careful exploration of potential local Influences before policy change and to 
examine the actual outcomes after their Introduction. 
13.3.2 Evidence of policy Impact In a local setting 
To explore the actual effects and consequences of Korean pharmaceutical policies, 66 
months of Korean pharmaceutical claims were investigated. Two recent policies, the 
Pharmaceutical Expenditure Rationalisation Plan (PERP) and the new cost-sharing 
programme, were examined using an TTS design in Chapters 8 to 11. While the PERP is 
a comprehensive policy package including four different sets of measures, a price 
control measure was mainly explored owing to the delayed implementation of other 
measures. Quantitative Investigation was followed by a qualitative study that explored 
contextual barriers to evidence-based policy-making In a local setting. Semi-structured 
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In-depth interviews were conducted with eight core personnel who were either policy- 
makers or influential experts affecting policy-makers. During the interviews, 
participants discussed how and why pharmaceutical policy studies have remained a 
neglected field in South Korea. 
The empirical research supported and clarified the messages from the systematic 
reviews. Quantitative investigation revealed that the new cost-sharing scheme might 
achieve the objective of cost containment to a limited degree, while the price cut did 
not appear to achieve any of its intended effects. In response to rising private expense, 
Korean patients were likely to reduce drug use not as a result of clinical need, but out 
of financial anxiety. Little evidence was apparent that supported the cost-conscious 
behaviour of patients owing to the copayment Increase. The copayment increase was 
likely to have achieved only a marginal policy effect, while Increasing social Inequity by 
discouraging patients from access to essential medication In some conditions. For 
example, copayments apparently had little effect on patients' access to 
anti hypertensives. By contrast, copayments were associated with a reduction in 
patients' access to antihyperlipidemics, that are generally more expensive than 
anti hypertensives in the Korean market. This raises concerns not only for long-term 
health consequences, but also in long-term prospects for healthcare spending. 
The sensitivity of demand to price Increases shown In the antihyperlipidemics market 
was unexpectedly large in Korea. Utilisation trends fluctuated according to policies - 
use went up after the price cut and down after the copayment Increase. Further sub- 
analyses demonstrated that patients with generic antihyperlipidemics might present an 
instant response to copayment changes, In comparison with the prescribed brand- 
named products, which showed a gradual effect. The most plausible explanation of the 
responses may be financial worries among patients who might be in the less privileged 
strata of society. International experience suggests that copayment Increases show 
little direct influence in patients with chronic conditions except In those from the 
socially disadvantaged group. Given the conditions of pre-existing high levels of 
copayment in Korea, in this regard, Korean patients under financial pressure have been 
more likely to feel the burden of needing costly long-term medications, to take generic 
products and, thus, to be Influenced more by cost changes. In addition, misconception 
about the new cost-sharing programme might in part influence a fall In use. 
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Another important feature uncovered In this thesis was that the gap between value and 
volume of generic share has been maintained at around 10 per cent In two chronic 
medication markets in Korea over more than 5 years. Two explanations were 
suggested by Korean policy-makers in the qualitative exploration. First, the level of 
generic prices has been determined generously just slightly below than that of brand- 
named counterparts in the Korean market. Second, among generics, expensive 
branded-generics have been more likely to be used. 
These might produce excessive profits for generic businesses and foster manufacturers 
concentrating on maintaining their generic market share by commercial marketing 
activity or me-too innovation. Two recent studies similarly demonstrated that direct 
price control might reduce generic competition and maintain generic prices at a higher 
level than would result In a competitive market (Huh et al., 2006; Shin and Choi, 2008). 
One branch manager of an International pharmaceutical company pointed out that 
original manufacturers often did not cut their prices even after going off patent in the 
Korean market because their products were still competitive with their generic 
counterparts (DailyPharm, 2005b). This finding implies that savings from generic 
utilisation may not be considerable In the Korean market in spite of a sizable volume 
share of around 30-50%. In the successive qualitative investigation, Korean policy- 
makers have generally confirmed the weaknesses of existing policies suggested by the 
empirical analyses of this project. 
13.3.3 Contextual issues and challenges of evidence-based policy- 
making 
So far in Korea, not only the two policy interventions examined in this thesis, but also 
other major pharmaceutical policies (including the Best Prescribing Project or 
pharmacist incentives for generic substitution) have shown few of their intended 
effects. Many policy efforts (such as generic prescribing, reference-pricing, or 
incentives for saving prescribing costs) have, hardly progressed beyond theoretical 
debates or pilot trials. The qualitative Investigation showed that a complex set of local 
factors has challenged the development of optimal policies. Most of all, government 
policy has not been supported by medical providers, and has often faced severe 
resistance from them. The situation has been aggravated by a weak political will as 
well as by poor science to support policy change. 
303 " 
Korean policy-makers discussed the possible causes of the lack of success and 
suggested the following as the major weaknesses of the current system: 
" lack of scientific grounds, expertise, experience, or resources for policy decisions 
and implementation; 
  lack of measures to amend prescribing behaviour; 
  defects In the Korean generic market; 
 a weak position of Korea within the global pharmaceutical market; 
  Insufficient policy attention to patients' welfare. 
From the policy-makers arguments, four main themes emerged that might explain the 
gap between evidence and policy in this particular setting despite the clear awareness 
of the shortcomings among policy-makers. They were the shortage of resources, the 
absence ofsystematrc arrangements, the lack of trust and the nature ofpolicy-making. 
In the background, I argued that the shortage of evidence has been a hurdle to the 
decision-making process in South Korea. This thesis has demonstrated that the lack of 
knowledge In Korea not only reflects a shortage of scientific knowledge from research, 
but also suggests the absence of a knowledge-building system. Relevant resources are 
lacking, which Include tangible and intangible elements such as human resources, 
experience and expertise, a systematic network amongst people and/or institutions, 
and appropriate Information support and dissemination systems. 
In the last decade, resource constraints have been apparent In the Korean healthcare 
system. Faced with similar concerns to those of rich nations, Korean pharmaceutical 
policies are evolving rapidly, and tend to follow International trends. Unfortunately, 
efforts as well as time have been lacking to create a social consensus In crucial issues 
such as priority of healthcare resource allocation. This weakens the authority to 
introduce policy Interventions or Implement them properly after introduction. 
Without the development of a supporting social system and knowledge base, hasty 
policy change has apparently raised social distrust and tension between the authorities 
and professionals. Rowe and Cainan (2006; p390) suggest that the lack of trust 
renders people to have a "belief that others might harm us "I which requires constant 
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monitoring, prescriptive regulations, intensive supervision, and/or risk aversion. The 
policy cycle inevitably becomes unhealthy In these social environments. On one hand, 
widespread distrust and policy resistance has Impeded the Introduction of some 
interventions controlling prescribing behaviour. This keeps Korean policies controlling 
patient demand or drug prices, which potentially results In deteriorating social equity 
and market competition. On the other hand, they undermine the development of a 
fundamental atmosphere for evidence-based policy-making, coupled with the 
knowledge deficit. 
13.4 Strengths and limitations 
This project has several strengths. By including three robust research designs, the 
reliability of outcomes from systematic reviews was improved. In quantitative analyses, 
credibility was much Improved in two aspects: 1) by crosschecking analysis results 
through two statistical tools; and 2) by constructing long-term time series compared 
with the former Korean studies. In addition, two-layer analyses - overall and 
therapeutic subgroups - provided a unique chance to obtain Insight Into Korean market 
conditions. The strength of this research is most evident in the multidisciplinary and 
applied nature of the research, using both quantitative and qualitative investigations to 
focus on a single project. It Is Increasingly recognised that both quantitative and 
qualitative studies have clear limitations on their own, but are able to corroborate one 
another through compensating for the weaknesses (Denscombe, 2007b; Pope and 
Mays, 2006). Two heterogenic methods found several well-matched issues, which 
definitely enhanced the validity of the findings. Moreover, in-depth interviews 
expanded the subjects beyond those able to be addressed with quantitative data. 
Furthermore, they formulated good grounds for the researcher's arguments, which was 
troublesome owing to the lack of existing relevant studies. 
However, this research also has some limitations. Most of them have been already 
discussed at the end of each study. The important issues are recapped here for the 
purpose of summarising, along with those of the whole project. 
The systematic reviews have shortcomings as follows. Firstly, they were conducted by 
one reviewer, so could be viewed as subjective In some quarters, This was reduced as 
much as possible by setting all criteria clearly In advance. Secondly, It Included only 
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two electronic databases, which might not be sufficient to identify all relevant studies. 
To lessen the- loss of potential studies, a comprehensive hand-search was carried out 
with references from relevant reviews. Thirdly, potentially worthwhile studies could be 
excluded by the inclusion criteria that limited to well-controlled studies. 
The empirical analyses have the following limitations. First, they employed pharmacy 
claims, which made it impossible to Investigate patient-level changes after policy 
Interventions. At the beginning of the project, the plan was to analyse patient-level 
data taken by hospitals, but data was not made available to permit this. Second, 
exploring the long-term results of the SPD was also planned but this was not possible 
as data before 2003 was unavailable. Third, all findings need to be qualified with a 
longer-term examination. Fourth, caution is required regarding the generalisability of 
findings for two chronic medications to other therapeutic classes. Finally, caution is 
needed to generalise qualitative findings beyond the study population, although 
participants were thought a typical group closely Involved In Korean pharmaceutical 
policy-making. 
13.5 Recommendations for Korean pharmaceutical policy 
First, policies limiting patient demand such as cost-sharing seem to sacrifice equity for 
only a marginal reduction in pharmaceutical costs in Korean society. The intention that 
the copayment increase based on prescription costs might mainly affect patients with 
less-essential drugs was not realised. In this regard, prescription costs as an indirect 
indicator of discretionary utilisation may not be appropriate. Explicit guidelines are 
helpful to achieve the policy aim. For example: 
" Providing a clear list of the limited drugs such as that in differential 
copayments programmes (including reference-price systems), prior-authorisations 
or step-therapy approaches is worth considering because it can achieve selective 
reduction in less essential consumption, compared to a fixed rate of copayment. 
Providing accessible information directly to patients can be another option. 
One interesting and practical suggestion from previous research is worthy of 
introducing here. Yoon (2008) proposed the indication of differences between a 
prescribed product and a possible lower-priced alternative in prescription (or 
dispensing) receipt to alerting price consciousness. 
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Second, the importance of generics needs to be augmented given that new and 
expensive drugs lead the growth of expenditure inflation. In South Korea, however, 
before going further to a fully-fledged generic policy, the generic market must be 
revisited to ensure that a policy change results in containing costs effectively without 
compromising quality and equity. 
" There is an urgent need to clarify the definition of generics, to set up 
classification parameters and to develop a database capturing the market 
performance of generics. 
  It is problematic to maintain the small price gap between generics and brand- 
named drugs. Cutting generic prices substantially and restoring price competition 
are two prerequisites for improving the performance of generic policies. One 
previous study found that the price variation within a single active Ingredient is 
significantly large, between 40 and 70 per cent and suggested the removal of price 
differences by cutting generic prices equal to the least priced product unless it 
sacrifices quality (Yoon, 2008). 
 A breakthrough reform is required in the current blo-equivalence validation 
programme (BVP) toward reducing the rate of dependence on data from 
manufacturers and strengthening the watchdog system after passing through the 
BVP. In the local market, the most fundamental issue for reducing generic policy 
resistance is definitely interchangeability of generic products from the clinical point 
of view. One study reported that cheaper generics occupy a smaller market share 
in the Korean market (Shin and Choi, 2008), reflecting a social view on generic 
products In some quarters, i. e. the lack of confidence about the quality of `cheap' 
generic products. This is in line with the finding of this study suggesting the 
tendency to increase the use of expensive medications after decreasing prices. 
Some local clinics advertise themselves as giving high quality pharmaceutical care 
by quoting the results from the authority assessing them as a high spender. 
" Alternatively, first-line therapies can be effective options In achieving cost 
containment as well as quality of care. For example, adhering to evidence-based 
guidelines may achieve considerable savings in the treatment of high blood 
pressure that has well-established prescribing guidelines (Bradford et al., 1999; 
Fischer and Avorn, 2004a). 
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Third, it requires steady as well as urgent building of a knowledge base. The empirical 
findings from both quantitative and qualitative, studies continuously exhibited the 
paucity of available local evidence in South Korea. To extend knowledge, the following 
needs have to be noted. 
" Fundamentally, a qualified workforce needs to be developed. However, 
developing a qualified workforce will take time and so must be accompanied by 
efforts to seek the most cost-effective way of utilising present human resources. 
Examples may include networking academic institutions. This can facilitate sharing 
of expertise among professionals and Integration of inter-professional teams and in 
so doing, be the basis of multi-disciplinary approaches, which are Increasingly 
valuable in social sciences. 
  The existing data on pharmaceuticals should be expanded to a store of basic 
information (such as local epidemiological data and cost-effectiveness data). In 
addition, variables reflecting real diagnoses, case-mix adjustment and biological 
measures of morbidity (e. g. blood pressure, cholesterol level, and/or side effects) 
must be developed. 
" The objectives of research require diversification to explore the negative 
aspects of policy Interventions. For example, the quantitative investigation of this 
thesis demonstrated potential policy consequences in therapeutic subgroup 
analyses, but not In analyses with overall pharmaceuticals. 
Fourth, to overcome the weaknesses of the current system uncovered by the 
qualitative investigation, greater efforts should be made to reach a consensus on 
'trade-off' between efficiency and equity, costs and quality, or health and wealth. It is 
also necessary to make an agreement about the objectives and the desired outcomes 
of interventions prior to policy change. Without a shared view on public resources 
among the members of society, any good interventions can be overwhelmed by 
'bypass' strategies striving for private profits in the market, Making a consensus can be 
facilitated by the following: 
" Open discussion Is required to set social priority In resource allocation, which is 
lacking even among policy-makers engaged In the Interview. Recently, cost- 
effectiveness Is Increasingly stressed as a priority by the Korean authorities, though 
this Is challenged significantly by the lack of credible economic evidence (Choi, 
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2008; Lee et al., 2005). Without the support of credible economic evidence, the 
result may be Inferior quality of care or the augmentation of overall costs if cost- 
effective items are restricted merely owing to expensive prices. On this issue, the 
establishment of the National Evidence-based Healthcare Collaborating Agency 
(NECA) offers the prospect of a more systematic discussion of priority Issues at a 
national level. Hopefully, this will play a vital role in developing principles for 
assessing the cost-effectiveness of new drugs and treatment. Additionally, it would 
be beneficial to expand its scope to explore policy cost-effectiveness in the not- 
too-distant future. 
  Communal values need to be disseminated to the members of society. In 
particular, medical students (including other professional students) and trainee 
doctors need more opportunities to understand the complex Issues and dilemmas 
of the healthcare arena (such as finite resources, prioritisation, and cost- 
effectiveness) given that most professionals practice privately after graduation. It 
may therefore be worth developing policy options to alter prescribing practices 
striving for cost-effective medications in major teaching hospitals, because Korean 
doctors are likely to establish their prescribing behaviour in the residency period 
(Kim, 2005). It is also important to provide patients with information about a 
resource-limited world because enlightened patients can create an important new 
source of legitimacy In formulating social consensus on healthcare issues. 
  Although there are limitations in making policies solely based on evidence, the 
importance of scientific evidence must not be undermined. A body of evidence 
provides standards for the decision-making process, through which-the process 
becomes more transparent by being able to show explicit reasons for decisions 
(Daniels and Sabin, 1997). This can strengthen decision-making, weaken the top- 
down tradition, and minimise policy consequences. Fair decision-making will 
improve the credibility of the system and be a good way of restoring social trust. 
13.6 Future research opportunities 
The systematic reviews highlighted a large knowledge gap in pharmaceutical policy 
evaluation studies. Overall, most policy interventions have been under-researched, 
except for a small range of interventions described above. Except in a handful of 
settings, most nations have neglected evaluation of their pharmaceutical interventions, 
Long-term outcomes of policy interventions are generally unknown. There is a lack of 
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focus on the negative effects of policies, which should all be listed and publicised. 
Above all, studying the association between pharmaceutical policies and individual 
patient outcomes appears warranted. 
Few researchers appear to be interested in the possible different clinical effectiveness 
between original and generic products, while interests in generic policies are increasing. 
It may be interesting to explore outcomes from brand versus generic drugs with long- 
term cohort studies. Cost-effectiveness studies of policy changes are thought valuable 
In programmes with high administrative costs. Further exploration Into the relationship 
between the characteristics of prescribers and outcomes of budgetary constraints 
would be extremely useful. 
Empirical studies of Korean pharmaceutical policies raised a number of issues that 
warrant further exploration. Causes and longer-term effects of reducing essential drug 
use should be tackled at the individual level. A closer investigation into why the 
utilisation of anti hyperiipidemics was more susceptible to policy changes, and who 
actually reduces drug use in socially disadvantaged groups, appears urgent. Studying 
other therapeutic sub-classes is recommended. Given the objectives of the new cost- 
sharing scheme, it may be interesting to examine if the policy influence in symptom- 
relief and chronic medications operates differently. Further analyses employing market 
price data deserve attention to verify the real impact of the new pricing programme. 
Lastly, qualitative investigation must be expanded and balanced by addressing other 
perspectives, for instance, those of prescribers, industry and the general population. 
Future research should strive to Improve methodologies Including the development of 
standards In the realms of outcome variables. Relating to this Issue, the credibility of 
Korean databases needs to be quantified. 
13.7 Concluding remarks 
Confronting mounting financial pressure on healthcare budgets, multifaceted strategies 
are increasingly adopted in the pharmaceutical arena in particular by the developed 
world. Throughout this thesis, it becomes clear that there is no'holy grail' of 
pharmaceutical strategy for any local setting. Often, interventions have not produced 
equivalent effects in different settings. The policy cycle is influenced by a variety of 
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factors änd policy effects are the results of interactions of those factors. There will 
always be dilemmas in balancing the needs from various stakeholders and viewpoints 
that may show a considerable divergence according to local environments. Policy- 
making is often about political decisions concerning affordability and appropriateness 
and, thus, a political value at the time of formulation is frequently a primary 
determinant of policy change. Scientific evidence is not the prime force of policy 
changes even though the significance of evidence Is increasingly argued in the recent 
decade. 
Reviews of international experience demonstrate that the concept of evidence-based 
policy-making sounds hollow In this arena; some policies tend to be employed 
continuously regardless of poor (sometimes adverse) evidence, while others seem 
under-used even though promising evidence exists. Thus, generalisation of 
international experience is certainly limited In a local setting. Ironically, the reality that 
de-emphasises evidence augments the significance of rigorous policy evaluation in 
each local setting to reduce policy uncertainties and produce better prospects in this 
field. Nevertheless, pharmaceutical policy evaluation is one of the most under- 
researched scopes in less-developed countries. 
A good example of this was revealed by the empirical exploration of Korean policies in 
this thesis. It was seen that Korea is still left with suboptimal strategies and has faced 
considerable resistance to moving towards strategies that may be more effective. So far, 
suboptimal measures have disrupted equity objectives with only minimal improvements 
in efficiency and costs in Korean society. Despite aggressively seeking improvement at 
all times, actual changes appeared faint and slow. Regulating pharmaceuticals is 
challenged by lack of available information, widespread distrust, resource constraints, 
and strong professionals. Korean policy-makers generally support the international 
trend of cost-effectiveness and evidence-based policy-making as the prospect of the 
local policy direction. Unfortunately, however, these subjects remain mostly at a 
superficial level of debate in Korea. Therefore, the awareness seems to need more 
rigid and wide social acknowledgement to produce effective changes in this arena and 
must be the subject of continuing debate. 
Hence, despite the clear limitations in generalisability and transferability, international 
experience has been valuable as a learning tool for policy-makers and as an important 
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initiative of policy reform for some considerable time in this setting. Therefore, it is 
Important to remember that drug policies are often derived from a complex mix of 
constrained evidence, sometimes irrational judgments and wishful thinking, perhaps 
focusing on benefits and Ignoring the potential negative consequences. The predictions 
made based upon such imperfect grounds could easily collapse with the failure of 
engagement with contextual specificities. These drawbacks are real but could be 
minimised by the careful development of policy. It may be necessary to start by being 
cautious In generalisation of the policy Impact exhibited In foreign settings amid Korean 
policy environments where there Is a paucity of local evidence. At the same time, it Is 
necessary to develop policy-making capacity In the face of an immature evidence base. 
Efforts that build research capacity and seek local evidence are essential to strengthen 
such capacity as well as to be an ultimate solution to the absence of a knowledge base, 
312 
List of acronyms 
AAP Actual Acquisition Price system 
ACEI angiotensin-converting enzyme Inhibitors 
ACF autocorrelation function 
ADHD Attention-Deficit Hyperactivity Disorder 
AIDS Acquired Immune deficiency syndrome 
ARB angiotensin II receptor blockers 
ARIMA autoregressive Integrated moving average 
ATC Anatomic Therapeutic Chemical 
BPP Better Prescribing Project 
BVP Bio-equivalence Validation Programme 
CA copayment adjustment 
CBA controlled before and after study 
CCB calcium channel blocker 
CERM Committee on Evaluation of the Reimbursement of Medicines 
COX2I Cox 2 selective Inhibitor 
CRD Centre for Reviews and Dissemination 
CRRM Committee on Reconcilliation of the Reimbursement of Medicines 
DDD defined daily dose 
DTC direct-to-consumer 
DUR drug utilisation review 
DW Durbin-Watson d statistic 
EBM evidence based medicine 
EBP evidence based policy-making 
EGLS estimated generalised least squares 
EMEA European Medicines Agency 
EPOC Cochrane Effectiveness Practice and Organisation of Care collaborative review group 
FDA Food & Drug Administration 
FFS fee-for-service 
GDP gross domestic product 
GNI gross national Income 
GSL general sales list 
HERA histamine type 2 receptor antagonists 
HIRA Health Insurance Review & Assessment Service 
HMG CoA 3-hydroxy-3-methyl-glutaryi-CoA 
ITS interrupted time series 
KFDA Korea Food & Drug Administration 
KRW Korean Won 
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MAC Maximum Allowable Cost 
MAP Medical Aid Programme 
MOHW Ministry Of Heaith and Welfare 
MRI Magnetic resonance imaging 
NCE new chemical entity 
NFMI National Federation of Medical Insurance 
NHI National Health Insurance 
NHIC National Health Insurance Corporation 
NHS National Health Service 
NICE National Institute for Clinical Excellence 
NL negative list 
NSA non-sedating antihistamines 
NSAID non-steroidal anti-inflammatory drug 
OECD Organisation for Economic Co-operation and Development 
OLS ordinary least-squares 
OTC over-the-counter 
PACF partial autocorrelation function 
PACT prescribing analysis and cost 
PDL Preferred Drug List 
PERP Pharmaceutical Expenditure Rationalisation Plan 
PET positron emission tomography 
POM prescription only medicine 
PPI proton pump Inhibitor 
PPP purchasing power parity 
PPRS Pharmaceutical Price Regulation Scheme 
QOF Quality and Outcomes Framework 
R&D Research and Development 
RCT randomised controlled trial 
RFID radio frequency Identification 
SNRI serotonin-norepinephrine reuptake Inhibitor 
SPD Separation of Prescribing and Dispensing of drugs 
SSRI selective serotonin reuptake Inhibitor 
TNC transnational corporation 
TRP triennial re-pricing 
UK United Kingdom 
US United States 
USA United States of America 
WHO World Health Organization 
WTO World Trade Organization 
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Annex+i: OECD raw data 
a) Social expenditure 
Total social expenditure 
Public, % gross domestic product 
Countries 1980 1985 1990 1995 2000 2003 
Australia 11 13.1 14.1 17.1 17.9 17.8 
Austria 22.6 23.9 23.7 26.6 25.3 26.1 
Belgium 23.5 26.1 25 26.4 25.3 26.5 
Canada 14.5 17.3 18.2 19.1 16.6 17.3 
Czech Republic n/a n/a 16 18.2 20 21 
Denmark 25.2 24.1 25.5 28.9 25.8 27,7 
Finland 18.2 22.7 24.3 27.4 21.1 22.1 
France 20.8 26 25.2 28,4 27.6 28.5 
Germany 22.4 22.9 21.9 26.6 26.3 27.2 
Greece 10.2 16 16.6 17.2 19 19.2 
Hungary n/a n/a n/a n/a 20.2 22.3 
Iceland n/a n/a 13,7 15.2 15 18 
Ireland 16.8 21.8 15.5 16.3 13.6 15.9 
Italy 18 20.8 19.9 19.8 23.2 24.2 
Japan 10.6 11.4 11.5 14.1 16.3 18.1 
Korea n/a n/a 3 3.5 5.1 5.7 
Luxembourg 20.7 20.2 19.2 20.8 19.8 20,7 
Mexico n/a 119 3.6 4.7 5.8 6.8 ' 
Netherlands 24.8 25 25,4 23.5 19.4 20.6 
New Zealand 17.2 17.9 21.8 18.9 19.1 17.9 
Norway 16.8 17.8 22.3 23.4 22.1 24.8 
Poland n/a n/a 14.8 22.6 20.6 22.2 
Portugal 10.2 10.4 13 17.2 19,1 22.1 
Slovak Republic n/a n/a n/a 18.6 17.9 17.2 
Spain 15.5 17,8 20 21.5 20.4 20.2 
Sweden 28.3 29.4 30.2 32.1 28.3 30,6 
Switzerland 13.6 14.5 13.4 17.5 17.8 20.4 
Turkey 4.4 4.2 7.6 7.5 n/a n/a 
United Kingdom 16.9 19.9 17.3 20.5 19.2 20.7 
United States 13 12.7 13.2 15.2 14.4 16 
Source: OECD HEALTH DATA 2008, June 08 
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b) Total expenditure on health 
Public expenditure on health 
gross domestic product 
Countries 1980 1985 1990 1995 2000 2003 
Australia 3.9 d 4.6 d 4.6 d 4.9 d 5.5 d 5.7 d 
Austria 5.1 4.9 6.1 b 7 7.5 7,7 
Belgium n/a n/a n/a 6.5 n/a n/a 
Canada 5.3 6.1 6.6 6.4 b 6.2 6,9 
Czech Republic n/a n/a 4.6 6.4 5.9 b 6.7 b 
Denmark 7.9 7.3 6.9 6.7 6.8 n/a b 
Finland 5 5.6 6.2 5.7 b 5.1 5.9 
France 5.6 6.3 6.4 7.7 b 7.5 8.7 b 
Germany 6.6 6.8 6.3 8.2 8.2 8.5 
Greece 3.3 n/a 3.5 4.5 4.7 b 5.4 
Hungary n/a n/a n/a 6.1 4.9 6 
Iceland 5.5 6.3 6.8 6.9 7.7 8.5 
Ireland 6.8 5.7 4.4 b 4.8 4.6 5.6 
Italy n/a n/a 6.1 5.1 5.8 6.2 
Japan 4.7 4.8 4.6 5.7 b 6.2 6.6 
Korea 0.8 1.1 1.6 1.5 2.2 2.8 
Luxembourg 4.8 4.6 5 5.1 b 5.2 6.8 b 
Mexico n/a n/a 2 2.4 2.6 2.8 
Netherlands 5.1 5.2 5.4 5.9 5 n/a 
New Zealand 5.2 4.4 5.7 5.5 6 6.3 
Norway 5.9 5.6 6.3 6.6 6.9 8.4 
Poland n/a n/a 4.4 4 3.9 4.4 
Portugal 3.4 3.1 3.8 4.9 b 6.4 b 7.1 
Slovak Republic n/a n/a n/a n/a 4.9 5.2 
Spain 4.2 4.3 5.1 5.4 5.2 5.7 b 
Sweden 8.2 7.7 7.4 6.9 7 7.8 
Switzerland n/a 3.9 4.3 5.2 5.7 6.7 
Turkey 1 1.1 2.2 2.4 3.1 4.3 
United Kingdom 5 5 5 5.8 5.8 6.6 b 
United States 3.6 4 4.7 6 5.8 6.7 
Source: OECD HEALTH DATA 2008, June 08 
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c) Pharmaceuticals and other medical non-durables 
Pub. exp. on pharmaceuticals & other medk. non-durables 
I/o gross domestic product. 
Countries 1980 1985 1990 1995 2000 2003 
Australia 0.2 0.3 0.3 0.5 0.7 0.7 
Austria n/a n/a 0.4 b 0.5 0.8 0.9 
Belgium 0.6 0.6 0.5 0.6 n/a 0.9 
Canada 0.1 0.2 0.3 0.4 0.5 0.6 
Czech Republic n/a n/a 0.9 1.5 1.2 b 1.4 
Denmark 0.3 0.3 0.2 0.4 0.4 0.5 b 
Finland 0.3 0.3 0.3 0.5 b 0.5 0.6 
France 0.7 0.9 0.9 1.0 b 1.2 1.3 b 
Germany 0.8 0.9 0.9 0.9 1 1.2 
Greece 0.7 n/a 0.5 1 0.9 b 1.2 
Hungary n/a n/a n/a 1.2 1.2 1.4 
Iceland 0.5 0.7 0.9 0.9 0.8 0.9 
Ireland n/a n/a n/a n/a n/a n/a 
Italy n/a n/a 0.9 0.6 0.8 0.9 
Japan n/a 0.7 0.8 1.0 b 0.9 1,1 
Korea 0.1 0.1 0.2 0.2 0,4 0.7 
Luxembourg 0.7 0.7 0.7 0.5 b 0.5 0.6 b 
Mexico n/a n/a n/a n/a 0.0 d 0.1 
Netherlands 0.4 0.4 0.5 0.8 0.5 n/a 
New Zealand 0.6 0.5 0.7 0.7 n/a n/a 
Norway 0.3 0.3 0.4 n/a 0.5 0.5 
Poland n/a n/a n/a 0.8 0.6 0.8 
Portugal 0.7 0.9 0.9 1.2 1.1 b 1.2 
Slovak Republic n/a n/a n/a n/a 1.5 1.9 
Spain 0.7 0.7 0.8 1 1.1 1.4 b 
Sweden 0.4 0.4 0.5 0,7 0.8 0.8 
Switzerland n/a n/a n/a 0.5 0.7 0.8 
Turkey n/a 0.3 0.7 n/a 0.8 n/a 
United Kingdom 0.5 0.5 0.5 0.7 n/a n/a 
United States 0.1 0.1 0.1 0.2 0.3 0,4 
Source: OECD HEALTH DATA 2008, June 08 
b: Break In series 
d: Differences in methodology 
n/a: Data not available 
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Annex 2: Searching strategy for policies influencing patients 
1. Drug Polic$/ or Drug Regulation? / or Health Polic$/ or Pharmaceutical Regulation? / or 
Pharmaceutical Polic$/ or Managed Care? / or Prescribing/ 
2. ((regulat$ or restrict$ or pay$ or drug? or pharmaceutlc$ or medicine? or medicament? or 
medicat$ or generic? ) adj5 (coverage or utili? ation or polic$ or system? or program$ or 
schedule or prescri$ or expenditure? )). tw. 
3.1or2 
4. (patient? or consumer? or beneficlar$ or user? or medi$ population? or household? ). ab, tw. 
5. (cost-sharing or (cost? adj3 (sharing or share))). ti, ab, tw. 
6. (out-of-pocket or (out of pocket? adj3 pay$)). ti, ab, tw. 
7. (copay$ or co pay$). tl, ab, tw. 
8. ((prescrib$ or prescription? or pharmaceutic$ or pharmacy or pharmacies or dispens$ or user 
or user$ or patient or patient$) adj3 (charg$ or fee? )). ti, ab, tw. 
9. ((charg$ or fee? ) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or 
medicat$)). tw. 
10. ((coinsurance or deductible? ) adj3 (drug or drugs or pharmaceutic$ or medicines or 
medicament? or medicat$)). tw. 
11. or/5-10 
12. DTC/ or OTC/ 
13. (direct-to-consumer? or (direct? adj3 consumer? ) or over-the-counter? or (over? AdJ3 
counter? )). ti, ab, tw. 
14.12 or 13 
15. (formulary or formularies or positive list? or negative list? ). ti, ab, tw. 
16. ((drug? or pharmaceutlc$ or medicine? or medica$ or prefer$) adj3 (list? or 
cover$)). ti, ab, tw. 
17. ((reimburse$ or insur$ or (third party adj1 pay$) or benefit plan? or withdraw$) adJ4 (drug 
or drugs or pharmaceutic$ or pharmacy or pharmacies or medicines or medicament? or 
medicat$)). ti, ab, tw. 
18. ((pay$ or reimburse$) adj3 (cess$ or restrict$ or polic$)). ab, tw. 
19. (reference$ adj3 (price? or pricing)). ti, ab, tw. 
20. (index$ adJ3 (price? or prlcing)). tw. 
21. ((prescib$ or prescription? or benefit) adJ3 (limit$ or cap$)). ti, ab, tw. 
22. ((step therapy or tiered benefit) adj3 (drug or drugs or pharmaceutlc$ or medicines or 
medicament? or medicat$)). tw. 
23. or/15-22 
24. *Drug Information Services/ and (patient? or consumer? ). tw. 
25. *Patient Education/ 
26. ((educat$ or Inform$) adj3 (patient? or consumer? )). tw. 
27. or/24-26 
28.11 or 14 or 23 or 27 
29. (((health or patient$) adj1 outcome? ) or readmission? ). tw. 
30. ((control$ or containment or curtailment or reduc$ or save or saving) adJ3 cost? ). tw. 
31. ((drug or drugs or pharmaceutlc$ or medicines or medicament? or medicat$ or presclb$ or 
prescription? or relmburs$) adj3 (use$ or cost? or expenditure? or expense? )). ab, tw. 
32. *Adverse Drug Reaction/ or (safe$ adjl (drug or drugs or pharmaceutlc$ or medicines or 
medicament? or medicat$)). tw. 
33. (drug use$ or drug utili? atlon or ((medical care or healthcare or health care or resource) 
adjl(us$ or utili? tion)) or institutionali$ or hospitali$). ab, tw. 
34. ((prescrlb$ or prescrlp$) adj2 (attitude or variation? or behavior or behaviour or pattern? or 
practice? or habit? or accurate or trend? or cost? or change? or shift$ or rational? or 
reduc$ or influenc$ or expenditure? )). ab, tw. 
35. or/29-34 
36. randomized controlled trial. pt. 
37. ((control or comparison) adjl(group? or participant? )). ab. 
38. ((time adj series) or time-series). ti, ab, tw. 
39. (pre-post or ((pre test or pretest) adJ4 (posttest or post test))). ab, tw. 
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40. (beföre-after or (before adj2 after)). ab, tw. 
41. or/36-40 
42.3 and 4 and 28 and 35 and 41 
43. (opiold or abuse or alcohol or smok$ or captoprii or addiction or virus or antibody or 
energy). ti, ab. 
44. ((pharmac$ or nurse? ) adj2 (led or based or manage$ or delivered or service? or 
collaboration? or counsel$)). ti, ab. 
45. (discharg$ or placebo or depression or hip or asthma or homeopath$ or dementia or rhinitis 
or COPD or radiography or satisfaction or heart or transplant$). ti. 
46. (cost-effectiveness or cost-miniml? ation or (economic adj1(analys$ or stud$ or 
evaluation? ))). ti. 
47. or/43-46 
48. editorial. pt. 
49. letter. pt. 
50, comment. pt. 
51. or/48-50 
52. animals/ 
53. humans/ 
54.52 not 53 
55.47 or 51 or 54 
56.42 not 55 
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Annex, 3: Searching strategy for policies influencing providers 
1. Drug Polic$/ or Drug Regulation? / or Health Poiic$/ or Pharmaceutical Regulation? / or 
Pharmaceutical Polic$/ or Managed Care? / 
2. ((regulat$ or restrict$ or pay$ or drug? or pharmaceutic$ or medicine? or medica$ or 
generic? ) adjS (coverage or utili? ation or polic$ or system? or program$ or schedule or 
prescri$ or expenditure? )). tw. 
3.1or2 
4. *Nurses/ or *Nurse Clinicians/ or *Nurse Practitioners/ or *Pharmacists/ or *Pharmacies/ or 
*Pharmacy/ or *Hospitals/ 
5. (physician$ or GP? or doctor? or prescriber? or group pract$ or Institutional pract$ or 
partnership pract$ or family pract$ or general pract$ or office pract$ or private pract$ or 
primary pract$ or nurse? or pharmac$ or hospital? ). tw. 
6.4 or 5 
7. (formulary or formularies or positive list? or negative list? ). ti, ab, tw. 
8. ((drug? or pharmaceutic$ or medicine? or medica$ or prefer$) adJ3 (list? or cover$)). ti, ab, tw. 
9. ((reimburse$ or insur$ or (third party adji pay$) or benefit plan? or withdraw$) adj4 (drug 
or drugs or pharmaceutlc$ or pharmacy or pharmacies or medicines or medicament? or 
medicat$)). ti, ab, tw. 
10. ((pay$ or reimburse$) adj3 (cess$ or restrict$ or poiic$)). ab, tw. 
11. (reference$ adj3 (price? or pricing)). ti, ab, tw. 
12. (index$ adj3 (price? or pricing)). tw. 
13. ((presclb$ or prescription? or benefit) adj3 (limit$ or cap$)). ti, ab, tw. 
14. ((step therapy or tiered benefit) adj3 (drug or drugs or pharmaceutic$ or medicines or 
medicament? or medicat$)). tw. 
15. ((pre-author)#ation? or preauthorl#ation? or prior authorl#ation? ) adj3 (drug or drugs or 
pharmaceutic$ or medicines or medicament? or medicat$)). tw. 
16. *"Pharmacy and Therapeutics Committee"/ or ((drug? or formulary or pharmac$) adj3 
committee? ). tw. 
17. or/7-16 
18. ((drug? or pharmaceutic$ or prescrib$ or prescrlp$) adj1 budget? ). tl, ab, tw. 
19. (((local$ or global$) adj3 budget$) and (general pract$ or GP? or physician? or doctor? )). tw. 
20. (fundhold$ adj3 (general pract$ or GP? or physician? or doctor? )). tw. 
21. (incentive? adji (plan? or money$ or financ$ or payment? or reimburs$)). tw. 
22. (capitation or salaries or salary or Income? or wages or fringe benefit? or benchmarking). tw. 
23. or/18-22 
24. -((information or reminder? or feedback or monitor$) adj3 (drug or drugs or 
pharmaceutic$ or medicines or medicament? or medicat$ or prescri$)). tw. 
25. *Guidelines/ or *Practice Guidelines/ 
26. ((guideline? or recommendation? or protocol) adj3 (drug or drugs or pharmaceutic$ or 
medicines or medicament? or medicat$)). tw. 
27. ((prescrlb$ or prescip$) adji scheme? ). tw. 
28. or/24-27 
29. (generic adj3 (price? or pricing or substitut$ or foster$)). ti, ab, tw. 
30. (generic$ adj3 (presci$ or drug or drugs or pharmaceutic$ or medicines or medicament? or 
medicat$)). tw. 
31.29 or 30 
32. (((academl$ or group) adji detail$) or outreach or out-reach or visit? or letter? or mail$ or 
telephon$ or phon$). tw. 
33, (advert$ or promot$ or market$). tw. 
34. (quality adj3 (framework or pay$)). ti, ab, tw. 
35. (drug or drugs or pharmaceutfc$ or medicines or medicament? or medicat$). tw. 
36. (32 or 33 or 34) and 35 
37.17 or 23 or 28 or 31 or 36 
38. (((health or patient$) adji outcome? ) or readmission? ). tw. 
39. ((control$ or containment or curtailment or reduc$ or save or saving) adj3 cost? ), tw. 
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11 40. ((drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$ or prescib$ or 
prescription? or reimburs$) adj3 (use$ or cost? or expenditure? or expense? )). ab, tw, 
41. *Adverse Drug Reaction/ or (safe$ adji (drug or drugs or pharmaceutic$ or medicines or 
medicament? or medicat$)). tw. 
42. (drug use$ or drug utili? ation or ((medical care or healthcare or resource) adji utiii? tion) or 
institutional! $ or hospitaii$). ab, tw. 
43. ((prescrib$ or prescrip$) adj2 (attitude or variation? or behavior or behaviour or pattern? or 
practice? or habit? or accurate or trend? or cost? or change? or shift$ or rational? or 
reduc$ or influenc$ or expenditure? or adherence)). ab, tw. 
44. or/38-43 
45. randomized controlled trial-pt, 
46. (randomi$ or ((control or comparison) adji (group? or participant? ))). ab. 
47. ((time adj series) or time-series). ti, ab, tw. 
48. (pre-post or ((pre test or pretest) adj4 (posttest or post test))). ab, tw. 
49. (before-after or (before adJ2 after)). ab, tw. 
50. or/45-49 
51.3 and 6 and 37 and 44 and 50 
52. (opiold or abuse or alcohol or smok$ or captopril or addiction or virus or antibody or energy 
or syringe or detoxification or BDRs or bypass or knee or PET or stent or skin). ti, ab. 
53. (((cost or burden) adj2 illness) or (neurological adji disorder? ) or (medica$ adji error? ) or 
((behavioral or behavioural) adji disorder? ) or (residen$ adJ2 program$) or case- 
control). tl, ab, 
54. ((pharmac$ or nurse? ) adj2 (led or based or menage$ or delivered or service? or 
collaboration? or counsel$)). ti, ab. 
55. (discharg$ or placebo or depression or hip or asthma or homeopath$ or dementia or rhinitis 
or COPD or radio$ or satisfaction or heart or transplant$ or prevent$ or fracture or 
rehabilitation or misclassification or Indigent or epidemioiogy). ti. 
56. (cost-effectiveness or cost-minima? ation or (economic adji (analys$ or stud$ or 
evaluation? ))). ti. 
57. (incremental adji cost adji effective adji ratio? ). tw. 
58. or/52-57 
59. editorial. pt. 
60. letter. pt. 
61, comment. pt. 
62. or/59-61 
63. animals/ 
64. humans/ 
65.63 not 64 
66.58 or 62 or 65 
67.51 not 66 
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Annex 4: Searching strategy for policies influencing industry 
1. Drug Pollc$/ or Drug Regulation? / or Health Polic$/ or Pharmaceutical Regulation? / or Pharmaceutical 
Polic$/ or Managed Care? / or Health Care/ or Madicaid/ 
2. ((drug? or pharmaceutic$ or medicine? or medica$) adj5 (regulat$ or restrict$ or polic$ or system? or 
program$ or schedule or expenditure? or scheme or plan$)). tw. 
3.1 or 2 
4. ((reference$ or least or maximum or allow$) adJ3 (price? or pricing or cost)). ti, ab, tw. 
5. ((index$ or reimburs$ or list$) adj3 (price? or pricing or cost)). tw. 
6. ((control$ or reduc$ or cut$ or regular$ or negotlat$ or fix$ or polic$) adj3 (price? or pricing or 
volume)). tw. 
7. ((price? or pricing) adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$ or 
compet$)). tw. 
8. (patent adj3 (drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$)). tw. 
9. (profit? adj3 (control$ or reduc$ or regulat$ or fix$ or restrict$ or return)). tw. 
10. or/4-9 
It. *Drug Approval/ or (approv$ adj3 (drug or durgs or pharmaceutic$ or medicines or medicament? or 
medicat$)). tw. 
12. *Marketing/ or *Marketing of Health Services/ or *Advertising/ or *Licensure/ or *Drug Labeling/ 
13. ((Iicens$ or registrat$ or label$ or authorl$) adj3 (drug or drugs or pharmaceutic$ or medicines or 
medicament? or medicat$ or market)). tw. 
14. or/11-13 
15. (generic adJ3 (price? or pricing)). tw. 
16. (generic$ adj3 (market or compet$)). tw. 
17.15 or 16 
18.10 or 14 or 17 
19. (((health or patient$) adji outcome? ) or readmission? ). tw. 
20. ((control$ or containment or curtailment or reduc$ or sav$ or cut$ or down$) adJ3 (cost? or pric$)). tw. 
21. (market adj2 shar$). tw. 
22. ((drug or drugs or pharmaceutic$ or medicines or medicament? or medicat$ or prescib$ or 
prescription? or reimburs$) adJ3 (use$ or cost? or expenditure? or expense? )). ab, tw. 
23. *Adverse Drug Reaction/ or (safe$ adjl (drug or drugs or pharmaceutlc$ or medicines or medicament? 
or medicat$)). tw. 
24. (drug use$ or drug utili? ation or ((medical care or healthcare or resource) adjl utili? tion) or 
Institutionali$ or hospitali$). ab, tw. 
25. ((prescrib$ or prescrip$) adJ2 (attitude or variation? or behavior or behaviour or pattern? or practice? 
or habit? or accurate or trend? or cost? or change? or shift$ or rational? or reduc$ or influenc$ or 
expenditure? or adherence)). ab, tw. 
26. or/19-25 
27. randomized controlled trial. pt. 
28. (random! $ or ((control or comparison) adji (group? or participant? ))). ab. 
29. ((time adj series) or time-series). tl, ab, tw. 
30. (regression or extrapol$ or (generals? ed adji estimating adji equation? ) or (longitudinal adji data) or 
(repeated adjl measures) or (least adji squares) or (smoothing adj2 model? ) or autocorrelation). ti, ab, tw. 
31. (pre-post or (pre adj2 post)). ab, tw. 
32. (before-after or (before adj2 after)). ab, tw. 
33. or/27-32 
34.3 and 18 and 33 
35. (opioid or placebo or reflumilast or exenatide or ectomy or athlete? or sport? or lactation or 
acupucture or inject$ or (clinical adj2 trial? )). ti, ab. 
36. (pharmacokinetic? or radio$ or tumor or tobacco or cigarette or vaccine? or alcohol or rat or mice or 
mouse or rabbit? or pig? or gene). ti, ab. 
37. editorial. pt. 
38. letter. pt. 
39, comment. pt. 
40. or/35-39 
41. animals/ 
42. humans/ 
43.41 not 42 
44.40 or 43 
45.34 not 44 
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Annex 6: Characteristics of excluded studies and references 
a) Pharmaceutical oiicies Influencing atients 
Study Cause for exclusion Intervention Setting 
Balkrlshnan etal. 2001 before and after study cost-sharing USA 
Birch 1986 before and after study cost-sharing UK 
Chalker 1995 post-test only control group design cost-sharing Nepal 
Cunningham 2005 before and after study cost-sharing USA 
Delate and Henderson 2005 less than 6 months educational approach USA 
Huang and Tung 2006 before and after study cost-sharing Taiwan 
Krol etal. 2004 less than 6 months educatlonal approach Netherlands 
Parsons eta/. 2004 less than 6 months educational approach UK 
Pilote eta/. 2002 before and after study cost-sharing Canada 
Rector eta/. 2003 post-test only control group design tiered formulary USA 
Trygstad etal. 2006 before and after study 
OTC switch 
reimbursement coverage 
USA 
Tseng eta/. 2004 post-test only control group design annual cap USA 
b) Pharmaceutical policies influencing providers 
Study Cause for exclusion Intervention Setting 
Adair and Holmgren 2005 single institution distribution of samples USA 
Albartii-Ballesteros eta/. 2002 before and after study educational approach Spain 
Angunawela eta/. 1991 less than 6 months educational approach Sri Lanka 
Babington etal. 1983 before and after study educational approach USA 
Baikrishnan eta!. 2001 
Bernstein etal, 2005 
before and after study 
before and after study 
reimbursement restriction 
educational approach 
USA 
USA 
Bjornson eta/. 1990 less than 6 months educational approach USA 
Bloom and Jacobs 1985 before and after study reimbursement restriction USA 
Carey eta/. 1992 
TVAMV ~ ý~ T before and after study educational approach Australia 
Cunningham 2005 before and after study reimbursement restriction USA 
Denig eta!. 1990 less than 6 months educational approach Netherlands 
Dormuth eta/, 2004 less than 6 months educational approach Canada 
Duborlja-Kovacevic 2006 before and after study educational approach Montenegro 
Elkharrat etal. 1998 before and after study educational approach France 
Fagundes eta/. 2007 qualitative study educational approach Portugal 
Fick eta/. 2004 no Interpretable data presented educational approach USA 
(continued) 
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Pharmaceutical policles Influencing providers (continued) 
Study Cause for exclusion Intervention 
TM 
Setting 
Fontaine etal, 2006 less than 6 months educational approach France 
Frighetto etal. 1992 
Fudge eta/. 1993 
Gehfbach eta/. 1984 
Gleason etat. 2004 
Gleason etal. 2005 
Goldfarb eta/. 1999 
Guo etal. 1995 
Hadiyono etal. 1996 
before and after study reimbursement restriction Canada 
before and after study educational approach USA 
single Institution educational approach USA 
Improper comparison group educational approach USA chosen (CSA) 
before and after study reimbursement restriction USA 
before and after study reimbursement restriction USA 
before and after study educational approach USA 
less than 6 months educational approach Indonesia 
Hall 1990 before and after study educational approach UK 
I-leaden eta/. 2006 less than 6 months reimbursement restriction USA 
Kersemakers eta/. 2000 before and after study educational approach Netherlands 
Knight eta/. 2000 before and after study educational approach USA 
Kotzan etal. 1996 post-test only control group design reimbursement restriction USA 
Kozma etal. 1990 before and after study reimbursement restriction USA 
Kreling etal, 1989 before and after study reimbursement restriction USA 
Latour-Perez etat. 2000 less than 6 months educational approach Spain 
Layton etat. 2006 before and after study reimbursement restriction Thailand 
Lee and Malone 2003 before and after study SPD South Korea 
Limpanasithikul eta/. 2002 less than 6 months reimbursement restriction Thailand 
Mallet eta!. 2001 before and after study educational approach Kenya 
Martens eta!. 2006 no Interpretable data presented educational approach Netherlands 
McCaig etas. 1999 before and after study educational approach UK 
McCombs etal. 2002 before and after study reimbursement restriction USA 
McEinay etal. 1995 before and after study educational approach UK 
McManus eta!. 2001 before and after study generic substitution Australian 
McMullin eta!, 1999 before and after study educational approach USA 
Momani eta/. 2002 less than 6 months reimbursement restriction USA 
Murray etal. 2005 before and after study educational approach UK 
Ozkurt eta/. 2005 before and after study reimbursement restriction Turkey 
Park etal, 2005 before and after study SPD South Korea 
Parsons etal, 2004 less than 6 months educational approach UK 
(ennt# ued) 
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Pharmaceutical policies influencing providers (continued) 
Study Cause for exclusion Intervention Setting 
Philips eta/. 2001 before and after study Incentives UK 
Raisch and Sleath 1999 less than 6 months educational approach USA 
Risser et al. 2005 post-test only control group design reimbursement restriction USA 
Rolle etal. 1995 before and after study reimbursement restriction Italy 
Rosich et al. 2005 before and after study educational approach Spain 
Roth et al. 2001 before and after study educational approach USA 
Schmidt etat. 1998 single Institution educational approach Sweden 
Schdffskl and Graf von der before and after study Incentives Germany Schulenburg 1997 
Scoble et ol. 2003 post-test only control group design educational approach UK 
Shankar etal. 2007 before and after study educational approach Nepal 
Sharma eta/. 2003 before and after study educational approach India 
Sketrls et al. 2005 before and after study educational approach Canada 
Smith etal. 1998 less than 6 months educational approach USA 
Strikwerda etal. 1994 less than 6 months educational approach Netherlands 
Tseng etal. 2006 before and after study reimbursement restriction USA 
Walley etal. 2000 before and after study Incentives Ireland 
Walton eta/. 1997 less than 6 months educational approach UK 
Wang and Pauly 2005 before and after study reimbursement restriction USA 
Wathen and Dean 2004 before and after study educational approach UK 
Watkins etal, 2004 qualitative study educational approach UK 
Welch eta/. 2000 before and after study educational approach Australia 
Wilson etal. 2005 before and after study reimbursement restriction USAM 
Wu and Gray 1990 
Wyatt etal. 1992 
before and after study 
before and after study 
educational approach 
reimbursement restriction 
USA 
UK 
Yakabowich etal. 1994 before and after study reimbursement restriction Canada 
Yeo etal. 1994 qualitative study educational approach Australia 
330 
Annex 6: Characteristics of excluded studies and references 
c) Pharmaceutical policies influencing industry 
Study Cause for exclusion Intervention Setting 
Anis before and after study price control Canada 
Germany, 
Costa-Font and Kanavos 2007 unclear when Intervention occurred parallel Importing Netherlands, 
Gill etal. 2000 before and after study reference-pricing Canada 
Jiang eta/. 2004 before and after study price control China 
Martini eta/. 1996 before and after study price control Italia 
McManus eta/. 2001 before and after study price control Australia 
Meng eta/. 2005 before and after study price control China 
Okunade 2001 cross-sectional study profit control USAM 
AMCP1) format dossier Spooner etal. 2007 one group posttest-only design requests 
USA 
Stargardt etal, 2005 descriptive study reference-pricing Germany 
Stargardt eta/. 2007 before and after study market deregulation Germany 
1) Academy of Managed Care Pharmacy 
References to studies excluded from this review 
Adair, R. F& Holmgren, L. R. (2005) Do drug samples Influence resident prescribing behavior? 
A randomized trial. American Journal of Medic/ne. 118 (8), 881-4. 
Albanil-Bailesteros, M. R., Calvo-Rey, C. & Sanz-Cuesta, T. (2002) [Changes in antibiotics 
prescription in primary care] [Spanish]. Ana/es Espanoles de Pediatria. 57 (5), 420-5. 
Angunawela, I. I., Diwan, V. K. & Tomson, G. (1991) Experimental evaluation of the effects of 
drug information on antibiotic prescribing: a study In outpatient care in an area of Sri 
lanka. International Journal of Epidem/ology. 20 (2), 558-64. 
Babington, M. A., Robinson, L. A. & Monson, R. A. (1983) Effect of written Information on 
physicians' knowledge of drug prices. Southern Medica/Journal, 76 (3), 328-31, 
Balkrishnan, R., Byerly, W. G., Camacho, F. T., Shrestha, A. & Anderson, R. T. (2001) Effect of 
prescription benefit changes on medical care utilization In a Medicare HMO population. 
American Journal of Managed Care. 7 (11), 1093-100. 
Bernstein, S. L., Whitaker, D., Winograd, J. & Brennan, J. A. (2005) An electronic chart prompt 
to decrease proprietary antibiotic prescription to self-pay patients, Academic Emergency 
Medicine. 12 (3), 225-31. 
Birch, S, (1986) Relationship between Increasing prescription charges and consumption in 
groups not exempt from charges. Journal of the Royal College of General Practitioners. 
36 (285), 154-6. 
Bjornson, D. C., Rector, T. S., Daniels, C. E., Wertheimer, A. I., Snowdon, D. A. & Litman, T. J. 
(1990) Impact of a drug-use review program Intervention on prescribing after 
publication of a randomized clinical trial, American Journal of Hospital Pharmacy, 47 (7), 
1541-6. 
Bloom, B. S. & Jacobs, J. (1985) Cost effects of restricting cost-effective therapy, Medical Care. 
23 (7), 872-80. 
Carey, D. L., Day, R. 0., Cairns, D. R., Pearce, G. A., Wodak, A. D. & Lauchian, R. L. (1992) An 
attempt to Influence hypnotic and sedative drug use, Medical Journal ofAustralla. 156 
(6), 389-92. 
Chalker, J. (1995) Effect of a drug supply and cost sharing system on prescribing and utilization: 
a controlled trial from Nepal, Health Policy & Planning. 10 (4), 423-30. 
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Costa-Font, J. & Kanavos, P. (2007) (Constrained competition in parallel drug Importation: the 
case of slmvastatin in Germany, the Netherlands, and the United Kingdom] [Spanish]. 
Gaceta San/tarla. 21(1), 53-9. 
Cunningham, P. J. (2005) Medicaid cost containment and access to prescription drugs. Health 
Affairs 24 (3), 780-9. 
Delate, T. & Henderson, R. (2005) Effect of patient notification of formulary change on 
formulary adherence. Journal of Managed Care Pharmacy. 11(6), 493-8. 
Denig, P., Haaijer-Ruskamp, F. M. & Zijsling, D. H. (1990) Impact of a drug bulletin on the 
knowledge, perception of drug utility, and prescribing behavior of physicians. DICP. 24 
(1), 87-93. 
Dormuth, C. R., Maclure, M., Bassett, K., Jauca, C., Whiteside, C. & Wright, J. M. (2004) Effect 
of periodic letters on evidence-based drug therapy on prescribing behaviour: a 
randomized trial. Canadian Medical Association Journal. 171 (9), 1057-61. 
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Fund of Montenegro in the period 2000 - 2004: effects of drug utilization reform 
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Gehlbach, S. H., Wilkinson, W. E., Hammond, W. E., Clapp, N. E., Finn, A. L., Taylor, W. J. & 
Rodels, M. S. (1984) Improving drug prescribing In a primary care practice. Medical Care. 
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Gill, N. J., Frighetto, L., Marra, C. & Jewesson, P. (2000) Influence of the British Columbia 
reference drug program on hospital formularies: a survey of hospital pharmacy 
managers. Canadian Journal of Clinical Pharmacology. 7 (2), 109-14. 
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Annex 8: Differential effects of cost-sharing by drug classes 
Class Study Population Effects 
Increase copay 
antibiotic, I oxman eta/. 1987 non-elderly decrease (-46%) 
anticoagulants Blais eta/. 2001 elderly NS 
anticonvulsants Blais eta/. 2003 poor NS (temporal decrease) 
antidepressants Ong et al. 2003 general NS in men, decrease in women 
antigout preparations Andersson et al. 2006 general decrease after 1997 reform 
antihypertensives Blais et a/. 2001 elderly NS (temporal decrease) 
Klepser et al. 2007 non-children decrease (-5%) 
Starmans et a/. 1994 general NS 
asthma drugs Kozyrskyj eta/. 2001 children decrease (-15%) 
anxiolytics Ong et a/. 2003 general NS 
benzodiazepines Blais et a/. 2001 elderly NS (temporal decrease) 
bronchodilators Andersson et a/. 2006 general decrease after 1997 reform 
inhaled corticosteroids Blais et a/. 2003 poor decrease (-37%) 
neuroleptics Blais et al. 2003 poor NS (temporal decrease) 
nitrates Blais et a/. 2001 elderly NS (temporal decrease) 
NSAIDs* Andersson et al. 2006 general decrease after 1997 reform 
oral hypoglycemics Roblin et a/. 2005 non-children decrease in > $10 increase of copay 
sedatives Ong et a/. 2003 general NS 
SSR1s* Andersson et al. 2006 general down shift in level after 1997 reform 
SSRIs/SNRIs* Klepser et al. 2007 non-children decrease (-6%) 
statins Klepser etal. 2007 non-children decrease (-4%) 
v, iqur<rl antifungal Gurwitz etal. 1995 women NS prurfuct , 
relieve copaY 
antiglaucoma drugs Martikainen eta/. 2007 general increase (+ 21% -t 109%) 
* NSAIDs; nonste adal anti i nflammatory agent, SSRIs; ', eledrve serotonin reuptake inhibitor, SNRI; , erotonin/ 
norepinephrine reuptake inhibitor 
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Annex 19: Follow-up period by intervention 
Follow-up period 
Intervention - 12 months & Ni). of studies 12 months 60 months > 
60 months 
Total (%'') 99(54) 79(43) 7(4) 1851) (100) 
patents 46 
cost-sharng 9 18 3 30 
prescription caps 4 1 5 
tiered formulary 4 5 9 
educational approach 1 1 
OTC switch 1 1 
providers 119 
educational approaches 41 22 63 
rembursement restrictions 24 9 33 
incentives 9 8 17 
dbtrbution of samples 1 2 3 
mandatory generic substtution 1 1 
repeat prescribing 1 1 
SPD') 1 1 
iidi try 20 
pr-re control - reference pricing 4 8 2 14 
price control - others 2 1 3 
market authorisation 1 1 
patent regulation 1 1 
proft control 1 1 
1) rounded 
2) number of included studies by intervention; Schneew eiss et al. 2002 is inclu ded twice 
3) Separation of Prescribing and Dispe nsing of drugs 
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Annex 20: Outcome variables by intervention 
Intervention 
Ab. of 
studies 
Utilisation Expenditure Out-of- 
pocket 
Other 
services 
Heath 
outcomes use 
patients 46 42 23 9 g a 
cost-sharing 30 26 17 
prescription caps 5 5 2 2 
tiered formulary 9 9 8 7 2 
educational approach 1 1 1 
OTC switch 1 1 1 
providers 119 84 54 4 16 6 
educational approaches 63 q2 18 4 
reimbursement restrictions 33 28 20 3 10 
incentives 17 9 14 
distribution of samples 3 3 
mandatory generic substitution 1 1 1 
repeat prescribing 1 1 1 
SPDI) / I 
ridustry 19 11 12 4 3 
pr ice (ontrol - reference pricing 1; 11 9 4 ; 
price control - others 3 3 
market authorisation I 
patent regulation I 
profit control 1 
1) Separation of prescribing and dispensing of drugs 
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Annex 22: ARIMA modelling and an empirical example 
Annex 22: Autoregressive integrated moving average (ARIMA) 
modelling and an empirical example 
ARIMA model 
An ARIMA model is a model of the stochastic process which generated the observed 
time series. ARIMA modelling is an iterative process involving several steps; 1) 
Identification, 2) Estimation and 3) Diagnosis (McCain and McCleary, 1979). 
1) Identification 
At the identification step, correlogram, the autocorrelation function (ACF) and partial 
autocorrelatlon function (PACF) computed from the time series observations is used to 
select a tentative ARIMA model for the series. If the series Is nonstationary, it needs to 
be turned Into a stationary series (McCain and McCleary, 1979). A stationary series is 
one that has no secular trend in Its mean and variance. A nonstationary time series can 
be made stationary by differencing and in such a case a time series is technically said 
to be nonstationary in the homogeneous sense. Differencing can be performed 
regularly or seasonally. Autoregressive processes, moving average processes, seasonal 
autoregressive processes, seasonal moving average processes, or mixed processes of 
them can be specified on the basis of correlogram (McCain and McCleary, 1979). 
2) Estimation 
After a tentative ARIMA model has been Identified, the values of parameters, say the fi 
and 0, of the model are estimated (McCain and McCleary, 1979). Two basic criteria in 
estimating parameters should be satisfied (McDowall et al., 1980). First, the estimated 
autoregressive and moving average parameters should be statistically significant. 
Second, the estimated parameters must lie within the bounds of statlonarity and 
invertibility (statlonarity-invertibility conditions). The bounds of stationarity for the 
parameters Is 
-1 <V< +1. 
The bounds of invertibility Is 
-1<0v<+1. 
If p is more than one (ie. ARIMA models in a higher order autoregressive or moving 
average process) then the sum of's, or sum of 8s should be less than unity. 
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3) Diagnosis 
If a tentative model is statistically adequate, its residuals would satisfy two diagnostic 
criteria (McCain and McCleary, 1979). First, there are no spikes at lag 1 and the 
seasonal lags of the ACF and PACE. Second, these residuals must be white noise. The 
Box-Ljung Q statistic is often employed in practice to test this hypothesis. If either 
criterion is not met In the Estimation or Diagnosis step, then the whole process of 
identification, estimation, and diagnosis is repeated to select a new model. 
Impact Assessment Model 
An interrupted time series analysis aims to explore whether the intervention had any 
impact at the specific time point the intervention occurred (Shadish etal., 2002c). The 
underlying concept is to establish whether the intervention component adds 
significantly to predicting the behaviour of a time series over and above the prediction 
that is offered through an understanding of the regular and seasonal components of 
the noise. In other word, the impact of an intervention can be assessed after 
controlling a noise component (trend, seasonality and so forth) using an ARIMA model. 
Representing the ARIMA model as Nr, the impact assessment model may be written as 
Yt=f(Ic)+Nt 
where Yc is a dependent variable of Interest; Nt denotes a noise component; and f(It) 
denotes an intervention component (McCleary eta/., 1980a). 
Impact assessment begins with Identifying an ARIMA model for the time series, which 
describes the stochastic behaviour of the time series process. An Intervention 
component is then added to the Identified ARIMA model (McDowall et al., 1980). At 
this step, there are several distinct functions of f(It) which correspond to several 
distinct types of Impact. Among them three transfer functions are generally explored In 
empirical research, which reflect 1) an abrupt, permanent change, 2) a gradual, 
permanent change, and 3) an abrupt, temporary change (McCain and McCleary, 1979). 
1) Abrupt, permanent change 
An abrupt, permanent change is where the time series immediately changes its level at 
the time of the intervention and the change persists over time. The transfer function 
model for this intervention effect is written as: 
Yt=colt +Nt 
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where co is a parameter interpreted as the magnitude of the abrupt, permanent change 
and where Nt is an ARIMA model. The independent variable it is a dummy variable 
such that: 
It =0 before the intervention, t< 
1 after the intervention, tz/ 
where /is the time of the intervention (McCain and McCleary, 1979). 
Thus, the intervention hypothesis test for this transfer function is a test of significance 
for the co parameter which is the magnitude of the shift. 
2) Gradual, permanent change 
A gradual, permanent change can be characterised as beginning gradually at the 
introduction point rather than abruptly and the treatment effect persists for a long 
period, eroding slowly. The transfer function model for this intervention effect is written 
as: 
Yt=6Yt. 1+colt +Nt 
where c) is a parameter interpreted as the magnitude of changes at the moment of 
intervention and where S Is a parameter to be estimated from the data, determining 
how gradually the series will change from time to time. Again, NC refers an ARIMA 
model for noise and the independent variable It is a dummy variable (McCain and 
McCleary, 1979). The intervention hypothesis test for this transfer function is a test of 
significance for both w and S. When S is very small, for example S=0.1 or smaller, the 
impact can be interpreted abrupt and permanent rather than gradual (McCain and 
McCleary, 1979). 
3) Abrupt, temporary change 
The last transfer function model describes an abrupt but temporary intervention effect, 
That is: 
Yt=8Ym+Wt+Nc 
where It Is defined a pulse function such that 
It =0 before the Intervention, t<I 
1 at the moment of intervention, t=I 
=0 thereafter, t>1 
where ! 1s the time of the intervention (McCain and McCleary, 1979). 
The intervention causes a profound change in level at the time of introduction and the 
magnitude of change is w. However, after the temporary spike, the series has returned 
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to its pre-intervention level. The parameter S Is interpreted as the momentary rate of 
decay of the spike. When S 1s large, for example 8=0.9 or larger, the treatment effect 
erodes slowly, indicating a permanent change (McCain and McCleary, 1979). 
Specifying the Transfer Function 
The transfer function should be determined a priori. If there is a reasonable priori 
notion relating to the nature of the hypothesised effect, then a transfer function can be 
selected accordingly. However, in practice, it may be uncertain which transfer function 
may be more adequate. 
So, instead of making a priori choice of which transfer function to use, analyses often 
start with a transfer function for an abrupt, temporary change: 
Yt=8Y. 1+c, )It 
where It is defined as a pulse function as discussed above, The S parameter is a 
greater than zero but less than unity, that is: 
O<S<+1. 
These constraints on the 8 parameter are called the bounds of system stability 
(McDowall et al., 1980). If the 8 parameter Is not constrained to these bounds, then 
the time series system Is unstable, Indicating nonstationary. If the estimated value of 8 
is relatively large, say 8=0.9 or larger, then this could be considered as evidence of a 
permanent effect. Then, the analysis is replicated using a transfer function for a 
gradual, permanent change (i. e. the same equation as above but with It defined as a 
dummy variable). At this step If the estimated value of 8 Is relatively small, say 8=0.1 
or smaller, then this could be considered as evidence that the effect Is both permanent 
and abrupt. Then, the analysis Is replicated using a transfer function for an abrupt, 
permanent change (McCain and McCleary, 1979). Analyses in the present study 
followed the same principles unless there was a clear a priori notion as to the nature of 
the hypothesised Intervention effect. 
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Empirical example 
1. Visual examination of the time plot of the data series of interest 
The first step in the analysis is to plot observations against time to scrutinise any 
irregular variations or patterns of the series such as trend, seasonality, outliers and 
discontinuities. Figure a22-1 presents a time series graph of the 'costs per patient' each 
month in South Korea from January 2003 to June 2008. Two study policies to contain 
pharmaceutical expenditure were introduced at the 49"' (PERP) and 56th (Co) time 
points. 
Figure a22-1: Cost per patients 
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The plot shows a clear upward trend over time, indicating a nonstationary time series. 
Hence, visual examination of this time series data suggests differencing the raw data 
to make it stationary. 
2) Seasonality 
The plot also shows the seasonal periodicity. Individual drug costs rise in summer and 
fall in spring and autumn. This pattern repeats every year and the length of the cycle 
seems to be almost 12 months. Therefore, multiplicative ARIMA seasonal models would 
be considered if there is clear evidence in the residual analysis. 
3) Outlier and intervention impact from the visual examination 
There are neither prominent outliers in the data nor is there an abrupt drop or rise 
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demonstrated in the post-intervention data. It is seen that the underlying data 
structure appears to be altered after the second policy. 
2. Examination of correlogram to identify a'noise' model 
In specifying a tentative noise model, a time series data structure in the pre- 
intervention region is used. An ACF and PACF are estimated to investigate 
autocorrelations. The ACF shows an obvious trend in the data, suggesting differencing 
(Figure a22-2). Figure a22-3 shows the ACF estimated from the differenced data. A 
large spike is seen at lag-12 In the ACF, indicating seasonal periodicity. 
Figure a22-2: The ACF for the raw `costs per patient' series 
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Figure a22-3: The ACF for the regularly differenced `costs per patient' series 
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Figure a22-4: The correlogram for the regularly and seasonally differenced `costs 
series 
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To deal with the apparent seasonal periodicity, the series differenced seasonally as well 
as regularly is inspected. The seasonally differenced model looks like the most useful 
data structure to consider. The correlograrn presented in Figure a22-4 strongly 
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suggests at least one moving average term and indicates some autoregressive terms, 
possibly two. 
From the simplest model which is MA(1) on the differenced series, i. e. 
ARIMA(0,1,1)(0,1,0)2, several models with parameters slightly different from the ones 
in the simplest model are explored. The AIC values are used to choose a best model 
among them. From this point of view, the model given above produces the smallest 
AIC values and appears to be the most appropriate for the data. 
3. Estimation of parameters and check them within basic criteria 
Parameter estimates for an ARIMA (0,1,1)(0,1,0)12 are: 
u, = -0.7502 (s. e. = 0.1097) with z value = -6.84 
The first-order moving average parameter is statistically significant and within the 
bounds of invertibility. 
4. Examine residuals from obtained models and assess adequacy 
Figure a22-5 presents the fitted values and forward projection of the tentative model in 
parallel with the actual data. The fitted model seems to fit well with the superimposed 
the actual measured values in the pre-intervention period. 
Figure a22-5: The forward projection of the indentified model with the actual 
measured values 
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The projection looks consistent with the second period. However, in the third period 
after the second intervention, it looks as though the data may be different. To diagnose 
the identified model, residual analysis is performed. The Q statistic is not significant 
(p=0.680), indicating that the residuals from this tentative model are white noise. The 
overall diagnostic tests shown In Figure a22-6 confirm that this is a reasonable model. 
Figure a22-6: Residual analysis of ARIMA(0,1,1)(0,1,0)12 model 
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S. Fit the intervention component to the identified 'noise' model 
At the next step, an Intervention component Is added to the ARIMA model Identified in 
the stochastic process. From the primary segmented regression analysis, It Is discerned 
that drug expenditure may be lowered significantly after the second Intervention. 
Hence, a transfer function for abrupt, permanent change is employed. It is written as: 
Yt = wIPERPt + c02Cot + Nc 
where o Is a parameter interpreted as the magnitude of the abrupt, permanent 
change after the PERP, w2 Is a parameter interpreted as the magnitude of the abrupt, 
permanent change after coinsurance, and Nt is an ARIMA model. 
The model details from the analysis show that the coefficient for the first Intervention 
is non-significant, but for the second intervention is statistically significant. 
©1- -0.8536 (s. e. = 0.0813) with z value = -10.50 
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wl = -40.20 (s. e. = 415.36) with z value = 0.92 
(02 = -1447.86 (s. e. = 532.80) with z value = -2.72 
6. Diagnosis for the residuals of the full impact assessment model 
Although the Q statistic is non-significant (p=0.3136), the overall diagnostics for the 
model are less good (Figure a22-7). 
Figure a22-7: Residual analysis of the full impact model 
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When setting up the specified model with time series data for the period before the 
second Intervention and ignoring the first intervention as it appears non-significant, it 
produces coefficients that are consistent with the previous model and provide much 
improved diagnostics. This suggests that the identified model is a convincing model for 
the time series up until the second intervention covariate is applied. Although several 
tentative models are additionally explored, none generate better outcome in the 
diagnostic analysis. All models indicate that the data region after the second 
intervention is different from the other two regions. Unfortunately, this may be due to 
the relatively small number of time points available after the second Intervention and 
thus a better fitting model may not be available for the present study. 
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THE UNIVERSITY tX7k 
-DEPARTMENT OF 
HEALTH SCIENCES 
Topic Guide for Participants 
Policy-makers' Views on Pharmaceutical policies in Korean Context 
1. Your background 
  Your current and recent roles and responsibilities 
2. Your views on policy evidence available in Korea 
  Current source of evidence employed in policy-making in Korea 
  Plans for improving the quality of evidence 
3. Your experience in the pharmaceutical policy-making 
  Your views on policy outcomes and of which supporting evidence you have 
" Other potential factors that influence the policy decisions 
4. Opinions of the potential policies available to policy-makers 
" Causes of increasing drug spending 
" Current concerns to be tackled 
Potential policies you suggest 
  Barriers, feasibility, implications of the potential policies in Korean context 
S. Any other thoughts 
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THE UNJvERsirv(floih 
DEPA RTM f NT OF __ _ 
HEAUFFI SCIENCES 
Semi-structured questionnaire 
Evidence-based pharmaceutical policy-making in the Korean Context 
This research is being carried out as pail of a Doctorate in Health Policy Research. It has been reviewed 
and approved by the Department of Health Sciences Research Governance Committee, University of York. 
SECTION 1. About You: 
1. What is your background? (check' ad relevant items) 
1) Administration () 
2) Economics () 
3) Medicine () 
4) Nursing () 
5) Pharmacy ( 
6) Health Sciences/Health service research () 
7) Other () 
2. What is your current or recent role(s) in pharmaceutical regulation 
for the recent 10 years? (dw(k J relevant items) 
1) Policy-maker () 
2) Policy implementor () 
3) Policy adviser () 
4) Researcher () 
5) Other () 
3. How long have you been engaged in pharmaceutical regulations? 
1) less than 5 years () 2) between 5 and 10 years () 3) more than 10 years () 
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[SECTION 2 Your views on Evidence-based po/icy making in Korea: 
4. Please circle the number that most closely matches your opinion in 
each row about how often each of following evidence is used in the 
pharmaceutical policy-making process in Korea. 
Studies inveshgatiny Korean pharmaceutical regulations 
Studies investigating overseas' pharmaceutical regulations 
Comparative studies of pharmaceutical regulations 
Economic evaluation studies 
Reports after a business trip to foreign countries by 
governmental officers 
Experts' opinion 
Clinical research 
Otherl () 
Other2 () 
Never use Always use 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
1 2 3 4 5 
S. Please circle the number that most closely matches your opinion in 
each row about the aua/i of each of fo lowing evidence employed in 
the pharmaceutical policy-making process in Korea. 
Low quality 
Studies investigating Korean pharmaceutical regulations 1 
Studies investigating overseas' pharmaceutical regulations 1 
Comparative studies of pharmaceutical regulations 
Economic evaluation studies 
Reports after a business trip to foreign countries by 1 
governmental officers 
Experts' opinion 1 
Clinical research 
Otherl () 
Other2 ()1 
High quality 
2 3 4 `, 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
2 3 4 5 
6. Would you be satisfied with the sources of and quality of evidence 
employed in the pharmaceutical policy-making process in Korea? 
1) Very satisfied () 
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2) Satisfied () 
3) ) Neutral( 
4) ) Unsatisfied( 
5) Very unsatisfied () 
7. Which of following strategies do you think are in an essential need to 
improve Korean stance in Evidence-Based policy-making? Please 
answer if you choose Neritr/ Unsatisfied, or VQM unsatisfred in 
Question 5? (make three cho%sand check -%% them in parentheses) 
1) Constructing a proper database () 
2) Aggressive Involvement of government body(ies) In 
Developing/Evaluating/Disseminating body of evidence () 
3) Funding for research( ) 
4) Government/university/industry cooperation () 
5) Improving ability to use existing resources 
6) Making easier access to available data () 
7) Nurturing potential researchers () 
8) Other () 
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SECTION 3. Your views on current pharmaceutical regulations in 
Korea: 
8. From the following list of potential factors affecting the policy- 
making process of pharmaceutical regulations arrange them in order 
of importance that you think influences greater in Korean policy- 
making process. (you can suaaest other factors not on the following /ist or 
remove some of factors on the list and arrange them in order together with the 
following list) 
Scientific evidence (A)/ 
Social norm (B)/ 
Consumers' groups (C)/ 
Effects and consequences on pharmaceutical industry (D)/ 
Opinion leaders' perspective (E)/ 
Conventional precedents (F)/ 
Interest groups (professionals, manufacturers, wholesalers, etc. ) (G)/ 
Political context (H)/ 
Impact on other resource use (I)/ 
Overseas' experience (])/ 
Other () 
9. Which countries do you think are often benchmarked in the 
pharmaceutical policy-making process in Korea? (list more than three 
countries with no limitation) 
io. Would you have involved in the pharmaceutical policy-making 
process (including planning/development/de(. ision-- 
making/advisory/implementation/evaluation) of the following regulations 
recently introduced in Korea? (check ([relevant items; you can suaaest 
other regulations in which you have involved on 'Other#' with no limitations) 
1) Expanding 30% coinsurance for prescription drugs () 
2) Best Prescribing Project () 
3) Pharmaceutical Expenditure Rationalisation Plan 
4) Otherl () 
5) Other2 () 
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ii. Choose the option that most closely matches your opinion on the 
following statement: (check V only one in each of regulation) 
The impact of each of following regulations are in accord with the policy aims 
and expected effects in the stage of policy development. 
nx 
Expanding 30% coinsurance for prescription drugs 
Best Prescribing Project 
PERP*- price control 
PERP*- positive list/formal request of economic 
evaluation in listing 
Otherl () 
Other2 () 
* PERP refers to Pharmaceutical Expenditure Ratlonallsation Plan 
12. Please answer if you have any single regulation on which you choose 
P&AgM or Stro /y isa4 in Question 10. What do you think 
cause such differences in the regulation you choose Pisagj or 
StrpAlv 2tee in Question 10? 
Expanding 3Q% coinsurance for prescription drugs: 
Best Prescribing Project: 
PERP - price control: 
PERP - positive list/formal request of economic evaluation in listing: 
Otherl ( ): 
Other2 ( ): 
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13. Choose the option that most closely matches your opinion on the 
following statement: (check V only one in each of regulation) 
The each of following regulation brought unwanted consequences after 
implementation. 
e 
Expanding 30% coinsurance for prescription drugs 
Best Prescribing Project 
PERP*- price control 
PERP*- positive list/formal request of economic 
evaluation in listing 
Otherl () 
Other2 () 
" PFRP refers to Pharmaceutical Expenditure Rationalisation Plan 
14. Please answer if you have any single regulation on which you choose 
Agree or Strong( agree in Question 11. What do you think are 
unwanted consequences in each regulation you choose A or 
Strongly agree in Question 11? 
Expanding 30% coinsurance for prescription drugs: 
Best Prescribing Project: 
PERP - price control: 
PERP - positive list/formal request of economic evaluation in listing: 
Otherl ( ): 
Other2 ( ): 
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15. The following list of pharmaceutical policies displays regulations have 
been attempted but failed to introduction or just piloted so far during 
the recent decade in Korea. In your opinion, to tackle current 
challenges in Korean pharmaceutical sector each of regulation is: (you 
can suggest other regulation that were attempted but failed to introduce on 
'Other#' with no limitations) 
,ý 2ý' JcJ Jý'ý 
Reference pricing programme 
Prescribing budget 
Diagnosis-related group 
Generic name prescribing 
Otherl () 
Other2 () 
16. Please answer if you have any single regulation on which you choose 
ý[seful or Very usefu/in Question 14. What would you think causes 
the failure of introduction of the regulation you choose Vsefu/or ymy 
ý, sýin Question 14? 
Reference pricing programme: 
Prescribing budget: 
Diagnosis-related group: 
Generic name prescribing: 
Otherl ( ): 
Other2 ( ): 
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SECTION 4. Your views on future pharmaceutical regulations in Korea: 
17. Which one of the following do you think has caused an increase of 
pharmaceutical expenditure the most afterward in Korea? (rank them by 
writing the numbers 1,2 and 3 (or 4 if you suggest other option in 'Other') in 
parentheses: Most = 1) 
1) Price () 
2) Volume () 
3) Non cost-effective drug utilisation () 
4) Other 
() 
18. What do you think is the most serious issue to be considered in the 
process of Korean pharmaceutical policy-making? (make three choices 
and check V) 
1) Cost control () 
2) Improving organisational efficiency including government bodies, medical 
institutions, industry etc. () 
3) Rational use of medicines () 
4) Equity and affordable access across various social groups () 
5) Consumers' right () 
6) Accountability and transparency () 
7) Priority setting in resources allocation () 
8) Competitive pharmaceutical industry () 
9) Other () 
19. Who do you think should be the first target of policy in coping with 
the issue you suggest in the Question 17? (make more than one and no 
more than three c ices and check V) 
1) Authorities () go to Question 19 
2) Consumers () go to Question 20 
3) Prescribers or Dispensers () go to Question 21 
4) Domestic manufacturers () go to Question 22 
5) Global manufacturers () go to Question 23 
6) Wholesalers () go to Question 24 
7) Other () go to Question 25 
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º19-25 -4 Questions from 19 through 25 are about your suggestion on 
potential pharmaceutical policies in Korean context. 
Please suggest regulation(s) you think is effective to cope with the 
issues you suggest in Question 17 with targeting to each group who you 
choose in Question 18. (each question has the list of relevant pharmaceutical 
regulations that are only for your conve ence and this does not aim at guiding or 
limiting your opinion at all; you can freely alter one or some of them and also suaae, 
other regulations not on the list In your own view) 
20.1f you choose Au ritie in Question 18 please suggest 
regulation(s): 
for example; 
ý" Enhancing monosopny power 
f" Enhancing transparency In policy-making process 
" Establishment of quality control of generic products 
" Extending privatisation domain in the pharmaceutical sector 
" Improving accountability reports to the public or the industry 
ý" Making, evaluating, and disseminating of appropriate Information 
" Raising fund through beneflcleries' contribution 
" Raising fund through public resources 
" Raising public subsidy to disadvantaged groups 
21. If you choose Consumers in Question 18 please suggest 
regulation(s): 
For example; 
" Increasing copayment 
" Encouraging self-medication 
" Enlightening the cost-effective utilisation of drugs 
" Premium charge on costly drugs (eg. reference pricing, etc. ) 
" Prescription caps 
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22. If you choose Prescribers or Dis users In Question 18 please suggest 
regulation(s): 
'Por example; 
" Establishing curricular In medical/pharmacy schools to improve understanding 
! about public health care/drug policies 
" Financial incentives on prescribing (or dispensing) less-costly drugs 
" Mandatory generic name prescribing (substitution) 
1" Prescribing audit (Prescribing feedback, Drug utilization review, etc. ) 
1" Prescribing budget limit 
ý" 
Providing continuing medical education programmes to encourage cost-effective 
prescribing (dispensing) 
j" Reimbursement restriction ante facto (eg. prior authorisation, formulary, 
positive/negative list, preferred list, step therapy, reference pricing scheme etc. ) 
" Reimbursement restriction expiostfacto 
23. If you choose Domest mnyfacturers In Question 18 please suggest 
regulation(s): 
For example; 
" Direct price control (Price freezing, Price cut, Maximum allowance price, Actual 
acquisition price, etc. ) 
" Making no doubt about the bioequivaient test of generic products 
" Market transparency 
" Profit control 
" Reducing drug patent period 
" Regulating Direct-to-Consumer advertising 
" Reimbursement restriction ante Panto (eg. prior authorisation, formulary, 
, positive/negative list, preferred list, step therapy, reference pricing scheme etc. ) 
" Request economic evidence in the process of reimbursement decision 
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24. If you choose Global manufacturers in Question 18 please suggest 
regulation(s): 
For exam e 
" Direct price control (Price freezing, Price cut, Maximum allowance price, Actual 
acquisition price, etc. ) 
" Making no doubt about the bioequivalent test of generic products 
" Market transparency 
" Profit control 
" Reducing drug patent period 
" Regulating Direct-to-Consumer advertising 
" Reimbursement restriction ante facto (eg. prior authorisation, formulary, 
positive/negative list, preferred Iist, step therapy, reference pricing scheme etc. ) 
" Request economic evidence In the process of reimbursement decision 
25. If you choose Wholesalers in Question 18 please suggest 
regulation(s): 
For example; 
" Direct price control (eg. margin control, etc. ) 
" Elevating the level of approval standard 
" Expanding bidding system In drug contract 
Improving market transparency by central information body 
26. If you choose Oth eý ' In Question 18 please suggest regulation(s): 
Thank you for your participation. 
-The End- 
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p006 
(pO06: 4)NI; 7N 8ýýf ilzhý: Wil 2f 608 Al LH 17HL, QF02 LU AI! 9 SiE-- ?IF Ft CI : 
There are often sudden requests for policy reform, then, [policy-makers] have to come up 
with the request and carry it out in a very limited amount of time. 
(P006: 4)Oti'2H-S ägmu P-ýSL- M AIaOIIhi 0101 AIg(x1 Lt2t9. Lx-:? XFý J. i 
t 21 0t 
T' 
a El t- ) t-i 2A 
i. 
i 
l# 
0I 
=i 
T q4 Oil 
. 
01 is. 
9-9°J L! ü.: So when it comes to policy-making process, we end up using research 
materials or data that are either already done by someone else, or already on the market. I 
just don't think we really have any choice but to rely on experts' opinions. 
(P006; 6)rsg 2J-? @21 JIZU ! 22j Li-9 DIA 199-1 ýQý EiXIU 81 h. ý4zf ZJM 9- 9, k ei -F , i§ 
I-"'4P! IN &°MV LOOI It OI L} ` ýt WiR. : If you look at the outcomes of most 
evidence produced In Korea, they usually tend to cover just the general aspects of it and 
leave out all the details. 
(pOO6.20)J J V, b#9 214 Q! II M901 1I ig g7124 kß -1 i 097111 R2t0LA Cf.: I've 
heard that there have been some cases where certain negotiations were made under such 
monopsony. 
9zilýJa; QF (pOO6: 22)S L424_I +XH z1lS°-! -zil i01 ILM 7fß;; NEE )lI )f24I 
xlö 6 VEMAD. 3)11 fF)11)i Ql)1; --. g ZiC1I -A TA-fl 'II 91021, ... W; ' Q IA1S t! 2t, 
0IE $OffMS J9 F MM, zig f WO A °. S t' 4. ? IL- äs, "01 T UR.: The 
problem with South Korea's current policies is that they're price-centred, controlled ones, 
so they keep on lowering the price anyway. But there's a limit to that. We need policies that 
can encourage us to use drugs, or ingredients that are not as expensive. 
(pOO6.24)? iJ M XIISw, UIOilM°J (HEI fý4-P-f AUF, 49-1 P° fz01@ 01 9901 OiLIai -°IAF9I 010 
9 °i at U S8IC} L-)i a.: The main issue is not about the efficiency of medical services In a 
healthcare system, but about getting the approval of doctors 
(P006.: 26)OtA2US JJ UZI q P. M 91 X lAfä °J äýi?! 7F C4 I O1 4 WW) elm : It's no 
surprise that pharmaceutical companies dominating that type of Information draw people 
into their circles with their logic and reason. 
(p00622) 01; 4 OI Wig *a 09210,... t-2. I12 ald0121E7F mg ggl-w ImZlu ;> 2CIA 
. Y. 14 8H 01 ¬W4 31 8.: though this may sound a very theoretical and like one of those 
"Confucius sayings.. ",.. the government should continuously make an effort to enhance 
logical solutions, rationality, or clarity when carrying out policies. 
(P006: 4O) 19 7tOfl CH .º ! z-- &19- qA f2 ... C} OII OIL 01w, % RI)mm E Eo11 O1iu XliE lL- 
cil all cH F >I S* qk& M3Lk of cN M8 : We just don't really have much experience with 
all of these policy evaluations... like how to evaluate and systematise them,.. 
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p014 
(pO14; 4)AI9 _F ME Xfit1I21 ýtgpý T? 4 AI91A-i WTh k ?Iq )i ßt¬ 3 Wof8, : there were many 
cases where those evaluations have been made public mainly focused on the `good aspects' 
of them. 
(p014: 4) 7}7} X71741 R S1 OJ°l: 1 IR 'Jq$1 xý °_ Ql lrO171. E 91°1 A .: the short-term 
and fragmented policy evaluation 
(P014: 4)(2.1? M Ar] -Y-2 2)4AL : 110 
E422"ACEP- _- ; HOF Yoir-i24 äiß .2 lil: ý18111: 420,01 
3af Ef Moll F"Oi7I i $FýCii 0101 Rt MJ 21 °l 940411 ß 0l 010101@301 Rik{ 2A(4 
ýi zi.: They basically already liked what they saw In that short period of time, so they don't 
really seem to care too much about fully comprehending foreign policies or the systems 
that they're interested In as long as they like [the foreign systems], 
(pO14: 8)XilRf& DJ g24! Btoi atci W. LInl e -? -z. jt a oii i XiJUM Z4V; 5i, )il W01 JUoiXlM 
V! =Q O, 'A4 ý= 0 IN 2tJ ýnlX! JY)iiU Oiý+01 PI SID Yl. lM 0141 90l ttEt$i f iER.: Since 
the policy monograph is mostly focused on a system Itself, It's too bad that there isn't really 
any chance to evaluate whether that system would work or not for South Korea. 
(PO14: 8)ig99 $i&1 evidence) l U2} 01 El 741 -S R712t=ý1 94 I Lj I : ýL aa ßt01 8I: L, 
Venj8,2i izol iC L J»: 1XIXlt £ ek51f 0401 ai. s e#ol lI Välc} Linl -Satt 
, a, t, E Wg21p_l 21--? 7101F01XIXI UL- ? I°)i g (ViE-8.: I'd like to do more about the 
evidence you mentioned before, such as evidence on a certain policy evaluation or a 
system evaluation that we could use in the future. But it's not easy for us'to pursue In- 
depth research because policies continue to change, and also there aren't enough networks 
for us to reach out to those who might be able to help. 
(PO14: 11) 3492-9 41RU %_ 2^ DER, oQ IMM 91,06FAIt o19I CEOI Iii)f 2M JJF4o1Q 
Njyoil 24ctT 29m81 3)II i-M 'a OIR.: I didn't really have to face it directly. 
However, If I had been involved In either the NHIC or In the HIRA, then I would've 
understood the importance of it. 
(PO14: 36) i E- 011&4011 Ws 2J J 2-IUIIOIE WOW -AA t-IWOI t1 CIA I'M o tit ej m oI 
V&oi8. olLj mraoII}il IiyII-M Mief 8}L- A ? JXPl c4811lL- Wiff : 74M, :I don't think 
doctors who had previously been getting Illegitimate financial benefits by giving out new 
drugs or keeping changing prescriptions would change to generic prescriptions suddenly 
because of a policy. 
(P014: 36)M1%d Ai VW il Af`Gi 24-? R °I A1001. Mei eq XI 7l Olf F, 94214 7I QIi C pº 
PAU -, Ra W-, RIN Al W UF9M MiM OIL-WOia.: Doctors don't really believe 
In blo"equlvalence test Itself, But the thing is, you can't say that all bio-equlvaience tests 
are completely absurd, and the scientific facts they've learned In medical school are 
absolutely right. 
(pO14.39) Llnf WHt VtCiI MICH XH 1_°ý R VU goIX1, acil X0141 Yef tilt/ IRS¬t j#m, 
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ýIýiýl 7f ýFý ga cil r ; ýa Im RiCI24? 8.: So basically, there Is already a 
structure for this, but just not In a more concrete way. Also, they can't really do anything 
when it comes to the cultural aspect of medical professionals, which I think Is the most 
vital part. 
p017 
(p017.20)9442 EIV ¢il °IAIý9°-I 9NR 9a81 9, RSICD -192to1 NO fl :I think gaining the 
acceptance of doctors is crucial when it comes to carrying out a policy, 
(P017. "42) I, i2_. OIý[1i' OlitFzii]ý 21 MH4 7Cf,, k! 0I g1)1; =R. öl 
2ijO1 2 a" Ol, a, OiI& 0 41`011 24 äN SHOi, £It: xi 1 7IiE Oil ae e-7 SE v-r. ' loi 
2tß., : I'm not sure if we are going to be able to carry this [prescribing budget] out In a 
short period of time. We don't really have any Ideas or previous research on how to 
allocate the budget.. I just don't think we're ready yet. 
(p01Z64) 9- alU24 X1lUIEN 94 7113 kA U Ex 'it Gi LH 02 °XI3 A1312 JM Ale! 01 VvLVO[8. : 
Our country has, In some ways, Intended to maintain the domestic Industry by setting 
generous prices for generics. 
(P017.: 64)XMMUI ! 121'7i7i 1-71 E1-2011 D71 )M-fl R&DN äfl- 71 MC4 X 011"'WO )IIik$FL- 7iI ýtý º 
7MoiR. 31212M IN ff. : since generics are relatively at a premium price, the 
manufacturers continue to be in generic business for profit rather than to Invest that 
money towards researching and developing new drugs, it's natural from the manufacturers' 
perspective. 
p019 
(p019.: 8) i9XII 1YZi Z EfMM U19 : costs data In relation to an economic evaluation 
(p019,8)socIai sciencesoll CHPMý a fm VI- M4Wwwol 1Y71ät1- igqc-- -9.9 VMD ND OUni 
eixif wZF lGoli cw xi HID ? -kExi t; 4011 U& NO . 9g8I IIl tF4e! irt, 01: 11 8li- imr, 
atz tHM : There are times when researchers who aren't really specialists in the social 
science field get Involved In the evaluating process, and because of this, they simply make 
comparison with foreign policies or evaluate Korean policies tend to be too generalised... 
(p019: 24) (M W aI tf XII I1 I; °J of II aH Al I-a 01610 al ` III tH' tH o' 11 till I oll CH f-ý evidence 1: 
evidence on how to allocate the budget [to discuss a prescribing budget] 
(P0! 9: 24)Q)Qf W)iºL- P. PFL-ciº gMI240 )[9 E @zJº S*wº SILI)f ýU242p- )f2101 be 
9411 %01Mis. 01°I94)01h=2 942- QI ºoºeOWWW012401svoIlki. la1ioºEoM Ott 
0I 94 01 A ýI I- :ia.: I don't think the drug itself Is very pricy. However, one of our country's 
biggest problems Is that we tend to use drugs that are relatively high In price. This is 
because expensive drugs have more surpluses, which can cause illegal financial rebates in 
the end. 
(pO19: 36)Xio2 ga4 12J -a g ? 'E ig °011L- Cr"EJ Ie) IIeai P-F 011 E. º 14,1, CJ 0 19 42 22 
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South Korea still doesn't have much control when It comes to certain leading products, and 
there's a chance that International companies might even refuse to offer their products to 
us. 
(p019: 40) VEB RL- open-mind£ QEJ OIAI zig &t2IZ4P! 920 ; tOPiO l1cC1I :$ dOIIL- i of 
vo ej l ,H JIai =8. ;I think it's important for people to be open-minded and try to find 
what's best for our nation people. 
p028 
(0028: 14)WI el-? Xi§01 ä' °J 91419Oil Q P-} OIöU)f Tikf-i Zg°)i E1tOtAi NIkkO-zkll* kjAg 
R--; IJI '0T2 iC( 31Lý POI$tEA12I3? E MOI' 'M1111 "raoiOI&1)il-. X-MaQ 
91 XI It2J H til iAI2 01LI 6! °I al llýE2 A* $0FEA1 '# MAI 13 ±I Ek rol2, : Most 
researchers don't understand very well about the policy direction, So, whenever we ask 
them to write out policy reports to researchers, we normally request them to focus and 
verify the topics we mostly discuss and write about. 
(PO28: 18)UL- oºLi Eiloll Ar' dq9 SF 3 WQ FQ24L- cil oºjU 2i tfe aAi 
ON71, JA14 01? iPI 01°IJJE4°I 2101 Qý8I 2PUR )i0118.: It's like saying this is one of 
my top priorities. But If I had to rate this objectively, then it would be much more 
influenced by interest groups. 
(p028: 22) 9A -90Oil [N P1 19 )iß 219)IR-º0 l 11 Et 4 4A1IOil 01 V- 0111 L -34 : The evaluation for 
that would be the successor's responsibilities 
(P028. Z9) Y. 34 üiXl 561 NE 111 ah of ', J01 t oP Q 21 x) Qý oj)y. M 5Utxl)l. 
L42 L- QI S. V-9 3 LH XI 509 eil! ZIMIJ PN RO CNN UI tQ.: lt normally takes about three 
to five years to figure out if policies are really working or not, but policy-makers usually 
end up being replaced after that amount of time. 
(pO28: 40)OI I OtLInF Uist tILYS: OUB et Mi! R roe ý7i , Xf aim 8RAJ oiitiiij; a 
Xiltil Ita104; am W µL' Q( , °-2I iCQM zi71 911@011] Q M4011 XIL1I94 N24: zll- ;0 üi 
&}gj yt g aqo -t 28H 11 
W]i( ci 8.: Since America has plural Insurers, they. tend to 
implement generic policies easily with thinking In the way that someone else will eventually 
use the brand name anyway. However, [we have a single central Insurer so] If we use 
generic policies, then It would end up being misunderstood as protective trade policies. 
(P028: 60)(ma9V] .` Miok ci AIU'AILt 0FE Ai001LiOil CNi-` [Rf E)Iel: [for prior 
authorisation] [a standard of judgment] on whether this person really needs this or not 
p030 
(pO30.022 2 LE XIT124 äFCI SS ©i~Ic-F XIis' £1 01V T 1F01; l ¬tOP)IX(M 
,W ziiA; °M-_I iý . MüllN9äl: iüefL- :2 L' *voil mof ek el oIß, t2s... evenIf the 
evidence were objective, It's hard to apply It simply because of the difference between 
Korean system and other countries' systems, and .., 
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(p030: 10) of E NMI Vý °; tolai; =zi OýIPIAI, 24==Xl : epidemiology relating to chemical 
substances or epidemiologic researches [on local population] 
(p030: 10) 21°5O1I head-to-head 7F. : head-to-head data on drugs 
(p030: 10) til 41 31ä tNAi ... ' t1 161.14M bi di 4 3t} : needs a live, close network 
among research institutions 
(PO30: 16) bIXZ&N0111 )11Xi W)iIL"5' U zi1710.1 W8[t! VIViIM Ft 9-C; - CiU(ifd 4°ý 
: ILI . 11921 :1 Li Sy01)i>L- UW P-D -ILI AýOIIM :I 
think it should be the final factor that 
we carry out this or that which doesn't harm in consumers. 
(pO30: 35) l Fl °_-ý'- °I/94 Ai '04i XiIXiIat )iLt aaI$t )11 7t9 °d2; 2J $XiI01)II= VCil aG4 I! XH 
4? -ILtzt01IMt WOI tjXI st=cl 4IM2 7iß g -12. iC4 MLlnt dtv OV 9t 7{I ythXFOILIM : 
Technically, the most important thing to do is to place both doctors and pharmacists under 
control, but that's easier said than done. So consumers would be the ones who would be 
directly affected by it.... 
(P030: 57)ixp°J MPe011 L+Xf1f 22t=r- 91/2tAI7f 22tc Q! XIU ZUM . z-9-ý Cl XF712I 
oI2. oIal Je°A OI9 OI2I Old P#OI 9 201M VMS Wcfel : Whetheryou're 
a doctor or a pharmacist or a consumer, I just hope they all can at least try to understand 
each other instead of focusing on either their own personal benefit, or their group... 
(pO3O: 58)L-SR miFD UO1WPIY-e! "WIM' -'rMfEFt9Xi? OI. OiG4 ýiL4 °IJ 7J XP 
Qroiwi oisloii CI PI aIK-01 -1 )II MEEK AI190i Flust : since we are usually pressured 
for time, we try to Introduce all these American and European policies, just add to, even if 
they are not necessarily the best ones for our country 
p047 
2M Q921 olF-J 2lAHU9u- It aH V@ V4 21WO e§ oI&J°! OLM ý40iI CH HA1 
ly7ff-ý Oe Rol %XI I °oI tt Oll AI Amol 2J If ?! L- 101 A VR 2.: It's also not 
being used because, so far, there basically hasn't been enough evidence available on other 
previous policy-making processes for us to learn from and use as an example whenever we 
have to make certain future decisions, 
(PO47: 4) i , 4fi§ V12Ail W ? iOIIMM &tOFMM ý-Jzl ? 9Llnf gy, )t,,.. 2: ýi7jg2'Nýg Ito a 
YMOIIM NY)iaoi V2429! OI 81101: 8Q MAiOI OILIaF ACi MA1V, ýtHýil °_ý' ý ýS7f 
91C4- 9atO 1LI 4.: I think It's important for the government to focus not only on the 
quantity aspect of establishing, evaluating, and promoting the policy evidence, but also on 
processing it In a more systematic way. 
(PO47. "6)1190114 AfV S? IIILiei zICi5S V 01111,21 . ßIE -HIXI EM 001I'. 1 ; XI Oizi Af tif_I 
WORM 01)II RAU )Hi6I101; ECFt 44yzlz 219 Uzi L42, -: mil Maim w el wii 01711 
U zk °_ U .I L- BýJü(I Mt Jew Oi v+ £1 9I W1124; = XI )I E. 21 I7 F a} XI Olt IVIV001 6101 
Mai§ afý41 iL alb, E -i ex e Wo131QLML J, 1 X12 xi 23ia xi oIi Jeeol ä[1 
gaaPil 419vE äI J -72.... -1 C4 z1251 Oil 0 lii aid 9 2°I *E Al tl Zt :. 141 Q! 3f aFZ $f i- 
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S 
: Oli °; 4iM Af9(; xilý, týºýOI?. 4 XI 01 Ci1°J Oý24 Xl fiýý ;ý 5'1ý ý 712 
äf8, : At first, opinion leaders and other people, such as a group of consumers, would 
announce something like `these are the problems In a policy, and it should be reformed: 
However, when it comes to the process of carrying out the policy, cases from other 
countries or pre-existing evaluations are taken into consideration. In the next step, other 
example cases and evidence grounds may play an important role, and then, the 
pharmaceutical industry or some Interest groups would play a part in deciding how strongly 
they enact... 
(p047: 6)xil94 11 A129 ZVc4° 011 AI iN 110 41 cl. ýl S al Lf XI L- St 2 LI of : Since the influence 
of a pharmaceutical company Is not explicit In outside... 
(pO47: 14) 1-4 Oil LH QBAl 9IAt24 94 At71 CHJ$[I ?1 9EDt Niet-7i 012 Oil 1aI alp a UaiAj 
I& XI ff JNg Ct a. tPI V LI Gt.: Since there's already too much conflict between 
doctors and pharmacists, I think it's best to stay neutral rather than firing them by 
favouring one side over another. 
(pO47.: 16) : ON 01 -9 atct. i=lk )121 14 ýtý t1' 't poi i oizii °! ýt taoý aF fflj 
? -ILt? 40ilk1L- P° i- 
I -axii oifki all a-°17f Wý QF tMOIalA-! Ahura -9psI Rg F 
V j= pi pi gW IIý Cii J III ýoH7t w1 c28 :I don't think people In our country, 
especially the service providers, still believe that the quality of generics Is just good as 
other brand-named drugs. I think this is what is holding us back from enforcing all these 
useful policies that are out there. 
C1, j -: ý73 (PO47.22)g81 P-FR QIII D, o i 7iß'9901 . x= G-I '. I ff 
# MOk13 p}xl ýtý Id zi g 7i 
ýI afý XI aý 49Vý 4ý21; i NF °z180l'lis. ý CHI. l Xi °xi 
aid date f2191M X1 *1 i~! 4_° V14 '12.1 Ct M 2,1wa 8f. 1: After patents expire, I 
think the price competition should be more in force. I also think -- consumers pay much 
more than a marginal cost on the products not resulted from the R&D Just in order that 
such extra expenses can help maintain a certain industry--is really unnecessary. 
p048 
(p048'4) Y-Z5 bi1, ý'JMU-ý}tF'1 doff 1 r4 eA t}-? 1. L: doing another before evaluating a 
policy Introduced ahead 
(P0'18., 6) -iLj 24; qP4 t-E! OIL} U8 working paperWE Oil 95 G}° .ý jta2 R7fFj äiL 
Wg CII * aR aft Q W-4Q P ,-i 3o( WE Q .: If you take a look at other working 
papers or essays from other countries, you can see how there are various evaluative 
procedures, we [South Korea] rarely do like that. 
(pO48. "6) dN U21 -? -95A O 22ýtF 312 °! a9Oill! 14W8I i M4Zr1?! tttl! l r +äix1L. 
8toiß. awl S#I2, tN MM descrlptlve@ý 9 S48fM,. descriptive t4 NiIAJ xiai of 
Eg$tL- WVU aH4l5 8H )II ' Iýý : Either the government or other organisations In 
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South Korea that would recruit researchers for policy research prefer more descriptive 
methods than In-depth analytic ones, they just want things to be explained descriptively 
and in certain ways they want them to be explained. 
(pO48., 42)V Ail -N-! °i 7F IOi 01 EJ Ol 6t zi 2., Z oiI ý X11 J1 4 V11% Qt Q8Q tgOl 
71 Uff ¢N 7iL- aT-R X94 VUO1S.: Even though we are covered by insurance 
and can go to a hospital whenever we have to, still there are many cases when you can't 
even go If you're In extremely critical condition. 
(PlM8: 96)y PI -°I)t V1OF7FXIi, 4481 OPiOllw )M i Olillpl tprag7I6,12i2 ä}1- )II Q` äl 
2101 8: There are a number of those (government bodies] who are mainly focused on their 
group-interest, well, especially with drug pricing policies 
QF -I t )il B .: The (P048: 52) )f If 123 0124 ýt 2ý 9J A-i 2110'4 01 1- 01 °! 71 ff8 011 
biggest problem is that doctors prescribe certain drugs because they have an economic 
interest in doing so. 
(pO48: 58) Xi i' 171 off 7ik1 iai -N 24 91 01 04 71 XI o19 is} 712H Gi V OH XI PI Al f; zizi N 
i°! L-9 zio! it i? F Ci2 C12 R: I can't really think of a good way to ensure this 
price competition unless we get rid of all the Illegal trading we discussed so far. 
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Annex 26: Summary of questionnaire responses 
a) Question 4 and 5: Rating in frequency and quality of evidence employed in the current 
pharmaceutical policy-making process (5=highest, 1=lowest) 
Frequency 
Studies investigating 
overseas drug policies/ 
Studies investigating 
Korean drug policies 
Reports after 
business trip to 
oversea 
Quality 
Clinical research 
Studies investigating 
overseas drug 
policies 
Studies Investigating 
Korean drug policies 
Reports after a 
business trip to 
oversea 
Comparative studies of 
pharmaceutical 
policies 
Economic evaluation 
studies 
p014 
- P012 
Experts' opinion -p019 - P022 
--- P020 
p030 
ýkHti 
Comparative studies 
of pharmaceutical 
policies 
Economic evaluation 
studies 
p014 
po 17 
19 [ xperts' opinion -_PO Z2 Vo? 8 
WJO 
Ir048 
b) Question 6: General satisfaction with existing evidence 
5 
3 
1 
I 
4 
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Clinical research 
S n_ 
uI (IuC: puuIJIIdIIC ItbljuiI9 
c) Question 7: Primary requisites for good evidence 
Constructing a proper database 
Government/university/industry 
cooperation 
Involvement of governmental body 
Improving ability to use existing 3 
resources 
Nuturing potential researchers 3 
Making easier access to available data 2 
Raising research funding 1 
4 
d) Question 9: Countries often benchmarked in South Korea 
Japan 9 
Australia 8 
US 8 
UK 7 
France 6 
Germany 5 
Sweden 1111111111111114 
Canada 1 
developedEU 1 
Italy =1 
Taiwan M1 
5 
5 
e) Question 10: Policies participants having involved so far among selected pharmaceutical 
policies 
7 
3 
cost- Rest 
sharing Prescribing 
reschedule Project 
IN 
PERP Actual 
Acquisition 
Mice 
system 
f) Question 11 and 13: Positive and negative effects of four current policies 
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The impacts of each of following policy are in The each of following policy brought 
accord with the policy aims and expected unwanted consequences after 
effects in the stage of policy development. implementation. 
Cost-sharing reschedule Cost-sharing reschedule 
4 
1 1 
strongly agree neutral d' agree strongly 
strongly agree neutral disagree strongly 
agree 
disagree agree disagree 
Best Prescribing Project 
Best Prescribing Project 
h 9 
2 
strongly agree neutral disagree strongly 
strongly agree neutral disagree strongly 
disagree agree disagree 
agree 
PERP-price cut/agreement 
PERP-price cut/agreement 
Ii 
strongly agree neutral disagree strongly 
strongly agree neutral disagree strongly 
disagree agree disagree 
agree 
PERP-positive list/formal economic evaluation 
6 
PERP-Positiva list/ formal economic evaluation 
t   ,. strongly agree neutral disagree strongly strongly agree neutral disagree strongly disagree agree disagree 
agree 
397 
g) Question 15: Opinions on some of potential policies 
Reference pricing 
4 
3 
t1 
very useful useful neutral unuseful very 
unuseful 
Prescribing budget 
4 
22 
i 
very useful useful neutral unuseful very 
unuseful 
Diagnosis-related group 
lIla 
very useful useful neutral unuseful very 
unuseful 
Generic name prescribing 
iii 
very useful useful neutral unuseful very 
unuseful 
h) Question 17: Factors inflating pharmaceutical expenditure in South Korea 
(1 =most influential, 3=least influential) 
,, oo6 
ýilll/ -VI1111111C 
---residual 
price 
`) 
i) Question 19: stakeholders under control in priority 
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PrescTt*. rs or 7 
Dispensers 
Authordes 5 
Consumers 4 
Domestic 3 
manufacturers 
Gbwl 3 
manufacturers 
Who salers 
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